{"2cc1bedf99000878d30f72135b26a8d3b00073f6": [["Main Text:At present, there are seven coronaviruses that are known to infect humans.", [["coronaviruses", "ORGANISM", 38, 51], ["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["seven coronaviruses", "PROBLEM", 32, 51], ["coronaviruses", "OBSERVATION", 38, 51]]], ["The four endemic human coronaviruses OC43, 229E, HKU1 and NL63 cause mild upper respiratory tract infections while pandemic virus SARS-CoV-2, and earlier SARS-CoV and MERS-CoV, can cause severe pneumonia with acute respiratory distress syndrome, multi-organ failure, and death 5 (1,2).", [["upper respiratory tract", "ANATOMY", 74, 97], ["respiratory", "ANATOMY", 215, 226], ["multi-organ", "ANATOMY", 246, 257], ["respiratory tract infections", "DISEASE", 80, 108], ["SARS", "DISEASE", 130, 134], ["pneumonia", "DISEASE", 194, 203], ["acute respiratory distress syndrome", "DISEASE", 209, 244], ["multi-organ failure", "DISEASE", 246, 265], ["death", "DISEASE", 271, 276], ["human", "ORGANISM", 17, 22], ["coronaviruses OC43", "ORGANISM", 23, 41], ["229E", "GENE_OR_GENE_PRODUCT", 43, 47], ["HKU1", "GENE_OR_GENE_PRODUCT", 49, 53], ["NL63", "GENE_OR_GENE_PRODUCT", 58, 62], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 74, 97], ["pandemic virus SARS-CoV-2", "ORGANISM", 115, 140], ["SARS-CoV", "ORGANISM", 154, 162], ["MERS-CoV", "ORGANISM", 167, 175], ["human", "SPECIES", 17, 22], ["pandemic virus SARS-CoV", "SPECIES", 115, 138], ["MERS-CoV", "SPECIES", 167, 175], ["human coronaviruses", "SPECIES", 17, 36], ["SARS-CoV-2", "SPECIES", 130, 140], ["SARS-CoV", "SPECIES", 154, 162], ["MERS-CoV", "SPECIES", 167, 175], ["The four endemic human coronaviruses OC43", "TEST", 0, 41], ["HKU1", "TEST", 49, 53], ["mild upper respiratory tract infections", "PROBLEM", 69, 108], ["pandemic virus SARS", "PROBLEM", 115, 134], ["CoV", "TEST", 135, 138], ["earlier SARS", "PROBLEM", 146, 158], ["severe pneumonia", "PROBLEM", 187, 203], ["acute respiratory distress syndrome", "PROBLEM", 209, 244], ["multi-organ failure", "PROBLEM", 246, 265], ["death", "PROBLEM", 271, 276], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["upper", "ANATOMY_MODIFIER", 74, 79], ["respiratory tract", "ANATOMY", 80, 97], ["infections", "OBSERVATION", 98, 108], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["pneumonia", "OBSERVATION", 194, 203], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["respiratory distress syndrome", "OBSERVATION", 215, 244], ["multi-organ", "ANATOMY", 246, 257], ["failure", "OBSERVATION", 258, 265]]], ["In order to enable development of effective therapeutic interventions, a central goal of ongoing research into the COVID-19 pandemic is to determine the features of SARS-CoV-2 that provide it with a lethal combination of high infectivity and high pathogenicity.Main Text:SARS-CoV-2 has acquired novel functions that promote its harsh disease phenotype.", [["SARS", "DISEASE", 165, 169], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 271, 281], ["SARS-CoV", "SPECIES", 165, 173], ["effective therapeutic interventions", "TREATMENT", 34, 69], ["the COVID", "TEST", 111, 120], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["high infectivity", "PROBLEM", 221, 237], ["high pathogenicity", "PROBLEM", 242, 260], ["SARS-CoV", "PROBLEM", 271, 279], ["acquired novel functions", "PROBLEM", 286, 310], ["its harsh disease phenotype", "PROBLEM", 324, 351], ["high infectivity", "OBSERVATION", 221, 237], ["high pathogenicity", "OBSERVATION", 242, 260], ["SARS-CoV", "OBSERVATION", 271, 279]]], ["While the previous closely related SARS-CoV did not significantly spread past the lungs, a recent study 10 reported damage or severe inflammation in SARS-CoV-2 patients' endothelial cells in the heart, kidneys, liver and intestines, suggestive of a vascular infection rather than a respiratory disease (3).", [["lungs", "ANATOMY", 82, 87], ["endothelial cells", "ANATOMY", 170, 187], ["heart", "ANATOMY", 195, 200], ["kidneys", "ANATOMY", 202, 209], ["liver", "ANATOMY", 211, 216], ["intestines", "ANATOMY", 221, 231], ["vascular", "ANATOMY", 249, 257], ["respiratory", "ANATOMY", 282, 293], ["SARS", "DISEASE", 35, 39], ["inflammation", "DISEASE", 133, 145], ["SARS", "DISEASE", 149, 153], ["vascular infection", "DISEASE", 249, 267], ["respiratory disease", "DISEASE", 282, 301], ["SARS-CoV", "ORGANISM", 35, 43], ["lungs", "ORGAN", 82, 87], ["patients", "ORGANISM", 160, 168], ["endothelial cells", "CELL", 170, 187], ["heart", "ORGAN", 195, 200], ["kidneys", "ORGAN", 202, 209], ["liver", "ORGAN", 211, 216], ["intestines", "ORGAN", 221, 231], ["vascular", "MULTI-TISSUE_STRUCTURE", 249, 257], ["endothelial cells", "CELL_TYPE", 170, 187], ["patients", "SPECIES", 160, 168], ["SARS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 149, 157], ["a recent study", "TEST", 89, 103], ["damage", "PROBLEM", 116, 122], ["severe inflammation in SARS", "PROBLEM", 126, 153], ["CoV", "TEST", 154, 157], ["a vascular infection", "PROBLEM", 247, 267], ["a respiratory disease", "PROBLEM", 280, 301], ["lungs", "ANATOMY", 82, 87], ["severe", "OBSERVATION_MODIFIER", 126, 132], ["inflammation", "OBSERVATION", 133, 145], ["endothelial cells", "OBSERVATION", 170, 187], ["heart", "ANATOMY", 195, 200], ["kidneys", "ANATOMY", 202, 209], ["liver", "ANATOMY", 211, 216], ["intestines", "ANATOMY", 221, 231], ["suggestive of", "UNCERTAINTY", 233, 246], ["vascular", "ANATOMY", 249, 257], ["infection", "OBSERVATION", 258, 267], ["respiratory disease", "OBSERVATION", 282, 301]]], ["The attachment of SARS-CoV-2 to a host cell is initiated by S binding to its cognate receptor angiotensin-converting enzyme 2 (ACE2), with higher affinity as compared to SARS-CoV (4) (5) (6) .Main Text:A novel S1/S2 polybasic furin protease cleavage site stimulates entry into host cells and cell-cell 15 fusion (4, 7, 8) .", [["cell", "ANATOMY", 39, 43], ["cells", "ANATOMY", 282, 287], ["cell", "ANATOMY", 292, 296], ["cell", "ANATOMY", 297, 301], ["SARS", "DISEASE", 18, 22], ["angiotensin", "CHEMICAL", 94, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 28], ["host cell", "CELL", 34, 43], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 94, 125], ["ACE2", "GENE_OR_GENE_PRODUCT", 127, 131], ["4) (5) (6)", "SIMPLE_CHEMICAL", 180, 190], ["S2", "GENE_OR_GENE_PRODUCT", 213, 215], ["furin", "GENE_OR_GENE_PRODUCT", 226, 231], ["cells", "CELL", 282, 287], ["cell", "CELL", 292, 296], ["angiotensin-converting enzyme 2", "PROTEIN", 94, 125], ["ACE2", "PROTEIN", 127, 131], ["S1", "PROTEIN", 210, 212], ["S2", "PROTEIN", 213, 215], ["polybasic furin protease cleavage site", "PROTEIN", 216, 254], ["host cells", "CELL_TYPE", 277, 287], ["SARS-CoV", "SPECIES", 170, 178], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["converting enzyme", "TEST", 106, 123], ["higher affinity", "PROBLEM", 139, 154], ["SARS", "TEST", 170, 174], ["A novel S1/S2 polybasic furin protease cleavage", "TREATMENT", 202, 249], ["cell-cell 15 fusion", "TREATMENT", 292, 311], ["SARS", "OBSERVATION", 18, 22], ["host cell", "OBSERVATION", 34, 43], ["host cells", "OBSERVATION", 277, 287]]], ["Inside the host cell, human coronaviruses remodel the lipid metabolism to facilitate virus replication (9) .", [["cell", "ANATOMY", 16, 20], ["host cell", "CELL", 11, 20], ["human", "ORGANISM", 22, 27], ["coronaviruses", "ORGANISM", 28, 41], ["lipid", "SIMPLE_CHEMICAL", 54, 59], ["human", "SPECIES", 22, 27], ["human coronaviruses", "SPECIES", 22, 41], ["facilitate virus replication", "TREATMENT", 74, 102], ["host cell", "OBSERVATION", 11, 20]]], ["Infection by SARS-CoV-2 triggers an unusually impaired and dysregulated immune response (10) and a heightened inflammatory response (11) working in synergy with interferon production in the vicinity of infected cells to drive a feed-forward loop to upregulate ACE2 and further escalate infection (12) .", [["cells", "ANATOMY", 211, 216], ["SARS", "DISEASE", 13, 17], ["infection", "DISEASE", 286, 295], ["SARS-CoV-2", "ORGANISM", 13, 23], ["interferon", "GENE_OR_GENE_PRODUCT", 161, 171], ["cells", "CELL", 211, 216], ["ACE2", "GENE_OR_GENE_PRODUCT", 260, 264], ["interferon", "PROTEIN", 161, 171], ["infected cells", "CELL_TYPE", 202, 216], ["ACE2", "PROTEIN", 260, 264], ["SARS-CoV", "SPECIES", 13, 21], ["Infection", "PROBLEM", 0, 9], ["SARS", "TEST", 13, 17], ["CoV", "TEST", 18, 21], ["an unusually impaired and dysregulated immune response", "PROBLEM", 33, 87], ["a heightened inflammatory response", "PROBLEM", 97, 131], ["interferon production", "TREATMENT", 161, 182], ["infected cells", "PROBLEM", 202, 216], ["forward loop to upregulate ACE2", "TREATMENT", 233, 264], ["further escalate infection", "PROBLEM", 269, 295], ["inflammatory", "OBSERVATION_MODIFIER", 110, 122], ["infected cells", "OBSERVATION", 202, 216]]], ["20 In the search for additional novel functions that contribute to the observed extreme pathology of infection, we determined the structure of the SARS-CoV-2 S glycoprotein by cryo-EM (Fig.1) .Main Text:We discovered in our structure that the S trimer tightly binds three LA molecules in specific 4 binding pockets, endowing a scavenger function on S, poised to impact lipid remodeling and fuel SARS-CoV-2 pathologies.Main Text:We expressed SARS-CoV-2 S as a secreted trimer (13) in MultiBac (14) baculovirus-infected Hi5 insect cells using ESF921 media which contains cod liver oil as a nutrient supplement (Corey Jacklin, Expression Systems, personal communication).", [["cells", "ANATOMY", 529, 534], ["liver oil", "ANATOMY", 573, 582], ["infection", "DISEASE", 101, 110], ["LA", "CHEMICAL", 272, 274], ["ESF921", "CHEMICAL", 541, 547], ["SARS-CoV-2 S glycoprotein", "GENE_OR_GENE_PRODUCT", 147, 172], ["lipid", "SIMPLE_CHEMICAL", 369, 374], ["MultiBac (14) baculovirus", "ORGANISM", 483, 508], ["Hi5 insect cells", "CELL", 518, 534], ["ESF921", "SIMPLE_CHEMICAL", 541, 547], ["liver", "ORGAN", 573, 578], ["oil", "ORGANISM_SUBSTANCE", 579, 582], ["SARS-CoV-2 S glycoprotein", "PROTEIN", 147, 172], ["S trimer", "PROTEIN", 243, 251], ["LA molecules", "PROTEIN", 272, 284], ["MultiBac (14) baculovirus-infected Hi5 insect cells", "CELL_LINE", 483, 534], ["baculovirus", "SPECIES", 497, 508], ["the observed extreme pathology of infection", "PROBLEM", 67, 110], ["the SARS", "TEST", 143, 151], ["CoV", "TEST", 152, 155], ["specific 4 binding pockets", "PROBLEM", 288, 314], ["lipid remodeling", "PROBLEM", 369, 385], ["fuel SARS", "TEST", 390, 399], ["CoV-2 pathologies", "PROBLEM", 400, 417], ["SARS", "TEST", 441, 445], ["CoV", "TEST", 446, 449], ["baculovirus", "TREATMENT", 497, 508], ["infected Hi5 insect cells", "TREATMENT", 509, 534], ["ESF921 media", "TREATMENT", 541, 553], ["cod liver oil", "TREATMENT", 569, 582], ["a nutrient supplement", "TREATMENT", 586, 607], ["infection", "OBSERVATION", 101, 110], ["binding pockets", "OBSERVATION", 299, 314], ["lipid remodeling", "OBSERVATION", 369, 385], ["fuel SARS", "OBSERVATION", 390, 399], ["liver", "ANATOMY", 573, 578]]], ["Cod liver oil comprises hundreds 5 of FFAs including LA (15) while uninfected Hi5 cells contain very little LA (16) .", [["liver oil", "ANATOMY", 4, 13], ["Hi5 cells", "ANATOMY", 78, 87], ["FFAs", "CHEMICAL", 38, 42], ["LA", "CHEMICAL", 53, 55], ["LA", "CHEMICAL", 108, 110], ["Cod liver oil", "ORGANISM_SUBSTANCE", 0, 13], ["FFAs", "SIMPLE_CHEMICAL", 38, 42], ["Hi5 cells", "CELL", 78, 87], ["uninfected Hi5 cells", "CELL_TYPE", 67, 87], ["Cod liver oil", "TREATMENT", 0, 13], ["FFAs", "TEST", 38, 42], ["LA", "TEST", 53, 55], ["liver", "ANATOMY", 4, 9], ["very", "OBSERVATION_MODIFIER", 96, 100]]], ["We purified S using immobilized metal-affinity purification and size exclusion chromatography (SEC) (fig. S1).", [["immobilized metal", "TREATMENT", 20, 37], ["affinity purification", "TREATMENT", 38, 59], ["size exclusion chromatography", "TEST", 64, 93], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["Highly purified protein was used for cryo-EM data collection ( fig. S2 , table S1).", [["S2", "PROTEIN", 68, 70], ["table S1", "ANATOMY", 73, 81]]], ["After 3D classification and refinement without applying symmetry (C1) we obtained a 3.0\u00c5 closed conformation from 136,405 particles and a 3.5\u00c5 open conformation with one receptor-binding 10 domain (RBD) in the up position from 57,990 particles (figs.", [["receptor-binding 10 domain", "PROTEIN", 170, 196], ["RBD", "PROTEIN", 198, 201], ["3D classification", "TEST", 6, 23], ["a 3.0\u00c5 closed conformation", "TREATMENT", 82, 108], ["a 3.5\u00c5 open conformation", "TREATMENT", 136, 160]]], ["S2,S3).", [["S3", "GENE_OR_GENE_PRODUCT", 3, 5], ["S2", "PROTEIN", 0, 2], ["S3", "PROTEIN", 3, 5], ["S3", "ANATOMY", 3, 5]]], ["C3 symmetry was applied to the closed conformation particle pool yielding a 2.85\u00c5 map (Fig.1A , figs.", [["C3 symmetry", "PROBLEM", 0, 11]]], ["S2,S3).Main Text:The structure of S displays the characteristic overall shape observed for coronavirus S proteins in the closed and open conformations (17) (18) (19) with the closed form predominating in our data set ( Fig.1A , figs.", [["S3", "GENE_OR_GENE_PRODUCT", 3, 5], ["coronavirus S proteins", "GENE_OR_GENE_PRODUCT", 91, 113], ["S2", "PROTEIN", 0, 2], ["S3", "PROTEIN", 3, 5], ["coronavirus S proteins", "PROTEIN", 91, 113], ["coronavirus S proteins", "PROBLEM", 91, 113], ["S3", "ANATOMY", 3, 5], ["shape", "OBSERVATION_MODIFIER", 72, 77], ["coronavirus", "OBSERVATION", 91, 102], ["closed", "OBSERVATION_MODIFIER", 121, 127]]], ["S2-S4).", [["S2-S4", "GENE_OR_GENE_PRODUCT", 0, 5], ["S2", "PROTEIN", 0, 2], ["S4", "ANATOMY", 3, 5]]], ["Model building of the closed form evidenced additional density in the 15 RBDs in our structure (Fig.1B) .", [["additional density in the 15 RBDs", "PROBLEM", 44, 77], ["closed", "OBSERVATION", 22, 28], ["additional", "OBSERVATION_MODIFIER", 44, 54], ["density", "OBSERVATION", 55, 62], ["15 RBDs", "OBSERVATION_MODIFIER", 70, 77]]], ["The tube-like shape of this density was consistent with a fatty acid.", [["tube", "ANATOMY", 4, 8], ["fatty acid", "CHEMICAL", 58, 68], ["fatty acid", "CHEMICAL", 58, 68], ["tube", "TISSUE", 4, 8], ["fatty acid", "SIMPLE_CHEMICAL", 58, 68], ["The tube", "TREATMENT", 0, 8], ["this density", "PROBLEM", 23, 35], ["a fatty acid", "TREATMENT", 56, 68], ["tube", "OBSERVATION", 4, 8], ["like shape", "OBSERVATION_MODIFIER", 9, 19], ["density", "OBSERVATION", 28, 35], ["consistent with", "UNCERTAINTY", 40, 55], ["fatty acid", "OBSERVATION", 58, 68]]], ["Modeling conveyed LA based on size and shape similarity with LA bound to other proteins ( Fig.1B, fig. S5 ) (20, 21).", [["LA", "CHEMICAL", 18, 20], ["LA", "CHEMICAL", 61, 63], ["LA", "SIMPLE_CHEMICAL", 61, 63], ["LA", "PROTEIN", 61, 63], [".1B", "PROTEIN", 93, 96], ["LA bound", "PROBLEM", 61, 69], ["size", "OBSERVATION_MODIFIER", 30, 34]]], ["Liquid chromatography coupled ESI-TOF mass spectrometry (LS-MS) analysis confirmed the presence of a compound with the molecular weight of LA in our highly purified sample (Fig.1C) .", [["sample", "ANATOMY", 165, 171], ["LA", "CHEMICAL", 139, 141], ["LA", "SIMPLE_CHEMICAL", 139, 141], ["Liquid chromatography", "TEST", 0, 21], ["ESI", "TEST", 30, 33], ["LS-MS) analysis", "TEST", 57, 72], ["a compound", "PROBLEM", 99, 109], ["compound", "OBSERVATION_MODIFIER", 101, 109]]], ["20 Hallmarks of FFA-binding pockets in proteins are an extended 'greasy' tube lined by hydrophobic amino acids which accommodates the hydrocarbon tail, and a hydrophilic, often positively charged anchor for the acidic headgroup of the FFA.", [["FFA", "CHEMICAL", 16, 19], ["amino acids", "CHEMICAL", 99, 110], ["FFA", "CHEMICAL", 235, 238], ["amino acids", "CHEMICAL", 99, 110], ["hydrocarbon", "CHEMICAL", 134, 145], ["FFA", "SIMPLE_CHEMICAL", 16, 19], ["tube", "TISSUE", 73, 77], ["amino acids", "AMINO_ACID", 99, 110], ["FFA", "SIMPLE_CHEMICAL", 235, 238], ["hydrocarbon tail", "PROTEIN", 134, 150], ["FFA-binding pockets in proteins", "PROBLEM", 16, 47], ["an extended 'greasy' tube", "TREATMENT", 52, 77], ["hydrophobic amino acids", "TREATMENT", 87, 110], ["tube lined", "OBSERVATION", 73, 83], ["hydrocarbon tail", "OBSERVATION", 134, 150], ["hydrophilic", "OBSERVATION_MODIFIER", 158, 169], ["acidic headgroup", "OBSERVATION", 211, 227], ["FFA", "ANATOMY", 235, 238]]], ["In our structure, a hydrophobic 5 pocket is present which is mostly shaped by phenylalanines to form a bent tube into which the LA fits excellently (Fig.1D,E) .", [["LA", "CHEMICAL", 128, 130], ["phenylalanines", "CHEMICAL", 78, 92], ["phenylalanines", "SIMPLE_CHEMICAL", 78, 92], ["LA", "SIMPLE_CHEMICAL", 128, 130], ["a hydrophobic 5 pocket", "PROBLEM", 18, 40], ["phenylalanines", "TREATMENT", 78, 92], ["a bent tube", "TREATMENT", 101, 112], ["hydrophobic", "OBSERVATION_MODIFIER", 20, 31], ["pocket", "OBSERVATION_MODIFIER", 34, 40], ["mostly", "OBSERVATION_MODIFIER", 61, 67], ["shaped", "OBSERVATION_MODIFIER", 68, 74], ["bent tube", "OBSERVATION", 103, 112]]], ["Importantly, the anchor for the headgroup carboxyl is provided by an arginine (R408) and a glutamine (Q409) from the adjacent RBD in the trimer, giving rise to a composite LA-binding site (Fig.1E binding to ACE2 for cell entry.", [["cell", "ANATOMY", 216, 220], ["arginine", "CHEMICAL", 69, 77], ["R408", "CHEMICAL", 79, 83], ["glutamine", "CHEMICAL", 91, 100], ["Q409", "CHEMICAL", 102, 106], ["LA", "CHEMICAL", 172, 174], ["carboxyl", "CHEMICAL", 42, 50], ["arginine", "CHEMICAL", 69, 77], ["R408", "CHEMICAL", 79, 83], ["glutamine", "CHEMICAL", 91, 100], ["Q409", "CHEMICAL", 102, 106], ["headgroup carboxyl", "SIMPLE_CHEMICAL", 32, 50], ["arginine", "SIMPLE_CHEMICAL", 69, 77], ["R408", "SIMPLE_CHEMICAL", 79, 83], ["glutamine", "AMINO_ACID", 91, 100], ["Q409", "AMINO_ACID", 102, 106], ["LA", "SIMPLE_CHEMICAL", 172, 174], ["1E", "GENE_OR_GENE_PRODUCT", 193, 195], ["ACE2", "GENE_OR_GENE_PRODUCT", 207, 211], ["cell", "CELL", 216, 220], ["RBD", "PROTEIN", 126, 129], ["composite LA-binding site", "DNA", 162, 187], ["ACE2", "PROTEIN", 207, 211], ["the headgroup carboxyl", "TREATMENT", 28, 50], ["an arginine (R408)", "TREATMENT", 66, 84], ["a glutamine (Q409", "TREATMENT", 89, 106], ["the adjacent RBD", "PROBLEM", 113, 129], ["RBD", "OBSERVATION", 126, 129]]], ["We tested activity of our LA-bound S by competition enzyme- 15 linked immunosorbent assay (ELISA) and SEC with highly purified proteins confirming ACE2 binding ( Fig.2A,B) .", [["LA", "CHEMICAL", 26, 28], ["LA", "SIMPLE_CHEMICAL", 26, 28], ["ACE2", "GENE_OR_GENE_PRODUCT", 147, 151], ["LA-bound S", "PROTEIN", 26, 36], ["SEC", "PROTEIN", 102, 105], ["ACE2", "PROTEIN", 147, 151], ["our LA", "TEST", 22, 28], ["competition enzyme", "TEST", 40, 58], ["immunosorbent assay", "TEST", 70, 89], ["ELISA", "TEST", 91, 96], ["SEC", "TEST", 102, 105], ["ACE2 binding", "TEST", 147, 159]]], ["We modeled the receptor-bound structure (22) (Fig.2C ) and found that the LA-binding pocket and the receptor binding motif (Achilles Heel, AH) of the RBD are distal and non-overlapping.", [["LA", "CHEMICAL", 74, 76], ["RBD", "DISEASE", 150, 153], ["RBD", "GENE_OR_GENE_PRODUCT", 150, 153], ["Fig.2C", "PROTEIN", 46, 52], ["LA-binding pocket", "PROTEIN", 74, 91], ["receptor binding motif", "PROTEIN", 100, 122], ["RBD", "PROTEIN", 150, 153], ["the LA-binding pocket", "PROBLEM", 70, 91], ["the receptor binding motif", "TREATMENT", 96, 122], ["binding pocket", "OBSERVATION", 77, 91], ["Achilles Heel", "ANATOMY", 124, 137], ["RBD", "OBSERVATION", 150, 153], ["distal", "OBSERVATION_MODIFIER", 158, 164], ["non-overlapping", "OBSERVATION_MODIFIER", 169, 184]]], ["The LA-bound S we produce is prolifically used in Bristol for testing patient sera for antibodies in immunology assays, further confirming functionality.", [["sera", "ANATOMY", 78, 82], ["LA", "CHEMICAL", 4, 6], ["LA", "SIMPLE_CHEMICAL", 4, 6], ["Bristol", "SIMPLE_CHEMICAL", 50, 57], ["patient", "ORGANISM", 70, 77], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["antibodies", "PROTEIN", 87, 97], ["patient", "SPECIES", 70, 77], ["testing patient sera", "TEST", 62, 82], ["antibodies", "PROBLEM", 87, 97], ["immunology assays", "TEST", 101, 118]]], ["20 Based on our findings, we propose that the previously determined SARS-CoV-2 S structures represent an 'apo' form in absence of LA ligand.", [["SARS", "DISEASE", 68, 72], ["LA", "CHEMICAL", 130, 132], ["apo", "AMINO_ACID", 106, 109], ["LA ligand", "GENE_OR_GENE_PRODUCT", 130, 139], ["SARS-CoV-2 S structures", "DNA", 68, 91], ["LA ligand", "PROTEIN", 130, 139], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["We hypothesize that during SARS-CoV-2 infection, S proteins of the replicating virus accrete LA giving rise to the ligand-bound form.", [["infection", "DISEASE", 38, 47], ["LA", "CHEMICAL", 93, 95], ["SARS-CoV-2", "ORGANISM", 27, 37], ["S proteins", "GENE_OR_GENE_PRODUCT", 49, 59], ["LA", "SIMPLE_CHEMICAL", 93, 95], ["S proteins", "PROTEIN", 49, 59], ["ligand-bound form", "PROTEIN", 115, 132], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["CoV", "PROBLEM", 32, 35], ["2 infection", "PROBLEM", 36, 47]]], ["We 6 superimposed our LA-bound structure and the SARS-CoV-2 S 'apo' form (6, 17) and identified a gating helix located directly at the entrance of the binding pocket.", [["LA", "CHEMICAL", 22, 24], ["LA-bound structure", "PROTEIN", 22, 40], ["SARS-CoV-2 S 'apo' form", "DNA", 49, 72], ["binding pocket", "PROTEIN", 151, 165], ["the SARS", "TEST", 45, 53], ["CoV", "TEST", 54, 57], ["a gating helix", "PROBLEM", 96, 110], ["LA-", "OBSERVATION_MODIFIER", 22, 25], ["bound structure", "OBSERVATION", 25, 40], ["binding pocket", "OBSERVATION", 151, 165]]], ["This gating helix, upon LA binding, moved away by about 6\u00c5, with two tyrosines (Tyr365 and Tyr369) and Phe374 that line the gate swinging open (Fig.3A,B) .", [["LA", "CHEMICAL", 24, 26], ["tyrosines", "CHEMICAL", 69, 78], ["Tyr365", "CHEMICAL", 80, 86], ["Tyr369", "CHEMICAL", 91, 97], ["Phe374", "CHEMICAL", 103, 109], ["LA", "SIMPLE_CHEMICAL", 24, 26], ["Phe374", "SIMPLE_CHEMICAL", 103, 109], ["Fig.3A,B)", "PROTEIN", 144, 153]]], ["In the 'apo' SARS-CoV-2 S trimer (6, 17) , a gap exists between adjacent RBDs with the hydrophilic anchor residues which stabilize the LA headgroup 5 located ~10 \u00c5 away from the greasy tube entrance (Fig.3B) .", [["LA", "CHEMICAL", 135, 137], ["apo", "GENE_OR_GENE_PRODUCT", 8, 11], ["RBDs", "GENE_OR_GENE_PRODUCT", 73, 77], ["tube", "TISSUE", 185, 189], ["RBDs", "PROTEIN", 73, 77], ["hydrophilic anchor residues", "PROTEIN", 87, 114], ["Fig.3B", "PROTEIN", 200, 206], ["the 'apo' SARS", "TEST", 3, 17], ["CoV", "TEST", 18, 21], ["a gap exists between adjacent RBDs", "PROBLEM", 43, 77], ["the hydrophilic anchor residues", "TREATMENT", 83, 114], ["the LA headgroup", "TREATMENT", 131, 147], ["hydrophilic anchor residues", "OBSERVATION", 87, 114], ["LA headgroup", "OBSERVATION", 135, 147], ["greasy tube", "OBSERVATION", 178, 189]]], ["Upon LA binding, the gap closes, the adjacent RBD in the trimer moves towards its neighbour with anchor residues Arg408 and Gln409 locking down on the headgroup of LA (Fig.3B) .", [["LA", "CHEMICAL", 5, 7], ["Arg408", "CHEMICAL", 113, 119], ["LA", "CHEMICAL", 164, 166], ["Arg", "CHEMICAL", 113, 116], ["Gln409", "CHEMICAL", 124, 130], ["LA", "SIMPLE_CHEMICAL", 5, 7], ["Arg408", "AMINO_ACID", 113, 119], ["Gln409", "AMINO_ACID", 124, 130], ["LA", "SIMPLE_CHEMICAL", 164, 166], ["RBD", "PROTEIN", 46, 49], ["LA", "PROTEIN", 164, 166], [".3B", "PROTEIN", 171, 174], ["the adjacent RBD", "PROBLEM", 33, 49], ["anchor residues Arg", "TEST", 97, 116], ["the headgroup of LA", "TREATMENT", 147, 166], ["LA binding", "OBSERVATION_MODIFIER", 5, 15], ["RBD", "OBSERVATION", 46, 49]]], ["Overall, this results in a marked compaction of trimer architecture in the region formed by the three RBDs (Fig.3B ).Main Text:Next, we compared the sequences and structures of human coronaviruses, including SARS-CoV- 10 2, SARS-CoV, MERS-CoV and the four common circulating strains (Fig.3, table S3 ) and investigated whether the LA-binding pocket is conserved.", [["LA", "CHEMICAL", 331, 333], ["RBDs", "GENE_OR_GENE_PRODUCT", 102, 106], ["human", "ORGANISM", 177, 182], ["SARS-CoV- 10 2", "ORGANISM", 208, 222], ["SARS-CoV", "ORGANISM", 224, 232], ["MERS-CoV", "ORGANISM", 234, 242], ["LA", "GENE_OR_GENE_PRODUCT", 331, 333], ["RBDs", "PROTEIN", 102, 106], ["Fig.3B", "PROTEIN", 108, 114], ["Fig.3", "PROTEIN", 284, 289], ["LA-binding pocket", "PROTEIN", 331, 348], ["human", "SPECIES", 177, 182], ["human coronaviruses", "SPECIES", 177, 196], ["SARS-CoV- 10", "SPECIES", 208, 220], ["SARS-CoV", "SPECIES", 224, 232], ["MERS-CoV", "SPECIES", 234, 242], ["a marked compaction of trimer architecture in the region", "PROBLEM", 25, 81], ["the sequences", "TEST", 145, 158], ["human coronaviruses", "PROBLEM", 177, 196], ["SARS", "TEST", 208, 212], ["CoV", "TEST", 213, 216], ["SARS", "TEST", 224, 228], ["CoV", "TEST", 229, 232], ["MERS", "TEST", 234, 238], ["the LA-binding pocket", "PROBLEM", 327, 348], ["marked", "OBSERVATION_MODIFIER", 27, 33], ["compaction", "OBSERVATION", 34, 44], ["trimer architecture", "OBSERVATION", 48, 67], ["region", "ANATOMY_MODIFIER", 75, 81], ["human coronaviruses", "ANATOMY", 177, 196], ["LA", "OBSERVATION", 331, 333], ["binding pocket", "OBSERVATION", 334, 348]]], ["Sequence alignment shows that all residues lining the hydrophobic pocket and the anchor residues (Arg408/Gln409) in SARS-CoV-2 are fully conserved in SARS-CoV (Fig.3A) .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 116, 126], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 150, 158], ["hydrophobic pocket", "PROTEIN", 54, 72], ["SARS-CoV", "SPECIES", 150, 158], ["Sequence alignment", "TEST", 0, 18], ["all residues lining the hydrophobic pocket", "PROBLEM", 30, 72], ["the anchor residues", "PROBLEM", 77, 96], ["Arg408/Gln", "TREATMENT", 98, 108], ["SARS", "PROBLEM", 116, 120], ["hydrophobic pocket", "OBSERVATION", 54, 72], ["anchor residues", "OBSERVATION", 81, 96]]], ["Structural alignment of LA-bound RBDs within the trimer of SARS-CoV-2 and 'apo' SARS-CoV RBDs (19) reveals that the LA-binding pocket 15 is present and accessible in SARS-CoV.", [["LA", "CHEMICAL", 24, 26], ["LA", "CHEMICAL", 116, 118], ["LA", "SIMPLE_CHEMICAL", 24, 26], ["RBDs", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["LA", "SIMPLE_CHEMICAL", 116, 118], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 166, 174], ["LA", "PROTEIN", 24, 26], ["RBDs", "PROTEIN", 33, 37], ["LA-binding pocket 15", "PROTEIN", 116, 136], ["SARS-CoV", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 166, 174], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["'apo' SARS", "TEST", 74, 84], ["CoV RBDs", "TEST", 85, 93], ["the LA-binding pocket", "PROBLEM", 112, 133], ["alignment", "OBSERVATION_MODIFIER", 11, 20], ["LA", "OBSERVATION_MODIFIER", 24, 26], ["LA", "ANATOMY", 116, 118], ["binding pocket", "OBSERVATION", 119, 133]]], ["The greasy tube is flanked by a gating helix as in SARS-CoV-2, with Arg395/Gln396 of SARS-CoV pre-positioned 10\u00c5 and 11\u00c5 from the entrance, respectively, virtually identical to apo SARS-CoV-2 (Fig.3B,C) .", [["greasy tube", "ANATOMY", 4, 15], ["greasy tube", "TISSUE", 4, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 51, 61], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 85, 93], ["apo SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 177, 191], ["Fig.3B,C", "SIMPLE_CHEMICAL", 193, 201], ["CoV", "PROTEIN", 90, 93], ["SARS-CoV", "SPECIES", 85, 93], ["The greasy tube", "TREATMENT", 0, 15], ["a gating helix", "TREATMENT", 30, 44], ["CoV", "TEST", 56, 59], ["apo SARS", "TEST", 177, 185], ["CoV", "TEST", 186, 189], ["greasy tube", "OBSERVATION", 4, 15]]], ["In MERS-CoV, the gating helix and hydrophobic residues lining the pocket are also present.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["MERS-CoV", "SPECIES", 3, 11], ["the gating helix", "TREATMENT", 13, 29], ["hydrophobic residues lining the pocket", "PROBLEM", 34, 72], ["hydrophobic residues", "OBSERVATION", 34, 54], ["lining", "OBSERVATION_MODIFIER", 55, 61], ["pocket", "OBSERVATION_MODIFIER", 66, 72]]], ["Tyr365, Tyr369 and Phe374 are substituted by likewise hydrophobic leucines and a valine, respectively (Fig.3A,D) (19) .", [["Phe374", "CHEMICAL", 19, 25], ["valine", "CHEMICAL", 81, 87], ["Tyr365", "CHEMICAL", 0, 6], ["Tyr369", "CHEMICAL", 8, 14], ["Phe374", "CHEMICAL", 19, 25], ["leucines", "CHEMICAL", 66, 74], ["valine", "CHEMICAL", 81, 87], ["Tyr365", "GENE_OR_GENE_PRODUCT", 0, 6], ["Tyr369", "GENE_OR_GENE_PRODUCT", 8, 14], ["Phe374", "AMINO_ACID", 19, 25], ["valine", "AMINO_ACID", 81, 87], ["a valine", "TREATMENT", 79, 87], ["hydrophobic leucines", "OBSERVATION", 54, 74]]], ["The 20 Arg408/Gln409 pair is not conserved, however, we identify Asn501/Lys502 and Gln466 as potential anchor residues, located on a \u03b2-sheet and an \u03b1-helix within the adjacent RBD, up to 11\u00c5 away from the entrance (Fig.3D) .", [["Gln", "CHEMICAL", 14, 17], ["Gln", "CHEMICAL", 14, 17], ["Asn501", "CHEMICAL", 65, 71], ["Lys502", "CHEMICAL", 72, 78], ["Gln466", "CHEMICAL", 83, 89], ["Arg408", "GENE_OR_GENE_PRODUCT", 7, 13], ["Gln409", "AMINO_ACID", 14, 20], ["Asn501", "GENE_OR_GENE_PRODUCT", 65, 71], ["Lys502", "GENE_OR_GENE_PRODUCT", 72, 78], ["Gln466", "GENE_OR_GENE_PRODUCT", 83, 89], ["20 Arg408/Gln409 pair", "DNA", 4, 25], ["Asn501", "PROTEIN", 65, 71], ["Lys502", "PROTEIN", 72, 78], ["Gln466", "PROTEIN", 83, 89], ["\u03b2-sheet", "PROTEIN", 133, 140], ["\u03b1-helix", "PROTEIN", 148, 155], ["RBD", "PROTEIN", 176, 179], ["Fig.3D", "PROTEIN", 215, 221], ["potential anchor residues", "PROBLEM", 93, 118], ["a \u03b2-sheet", "TREATMENT", 131, 140], ["anchor residues", "OBSERVATION", 103, 118], ["RBD", "OBSERVATION", 176, 179]]], ["Thus, the greasy tube and hydrophilic anchor for binding 7 LA appear to be present in MERS-CoV, suggesting convergent evolution.", [["greasy tube", "ANATOMY", 10, 21], ["LA", "CHEMICAL", 59, 61], ["greasy tube", "TISSUE", 10, 21], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 86, 94], ["MERS-CoV", "SPECIES", 86, 94], ["the greasy tube and hydrophilic anchor", "TREATMENT", 6, 44], ["binding 7 LA", "PROBLEM", 49, 61], ["greasy tube", "OBSERVATION", 10, 21], ["hydrophilic anchor", "OBSERVATION", 26, 44], ["CoV", "ANATOMY", 91, 94], ["suggesting", "UNCERTAINTY", 96, 106], ["convergent", "OBSERVATION_MODIFIER", 107, 117], ["evolution", "OBSERVATION_MODIFIER", 118, 127]]], ["In HCoV OC43, gating helix and hydrophobic residues lining the pocket are largely conserved, while Tyr365, Tyr369 and Phe374 are replaced by methionines and alanine, respectively (Fig.3A) (18) .", [["methionines", "CHEMICAL", 141, 152], ["alanine", "CHEMICAL", 157, 164], ["Tyr365", "CHEMICAL", 99, 105], ["Tyr369", "CHEMICAL", 107, 113], ["Phe374", "CHEMICAL", 118, 124], ["methionines", "CHEMICAL", 141, 152], ["alanine", "CHEMICAL", 157, 164], ["HCoV OC43", "GENE_OR_GENE_PRODUCT", 3, 12], ["Tyr365", "GENE_OR_GENE_PRODUCT", 99, 105], ["Tyr369", "GENE_OR_GENE_PRODUCT", 107, 113], ["Phe374", "GENE_OR_GENE_PRODUCT", 118, 124], ["methionines", "SIMPLE_CHEMICAL", 141, 152], ["alanine", "AMINO_ACID", 157, 164], ["HCoV OC43", "PROTEIN", 3, 12], ["Tyr365", "PROTEIN", 99, 105], ["HCoV", "SPECIES", 3, 7], ["hydrophobic residues lining the pocket", "PROBLEM", 31, 69], ["alanine", "TEST", 157, 164], ["hydrophobic residues", "OBSERVATION", 31, 51], ["lining", "OBSERVATION_MODIFIER", 52, 58], ["pocket", "OBSERVATION_MODIFIER", 63, 69]]], ["Arg413 is located on the same helix as Arg408/Gln409 in SARS-CoV-2 and could serve as a hydrophilic anchor (Fig.3E) .", [["Arg413", "CHEMICAL", 0, 6], ["Arg413", "CHEMICAL", 0, 6], ["Arg413", "AMINO_ACID", 0, 6], ["Fig.3E", "PROTEIN", 108, 114], ["Arg", "TEST", 0, 3], ["CoV", "TEST", 61, 64]]], ["No gap exists in this presumed 'apo' form structure between the RBDs which 5 appear already in the locked conformation with no LA bound, likely obstructing the pocket entrance and constraining gating helix movement (Fig.3E, fig. S8 ) (18) .", [["LA", "CHEMICAL", 127, 129], ["apo", "AMINO_ACID", 32, 35], ["gap", "PROBLEM", 3, 6], ["LA bound", "PROBLEM", 127, 135], ["obstructing the pocket entrance", "PROBLEM", 144, 175], ["gap", "OBSERVATION", 3, 6], ["locked conformation", "OBSERVATION", 99, 118], ["no", "UNCERTAINTY", 124, 126], ["LA bound", "OBSERVATION_MODIFIER", 127, 135], ["likely", "UNCERTAINTY", 137, 143], ["obstructing", "OBSERVATION", 144, 155], ["pocket", "OBSERVATION_MODIFIER", 160, 166], ["entrance", "OBSERVATION_MODIFIER", 167, 175]]], ["In HCoV HKU1, the hydrophobic residues are again largely conserved, but a charged residue (Glu375) is positioned directly in front of the entrance, obstructing access for a putative LA ligand (Fig.3F) 25) , and many of the LA-binding residues are not present (Fig.3A) , indicating no obvious binding site for LA.Main Text:In summary, we find four molecular features mediating LA binding to SARS-CoV-2, and potentially also SARS-CoV and MERS-CoV S proteins: a conserved hydrophobic pocket, a gating helix, amino acid residues pre-positioned to interact with the LA carboxy headgroup, and 15 loosely packed RBDs in the 'apo' form.", [["LA", "CHEMICAL", 182, 184], ["LA", "CHEMICAL", 223, 225], ["LA", "CHEMICAL", 309, 311], ["LA", "CHEMICAL", 376, 378], ["amino acid", "CHEMICAL", 505, 515], ["LA", "CHEMICAL", 561, 563], ["Glu375", "CHEMICAL", 91, 97], ["amino acid", "CHEMICAL", 505, 515], ["carboxy", "CHEMICAL", 564, 571], ["HCoV HKU1", "GENE_OR_GENE_PRODUCT", 3, 12], ["Glu375", "AMINO_ACID", 91, 97], ["LA", "SIMPLE_CHEMICAL", 309, 311], ["LA", "SIMPLE_CHEMICAL", 376, 378], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 390, 400], ["MERS-CoV S proteins", "GENE_OR_GENE_PRODUCT", 436, 455], ["amino acid", "AMINO_ACID", 505, 515], ["RBDs", "CANCER", 605, 609], ["apo", "GENE_OR_GENE_PRODUCT", 618, 621], ["HCoV HKU1", "PROTEIN", 3, 12], ["LA ligand", "PROTEIN", 182, 191], ["LA", "PROTEIN", 223, 225], ["LA", "PROTEIN", 309, 311], ["SARS-CoV and MERS-CoV S proteins", "PROTEIN", 423, 455], ["hydrophobic pocket", "PROTEIN", 469, 487], ["gating helix", "PROTEIN", 491, 503], ["LA carboxy headgroup", "PROTEIN", 561, 581], ["RBDs", "PROTEIN", 605, 609], ["apo' form", "PROTEIN", 618, 627], ["HCoV", "SPECIES", 3, 7], ["the hydrophobic residues", "PROBLEM", 14, 38], ["a charged residue", "PROBLEM", 72, 89], ["a putative LA ligand (Fig.3F)", "TREATMENT", 171, 200], ["the LA-binding residues", "PROBLEM", 219, 242], ["obvious binding site", "PROBLEM", 284, 304], ["SARS", "TEST", 390, 394], ["CoV", "TEST", 395, 398], ["a conserved hydrophobic pocket", "PROBLEM", 457, 487], ["a gating helix", "TREATMENT", 489, 503], ["amino acid residues", "TREATMENT", 505, 524], ["the LA carboxy headgroup", "TREATMENT", 557, 581], ["hydrophobic residues", "OBSERVATION", 18, 38], ["obstructing", "OBSERVATION", 148, 159], ["binding residues", "OBSERVATION", 226, 242], ["no obvious", "UNCERTAINTY", 281, 291], ["hydrophobic pocket", "OBSERVATION", 469, 487]]], ["On the other hand, in each of the four common circulating HCoVs, it appears that one or more of these four architectural prerequisites are lacking in the S protein structures (Fig. 3) .", [["HCoVs", "GENE_OR_GENE_PRODUCT", 58, 63], ["S protein structures", "PROTEIN", 154, 174], ["architectural", "OBSERVATION_MODIFIER", 107, 120], ["prerequisites", "OBSERVATION", 121, 134]]], ["LA-binding to SARS-CoV-2 S protein triggers a locking down of the hydrophilic anchor and a compaction of the RBD trimer (Fig.3B) .", [["LA", "CHEMICAL", 0, 2], ["LA", "SIMPLE_CHEMICAL", 0, 2], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["SARS-CoV-2 S protein", "PROTEIN", 14, 34], ["hydrophilic anchor", "PROTEIN", 66, 84], ["RBD trimer", "PROTEIN", 109, 119], ["Fig.3B", "PROTEIN", 121, 127], ["LA", "TEST", 0, 2], ["SARS", "TEST", 14, 18], ["CoV", "TEST", 19, 22], ["the hydrophilic anchor", "PROBLEM", 62, 84], ["hydrophilic anchor", "OBSERVATION", 66, 84], ["RBD trimer", "OBSERVATION", 109, 119]]], ["This lockdown could contribute to the observed prevalence of closed conformation in our cryo-EM 20 data set.", [["closed conformation", "PROBLEM", 61, 80], ["closed", "OBSERVATION", 61, 67]]], ["It could also help stabilize the S1 region comprising the N-terminal domain and the RBD.", [["RBD", "DISEASE", 84, 87], ["N", "CHEMICAL", 58, 59], ["S1 region", "PROTEIN", 33, 42], ["N-terminal domain", "PROTEIN", 58, 75], ["RBD", "PROTEIN", 84, 87], ["S1", "ANATOMY", 33, 35], ["region", "ANATOMY_MODIFIER", 36, 42], ["terminal", "ANATOMY_MODIFIER", 60, 68], ["RBD", "OBSERVATION", 84, 87]]], ["Of note, the AH epitope, central to ACE2 binding, appears to be conformationally preorganized in our closed conformation (Fig.2C) indicating a generally more rigid RBD 8 structure when LA is bound.", [["LA", "CHEMICAL", 185, 187], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["LA", "SIMPLE_CHEMICAL", 185, 187], ["AH epitope", "PROTEIN", 13, 23], ["ACE2", "PROTEIN", 36, 40], ["RBD 8 structure", "PROTEIN", 164, 179], ["LA", "PROTEIN", 185, 187], ["the AH epitope", "PROBLEM", 9, 23], ["central to ACE2 binding", "PROBLEM", 25, 48], ["a generally more rigid RBD 8 structure", "PROBLEM", 141, 179], ["appears to be", "UNCERTAINTY", 50, 63], ["rigid", "OBSERVATION_MODIFIER", 158, 163], ["RBD", "OBSERVATION", 164, 167]]], ["While direct crosstalk in between the LA-binding pocket and the AH epitope is not apparent from our structure (Fig.2C) , the overall conformational changes in the RBD trimer (Fig.3B ) could conceivably impact ACE2 docking and infectivity.", [["LA", "CHEMICAL", 38, 40], ["LA", "SIMPLE_CHEMICAL", 38, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 209, 213], ["LA-binding pocket", "PROTEIN", 38, 55], ["AH epitope", "PROTEIN", 64, 74], ["Fig.2C", "PROTEIN", 111, 117], ["RBD trimer", "PROTEIN", 163, 173], ["Fig.3B", "PROTEIN", 175, 181], ["ACE2", "PROTEIN", 209, 213], ["the LA-binding pocket", "PROBLEM", 34, 55], ["the overall conformational changes in the RBD trimer", "PROBLEM", 121, 173], ["binding pocket", "OBSERVATION", 41, 55], ["not apparent", "UNCERTAINTY", 78, 90], ["conformational changes", "OBSERVATION", 133, 155], ["RBD trimer", "OBSERVATION", 163, 173]]], ["The S protein's highly selective binding of LA originates from the very well-defined size and shape complementarity afforded by the LA-binding pocket (Fig. 1B,D) , which is supported by the 5 observation that we only detected LA in our analyses (Fig. 1C) .", [["LA", "CHEMICAL", 44, 46], ["LA", "CHEMICAL", 132, 134], ["LA", "CHEMICAL", 226, 228], ["LA", "SIMPLE_CHEMICAL", 44, 46], ["LA", "SIMPLE_CHEMICAL", 132, 134], ["S protein", "PROTEIN", 4, 13], ["LA-binding pocket", "PROTEIN", 132, 149], ["The S protein", "TEST", 0, 13], ["the LA-binding pocket", "PROBLEM", 128, 149], ["selective", "OBSERVATION_MODIFIER", 23, 32], ["LA", "OBSERVATION", 44, 46], ["very", "OBSERVATION_MODIFIER", 67, 71], ["size", "OBSERVATION_MODIFIER", 85, 89], ["shape", "OBSERVATION_MODIFIER", 94, 99], ["complementarity", "OBSERVATION", 100, 115], ["LA", "OBSERVATION_MODIFIER", 132, 134], ["binding pocket", "OBSERVATION", 135, 149]]], ["The LA-binding pocket thus presents a promising target for future development of small molecule inhibitors (e.g. LA mimetics) that, for example, could irreversibly lock S in the closed conformation.Main Text:A recent proteomic and metabolomic study of COVID-19 patient sera evidenced continuous decrease of FFAs including LA (26) .", [["sera", "ANATOMY", 269, 273], ["LA", "CHEMICAL", 4, 6], ["LA", "CHEMICAL", 113, 115], ["FFAs", "CHEMICAL", 307, 311], ["LA", "CHEMICAL", 322, 324], ["LA (26)", "CHEMICAL", 322, 329], ["LA", "SIMPLE_CHEMICAL", 4, 6], ["LA", "SIMPLE_CHEMICAL", 113, 115], ["patient", "ORGANISM", 261, 268], ["sera", "ORGANISM_SUBSTANCE", 269, 273], ["FFAs", "SIMPLE_CHEMICAL", 307, 311], ["patient", "SPECIES", 261, 268], ["The LA-binding pocket", "PROBLEM", 0, 21], ["small molecule inhibitors", "TREATMENT", 81, 106], ["LA mimetics", "TREATMENT", 113, 124], ["metabolomic study", "TEST", 231, 248], ["COVID", "TEST", 252, 257], ["patient sera", "TEST", 261, 273], ["continuous decrease of FFAs", "PROBLEM", 284, 311], ["binding pocket", "OBSERVATION", 7, 21], ["small molecule inhibitors", "OBSERVATION", 81, 106], ["closed", "OBSERVATION", 178, 184]]], ["Lipid metabolome remodeling is a common element of 10 viral infection (27, 28) , including by the baculovirus (29) used here to express S. For coronaviruses, the LA to arachidonic acid (AA) metabolic pathway was identified as the epicentre of lipid remodeling (9) .", [["viral infection", "DISEASE", 54, 69], ["LA", "CHEMICAL", 162, 164], ["arachidonic acid", "CHEMICAL", 168, 184], ["AA", "CHEMICAL", 186, 188], ["arachidonic acid", "CHEMICAL", 168, 184], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["baculovirus", "ORGANISM", 98, 109], ["coronaviruses", "ORGANISM", 143, 156], ["LA", "SIMPLE_CHEMICAL", 162, 164], ["arachidonic acid", "SIMPLE_CHEMICAL", 168, 184], ["AA", "SIMPLE_CHEMICAL", 186, 188], ["lipid", "SIMPLE_CHEMICAL", 243, 248], ["baculovirus", "SPECIES", 98, 109], ["Lipid metabolome remodeling", "PROBLEM", 0, 27], ["10 viral infection", "PROBLEM", 51, 69], ["the baculovirus", "TEST", 94, 109], ["coronaviruses", "PROBLEM", 143, 156], ["the LA to arachidonic acid (AA) metabolic pathway", "PROBLEM", 158, 207], ["lipid remodeling", "TREATMENT", 243, 259], ["metabolome remodeling", "OBSERVATION", 6, 27], ["common element", "OBSERVATION_MODIFIER", 33, 47], ["viral", "OBSERVATION_MODIFIER", 54, 59], ["infection", "OBSERVATION", 60, 69], ["lipid remodeling", "OBSERVATION", 243, 259]]], ["Interestingly, exogenous supplement of LA or AA suppressed virus replication (9) .", [["LA", "CHEMICAL", 39, 41], ["AA", "CHEMICAL", 45, 47], ["LA", "SIMPLE_CHEMICAL", 39, 41], ["AA", "SIMPLE_CHEMICAL", 45, 47], ["AA suppressed virus replication", "TREATMENT", 45, 76]]], ["It is remarkable in this context that the S trimer of SARS-CoV-2 binds LA with astonishing specificity, and we consider it highly unlikely that this is mere coincidence.", [["SARS", "DISEASE", 54, 58], ["LA", "CHEMICAL", 71, 73], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["LA", "GENE_OR_GENE_PRODUCT", 71, 73], ["S trimer", "PROTEIN", 42, 50]]], ["15 Virus-induced lipid metabolome remodeling alters three separate processes in cells (9, 27, 28) : (i) energy homeostasis via changes in catabolic and anabolic precursor equilibria; (ii) fluidity and elasticity of biological membranes, via changes in e.g. saturated/unsaturated fatty acid ratio in phospholipids; and (iii) cell signaling, via changes in levels of lipid-based cell signaling precursors.", [["cells", "ANATOMY", 80, 85], ["membranes", "ANATOMY", 226, 235], ["cell", "ANATOMY", 324, 328], ["cell", "ANATOMY", 377, 381], ["fatty acid", "CHEMICAL", 279, 289], ["unsaturated fatty acid", "CHEMICAL", 267, 289], ["Virus", "ORGANISM", 3, 8], ["lipid", "SIMPLE_CHEMICAL", 17, 22], ["cells", "CELL", 80, 85], ["membranes", "CELLULAR_COMPONENT", 226, 235], ["unsaturated fatty acid", "SIMPLE_CHEMICAL", 267, 289], ["phospholipids", "SIMPLE_CHEMICAL", 299, 312], ["cell", "CELL", 324, 328], ["lipid", "SIMPLE_CHEMICAL", 365, 370], ["cell", "CELL", 377, 381], ["15 Virus", "PROBLEM", 0, 8], ["lipid metabolome remodeling", "PROBLEM", 17, 44], ["energy homeostasis via changes in catabolic and anabolic precursor equilibria", "PROBLEM", 104, 181], ["elasticity of biological membranes", "PROBLEM", 201, 235], ["e.g. saturated/unsaturated fatty acid ratio", "TEST", 252, 295], ["phospholipids", "TEST", 299, 312], ["cell signaling", "TEST", 324, 338], ["lipid", "TEST", 365, 370], ["lipid metabolome", "OBSERVATION", 17, 33], ["biological membranes", "OBSERVATION", 215, 235], ["cell", "OBSERVATION", 377, 381], ["signaling precursors", "OBSERVATION", 382, 402]]], ["By SARS-CoV-2, significant changes in cell signaling are anticipated due to LA to 20 AA metabolome remodeling, since the LA biosynthetic pathway leads to eicosanoids, which are prominent signaling molecules involved in inflammatory processes (30) .", [["cell", "ANATOMY", 38, 42], ["LA", "CHEMICAL", 76, 78], ["AA", "CHEMICAL", 85, 87], ["LA", "CHEMICAL", 121, 123], ["eicosanoids", "CHEMICAL", 154, 165], ["eicosanoids", "CHEMICAL", 154, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 3, 13], ["cell", "CELL", 38, 42], ["LA", "SIMPLE_CHEMICAL", 121, 123], ["signaling molecules", "PROTEIN", 187, 206], ["CoV", "TEST", 8, 11], ["significant changes in cell signaling", "PROBLEM", 15, 52], ["LA to 20 AA metabolome remodeling", "PROBLEM", 76, 109], ["prominent signaling molecules", "PROBLEM", 177, 206], ["inflammatory processes", "PROBLEM", 219, 241], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["cell signaling", "OBSERVATION", 38, 52], ["remodeling", "OBSERVATION", 99, 109], ["eicosanoids", "OBSERVATION_MODIFIER", 154, 165], ["prominent", "OBSERVATION_MODIFIER", 177, 186], ["signaling molecules", "OBSERVATION", 187, 206], ["inflammatory", "OBSERVATION_MODIFIER", 219, 231]]], ["LA itself is detected by FFA receptor GPR40/FFAR1 (31) .", [["LA", "CHEMICAL", 0, 2], ["LA", "SIMPLE_CHEMICAL", 0, 2], ["FFA", "SIMPLE_CHEMICAL", 25, 28], ["GPR40", "GENE_OR_GENE_PRODUCT", 38, 43], ["FFAR1 (31)", "GENE_OR_GENE_PRODUCT", 44, 54], ["FFA receptor", "PROTEIN", 25, 37], ["GPR40", "PROTEIN", 38, 43], ["FFAR1 (31)", "PROTEIN", 44, 54]]], ["GPR40-mediated FFA signaling is a powerful mediator of 9 inflammation in human tissues and in animal models (32) .", [["tissues", "ANATOMY", 79, 86], ["FFA", "CHEMICAL", 15, 18], ["inflammation", "DISEASE", 57, 69], ["GPR40", "GENE_OR_GENE_PRODUCT", 0, 5], ["FFA", "SIMPLE_CHEMICAL", 15, 18], ["human", "ORGANISM", 73, 78], ["tissues", "TISSUE", 79, 86], ["GPR40", "PROTEIN", 0, 5], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["GPR40", "TEST", 0, 5], ["9 inflammation in human tissues", "PROBLEM", 55, 86], ["inflammation", "OBSERVATION", 57, 69], ["human tissues", "ANATOMY", 73, 86]]], ["Regarding the potential impact of LA pathway remodeling on fluidity and elasticity of biological membranes, we note that the FFA composition of phospholipid bilayers is a key element in maintaining surface tension in lungs, and alteration of LA pathway lipid composition is observed in acute respiratory distress syndrome and severe pneumonia (33) , both of which are key symptoms of SARS-CoV-2 5 infection.Main Text:The present study reveals that SARS-CoV-2 comprises a FFA-binding pocket that specifically accretes LA, and suggests that this could be a feature shared with SARS-CoV and MERS-CoV.Main Text:The high affinity, high specificity LA scavenger function conveyed by our results could confer a tissue-independent mechanism by which pathogenic coronavirus infection drives immune (19)); MERS CoV (forest green, grey, PDBID 5X5F (19)) and OC43 RBDs (olive, grey PDBID 6NZK, (18)).", [["membranes", "ANATOMY", 97, 106], ["phospholipid bilayers", "ANATOMY", 144, 165], ["surface", "ANATOMY", 198, 205], ["lungs", "ANATOMY", 217, 222], ["respiratory", "ANATOMY", 292, 303], ["tissue", "ANATOMY", 704, 710], ["LA", "CHEMICAL", 34, 36], ["FFA", "CHEMICAL", 125, 128], ["LA", "CHEMICAL", 242, 244], ["acute respiratory distress syndrome", "DISEASE", 286, 321], ["pneumonia", "DISEASE", 333, 342], ["SARS", "DISEASE", 384, 388], ["infection", "DISEASE", 397, 406], ["SARS", "DISEASE", 448, 452], ["FFA", "CHEMICAL", 471, 474], ["LA", "CHEMICAL", 517, 519], ["LA", "CHEMICAL", 643, 645], ["coronavirus infection", "DISEASE", 753, 774], ["LA", "SIMPLE_CHEMICAL", 34, 36], ["membranes", "CELLULAR_COMPONENT", 97, 106], ["FFA", "SIMPLE_CHEMICAL", 125, 128], ["phospholipid bilayers", "SIMPLE_CHEMICAL", 144, 165], ["surface", "CELLULAR_COMPONENT", 198, 205], ["lungs", "ORGAN", 217, 222], ["LA", "SIMPLE_CHEMICAL", 242, 244], ["lipid", "SIMPLE_CHEMICAL", 253, 258], ["SARS-CoV-2 5", "ORGANISM", 384, 396], ["SARS-CoV-2", "ORGANISM", 448, 458], ["FFA", "SIMPLE_CHEMICAL", 471, 474], ["LA", "PATHOLOGICAL_FORMATION", 517, 519], ["SARS-CoV", "ORGANISM", 575, 583], ["MERS-CoV", "ORGANISM", 588, 596], ["tissue", "TISSUE", 704, 710], ["coronavirus", "ORGANISM", 753, 764], ["olive", "ORGANISM_SUBDIVISION", 858, 863], ["FFA-binding pocket", "PROTEIN", 471, 489], ["SARS-CoV", "SPECIES", 384, 392], ["SARS-CoV", "SPECIES", 448, 456], ["SARS-CoV", "SPECIES", 575, 583], ["MERS-CoV", "SPECIES", 588, 596], ["LA pathway", "PROBLEM", 34, 44], ["the FFA", "TEST", 121, 128], ["phospholipid bilayers", "PROBLEM", 144, 165], ["surface tension in lungs", "PROBLEM", 198, 222], ["LA pathway lipid composition", "PROBLEM", 242, 270], ["acute respiratory distress syndrome", "PROBLEM", 286, 321], ["severe pneumonia", "PROBLEM", 326, 342], ["key symptoms", "PROBLEM", 368, 380], ["SARS", "PROBLEM", 384, 388], ["CoV-2 5 infection", "PROBLEM", 389, 406], ["The present study", "TEST", 417, 434], ["SARS", "TEST", 448, 452], ["a FFA-binding pocket", "PROBLEM", 469, 489], ["SARS", "PROBLEM", 575, 579], ["The high affinity", "PROBLEM", 607, 624], ["pathogenic coronavirus infection", "PROBLEM", 742, 774], ["MERS CoV", "TEST", 796, 804], ["remodeling", "OBSERVATION", 45, 55], ["biological membranes", "OBSERVATION", 86, 106], ["phospholipid bilayers", "OBSERVATION", 144, 165], ["surface tension", "OBSERVATION", 198, 213], ["lungs", "ANATOMY", 217, 222], ["acute", "OBSERVATION_MODIFIER", 286, 291], ["respiratory distress", "OBSERVATION", 292, 312], ["severe", "OBSERVATION_MODIFIER", 326, 332], ["pneumonia", "OBSERVATION", 333, 342], ["high affinity", "OBSERVATION_MODIFIER", 611, 624]]], ["(F) HKU1 RBD (brown, PDBID 5GNB (23)) and RBD from LA-bound SARS-CoV-2 S (cyan).", [["LA", "CHEMICAL", 51, 53], ["HKU1 RBD", "PROTEIN", 4, 12], ["RBD", "PROTEIN", 42, 45], ["LA", "PROTEIN", 51, 53], ["RBD", "TEST", 9, 12], ["PDBID", "TEST", 21, 26], ["RBD", "PROBLEM", 42, 45], ["LA", "TEST", 51, 53], ["bound SARS", "TEST", 54, 64], ["CoV", "TEST", 65, 68]]]], "e415f01a5727149973f0431136ec1f21464e028b": [["The novel coronavirus outbreak in mainland China has rapidly spread across the globe.", [["coronavirus", "DISEASE", 10, 21], ["coronavirus", "ORGANISM", 10, 21], ["coronavirus", "SPECIES", 10, 21], ["The novel coronavirus outbreak", "PROBLEM", 0, 30], ["coronavirus", "OBSERVATION_MODIFIER", 10, 21], ["outbreak", "OBSERVATION_MODIFIER", 22, 30], ["mainland", "ANATOMY_MODIFIER", 34, 42], ["rapidly", "OBSERVATION_MODIFIER", 53, 60], ["spread", "OBSERVATION_MODIFIER", 61, 67], ["globe", "ANATOMY", 79, 84]]], ["Within 2 mo since the outbreak was first reported on December 31, 2019, a total of 566 Severe Acute Respiratory Syndrome (SARS CoV-2) cases have been confirmed in 26 other countries.", [["Acute Respiratory Syndrome", "DISEASE", 94, 120], ["SARS", "DISEASE", 122, 126], ["Severe Acute Respiratory Syndrome (SARS CoV-2", "SPECIES", 87, 132], ["Severe Acute Respiratory Syndrome", "PROBLEM", 87, 120], ["SARS CoV", "TEST", 122, 130], ["Severe", "OBSERVATION_MODIFIER", 87, 93], ["Acute", "OBSERVATION_MODIFIER", 94, 99], ["Respiratory Syndrome", "OBSERVATION", 100, 120]]], ["Travel restrictions and border control measures have been enforced in China and other countries to limit the spread of the outbreak.", [["Travel restrictions", "TREATMENT", 0, 19], ["border control measures", "TREATMENT", 24, 47]]], ["We estimate the impact of these control measures and investigate the role of the airport travel network on the global spread of the COVID-19 outbreak.", [["these control measures", "TREATMENT", 26, 48], ["the COVID", "TEST", 128, 137]]], ["Our results show that the daily risk of exporting at least a single SARS CoV-2 case from mainland China via international travel exceeded 95% on January 13, 2020.", [["SARS", "DISEASE", 68, 72]]], ["We found that 779 cases (95% CI: 632 to 967) would have been exported by February 15, 2020 without any border or travel restrictions and that the travel lockdowns enforced by the Chinese government averted 70.5% (95% CI: 68.8 to 72.0%) of these cases.", [["CI", "TEST", 29, 31], ["CI", "TEST", 217, 219]]], ["In addition, during the first three and a half weeks of implementation, the travel restrictions decreased the daily rate of exportation by 81.3% (95% CI: 80.5 to 82.1%), on average.", [["CI", "TEST", 150, 152]]], ["At this early stage of the epidemic, reduction in the rate of exportation could delay the importation of cases into cities unaffected by the COVID-19 outbreak, buying time to coordinate an appropriate public health response.", [["the epidemic", "PROBLEM", 23, 35], ["the COVID", "TEST", 137, 146], ["epidemic", "OBSERVATION_MODIFIER", 27, 35], ["reduction", "OBSERVATION_MODIFIER", 37, 46]]]], "PMC6384061": [["INTRODUCTIONThe complicated multicellular epithelial surfaces of the intestine contain the primary sites of infection for many gastrointestinal (GI) pathogens and the interfaces for interactions with microorganisms (1, 2).", [["multicellular epithelial surfaces", "ANATOMY", 28, 61], ["intestine", "ANATOMY", 69, 78], ["sites", "ANATOMY", 99, 104], ["gastrointestinal", "ANATOMY", 127, 143], ["infection", "DISEASE", 108, 117], ["gastrointestinal (GI) pathogens", "DISEASE", 127, 158], ["multicellular epithelial surfaces", "TISSUE", 28, 61], ["intestine", "ORGAN", 69, 78], ["gastrointestinal", "ANATOMICAL_SYSTEM", 127, 143], ["The complicated multicellular epithelial surfaces of the intestine", "PROBLEM", 12, 78], ["infection", "PROBLEM", 108, 117], ["many gastrointestinal (GI) pathogens", "PROBLEM", 122, 158], ["microorganisms", "PROBLEM", 200, 214], ["complicated", "OBSERVATION_MODIFIER", 16, 27], ["multicellular epithelial surfaces", "OBSERVATION", 28, 61], ["intestine", "ANATOMY", 69, 78], ["primary", "OBSERVATION_MODIFIER", 91, 98], ["infection", "OBSERVATION", 108, 117], ["gastrointestinal", "ANATOMY", 127, 143]]], ["However, fundamental knowledge of intestinal epithelial cell (IEC)-pathogen interactions in pigs is limited due to the lack of a reliable in vitro model that recapitulates the complicated intestinal epithelium in vivo.", [["intestinal epithelial cell", "ANATOMY", 34, 60], ["IEC", "ANATOMY", 62, 65], ["intestinal epithelium", "ANATOMY", 188, 209], ["intestinal epithelial cell", "CELL", 34, 60], ["IEC", "CELL", 62, 65], ["pigs", "ORGANISM", 92, 96], ["intestinal epithelium", "TISSUE", 188, 209], ["intestinal epithelial cell", "CELL_TYPE", 34, 60], ["pigs", "SPECIES", 92, 96], ["pigs", "SPECIES", 92, 96], ["intestinal epithelial cell", "PROBLEM", 34, 60], ["pathogen interactions", "PROBLEM", 67, 88], ["the complicated intestinal epithelium", "PROBLEM", 172, 209], ["intestinal", "ANATOMY", 34, 44], ["epithelial cell", "OBSERVATION", 45, 60], ["intestinal epithelium", "ANATOMY", 188, 209]]], ["The intestinal epithelium is composed of villi and crypts, and the self-renewing and undifferentiated stem cells in the crypt zone are responsible for the renewal of an entire unit (3, 4).", [["intestinal epithelium", "ANATOMY", 4, 25], ["villi", "ANATOMY", 41, 46], ["crypts", "ANATOMY", 51, 57], ["stem cells", "ANATOMY", 102, 112], ["crypt zone", "ANATOMY", 120, 130], ["intestinal epithelium", "TISSUE", 4, 25], ["villi", "MULTI-TISSUE_STRUCTURE", 41, 46], ["crypts", "MULTI-TISSUE_STRUCTURE", 51, 57], ["stem cells", "CELL", 102, 112], ["crypt zone", "TISSUE", 120, 130], ["self-renewing and undifferentiated stem cells", "CELL_TYPE", 67, 112], ["villi and crypts", "PROBLEM", 41, 57], ["intestinal epithelium", "ANATOMY", 4, 25], ["villi", "ANATOMY", 41, 46], ["crypts", "OBSERVATION_MODIFIER", 51, 57], ["undifferentiated stem cells", "OBSERVATION", 85, 112], ["crypt", "ANATOMY", 120, 125], ["zone", "ANATOMY_MODIFIER", 126, 130], ["responsible for", "UNCERTAINTY", 135, 150], ["entire", "OBSERVATION_MODIFIER", 169, 175]]], ["Unlike the classical in vitro models of transformed cancer cell lines, enteroids derived from intestinal crypts contain a stem cell niche and diverse highly polarized intestinal epithelial cell types (enterocytes, goblets, enteroendocrine cells, and Paneth cells); thus, these enteroids well mimic the diverse cellular nature and physiological activity of the intestine in vivo and represent a new in vitro model of infection of the intestinal epithelium by enteric pathogens (5\u20137).", [["cancer cell lines", "ANATOMY", 52, 69], ["enteroids", "ANATOMY", 71, 80], ["intestinal crypts", "ANATOMY", 94, 111], ["stem cell niche", "ANATOMY", 122, 137], ["intestinal epithelial cell", "ANATOMY", 167, 193], ["enterocytes", "ANATOMY", 201, 212], ["goblets", "ANATOMY", 214, 221], ["enteroendocrine cells", "ANATOMY", 223, 244], ["Paneth cells", "ANATOMY", 250, 262], ["cellular", "ANATOMY", 310, 318], ["intestine", "ANATOMY", 360, 369], ["intestinal epithelium", "ANATOMY", 433, 454], ["cancer", "DISEASE", 52, 58], ["infection", "DISEASE", 416, 425], ["cancer cell lines", "CELL", 52, 69], ["enteroids", "CELL", 71, 80], ["intestinal crypts", "MULTI-TISSUE_STRUCTURE", 94, 111], ["stem cell", "CELL", 122, 131], ["intestinal epithelial cell types", "CELL", 167, 199], ["enterocytes", "CELL", 201, 212], ["goblets", "CELL", 214, 221], ["enteroendocrine cells", "CELL", 223, 244], ["Paneth cells", "CELL", 250, 262], ["cellular", "CELL", 310, 318], ["intestine", "ORGAN", 360, 369], ["intestinal epithelium", "TISSUE", 433, 454], ["transformed cancer cell lines", "CELL_LINE", 40, 69], ["stem cell niche", "CELL_TYPE", 122, 137], ["intestinal epithelial cell types", "CELL_TYPE", 167, 199], ["enterocytes", "CELL_TYPE", 201, 212], ["goblets", "CELL_TYPE", 214, 221], ["enteroendocrine cells", "CELL_TYPE", 223, 244], ["Paneth cells", "CELL_TYPE", 250, 262], ["transformed cancer cell lines", "PROBLEM", 40, 69], ["enteroids", "PROBLEM", 71, 80], ["intestinal crypts", "PROBLEM", 94, 111], ["a stem cell niche", "PROBLEM", 120, 137], ["diverse highly polarized intestinal epithelial cell types", "PROBLEM", 142, 199], ["Paneth cells", "PROBLEM", 250, 262], ["these enteroids", "PROBLEM", 271, 286], ["infection of the intestinal epithelium", "PROBLEM", 416, 454], ["cancer cell lines", "OBSERVATION", 52, 69], ["intestinal crypts", "ANATOMY", 94, 111], ["stem cell niche", "OBSERVATION", 122, 137], ["diverse", "OBSERVATION_MODIFIER", 142, 149], ["highly", "OBSERVATION_MODIFIER", 150, 156], ["polarized", "OBSERVATION_MODIFIER", 157, 166], ["intestinal epithelial cell types", "OBSERVATION", 167, 199], ["enterocytes", "ANATOMY", 201, 212], ["Paneth cells", "OBSERVATION", 250, 262], ["diverse", "OBSERVATION_MODIFIER", 302, 309], ["cellular nature", "OBSERVATION", 310, 325], ["physiological activity", "OBSERVATION", 330, 352], ["intestine", "ANATOMY", 360, 369], ["new", "OBSERVATION_MODIFIER", 394, 397], ["infection", "OBSERVATION", 416, 425], ["intestinal epithelium", "ANATOMY", 433, 454], ["enteric", "OBSERVATION_MODIFIER", 458, 465], ["pathogens", "OBSERVATION", 466, 475]]], ["Intestinal enteroids maintain the unique characteristics of the tissue from which they are derived and recapitulate many of the biological and physiological properties of the small intestine in vivo (4, 6, 8).", [["Intestinal enteroids", "ANATOMY", 0, 20], ["tissue", "ANATOMY", 64, 70], ["small intestine", "ANATOMY", 175, 190], ["Intestinal enteroids", "CANCER", 0, 20], ["tissue", "TISSUE", 64, 70], ["small intestine", "ORGAN", 175, 190], ["Intestinal enteroids", "PROBLEM", 0, 20], ["tissue", "OBSERVATION", 64, 70], ["small intestine", "ANATOMY", 175, 190]]], ["As a result, since rodent and human intestinal enteroids were first reported in 2009 and in 2010, respectively, intestinal enteroids have been applied in enteric infection research and have yielded exciting new insights into a variety of aspects of host-virus interactions in the GI tract (4, 7, 9\u201311).", [["intestinal enteroids", "ANATOMY", 36, 56], ["intestinal enteroids", "ANATOMY", 112, 132], ["GI tract", "ANATOMY", 280, 288], ["enteric infection", "DISEASE", 154, 171], ["rodent", "ORGANISM", 19, 25], ["human", "ORGANISM", 30, 35], ["intestinal enteroids", "CANCER", 36, 56], ["intestinal enteroids", "CANCER", 112, 132], ["host-virus", "ORGANISM", 249, 259], ["GI tract", "ORGANISM_SUBDIVISION", 280, 288], ["rodent", "SPECIES", 19, 25], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["human intestinal enteroids", "PROBLEM", 30, 56], ["intestinal enteroids", "TREATMENT", 112, 132], ["host-virus interactions", "TREATMENT", 249, 272], ["intestinal", "ANATOMY", 36, 46], ["intestinal", "ANATOMY", 112, 122], ["enteric", "OBSERVATION_MODIFIER", 154, 161], ["infection", "OBSERVATION", 162, 171], ["virus", "OBSERVATION", 254, 259], ["GI tract", "ANATOMY", 280, 288]]], ["However, enteric infection in porcine intestinal enteroids has not yet been reported.INTRODUCTIONPorcine epidemic diarrhea virus (PEDV), a member of the alphacoronavirus genus in the family Coronaviridae, is the foremost causative agent of acute diarrhea, dehydration, and high mortality rates in seronegative neonatal piglets, which result in substantial economic losses each year (12, 13).", [["intestinal enteroids", "ANATOMY", 38, 58], ["enteric infection", "DISEASE", 9, 26], ["diarrhea", "DISEASE", 114, 122], ["diarrhea", "DISEASE", 246, 254], ["dehydration", "DISEASE", 256, 267], ["porcine", "ORGANISM", 30, 37], ["intestinal", "ORGAN", 38, 48], ["INTRODUCTIONPorcine epidemic diarrhea virus", "ORGANISM", 85, 128], ["alphacoronavirus genus", "ORGANISM", 153, 175], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 190, 203], ["piglets", "ORGANISM", 319, 326], ["porcine", "SPECIES", 30, 37], ["diarrhea virus", "SPECIES", 114, 128], ["piglets", "SPECIES", 319, 326], ["porcine", "SPECIES", 30, 37], ["INTRODUCTIONPorcine epidemic diarrhea virus", "SPECIES", 85, 128], ["PEDV", "SPECIES", 130, 134], ["enteric infection in porcine intestinal enteroids", "PROBLEM", 9, 58], ["INTRODUCTIONPorcine epidemic diarrhea virus", "PROBLEM", 85, 128], ["PEDV", "PROBLEM", 130, 134], ["acute diarrhea", "PROBLEM", 240, 254], ["dehydration", "PROBLEM", 256, 267], ["high mortality rates", "PROBLEM", 273, 293], ["seronegative neonatal piglets", "PROBLEM", 297, 326], ["substantial economic losses", "PROBLEM", 344, 371], ["enteric", "OBSERVATION_MODIFIER", 9, 16], ["infection", "OBSERVATION", 17, 26], ["intestinal", "ANATOMY", 38, 48], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["diarrhea", "OBSERVATION", 246, 254], ["high", "OBSERVATION_MODIFIER", 273, 277], ["seronegative neonatal piglets", "OBSERVATION", 297, 326], ["substantial", "OBSERVATION_MODIFIER", 344, 355], ["economic", "OBSERVATION_MODIFIER", 356, 364], ["losses", "OBSERVATION_MODIFIER", 365, 371]]], ["PEDV is highly enteropathogenic, primarily infects the villous epithelia of the small intestine, blunts the affected villi, and disrupts mucosal barrier integrity in vivo (14, 15).", [["villous epithelia", "ANATOMY", 55, 72], ["small intestine", "ANATOMY", 80, 95], ["villi", "ANATOMY", 117, 122], ["mucosal barrier", "ANATOMY", 137, 152], ["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["villous epithelia", "TISSUE", 55, 72], ["small intestine", "ORGAN", 80, 95], ["villi", "MULTI-TISSUE_STRUCTURE", 117, 122], ["mucosal barrier", "TISSUE", 137, 152], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["blunts the affected villi", "PROBLEM", 97, 122], ["highly", "OBSERVATION_MODIFIER", 8, 14], ["enteropathogenic", "OBSERVATION", 15, 31], ["villous", "ANATOMY_MODIFIER", 55, 62], ["epithelia", "ANATOMY_MODIFIER", 63, 72], ["small intestine", "ANATOMY", 80, 95], ["affected villi", "ANATOMY", 108, 122], ["mucosal", "OBSERVATION_MODIFIER", 137, 144], ["barrier", "OBSERVATION_MODIFIER", 145, 152], ["integrity", "OBSERVATION_MODIFIER", 153, 162]]], ["The identity of the specific cell types targeted (enterocytes, goblet cells, Paneth cells, microfold cells, tuft cells, or stem cells) by PEDV infection in vivo has remained elusive.", [["cell", "ANATOMY", 29, 33], ["enterocytes", "ANATOMY", 50, 61], ["goblet cells", "ANATOMY", 63, 75], ["Paneth cells", "ANATOMY", 77, 89], ["microfold cells", "ANATOMY", 91, 106], ["tuft cells", "ANATOMY", 108, 118], ["stem cells", "ANATOMY", 123, 133], ["infection", "DISEASE", 143, 152], ["cell", "CELL", 29, 33], ["enterocytes", "CELL", 50, 61], ["goblet cells", "CELL", 63, 75], ["Paneth cells", "CELL", 77, 89], ["microfold cells", "CELL", 91, 106], ["tuft cells", "CELL", 108, 118], ["stem cells", "CELL", 123, 133], ["PEDV", "GENE_OR_GENE_PRODUCT", 138, 142], ["enterocytes", "CELL_TYPE", 50, 61], ["goblet cells", "CELL_TYPE", 63, 75], ["Paneth cells", "CELL_TYPE", 77, 89], ["microfold cells", "CELL_TYPE", 91, 106], ["tuft cells", "CELL_TYPE", 108, 118], ["stem cells", "CELL_TYPE", 123, 133], ["PEDV", "SPECIES", 138, 142], ["the specific cell types", "TEST", 16, 39], ["goblet cells", "TEST", 63, 75], ["Paneth cells", "TEST", 77, 89], ["microfold cells", "TEST", 91, 106], ["tuft cells", "PROBLEM", 108, 118], ["stem cells", "PROBLEM", 123, 133], ["PEDV infection", "PROBLEM", 138, 152], ["specific cell types", "OBSERVATION", 20, 39], ["enterocytes", "ANATOMY", 50, 61], ["stem cells", "OBSERVATION", 123, 133], ["infection", "OBSERVATION", 143, 152]]], ["However, most in vitro studies of PEDV have been performed in nonporcine cell lines, such as Vero cells from African green monkey kidney and HEK293 cells from human embryonic kidney (16\u201318).", [["cell lines", "ANATOMY", 73, 83], ["Vero cells", "ANATOMY", 93, 103], ["kidney", "ANATOMY", 130, 136], ["HEK293 cells", "ANATOMY", 141, 153], ["embryonic kidney", "ANATOMY", 165, 181], ["PEDV", "CHEMICAL", 34, 38], ["PEDV", "SIMPLE_CHEMICAL", 34, 38], ["nonporcine cell lines", "CELL", 62, 83], ["Vero cells", "CELL", 93, 103], ["green monkey kidney", "ORGANISM", 117, 136], ["HEK293 cells", "CELL", 141, 153], ["human", "ORGANISM", 159, 164], ["embryonic", "CANCER", 165, 174], ["kidney", "ORGAN", 175, 181], ["PEDV", "PROTEIN", 34, 38], ["nonporcine cell lines", "CELL_LINE", 62, 83], ["Vero cells", "CELL_LINE", 93, 103], ["HEK293 cells", "CELL_LINE", 141, 153], ["green monkey", "SPECIES", 117, 129], ["human", "SPECIES", 159, 164], ["PEDV", "SPECIES", 34, 38], ["African green monkey", "SPECIES", 109, 129], ["human", "SPECIES", 159, 164], ["vitro studies", "TEST", 17, 30], ["PEDV", "PROBLEM", 34, 38], ["nonporcine cell lines", "TREATMENT", 62, 83], ["Vero cells", "TEST", 93, 103], ["HEK293 cells", "TEST", 141, 153], ["human embryonic kidney", "TEST", 159, 181], ["cell lines", "OBSERVATION", 73, 83], ["kidney", "ANATOMY", 130, 136], ["HEK293 cells", "OBSERVATION", 141, 153], ["embryonic", "ANATOMY_MODIFIER", 165, 174], ["kidney", "ANATOMY", 175, 181]]], ["Unlike normal mammalian cells, Vero cells are interferon (IFN)-deficient cells that are incapable of producing type I interferons when infected by viruses (19).", [["cells", "ANATOMY", 24, 29], ["Vero cells", "ANATOMY", 31, 41], ["cells", "ANATOMY", 73, 78], ["normal mammalian cells", "CELL", 7, 29], ["Vero cells", "CELL", 31, 41], ["interferon (IFN)", "GENE_OR_GENE_PRODUCT", 46, 62], ["cells", "CELL", 73, 78], ["type I interferons", "GENE_OR_GENE_PRODUCT", 111, 129], ["normal mammalian cells", "CELL_TYPE", 7, 29], ["Vero cells", "CELL_LINE", 31, 41], ["interferon (IFN)-deficient cells", "CELL_LINE", 46, 78], ["type I interferons", "PROTEIN", 111, 129], ["Vero cells", "PROBLEM", 31, 41], ["interferon (IFN)", "TREATMENT", 46, 62], ["deficient cells", "PROBLEM", 63, 78], ["type I interferons", "PROBLEM", 111, 129], ["mammalian cells", "OBSERVATION", 14, 29], ["Vero cells", "OBSERVATION", 31, 41]]], ["IPEC-J2 cells, a nontransformed porcine jejunum epithelial cell line from nonsuckling piglets (20), do not mimic the in vivo complicated epithelia, and PEDV clinical isolates generally do not replicate very well in porcine nontransformed epithelial cells such as IPEC-J2 cells (21, 22).", [["IPEC-J2 cells", "ANATOMY", 0, 13], ["jejunum epithelial cell line", "ANATOMY", 40, 68], ["epithelia", "ANATOMY", 137, 146], ["epithelial cells", "ANATOMY", 238, 254], ["IPEC-J2 cells", "ANATOMY", 263, 276], ["IPEC-J2 cells", "CELL", 0, 13], ["porcine", "ORGANISM", 32, 39], ["jejunum epithelial cell line", "CELL", 40, 68], ["piglets", "ORGANISM", 86, 93], ["epithelia", "TISSUE", 137, 146], ["porcine", "ORGANISM", 215, 222], ["nontransformed epithelial cells", "CELL", 223, 254], ["IPEC-J2 cells", "CELL", 263, 276], ["IPEC-J2 cells", "CELL_LINE", 0, 13], ["nontransformed porcine jejunum epithelial cell line", "CELL_LINE", 17, 68], ["porcine nontransformed epithelial cells", "CELL_TYPE", 215, 254], ["IPEC-J2 cells", "CELL_LINE", 263, 276], ["porcine", "SPECIES", 32, 39], ["piglets", "SPECIES", 86, 93], ["porcine", "SPECIES", 215, 222], ["PEDV", "SPECIES", 152, 156], ["porcine", "SPECIES", 215, 222], ["IPEC", "TEST", 0, 4], ["J2 cells", "PROBLEM", 5, 13], ["a nontransformed porcine jejunum epithelial cell line", "TREATMENT", 15, 68], ["PEDV clinical isolates", "PROBLEM", 152, 174], ["IPEC-J2 cells", "TEST", 263, 276], ["J2 cells", "OBSERVATION", 5, 13], ["porcine", "ANATOMY_MODIFIER", 32, 39], ["jejunum", "ANATOMY", 40, 47], ["epithelial cell line", "OBSERVATION", 48, 68], ["nontransformed epithelial cells", "OBSERVATION", 223, 254], ["J2 cells", "OBSERVATION", 268, 276]]], ["The absence of a robust experimental in vitro system that can recapitulate the in vivo PEDV infection process is a bottleneck hampering the investigation of PEDV pathogenesis and the development of novel rational strategies against PEDV infection.", [["infection", "DISEASE", 92, 101], ["PEDV infection", "DISEASE", 232, 246], ["PEDV", "GENE_OR_GENE_PRODUCT", 157, 161], ["PEDV", "ORGANISM", 232, 236], ["PEDV", "SPECIES", 87, 91], ["PEDV", "SPECIES", 157, 161], ["PEDV", "SPECIES", 232, 236], ["a robust experimental in vitro system", "PROBLEM", 15, 52], ["PEDV infection process", "PROBLEM", 87, 109], ["PEDV pathogenesis", "PROBLEM", 157, 174], ["novel rational strategies", "TREATMENT", 198, 223], ["PEDV infection", "PROBLEM", 232, 246], ["infection", "OBSERVATION", 92, 101], ["infection", "OBSERVATION", 237, 246]]], ["Therefore, the development of in vitro models that can closely recapitulate the porcine intestine is crucial for expanding the current knowledge of PEDV pathogenesis and facilitating further biological investigations of host-PEDV interactions.INTRODUCTIONIn the present study, we generated crypt cell-derived enteroids and used this model to study PEDV infection.", [["intestine", "ANATOMY", 88, 97], ["crypt cell", "ANATOMY", 290, 300], ["enteroids", "ANATOMY", 309, 318], ["infection", "DISEASE", 353, 362], ["porcine", "ORGANISM", 80, 87], ["intestine", "ORGAN", 88, 97], ["PEDV", "CANCER", 148, 152], ["PEDV", "GENE_OR_GENE_PRODUCT", 225, 229], ["crypt cell-derived enteroids", "CELL", 290, 318], ["PEDV", "ORGANISM", 348, 352], ["crypt cell-derived enteroids", "CELL_LINE", 290, 318], ["porcine", "SPECIES", 80, 87], ["porcine", "SPECIES", 80, 87], ["PEDV", "SPECIES", 148, 152], ["PEDV", "SPECIES", 348, 352], ["PEDV pathogenesis", "PROBLEM", 148, 165], ["the present study", "TEST", 258, 275], ["crypt cell", "TREATMENT", 290, 300], ["enteroids", "TREATMENT", 309, 318], ["this model", "TREATMENT", 328, 338], ["PEDV infection", "PROBLEM", 348, 362], ["intestine", "ANATOMY", 88, 97], ["crypt cell", "OBSERVATION", 290, 300], ["infection", "OBSERVATION", 353, 362]]], ["The results revealed that porcine enteroids were susceptible to PEDV infection and recapitulated many of the events associated with PEDV infection in porcine intestines in vivo.", [["enteroids", "ANATOMY", 34, 43], ["intestines", "ANATOMY", 158, 168], ["PEDV", "CHEMICAL", 64, 68], ["infection", "DISEASE", 69, 78], ["PEDV", "CHEMICAL", 132, 136], ["infection", "DISEASE", 137, 146], ["porcine", "ORGANISM", 26, 33], ["enteroids", "GENE_OR_GENE_PRODUCT", 34, 43], ["PEDV", "ORGANISM", 64, 68], ["PEDV", "GENE_OR_GENE_PRODUCT", 132, 136], ["porcine", "ORGANISM", 150, 157], ["intestines", "ORGAN", 158, 168], ["porcine", "SPECIES", 26, 33], ["porcine", "SPECIES", 150, 157], ["porcine", "SPECIES", 26, 33], ["PEDV", "SPECIES", 64, 68], ["PEDV", "SPECIES", 132, 136], ["porcine", "SPECIES", 150, 157], ["porcine enteroids", "PROBLEM", 26, 43], ["PEDV infection", "PROBLEM", 64, 78], ["the events", "PROBLEM", 105, 115], ["PEDV infection in porcine intestines", "PROBLEM", 132, 168], ["infection", "OBSERVATION", 69, 78], ["PEDV", "OBSERVATION_MODIFIER", 132, 136], ["infection", "OBSERVATION", 137, 146], ["intestines", "ANATOMY", 158, 168]]], ["Collectively, these data illustrate that porcine enteroids, which recapitulate the key properties of the in vivo intestinal epithelium, provide an invaluable resource for addressing fundamental aspects of enteric coronaviruses that cannot be modeled using traditional cell lines.Generation of porcine intestinal enteroids derived from intestinal crypt stem cells. ::: RESULTSTo closely mimic the events associated with enteric virus infection in the swine intestine, we generated primary porcine enteroid cultures derived from piglet intestinal crypts containing leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5)-positive (Lgr5+) stem cells.", [["enteroids", "ANATOMY", 49, 58], ["intestinal epithelium", "ANATOMY", 113, 134], ["cell lines", "ANATOMY", 268, 278], ["intestinal enteroids", "ANATOMY", 301, 321], ["intestinal crypt stem cells", "ANATOMY", 335, 362], ["intestine", "ANATOMY", 456, 465], ["enteroid cultures", "ANATOMY", 496, 513], ["piglet intestinal crypts", "ANATOMY", 527, 551], ["Lgr5+) stem cells", "ANATOMY", 640, 657], ["enteric virus infection", "DISEASE", 419, 442], ["leucine", "CHEMICAL", 563, 570], ["leucine", "CHEMICAL", 563, 570], ["porcine", "ORGANISM", 41, 48], ["enteroids", "GENE_OR_GENE_PRODUCT", 49, 58], ["intestinal epithelium", "TISSUE", 113, 134], ["enteric coronaviruses", "ORGANISM", 205, 226], ["cell lines", "CELL", 268, 278], ["porcine", "ORGANISM", 293, 300], ["intestinal enteroids", "CELL", 301, 321], ["intestinal crypt stem cells", "CELL", 335, 362], ["enteric virus", "ORGANISM", 419, 432], ["swine", "ORGANISM", 450, 455], ["intestine", "ORGAN", 456, 465], ["porcine", "ORGANISM", 488, 495], ["enteroid cultures", "CELL", 496, 513], ["piglet", "ORGANISM", 527, 533], ["intestinal crypts", "MULTI-TISSUE_STRUCTURE", 534, 551], ["leucine-rich-repeat-containing G-protein-coupled receptor 5", "GENE_OR_GENE_PRODUCT", 563, 622], ["Lgr5", "GENE_OR_GENE_PRODUCT", 624, 628], ["traditional cell lines", "CELL_LINE", 256, 278], ["intestinal crypt stem cells", "CELL_TYPE", 335, 362], ["primary porcine enteroid cultures", "CELL_LINE", 480, 513], ["piglet intestinal crypts", "CELL_TYPE", 527, 551], ["leucine-rich-repeat", "DNA", 563, 582], ["G-protein-coupled receptor 5 (Lgr5)-positive (Lgr5+) stem cells", "CELL_LINE", 594, 657], ["porcine", "SPECIES", 41, 48], ["porcine", "SPECIES", 293, 300], ["swine", "SPECIES", 450, 455], ["porcine", "SPECIES", 488, 495], ["piglet", "SPECIES", 527, 533], ["porcine", "SPECIES", 41, 48], ["porcine", "SPECIES", 293, 300], ["swine", "SPECIES", 450, 455], ["porcine", "SPECIES", 488, 495], ["porcine enteroids", "PROBLEM", 41, 58], ["enteric coronaviruses", "PROBLEM", 205, 226], ["traditional cell lines", "TREATMENT", 256, 278], ["porcine intestinal enteroids", "TREATMENT", 293, 321], ["the events", "PROBLEM", 392, 402], ["enteric virus infection in the swine intestine", "PROBLEM", 419, 465], ["primary porcine enteroid cultures", "TREATMENT", 480, 513], ["piglet intestinal crypts", "PROBLEM", 527, 551], ["leucine", "TEST", 563, 570], ["repeat", "TEST", 576, 582], ["G-protein", "TEST", 594, 603], ["coupled receptor", "TEST", 604, 620], ["Lgr5", "TEST", 624, 628], ["positive (Lgr5+) stem cells", "PROBLEM", 630, 657], ["intestinal epithelium", "ANATOMY", 113, 134], ["enteric coronaviruses", "OBSERVATION", 205, 226], ["cell lines", "OBSERVATION", 268, 278], ["porcine intestinal enteroids", "OBSERVATION", 293, 321], ["intestinal crypt", "ANATOMY", 335, 351], ["stem cells", "OBSERVATION", 352, 362], ["virus", "OBSERVATION", 427, 432], ["intestine", "ANATOMY", 456, 465], ["intestinal crypts", "ANATOMY", 534, 551], ["stem cells", "OBSERVATION", 647, 657]]], ["Crypts from the duodenum, jejunum, or ileum were freshly isolated as described previously, with slight modification, and were cultured in a semisolid, laminin/collagen-rich Matrigel in proliferation medium to allow their differentiation into three-dimensional (3D) enteroids in 7 to 15 days using previously developed methods (4, 11, 23).", [["Crypts", "ANATOMY", 0, 6], ["duodenum", "ANATOMY", 16, 24], ["jejunum", "ANATOMY", 26, 33], ["ileum", "ANATOMY", 38, 43], ["duodenum", "MULTI-TISSUE_STRUCTURE", 16, 24], ["jejunum", "MULTI-TISSUE_STRUCTURE", 26, 33], ["ileum", "ORGAN", 38, 43], ["laminin", "GENE_OR_GENE_PRODUCT", 151, 158], ["collagen", "GENE_OR_GENE_PRODUCT", 159, 167], ["laminin", "PROTEIN", 151, 158], ["collagen", "PROTEIN", 159, 167], ["Crypts from the duodenum, jejunum, or ileum", "PROBLEM", 0, 43], ["a semisolid, laminin/collagen-rich Matrigel in proliferation medium", "TREATMENT", 138, 205], ["3D) enteroids", "TREATMENT", 261, 274], ["duodenum", "ANATOMY", 16, 24], ["jejunum", "ANATOMY", 26, 33], ["ileum", "ANATOMY", 38, 43], ["slight", "OBSERVATION_MODIFIER", 96, 102], ["modification", "OBSERVATION", 103, 115]]], ["After a period of approximately 1 to 2 weeks in Matrigel culture, the intestinal crypt cells proliferated and differentiated into 3D enteroids with a central lumen surrounded by an epithelium containing villus-like structures and budding crypt-like domains, which indicated that the crypt cells from all three small intestine regions could grow into enteroids (Fig. 1A).", [["intestinal crypt cells", "ANATOMY", 70, 92], ["enteroids", "ANATOMY", 133, 142], ["lumen", "ANATOMY", 158, 163], ["epithelium", "ANATOMY", 181, 191], ["villus-like structures", "ANATOMY", 203, 225], ["crypt", "ANATOMY", 238, 243], ["crypt cells", "ANATOMY", 283, 294], ["intestine", "ANATOMY", 316, 325], ["enteroids", "ANATOMY", 350, 359], ["intestinal crypt cells", "CELL", 70, 92], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 163], ["epithelium", "TISSUE", 181, 191], ["villus-like structures", "TISSUE", 203, 225], ["crypt cells", "CELL", 283, 294], ["intestine", "ORGAN", 316, 325], ["Matrigel culture", "CELL_LINE", 48, 64], ["intestinal crypt cells", "CELL_TYPE", 70, 92], ["crypt cells", "CELL_TYPE", 283, 294], ["Matrigel culture", "TEST", 48, 64], ["the intestinal crypt cells", "PROBLEM", 66, 92], ["a central lumen", "TREATMENT", 148, 163], ["an epithelium containing villus-like structures", "PROBLEM", 178, 225], ["budding crypt", "PROBLEM", 230, 243], ["the crypt cells", "PROBLEM", 279, 294], ["intestinal crypt", "ANATOMY", 70, 86], ["cells proliferated", "OBSERVATION", 87, 105], ["central", "ANATOMY_MODIFIER", 150, 157], ["lumen", "ANATOMY_MODIFIER", 158, 163], ["epithelium", "OBSERVATION", 181, 191], ["villus", "ANATOMY", 203, 209], ["budding crypt", "OBSERVATION", 230, 243], ["crypt cells", "OBSERVATION", 283, 294], ["small", "OBSERVATION_MODIFIER", 310, 315], ["intestine", "ANATOMY", 316, 325]]], ["Because most of the reported enteroid studies have been performed using ileal enteroids, we used ileal enteroids as representative intestinal enteroids and performed most of the experiments of the present study using ileal enteroids.", [["ileal enteroids", "ANATOMY", 72, 87], ["ileal enteroids", "ANATOMY", 97, 112], ["intestinal enteroids", "ANATOMY", 131, 151], ["ileal enteroids", "ANATOMY", 217, 232], ["ileal enteroids", "MULTI-TISSUE_STRUCTURE", 72, 87], ["intestinal enteroids", "CANCER", 131, 151], ["ileal enteroids", "CANCER", 217, 232], ["enteroid studies", "TEST", 29, 45], ["ileal enteroids", "TREATMENT", 72, 87], ["ileal enteroids", "TREATMENT", 97, 112], ["representative intestinal enteroids", "PROBLEM", 116, 151], ["the present study", "TEST", 193, 210], ["ileal enteroids", "TREATMENT", 217, 232], ["ileal", "ANATOMY", 72, 77], ["ileal", "ANATOMY", 97, 102], ["intestinal", "ANATOMY", 131, 141], ["ileal", "ANATOMY", 217, 222]]], ["To evaluate whether the differentiated enteroids could be cryopreserved and thawed and whether the resulting thawed cells could differentiate into enteroids, as previously reported, differentiated ileal enteroids were subjected to a freeze-thaw cycle and then differentiated as if they were freshly isolated crypt stem cells.", [["enteroids", "ANATOMY", 39, 48], ["cells", "ANATOMY", 116, 121], ["enteroids", "ANATOMY", 147, 156], ["ileal enteroids", "ANATOMY", 197, 212], ["crypt stem cells", "ANATOMY", 308, 324], ["enteroids", "CELL", 39, 48], ["cells", "CELL", 116, 121], ["ileal enteroids", "CELL", 197, 212], ["crypt stem cells", "CELL", 308, 324], ["freshly isolated crypt stem cells", "CELL_TYPE", 291, 324], ["the differentiated enteroids", "PROBLEM", 20, 48], ["the resulting thawed cells", "PROBLEM", 95, 121], ["differentiated ileal enteroids", "PROBLEM", 182, 212], ["a freeze-thaw cycle", "TREATMENT", 231, 250], ["freshly isolated crypt stem cells", "PROBLEM", 291, 324], ["ileal enteroids", "OBSERVATION", 197, 212], ["crypt stem cells", "OBSERVATION", 308, 324]]], ["The thawed ileal enteroid single cells grew into enteroids in 7 days (Fig. 1B), and thus, we developed a porcine crypt-derived 3D enteroid culture system.Generation of porcine intestinal enteroids derived from intestinal crypt stem cells. ::: RESULTSBecause the apical membrane of the 3D enteroids for viral infection faces the inside of the enteroids, infection of 3D enteroids is challenging.", [["ileal enteroid single cells", "ANATOMY", 11, 38], ["enteroids", "ANATOMY", 49, 58], ["crypt", "ANATOMY", 113, 118], ["intestinal enteroids", "ANATOMY", 176, 196], ["intestinal crypt stem cells", "ANATOMY", 210, 237], ["apical membrane", "ANATOMY", 262, 277], ["enteroids", "ANATOMY", 342, 351], ["viral infection", "DISEASE", 302, 317], ["infection", "DISEASE", 353, 362], ["ileal enteroid single cells", "CELL", 11, 38], ["porcine", "ORGANISM", 105, 112], ["crypt", "CELL", 113, 118], ["porcine", "ORGANISM", 168, 175], ["intestinal enteroids", "CELL", 176, 196], ["intestinal crypt stem cells", "CELL", 210, 237], ["apical membrane", "CELLULAR_COMPONENT", 262, 277], ["enteroids", "CANCER", 342, 351], ["thawed ileal enteroid single cells", "CELL_LINE", 4, 38], ["porcine crypt-derived 3D enteroid culture system", "CELL_LINE", 105, 153], ["intestinal crypt stem cells", "CELL_TYPE", 210, 237], ["porcine", "SPECIES", 168, 175], ["porcine", "SPECIES", 168, 175], ["The thawed ileal enteroid single cells", "TREATMENT", 0, 38], ["a porcine crypt", "PROBLEM", 103, 118], ["3D enteroid culture system", "TEST", 127, 153], ["porcine intestinal enteroids", "TREATMENT", 168, 196], ["viral infection", "PROBLEM", 302, 317], ["the enteroids", "PROBLEM", 338, 351], ["infection of 3D enteroids", "PROBLEM", 353, 378], ["ileal", "ANATOMY", 11, 16], ["porcine crypt", "OBSERVATION", 105, 118], ["porcine intestinal enteroids", "OBSERVATION", 168, 196], ["intestinal crypt", "ANATOMY", 210, 226], ["stem cells", "OBSERVATION", 227, 237], ["apical", "ANATOMY_MODIFIER", 262, 268], ["membrane", "ANATOMY_MODIFIER", 269, 277], ["viral", "OBSERVATION_MODIFIER", 302, 307], ["infection", "OBSERVATION", 308, 317], ["infection", "OBSERVATION", 353, 362]]], ["We thus sought to develop a porcine planar (two-dimensional [2D]) ileal enteroid culture in microplates, which would make them amenable to efficient infection and would allow deciphering of the complex interplay between viruses and epithelial cells.", [["epithelial cells", "ANATOMY", 232, 248], ["infection", "DISEASE", 149, 158], ["epithelial cells", "CELL", 232, 248], ["ileal enteroid culture", "CELL_LINE", 66, 88], ["epithelial cells", "CELL_TYPE", 232, 248], ["a porcine planar (two-dimensional [2D])", "TREATMENT", 26, 65], ["ileal enteroid culture in microplates", "TREATMENT", 66, 103], ["efficient infection", "PROBLEM", 139, 158], ["epithelial cells", "PROBLEM", 232, 248], ["ileal", "ANATOMY", 66, 71], ["infection", "OBSERVATION", 149, 158], ["epithelial cells", "OBSERVATION", 232, 248]]], ["Previous studies demonstrated that dissociated 3D mouse enteroids can generate planar enteroid monolayers with proper apical and basal polarity that largely recapitulate the many features of 3D enteroids and the in vivo intestinal epithelium (23, 24).", [["enteroids", "ANATOMY", 56, 65], ["enteroid monolayers", "ANATOMY", 86, 105], ["apical", "ANATOMY", 118, 124], ["enteroids", "ANATOMY", 194, 203], ["intestinal epithelium", "ANATOMY", 220, 241], ["mouse", "ORGANISM", 50, 55], ["enteroid monolayers", "CELL", 86, 105], ["enteroids", "CANCER", 194, 203], ["intestinal epithelium", "TISSUE", 220, 241], ["dissociated 3D mouse enteroids", "CELL_LINE", 35, 65], ["planar enteroid monolayers", "CELL_LINE", 79, 105], ["mouse", "SPECIES", 50, 55], ["mouse", "SPECIES", 50, 55], ["Previous studies", "TEST", 0, 16], ["dissociated 3D mouse enteroids", "PROBLEM", 35, 65], ["planar enteroid monolayers", "TREATMENT", 79, 105], ["3D enteroids", "PROBLEM", 191, 203], ["apical", "ANATOMY_MODIFIER", 118, 124], ["basal polarity", "OBSERVATION", 129, 143], ["many", "OBSERVATION_MODIFIER", 174, 178], ["3D enteroids", "OBSERVATION", 191, 203], ["intestinal epithelium", "ANATOMY", 220, 241]]], ["The 3D ileal enteroids that were expanded in Matrigel were harvested, mechanically dissociated, and seeded on Matrigel-coated microplates to establish 2D enteroids as described previously (24).", [["ileal enteroids", "ANATOMY", 7, 22], ["ileal enteroids", "CANCER", 7, 22], ["The 3D ileal enteroids", "TREATMENT", 0, 22], ["Matrigel-coated microplates", "TREATMENT", 110, 137], ["2D enteroids", "PROBLEM", 151, 163], ["ileal", "ANATOMY", 7, 12], ["enteroids", "OBSERVATION", 13, 22], ["expanded", "OBSERVATION_MODIFIER", 33, 41], ["Matrigel", "OBSERVATION_MODIFIER", 45, 53]]], ["After expansion and differentiation, the seeded cells grew out as large, contiguous sheets of epithelium with heterogeneity in terms of cell morphology and densities (Fig. 1C).", [["cells", "ANATOMY", 48, 53], ["epithelium", "ANATOMY", 94, 104], ["cell", "ANATOMY", 136, 140], ["cells", "CELL", 48, 53], ["epithelium", "TISSUE", 94, 104], ["cell", "CELL", 136, 140], ["seeded cells", "CELL_LINE", 41, 53], ["the seeded cells", "TEST", 37, 53], ["large, contiguous sheets of epithelium", "PROBLEM", 66, 104], ["expansion", "OBSERVATION_MODIFIER", 6, 15], ["differentiation", "OBSERVATION_MODIFIER", 20, 35], ["seeded cells", "OBSERVATION", 41, 53], ["large", "OBSERVATION_MODIFIER", 66, 71], ["epithelium", "ANATOMY_MODIFIER", 94, 104], ["heterogeneity", "OBSERVATION_MODIFIER", 110, 123], ["terms of cell morphology", "OBSERVATION", 127, 151], ["densities", "OBSERVATION_MODIFIER", 156, 165]]], ["A large number of villin-positive enterocytes were present on the apical surface and throughout the 2D monolayer (Fig. 1D), indicating the presence of mature enterocytes in the enteroids.", [["enterocytes", "ANATOMY", 34, 45], ["apical surface", "ANATOMY", 66, 80], ["2D monolayer", "ANATOMY", 100, 112], ["enterocytes", "ANATOMY", 158, 169], ["enteroids", "ANATOMY", 177, 186], ["villin", "GENE_OR_GENE_PRODUCT", 18, 24], ["apical surface", "CELLULAR_COMPONENT", 66, 80], ["2D monolayer", "CELL", 100, 112], ["enterocytes", "CELL", 158, 169], ["enteroids", "CANCER", 177, 186], ["villin", "PROTEIN", 18, 24], ["mature enterocytes", "CELL_TYPE", 151, 169], ["villin-positive enterocytes", "PROBLEM", 18, 45], ["mature enterocytes in the enteroids", "PROBLEM", 151, 186], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["positive enterocytes", "OBSERVATION", 25, 45], ["apical", "ANATOMY_MODIFIER", 66, 72], ["surface", "ANATOMY_MODIFIER", 73, 80], ["mature enterocytes", "OBSERVATION", 151, 169]]], ["Proliferating cells stained with Ki-67 protein and stem cells (Lgr5+) were present throughout the 2D monolayers, which suggested that our 2D enteroids maintain the features of stem cells and contain the transit-amplifying zone.", [["cells", "ANATOMY", 14, 19], ["stem cells", "ANATOMY", 51, 61], ["2D monolayers", "ANATOMY", 98, 111], ["enteroids", "ANATOMY", 141, 150], ["stem cells", "ANATOMY", 176, 186], ["cells", "CELL", 14, 19], ["Ki-67", "GENE_OR_GENE_PRODUCT", 33, 38], ["stem cells", "CELL", 51, 61], ["Lgr5+", "CELL", 63, 68], ["2D monolayers", "CELL", 98, 111], ["stem cells", "CELL", 176, 186], ["Proliferating cells", "CELL_TYPE", 0, 19], ["Ki-67 protein", "PROTEIN", 33, 46], ["stem cells", "CELL_TYPE", 51, 61], ["Lgr5", "PROTEIN", 63, 67], ["stem cells", "CELL_TYPE", 176, 186], ["Proliferating cells", "TEST", 0, 19], ["Ki", "TEST", 33, 35], ["protein", "TEST", 39, 46], ["stem cells", "TEST", 51, 61], ["Lgr5", "TEST", 63, 67], ["our 2D enteroids", "PROBLEM", 134, 150], ["stem cells", "PROBLEM", 176, 186], ["the transit", "TEST", 199, 210], ["stem cells", "OBSERVATION", 51, 61], ["stem cells", "OBSERVATION", 176, 186]]], ["We also identified Paneth (lysozyme C-positive [LYZ+]) cells, goblet (mucin 2-positive [Muc2+]) cells, and enteroendocrine (chromogranin A-positive [CHGA+]) cells in the 2D ileal enteroids (Fig. 1D).", [["Paneth", "ANATOMY", 19, 25], ["LYZ+]) cells", "ANATOMY", 48, 60], ["goblet (mucin 2-positive [Muc2+]) cells", "ANATOMY", 62, 101], ["enteroendocrine (chromogranin A-positive [CHGA+]) cells", "ANATOMY", 107, 162], ["ileal enteroids", "ANATOMY", 173, 188], ["lysozyme C", "GENE_OR_GENE_PRODUCT", 27, 37], ["goblet (mucin 2", "GENE_OR_GENE_PRODUCT", 62, 77], ["enteroendocrine", "CELL", 107, 122], ["chromogranin", "GENE_OR_GENE_PRODUCT", 124, 136], ["Paneth (lysozyme C-positive [LYZ+]) cells", "CELL_LINE", 19, 60], ["goblet (mucin 2-positive [Muc2+]) cells", "CELL_LINE", 62, 101], ["enteroendocrine (chromogranin A-positive [CHGA+]) cells", "CELL_LINE", 107, 162], ["Paneth (lysozyme C", "TEST", 19, 37], ["LYZ", "TEST", 48, 51], ["cells", "TEST", 55, 60], ["goblet (mucin", "TEST", 62, 75], ["Muc2", "TEST", 88, 92], ["cells", "TEST", 96, 101], ["enteroendocrine", "TEST", 107, 122], ["chromogranin", "TEST", 124, 136], ["CHGA+]) cells", "PROBLEM", 149, 162], ["enteroendocrine", "ANATOMY", 107, 122], ["ileal enteroids", "ANATOMY", 173, 188]]], ["Thus, the planar intestinal enteroids generated from budding crypt-like 3D enteroids include multiple cell lineages and recapitulate the various cellular phenotypes of the intestinal epithelium.", [["intestinal enteroids", "ANATOMY", 17, 37], ["crypt", "ANATOMY", 61, 66], ["3D enteroids", "ANATOMY", 72, 84], ["cell", "ANATOMY", 102, 106], ["cellular", "ANATOMY", 145, 153], ["intestinal epithelium", "ANATOMY", 172, 193], ["intestinal enteroids", "CANCER", 17, 37], ["crypt", "CELL", 61, 66], ["cell lineages", "CELL", 102, 115], ["cellular", "CELL", 145, 153], ["intestinal epithelium", "TISSUE", 172, 193], ["multiple cell lineages", "CELL_TYPE", 93, 115], ["the planar intestinal enteroids", "PROBLEM", 6, 37], ["budding crypt", "PROBLEM", 53, 66], ["3D enteroids", "TREATMENT", 72, 84], ["multiple cell lineages", "PROBLEM", 93, 115], ["intestinal", "ANATOMY", 17, 27], ["budding crypt", "OBSERVATION", 53, 66], ["multiple cell lineages", "OBSERVATION", 93, 115], ["various cellular phenotypes", "OBSERVATION", 137, 164], ["intestinal epithelium", "ANATOMY", 172, 193]]], ["Moreover, a lumen-like structure was identified in the differentiated planar 2D ileal enteroids (Fig. 1D).", [["lumen", "ANATOMY", 12, 17], ["ileal enteroids", "ANATOMY", 80, 95], ["a lumen-like structure", "PROBLEM", 10, 32], ["lumen", "OBSERVATION", 12, 17], ["differentiated", "OBSERVATION_MODIFIER", 55, 69], ["planar", "ANATOMY_MODIFIER", 70, 76], ["ileal enteroids", "OBSERVATION", 80, 95]]], ["Altogether, these results demonstrate that a planar swine enteroid culture can be generated from intestinal crypt stem cells.Porcine intestinal enteroids are susceptible to PEDV infection. ::: RESULTSTo determine whether porcine intestinal enteroids are permissive to infection by PEDV, we inoculated porcine ileal enteroids with the clinical isolate PEDV-JMS at increasing multiplicities of infection (MOIs).", [["intestinal crypt stem cells", "ANATOMY", 97, 124], ["intestinal enteroids", "ANATOMY", 133, 153], ["intestinal enteroids", "ANATOMY", 229, 249], ["ileal enteroids", "ANATOMY", 309, 324], ["infection", "DISEASE", 178, 187], ["infection", "DISEASE", 268, 277], ["PEDV", "CHEMICAL", 351, 355], ["JMS", "CHEMICAL", 356, 359], ["infection", "DISEASE", 392, 401], ["swine", "ORGANISM", 52, 57], ["intestinal crypt stem cells", "CELL", 97, 124], ["Porcine", "ORGANISM", 125, 132], ["intestinal enteroids", "CANCER", 133, 153], ["porcine", "ORGANISM", 221, 228], ["intestinal", "ORGAN", 229, 239], ["enteroids", "ORGANISM", 240, 249], ["PEDV", "SIMPLE_CHEMICAL", 281, 285], ["porcine", "ORGANISM", 301, 308], ["ileal", "MULTI-TISSUE_STRUCTURE", 309, 314], ["planar swine enteroid culture", "CELL_LINE", 45, 74], ["intestinal crypt stem cells", "CELL_TYPE", 97, 124], ["swine", "SPECIES", 52, 57], ["Porcine", "SPECIES", 125, 132], ["porcine", "SPECIES", 221, 228], ["porcine", "SPECIES", 301, 308], ["swine", "SPECIES", 52, 57], ["Porcine", "SPECIES", 125, 132], ["PEDV", "SPECIES", 173, 177], ["porcine", "SPECIES", 221, 228], ["PEDV", "SPECIES", 281, 285], ["porcine", "SPECIES", 301, 308], ["a planar swine enteroid culture", "TEST", 43, 74], ["Porcine intestinal enteroids", "PROBLEM", 125, 153], ["PEDV infection", "PROBLEM", 173, 187], ["porcine intestinal enteroids", "PROBLEM", 221, 249], ["infection", "PROBLEM", 268, 277], ["PEDV", "PROBLEM", 281, 285], ["porcine ileal enteroids", "TREATMENT", 301, 324], ["JMS", "PROBLEM", 356, 359], ["infection", "PROBLEM", 392, 401], ["intestinal crypt", "ANATOMY", 97, 113], ["stem cells", "OBSERVATION", 114, 124], ["intestinal", "ANATOMY", 133, 143], ["enteroids", "OBSERVATION", 144, 153], ["PEDV", "OBSERVATION_MODIFIER", 173, 177], ["infection", "OBSERVATION", 178, 187], ["intestinal", "ANATOMY", 229, 239], ["infection", "OBSERVATION", 268, 277], ["ileal", "ANATOMY", 309, 314], ["increasing", "OBSERVATION_MODIFIER", 363, 373], ["multiplicities", "OBSERVATION_MODIFIER", 374, 388], ["infection", "OBSERVATION", 392, 401]]], ["At 48 h postinfection (hpi), the numbers of PEDV genomes were substantially increased to levels 34- to 754-fold higher than their levels at 2 hpi and were correlated with the MOI (Fig. 2A), indicating that PEDV can infect enteroids.", [["enteroids", "ANATOMY", 222, 231], ["PEDV", "CHEMICAL", 206, 210], ["PEDV", "GENE_OR_GENE_PRODUCT", 44, 48], ["PEDV", "GENE_OR_GENE_PRODUCT", 206, 210], ["enteroids", "CANCER", 222, 231], ["PEDV genomes", "DNA", 44, 56], ["PEDV", "SPECIES", 44, 48], ["PEDV", "SPECIES", 206, 210], ["PEDV genomes", "PROBLEM", 44, 56], ["levels", "TEST", 89, 95], ["PEDV", "PROBLEM", 206, 210], ["PEDV genomes", "OBSERVATION", 44, 56], ["PEDV", "OBSERVATION", 206, 210]]], ["It is well established that PEDV primarily infects the small intestine and can infect all three regions (duodenum, jejunum, and ileum) of the small intestine.", [["small intestine", "ANATOMY", 55, 70], ["duodenum", "ANATOMY", 105, 113], ["jejunum", "ANATOMY", 115, 122], ["ileum", "ANATOMY", 128, 133], ["small intestine", "ANATOMY", 142, 157], ["PEDV", "CHEMICAL", 28, 32], ["PEDV", "GENE_OR_GENE_PRODUCT", 28, 32], ["small intestine", "ORGAN", 55, 70], ["duodenum", "MULTI-TISSUE_STRUCTURE", 105, 113], ["jejunum", "MULTI-TISSUE_STRUCTURE", 115, 122], ["ileum", "ORGAN", 128, 133], ["small intestine", "ORGAN", 142, 157], ["PEDV", "SPECIES", 28, 32], ["PEDV", "PROBLEM", 28, 32], ["small intestine", "ANATOMY", 55, 70], ["duodenum", "ANATOMY", 105, 113], ["jejunum", "ANATOMY", 115, 122], ["ileum", "ANATOMY", 128, 133], ["small intestine", "ANATOMY", 142, 157]]], ["To assess the potential existence of a disparity in susceptibility to PEDV infection among duodenal, jejunal, and ileal enteroids, we infected the three types of enteroids at the same MOI and monitored the viral replication kinetics.", [["duodenal", "ANATOMY", 91, 99], ["jejunal", "ANATOMY", 101, 108], ["ileal enteroids", "ANATOMY", 114, 129], ["infection", "DISEASE", 75, 84], ["PEDV", "CANCER", 70, 74], ["duodenal", "MULTI-TISSUE_STRUCTURE", 91, 99], ["jejunal", "MULTI-TISSUE_STRUCTURE", 101, 108], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 114, 129], ["enteroids", "CANCER", 162, 171], ["PEDV", "SPECIES", 70, 74], ["a disparity in susceptibility", "PROBLEM", 37, 66], ["PEDV infection", "PROBLEM", 70, 84], ["duodenal, jejunal, and ileal enteroids", "PROBLEM", 91, 129], ["enteroids", "TREATMENT", 162, 171], ["the viral replication kinetics", "TREATMENT", 202, 232], ["infection", "OBSERVATION", 75, 84], ["duodenal", "ANATOMY", 91, 99], ["jejunal", "ANATOMY", 101, 108], ["ileal enteroids", "ANATOMY", 114, 129], ["viral replication kinetics", "OBSERVATION", 206, 232]]], ["The duodenal, jejunal, and ileal enteroids were all infected by PEDV, and the results showed that the number of PEDV genomes had increased up to 63-fold at 24 hpi compared with the number at 2 hpi and peaked at 48 hpi, indicating successful PEDV replication in all three enteroids.", [["duodenal", "ANATOMY", 4, 12], ["jejunal", "ANATOMY", 14, 21], ["ileal enteroids", "ANATOMY", 27, 42], ["duodenal", "MULTI-TISSUE_STRUCTURE", 4, 12], ["jejunal", "MULTI-TISSUE_STRUCTURE", 14, 21], ["ileal enteroids", "CANCER", 27, 42], ["PEDV", "GENE_OR_GENE_PRODUCT", 112, 116], ["PEDV genomes", "DNA", 112, 124], ["PEDV", "SPECIES", 64, 68], ["PEDV", "SPECIES", 112, 116], ["PEDV", "SPECIES", 241, 245], ["The duodenal, jejunal, and ileal enteroids", "PROBLEM", 0, 42], ["PEDV", "PROBLEM", 64, 68], ["PEDV genomes", "PROBLEM", 112, 124], ["successful PEDV replication", "PROBLEM", 230, 257], ["duodenal", "ANATOMY", 4, 12], ["jejunal", "ANATOMY", 14, 21], ["ileal enteroids", "ANATOMY", 27, 42], ["infected", "OBSERVATION", 52, 60], ["PEDV genomes", "OBSERVATION", 112, 124], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["PEDV replication", "OBSERVATION", 241, 257]]], ["In addition, the enteroids derived from the duodenum, jejunum, and ileum exhibited similar viral replication kinetic levels after PEDV infection (Fig. 2B).", [["enteroids", "ANATOMY", 17, 26], ["duodenum", "ANATOMY", 44, 52], ["jejunum", "ANATOMY", 54, 61], ["ileum", "ANATOMY", 67, 72], ["infection", "DISEASE", 135, 144], ["duodenum", "ORGAN", 44, 52], ["jejunum", "MULTI-TISSUE_STRUCTURE", 54, 61], ["ileum", "ORGAN", 67, 72], ["PEDV", "SPECIES", 130, 134], ["the enteroids", "PROBLEM", 13, 26], ["similar viral replication kinetic levels", "PROBLEM", 83, 123], ["PEDV infection", "PROBLEM", 130, 144], ["duodenum", "ANATOMY", 44, 52], ["jejunum", "ANATOMY", 54, 61], ["ileum", "ANATOMY", 67, 72], ["similar", "OBSERVATION_MODIFIER", 83, 90], ["viral replication", "OBSERVATION", 91, 108], ["kinetic levels", "OBSERVATION", 109, 123], ["infection", "OBSERVATION", 135, 144]]], ["PEDV infection in ileal enteroids was further confirmed through an anti-PEDV nucleocapsid immunofluorescence assay (IFA) (Fig. 2C).", [["ileal enteroids", "ANATOMY", 18, 33], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 5, 14], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 18, 33], ["PEDV", "SPECIES", 0, 4], ["anti-PEDV", "SPECIES", 67, 76], ["PEDV infection", "PROBLEM", 0, 14], ["ileal enteroids", "TREATMENT", 18, 33], ["an anti-PEDV nucleocapsid immunofluorescence assay", "TEST", 64, 114], ["infection", "OBSERVATION", 5, 14], ["ileal", "ANATOMY", 18, 23]]], ["Successful PEDV infection in ileal enteroids resulted in a significant cytopathic effect and disruption of the enteroid structure starting at 24 hpi, and this structure continued to deteriorate over time (Fig. 2D).", [["ileal enteroids", "ANATOMY", 29, 44], ["enteroid structure", "ANATOMY", 111, 129], ["PEDV", "CHEMICAL", 11, 15], ["infection", "DISEASE", 16, 25], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 29, 44], ["PEDV", "SPECIES", 11, 15], ["Successful PEDV infection", "PROBLEM", 0, 25], ["ileal enteroids", "TREATMENT", 29, 44], ["a significant cytopathic effect", "PROBLEM", 57, 88], ["disruption of the enteroid structure", "PROBLEM", 93, 129], ["PEDV", "OBSERVATION_MODIFIER", 11, 15], ["infection", "OBSERVATION", 16, 25], ["ileal", "ANATOMY", 29, 34], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["cytopathic effect", "OBSERVATION", 71, 88]]], ["These results indicate that PEDV successfully infects enteroids and establishes a productive infection.Porcine intestinal enteroids are susceptible to PEDV infection. ::: RESULTSBecause intestinal enteroids contain multiple-cell-type compositions, we then took advantage of the multiple cellular phenotypes of intestinal enteroids and sought to clarify whether PEDV targets specific cell types in the porcine intestinal enteroids through double-immunofluorescence labeling (Fig. 3A).", [["enteroids", "ANATOMY", 54, 63], ["intestinal enteroids", "ANATOMY", 111, 131], ["intestinal", "ANATOMY", 186, 196], ["cell", "ANATOMY", 224, 228], ["cellular", "ANATOMY", 287, 295], ["intestinal enteroids", "ANATOMY", 310, 330], ["cell", "ANATOMY", 383, 387], ["intestinal enteroids", "ANATOMY", 409, 429], ["PEDV", "CHEMICAL", 28, 32], ["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 156, 165], ["PEDV", "CHEMICAL", 361, 365], ["PEDV", "GENE_OR_GENE_PRODUCT", 28, 32], ["enteroids", "CANCER", 54, 63], ["Porcine", "ORGANISM", 103, 110], ["intestinal enteroids", "CANCER", 111, 131], ["intestinal enteroids", "PATHOLOGICAL_FORMATION", 186, 206], ["cell", "CELL", 224, 228], ["cellular", "CELL", 287, 295], ["intestinal enteroids", "CANCER", 310, 330], ["PEDV", "SIMPLE_CHEMICAL", 361, 365], ["cell", "CELL", 383, 387], ["porcine", "ORGANISM", 401, 408], ["intestinal enteroids", "MULTI-TISSUE_STRUCTURE", 409, 429], ["PEDV", "PROTEIN", 28, 32], ["PEDV", "PROTEIN", 361, 365], ["Porcine", "SPECIES", 103, 110], ["porcine", "SPECIES", 401, 408], ["PEDV", "SPECIES", 28, 32], ["Porcine", "SPECIES", 103, 110], ["PEDV", "SPECIES", 151, 155], ["porcine", "SPECIES", 401, 408], ["PEDV", "PROBLEM", 28, 32], ["a productive infection", "PROBLEM", 80, 102], ["Porcine intestinal enteroids", "PROBLEM", 103, 131], ["PEDV infection", "PROBLEM", 151, 165], ["intestinal enteroids", "PROBLEM", 186, 206], ["multiple-cell-type compositions", "PROBLEM", 215, 246], ["intestinal enteroids", "TREATMENT", 310, 330], ["PEDV targets specific cell types", "PROBLEM", 361, 393], ["the porcine intestinal enteroids", "TREATMENT", 397, 429], ["productive", "OBSERVATION_MODIFIER", 82, 92], ["infection", "OBSERVATION", 93, 102], ["intestinal", "ANATOMY", 111, 121], ["enteroids", "OBSERVATION", 122, 131], ["PEDV", "OBSERVATION_MODIFIER", 151, 155], ["infection", "OBSERVATION", 156, 165], ["intestinal", "ANATOMY", 186, 196], ["enteroids", "OBSERVATION", 197, 206], ["multiple", "OBSERVATION_MODIFIER", 215, 223], ["-cell-type compositions", "OBSERVATION_MODIFIER", 223, 246], ["intestinal", "ANATOMY", 310, 320], ["intestinal", "ANATOMY", 409, 419]]], ["We detected PEDV infection in differentiated mature enterocyte cells that express villin, which serves as a surface marker for differentiated intestinal epithelial cells and is expressed in cells located in the brush border of the intestine (25, 26).", [["enterocyte cells", "ANATOMY", 52, 68], ["surface", "ANATOMY", 108, 115], ["intestinal epithelial cells", "ANATOMY", 142, 169], ["cells", "ANATOMY", 190, 195], ["brush border", "ANATOMY", 211, 223], ["intestine", "ANATOMY", 231, 240], ["infection", "DISEASE", 17, 26], ["PEDV", "GENE_OR_GENE_PRODUCT", 12, 16], ["enterocyte cells", "CELL", 52, 68], ["villin", "GENE_OR_GENE_PRODUCT", 82, 88], ["intestinal epithelial cells", "CELL", 142, 169], ["cells", "CELL", 190, 195], ["brush border", "MULTI-TISSUE_STRUCTURE", 211, 223], ["intestine", "ORGAN", 231, 240], ["differentiated mature enterocyte cells", "CELL_TYPE", 30, 68], ["villin", "PROTEIN", 82, 88], ["differentiated intestinal epithelial cells", "CELL_TYPE", 127, 169], ["PEDV", "SPECIES", 12, 16], ["PEDV infection", "PROBLEM", 12, 26], ["differentiated mature enterocyte cells", "PROBLEM", 30, 68], ["a surface marker", "TEST", 106, 122], ["differentiated intestinal epithelial cells", "PROBLEM", 127, 169], ["PEDV", "OBSERVATION_MODIFIER", 12, 16], ["infection", "OBSERVATION", 17, 26], ["differentiated mature", "OBSERVATION_MODIFIER", 30, 51], ["enterocyte cells", "OBSERVATION", 52, 68], ["intestinal", "ANATOMY", 142, 152], ["epithelial cells", "OBSERVATION", 153, 169], ["brush", "ANATOMY_MODIFIER", 211, 216], ["border", "ANATOMY_MODIFIER", 217, 223], ["intestine", "ANATOMY", 231, 240]]], ["Moreover, we observed PEDV infection (nucleocapsid positive) in Lgr5+ stem cells, Ki-67-positive (proliferating) cells, and Muc2+ goblet cells, although the number of PEDV-positive cells in the latter two cell populations was limited (Fig. 3A).", [["Lgr5+ stem cells", "ANATOMY", 64, 80], ["Ki-67-positive (proliferating) cells", "ANATOMY", 82, 118], ["Muc2+ goblet cells", "ANATOMY", 124, 142], ["PEDV-positive cells", "ANATOMY", 167, 186], ["cell", "ANATOMY", 205, 209], ["infection", "DISEASE", 27, 36], ["PEDV", "GENE_OR_GENE_PRODUCT", 22, 26], ["Lgr5", "GENE_OR_GENE_PRODUCT", 64, 68], ["Ki-67", "GENE_OR_GENE_PRODUCT", 82, 87], ["Muc2+ goblet cells", "CELL", 124, 142], ["PEDV", "GENE_OR_GENE_PRODUCT", 167, 171], ["cells", "CELL", 181, 186], ["cell populations", "CELL", 205, 221], ["Lgr5+ stem cells", "CELL_LINE", 64, 80], ["Ki-67-positive (proliferating) cells", "CELL_LINE", 82, 118], ["Muc2+ goblet cells", "CELL_TYPE", 124, 142], ["PEDV-positive cells", "CELL_LINE", 167, 186], ["PEDV", "SPECIES", 22, 26], ["PEDV infection", "PROBLEM", 22, 36], ["Lgr5+ stem cells", "TEST", 64, 80], ["Ki-67", "TEST", 82, 87], ["proliferating) cells", "PROBLEM", 98, 118], ["Muc2+ goblet cells", "PROBLEM", 124, 142], ["PEDV", "TEST", 167, 171], ["positive cells", "PROBLEM", 172, 186], ["PEDV", "OBSERVATION_MODIFIER", 22, 26], ["infection", "OBSERVATION", 27, 36], ["stem cells", "ANATOMY", 70, 80], ["goblet cells", "OBSERVATION", 130, 142], ["PEDV", "OBSERVATION", 167, 171], ["positive cells", "OBSERVATION", 172, 186], ["latter two", "OBSERVATION_MODIFIER", 194, 204], ["cell populations", "OBSERVATION", 205, 221]]], ["These results indicate that PEDV infects multiple cell lineages, including stem cells and goblet cells.", [["cell", "ANATOMY", 50, 54], ["stem cells", "ANATOMY", 75, 85], ["goblet cells", "ANATOMY", 90, 102], ["PEDV", "CHEMICAL", 28, 32], ["PEDV", "GENE_OR_GENE_PRODUCT", 28, 32], ["cell", "CELL", 50, 54], ["stem cells", "CELL", 75, 85], ["goblet cells", "CELL", 90, 102], ["PEDV", "PROTEIN", 28, 32], ["multiple cell lineages", "CELL_TYPE", 41, 63], ["stem cells", "CELL_TYPE", 75, 85], ["goblet cells", "CELL_TYPE", 90, 102], ["PEDV", "SPECIES", 28, 32], ["PEDV infects multiple cell lineages", "PROBLEM", 28, 63], ["stem cells", "PROBLEM", 75, 85], ["goblet cells", "PROBLEM", 90, 102], ["cell lineages", "OBSERVATION", 50, 63], ["stem cells", "OBSERVATION", 75, 85], ["goblet cells", "OBSERVATION", 90, 102]]], ["Thus, these data show that PEDV can infect enteroids, including enterocytes, stem cells, and goblet cells.Porcine intestinal enteroids are susceptible to PEDV infection. ::: RESULTSTo further verify whether PEDV infects multiple cell lineages in vivo, we subjected ileal tissues collected from PEDV-infected piglets to immunohistochemistry staining.", [["enteroids", "ANATOMY", 43, 52], ["enterocytes", "ANATOMY", 64, 75], ["stem cells", "ANATOMY", 77, 87], ["goblet cells", "ANATOMY", 93, 105], ["intestinal enteroids", "ANATOMY", 114, 134], ["cell", "ANATOMY", 229, 233], ["ileal tissues", "ANATOMY", 265, 278], ["PEDV", "CHEMICAL", 27, 31], ["infection", "DISEASE", 159, 168], ["PEDV", "GENE_OR_GENE_PRODUCT", 27, 31], ["enteroids", "CELL", 43, 52], ["enterocytes", "CELL", 64, 75], ["stem cells", "CELL", 77, 87], ["goblet cells", "CELL", 93, 105], ["Porcine", "ORGANISM", 106, 113], ["intestinal enteroids", "CANCER", 114, 134], ["PEDV", "GENE_OR_GENE_PRODUCT", 207, 211], ["cell", "CELL", 229, 233], ["ileal tissues", "TISSUE", 265, 278], ["PEDV", "ORGANISM", 294, 298], ["piglets", "ORGANISM", 308, 315], ["PEDV", "PROTEIN", 27, 31], ["enterocytes", "CELL_TYPE", 64, 75], ["stem cells", "CELL_TYPE", 77, 87], ["goblet cells", "CELL_TYPE", 93, 105], ["PEDV", "PROTEIN", 207, 211], ["Porcine", "SPECIES", 106, 113], ["piglets", "SPECIES", 308, 315], ["PEDV", "SPECIES", 27, 31], ["Porcine", "SPECIES", 106, 113], ["PEDV", "SPECIES", 154, 158], ["PEDV", "SPECIES", 207, 211], ["PEDV", "SPECIES", 294, 298], ["these data", "TEST", 6, 16], ["PEDV", "PROBLEM", 27, 31], ["enteroids", "PROBLEM", 43, 52], ["enterocytes, stem cells", "PROBLEM", 64, 87], ["goblet cells", "PROBLEM", 93, 105], ["Porcine intestinal enteroids", "PROBLEM", 106, 134], ["PEDV infection", "PROBLEM", 154, 168], ["PEDV infects multiple cell lineages", "PROBLEM", 207, 242], ["ileal tissues", "PROBLEM", 265, 278], ["PEDV", "PROBLEM", 294, 298], ["immunohistochemistry staining", "PROBLEM", 319, 348], ["enterocytes", "ANATOMY", 64, 75], ["stem cells", "OBSERVATION", 77, 87], ["goblet cells", "OBSERVATION", 93, 105], ["intestinal", "ANATOMY", 114, 124], ["enteroids", "OBSERVATION", 125, 134], ["PEDV", "OBSERVATION_MODIFIER", 154, 158], ["infection", "OBSERVATION", 159, 168], ["cell lineages", "OBSERVATION", 229, 242], ["ileal tissues", "ANATOMY", 265, 278], ["infected", "OBSERVATION_MODIFIER", 299, 307]]], ["Consistent with data from previous reports, PEDV infection caused severe atrophic enteritis, and PEDV antigen-positive cells were largely located along the sides of villi, suggesting that PEDV successfully infects ileal tissue (Fig. 3B) (27).", [["cells", "ANATOMY", 119, 124], ["sides", "ANATOMY", 156, 161], ["villi", "ANATOMY", 165, 170], ["ileal tissue", "ANATOMY", 214, 226], ["PEDV", "CHEMICAL", 44, 48], ["infection", "DISEASE", 49, 58], ["enteritis", "DISEASE", 82, 91], ["PEDV", "CHEMICAL", 188, 192], ["PEDV antigen", "GENE_OR_GENE_PRODUCT", 97, 109], ["villi", "MULTI-TISSUE_STRUCTURE", 165, 170], ["PEDV", "GENE_OR_GENE_PRODUCT", 188, 192], ["ileal tissue", "TISSUE", 214, 226], ["PEDV antigen-positive cells", "CELL_TYPE", 97, 124], ["PEDV", "PROTEIN", 188, 192], ["PEDV", "SPECIES", 44, 48], ["PEDV", "SPECIES", 97, 101], ["PEDV", "SPECIES", 188, 192], ["PEDV infection", "PROBLEM", 44, 58], ["severe atrophic enteritis", "PROBLEM", 66, 91], ["PEDV antigen", "TEST", 97, 109], ["positive cells", "PROBLEM", 110, 124], ["PEDV", "PROBLEM", 188, 192], ["infection", "OBSERVATION", 49, 58], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["atrophic", "OBSERVATION_MODIFIER", 73, 81], ["enteritis", "OBSERVATION", 82, 91], ["positive cells", "OBSERVATION", 110, 124], ["sides", "ANATOMY_MODIFIER", 156, 161], ["villi", "ANATOMY", 165, 170], ["suggesting that", "UNCERTAINTY", 172, 187], ["PEDV", "OBSERVATION", 188, 192], ["ileal tissue", "OBSERVATION", 214, 226]]], ["We also performed double-immunofluorescence staining of the same sample with anti-PEDV spike protein and anti-cell markers (villin, Lgr5, Ki-67, and Muc2) (Fig. 3C).", [["sample", "ANATOMY", 65, 71], ["anti-cell", "ANATOMY", 105, 114], ["anti-cell", "CELL", 105, 114], ["villin", "GENE_OR_GENE_PRODUCT", 124, 130], ["Lgr5", "GENE_OR_GENE_PRODUCT", 132, 136], ["Ki-67", "GENE_OR_GENE_PRODUCT", 138, 143], ["Muc2", "GENE_OR_GENE_PRODUCT", 149, 153], ["anti-PEDV spike protein", "PROTEIN", 77, 100], ["anti-cell markers", "PROTEIN", 105, 122], ["villin", "PROTEIN", 124, 130], ["Lgr5", "PROTEIN", 132, 136], ["Ki", "PROTEIN", 138, 140], ["67", "PROTEIN", 141, 143], ["Muc2", "PROTEIN", 149, 153], ["Fig. 3C", "PROTEIN", 156, 163], ["double-immunofluorescence staining", "TEST", 18, 52], ["anti-PEDV spike protein", "TEST", 77, 100], ["anti-cell markers", "TEST", 105, 122], ["villin", "TEST", 124, 130], ["Lgr5", "TEST", 132, 136], ["Ki", "TEST", 138, 140]]], ["As expected, villin, a marker of mature enterocytes, was present along the apical side of the intestinal villus, and PEDV infection was distributed throughout the villin-positive villi.", [["enterocytes", "ANATOMY", 40, 51], ["apical", "ANATOMY", 75, 81], ["intestinal villus", "ANATOMY", 94, 111], ["villi", "ANATOMY", 179, 184], ["infection", "DISEASE", 122, 131], ["villin", "GENE_OR_GENE_PRODUCT", 13, 19], ["enterocytes", "CELL", 40, 51], ["intestinal villus", "MULTI-TISSUE_STRUCTURE", 94, 111], ["PEDV", "GENE_OR_GENE_PRODUCT", 117, 121], ["villin", "GENE_OR_GENE_PRODUCT", 163, 169], ["villi", "MULTI-TISSUE_STRUCTURE", 179, 184], ["villin", "PROTEIN", 13, 19], ["mature enterocytes", "CELL_TYPE", 33, 51], ["villin", "PROTEIN", 163, 169], ["PEDV", "SPECIES", 117, 121], ["mature enterocytes", "PROBLEM", 33, 51], ["PEDV infection", "PROBLEM", 117, 131], ["mature enterocytes", "OBSERVATION", 33, 51], ["apical", "ANATOMY_MODIFIER", 75, 81], ["intestinal villus", "ANATOMY", 94, 111], ["PEDV", "OBSERVATION_MODIFIER", 117, 121], ["infection", "OBSERVATION", 122, 131], ["positive villi", "OBSERVATION", 170, 184]]], ["PEDV infection was primarily located on the tip and waist of villi, and Lgr5-positive cells were primarily concentrated at the bottom crypt area of intestinal villi.", [["tip", "ANATOMY", 44, 47], ["villi", "ANATOMY", 61, 66], ["Lgr5-positive cells", "ANATOMY", 72, 91], ["crypt area", "ANATOMY", 134, 144], ["intestinal villi", "ANATOMY", 148, 164], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 5, 14], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["tip", "TISSUE", 44, 47], ["villi", "MULTI-TISSUE_STRUCTURE", 61, 66], ["Lgr5", "GENE_OR_GENE_PRODUCT", 72, 76], ["crypt area", "TISSUE", 134, 144], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 148, 164], ["Lgr5-positive cells", "CELL_LINE", 72, 91], ["PEDV", "SPECIES", 0, 4], ["PEDV infection", "PROBLEM", 0, 14], ["villi", "TEST", 61, 66], ["Lgr5-positive cells", "PROBLEM", 72, 91], ["infection", "OBSERVATION", 5, 14], ["tip", "OBSERVATION_MODIFIER", 44, 47], ["villi", "ANATOMY", 61, 66], ["positive cells", "OBSERVATION", 77, 91], ["concentrated", "OBSERVATION_MODIFIER", 107, 119], ["bottom", "ANATOMY_MODIFIER", 127, 133], ["crypt", "ANATOMY_MODIFIER", 134, 139], ["intestinal villi", "ANATOMY", 148, 164]]], ["We easily identified significant PEDV infection in Lgr5+ cells in the crypt area (Fig. 3C), which indicates that PEDV infects Lgr5+ crypt stem cells, as observed in vitro in enteroids.", [["Lgr5+ cells", "ANATOMY", 51, 62], ["crypt area", "ANATOMY", 70, 80], ["Lgr5+ crypt stem cells", "ANATOMY", 126, 148], ["enteroids", "ANATOMY", 174, 183], ["infection", "DISEASE", 38, 47], ["Lgr5+ cells", "CELL", 51, 62], ["crypt area", "TISSUE", 70, 80], ["PEDV", "GENE_OR_GENE_PRODUCT", 113, 117], ["Lgr5+ crypt stem cells", "CELL", 126, 148], ["enteroids", "CANCER", 174, 183], ["Lgr5+ cells", "CELL_LINE", 51, 62], ["Lgr5+ crypt stem cells", "CELL_LINE", 126, 148], ["PEDV", "SPECIES", 33, 37], ["PEDV", "SPECIES", 113, 117], ["significant PEDV infection", "PROBLEM", 21, 47], ["Lgr5+ cells", "PROBLEM", 51, 62], ["PEDV", "PROBLEM", 113, 117], ["crypt stem cells", "PROBLEM", 132, 148], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["PEDV", "OBSERVATION_MODIFIER", 33, 37], ["infection", "OBSERVATION", 38, 47], ["Lgr5+ cells", "OBSERVATION", 51, 62], ["crypt", "ANATOMY", 70, 75], ["area", "ANATOMY_MODIFIER", 76, 80], ["crypt stem cells", "OBSERVATION", 132, 148]]], ["Unlike Lgr5 staining, which was concentrated in the bottom crypt, Ki-67-positive cells were distributed widely in the proliferative zone of the crypt and reached the waist area of villi (Fig. 3C).", [["bottom crypt", "ANATOMY", 52, 64], ["Ki-67-positive cells", "ANATOMY", 66, 86], ["proliferative zone", "ANATOMY", 118, 136], ["crypt", "ANATOMY", 144, 149], ["waist area", "ANATOMY", 166, 176], ["villi", "ANATOMY", 180, 185], ["Lgr5", "GENE_OR_GENE_PRODUCT", 7, 11], ["Ki-67", "GENE_OR_GENE_PRODUCT", 66, 71], ["crypt", "TISSUE", 144, 149], ["villi", "MULTI-TISSUE_STRUCTURE", 180, 185], ["Lgr5", "PROTEIN", 7, 11], ["Ki-67-positive cells", "CELL_LINE", 66, 86], ["Lgr5 staining", "TEST", 7, 20], ["the bottom crypt", "TEST", 48, 64], ["Ki-", "TEST", 66, 69], ["positive cells", "PROBLEM", 72, 86], ["Lgr5 staining", "OBSERVATION", 7, 20], ["concentrated", "OBSERVATION_MODIFIER", 32, 44], ["bottom", "ANATOMY_MODIFIER", 52, 58], ["crypt", "ANATOMY", 59, 64], ["positive cells", "OBSERVATION", 72, 86], ["widely", "OBSERVATION_MODIFIER", 104, 110], ["proliferative", "OBSERVATION_MODIFIER", 118, 131], ["zone", "OBSERVATION_MODIFIER", 132, 136], ["crypt", "ANATOMY", 144, 149], ["waist", "OBSERVATION_MODIFIER", 166, 171], ["villi", "ANATOMY", 180, 185]]], ["PEDV protein was occasionally observed in Ki-67+ proliferating epithelial cells and to a lesser degree in Muc2+ goblet cells (Fig. 3C).", [["Ki-67+ proliferating epithelial cells", "ANATOMY", 42, 79], ["Muc2+ goblet cells", "ANATOMY", 106, 124], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ki-67", "GENE_OR_GENE_PRODUCT", 42, 47], ["epithelial cells", "CELL", 63, 79], ["Muc2+ goblet cells", "CELL", 106, 124], ["PEDV protein", "PROTEIN", 0, 12], ["Ki-67+ proliferating epithelial cells", "CELL_LINE", 42, 79], ["Muc2+ goblet cells", "CELL_LINE", 106, 124], ["PEDV", "SPECIES", 0, 4], ["PEDV protein", "TEST", 0, 12], ["Ki", "TEST", 42, 44], ["proliferating epithelial cells", "PROBLEM", 49, 79], ["proliferating epithelial cells", "OBSERVATION", 49, 79], ["lesser degree", "OBSERVATION_MODIFIER", 89, 102], ["goblet cells", "OBSERVATION", 112, 124]]], ["These results demonstrate that PEDV is capable of infecting multiple cellular lineages, including enterocytes, stem cells, and goblet cells, as observed in vitro.", [["cellular", "ANATOMY", 69, 77], ["enterocytes", "ANATOMY", 98, 109], ["stem cells", "ANATOMY", 111, 121], ["goblet cells", "ANATOMY", 127, 139], ["PEDV", "CHEMICAL", 31, 35], ["PEDV", "GENE_OR_GENE_PRODUCT", 31, 35], ["cellular", "CELL", 69, 77], ["enterocytes", "CELL", 98, 109], ["stem cells", "CELL", 111, 121], ["goblet cells", "CELL", 127, 139], ["PEDV", "PROTEIN", 31, 35], ["enterocytes", "CELL_TYPE", 98, 109], ["stem cells", "CELL_TYPE", 111, 121], ["goblet cells", "CELL_TYPE", 127, 139], ["PEDV", "SPECIES", 31, 35], ["PEDV", "PROBLEM", 31, 35], ["infecting multiple cellular lineages", "PROBLEM", 50, 86], ["enterocytes, stem cells", "PROBLEM", 98, 121], ["goblet cells", "PROBLEM", 127, 139], ["PEDV", "OBSERVATION", 31, 35], ["cellular lineages", "OBSERVATION", 69, 86], ["enterocytes", "ANATOMY", 98, 109], ["stem cells", "OBSERVATION", 111, 121], ["goblet cells", "OBSERVATION", 127, 139]]], ["Thus, intestinal enteroids provide a unique platform for studying the multiple cellular targets of PEDV and the effect of PEDV infection on these various epithelial lineages.PEDV preferentially infects ileal enteroids compared with colonoids. ::: RESULTSPEDV largely infects the villous epithelial cells of the small intestine in vivo, although restricted infection has also been observed in the colon (15).", [["intestinal enteroids", "ANATOMY", 6, 26], ["cellular", "ANATOMY", 79, 87], ["epithelial", "ANATOMY", 154, 164], ["ileal enteroids", "ANATOMY", 202, 217], ["colonoids", "ANATOMY", 232, 241], ["villous epithelial cells", "ANATOMY", 279, 303], ["small intestine", "ANATOMY", 311, 326], ["colon", "ANATOMY", 396, 401], ["PEDV", "CHEMICAL", 122, 126], ["infection", "DISEASE", 127, 136], ["PEDV", "CHEMICAL", 174, 178], ["RESULTSPEDV", "CHEMICAL", 247, 258], ["infection", "DISEASE", 356, 365], ["intestinal enteroids", "CANCER", 6, 26], ["cellular", "CELL", 79, 87], ["PEDV", "GENE_OR_GENE_PRODUCT", 99, 103], ["PEDV", "GENE_OR_GENE_PRODUCT", 122, 126], ["epithelial lineages", "CELL", 154, 173], ["PEDV", "SIMPLE_CHEMICAL", 174, 178], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 202, 217], ["villous epithelial cells", "CELL", 279, 303], ["small intestine", "ORGAN", 311, 326], ["colon", "ORGAN", 396, 401], ["epithelial lineages", "CELL_TYPE", 154, 173], ["PEDV", "PROTEIN", 174, 178], ["villous epithelial cells", "CELL_TYPE", 279, 303], ["PEDV", "SPECIES", 122, 126], ["PEDV", "SPECIES", 174, 178], ["PEDV", "PROBLEM", 99, 103], ["PEDV infection", "PROBLEM", 122, 136], ["PEDV", "PROBLEM", 174, 178], ["ileal enteroids", "PROBLEM", 202, 217], ["restricted infection", "PROBLEM", 345, 365], ["intestinal", "ANATOMY", 6, 16], ["PEDV", "OBSERVATION", 99, 103], ["PEDV", "OBSERVATION_MODIFIER", 122, 126], ["infection", "OBSERVATION", 127, 136], ["epithelial lineages", "OBSERVATION", 154, 173], ["infects", "OBSERVATION_MODIFIER", 194, 201], ["ileal enteroids", "OBSERVATION", 202, 217], ["infects", "OBSERVATION", 267, 274], ["villous epithelial cells", "OBSERVATION", 279, 303], ["small intestine", "ANATOMY", 311, 326], ["restricted", "OBSERVATION_MODIFIER", 345, 355], ["infection", "OBSERVATION", 356, 365], ["colon", "ANATOMY", 396, 401]]], ["To recapitulate the segmental discrepancy of PEDV infection observed in vivo, we isolated crypt stem cells from ileal and colonic tissues from the same piglet.", [["crypt stem cells", "ANATOMY", 90, 106], ["ileal", "ANATOMY", 112, 117], ["colonic tissues", "ANATOMY", 122, 137], ["piglet", "ANATOMY", 152, 158], ["infection", "DISEASE", 50, 59], ["PEDV", "GENE_OR_GENE_PRODUCT", 45, 49], ["crypt stem cells", "CELL", 90, 106], ["ileal", "MULTI-TISSUE_STRUCTURE", 112, 117], ["colonic tissues", "TISSUE", 122, 137], ["piglet", "ORGANISM", 152, 158], ["crypt stem cells", "CELL_TYPE", 90, 106], ["PEDV", "SPECIES", 45, 49], ["PEDV infection", "PROBLEM", 45, 59], ["segmental", "OBSERVATION_MODIFIER", 20, 29], ["discrepancy", "OBSERVATION_MODIFIER", 30, 41], ["PEDV", "OBSERVATION_MODIFIER", 45, 49], ["infection", "OBSERVATION", 50, 59], ["crypt stem cells", "OBSERVATION", 90, 106], ["ileal", "ANATOMY", 112, 117], ["colonic tissues", "ANATOMY", 122, 137], ["same piglet", "OBSERVATION", 147, 158]]], ["The stem cells from both ileal and colonic crypts expanded and differentiated into enteroids and colonoids, respectively (Fig. 1A and 4A), but the rates of intestinal organoid differentiation were not identical.", [["stem cells", "ANATOMY", 4, 14], ["ileal", "ANATOMY", 25, 30], ["colonic crypts", "ANATOMY", 35, 49], ["enteroids", "ANATOMY", 83, 92], ["colonoids", "ANATOMY", 97, 106], ["intestinal organoid", "ANATOMY", 156, 175], ["stem cells", "CELL", 4, 14], ["ileal", "MULTI-TISSUE_STRUCTURE", 25, 30], ["colonic crypts", "MULTI-TISSUE_STRUCTURE", 35, 49], ["enteroids", "CELL", 83, 92], ["colonoids", "CELL", 97, 106], ["intestinal organoid", "CELL", 156, 175], ["stem cells", "CELL_TYPE", 4, 14], ["The stem cells", "TREATMENT", 0, 14], ["stem cells", "OBSERVATION", 4, 14], ["both", "ANATOMY_MODIFIER", 20, 24], ["ileal", "ANATOMY", 25, 30], ["colonic crypts", "ANATOMY", 35, 49], ["intestinal", "ANATOMY", 156, 166], ["organoid differentiation", "OBSERVATION", 167, 191]]], ["Approximately 7 days were required for the ileal crypt stem cells to differentiate into enteroids, whereas the colonic crypt stem cells required a longer time (approximately 2 weeks) to differentiate into colonoids (Fig. 4A).", [["ileal crypt stem cells", "ANATOMY", 43, 65], ["enteroids", "ANATOMY", 88, 97], ["colonic crypt stem cells", "ANATOMY", 111, 135], ["colonoids", "ANATOMY", 205, 214], ["ileal crypt stem cells", "CELL", 43, 65], ["colonic crypt stem cells", "CELL", 111, 135], ["ileal crypt stem cells", "CELL_TYPE", 43, 65], ["colonic crypt stem cells", "CELL_TYPE", 111, 135], ["the ileal crypt stem cells", "TREATMENT", 39, 65], ["enteroids", "PROBLEM", 88, 97], ["the colonic crypt stem cells", "PROBLEM", 107, 135], ["ileal crypt", "ANATOMY", 43, 54], ["stem cells", "OBSERVATION", 55, 65], ["colonic crypt", "ANATOMY", 111, 124], ["stem cells", "OBSERVATION", 125, 135]]], ["Consistent with the segmental discrepancy of PEDV infection observed in vivo in the intestine, PEDV infected both ileal enteroids and colonoids but showed restricted infection in colonoids (Fig. 4B).", [["intestine", "ANATOMY", 84, 93], ["ileal enteroids", "ANATOMY", 114, 129], ["colonoids", "ANATOMY", 134, 143], ["colonoids", "ANATOMY", 179, 188], ["PEDV", "CHEMICAL", 45, 49], ["infection", "DISEASE", 50, 59], ["PEDV", "CHEMICAL", 95, 99], ["infection", "DISEASE", 166, 175], ["PEDV", "GENE_OR_GENE_PRODUCT", 45, 49], ["intestine", "ORGAN", 84, 93], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 114, 129], ["colonoids", "CANCER", 134, 143], ["PEDV", "SPECIES", 45, 49], ["PEDV", "SPECIES", 95, 99], ["PEDV infection", "PROBLEM", 45, 59], ["PEDV infected both ileal enteroids and colonoids", "PROBLEM", 95, 143], ["restricted infection in colonoids", "PROBLEM", 155, 188], ["segmental", "OBSERVATION_MODIFIER", 20, 29], ["discrepancy", "OBSERVATION", 30, 41], ["PEDV infection", "OBSERVATION", 45, 59], ["intestine", "ANATOMY", 84, 93], ["ileal enteroids", "ANATOMY", 114, 129], ["restricted", "OBSERVATION_MODIFIER", 155, 165], ["infection", "OBSERVATION", 166, 175]]], ["The number of PEDV genome copies in colonoids at 72 hpi was increased only approximately 5-fold compared with that at 2 hpi, whereas the number of PEDV genome copies in ileal enteroids was substantially elevated from 24 to 72 hpi to reach values at 72 h that were 1,527-fold higher than those at 2 hpi.", [["colonoids", "ANATOMY", 36, 45], ["ileal enteroids", "ANATOMY", 169, 184], ["PEDV", "GENE_OR_GENE_PRODUCT", 14, 18], ["colonoids", "PATHOLOGICAL_FORMATION", 36, 45], ["PEDV", "GENE_OR_GENE_PRODUCT", 147, 151], ["ileal enteroids", "ORGAN", 169, 184], ["PEDV genome copies", "DNA", 14, 32], ["PEDV genome copies", "DNA", 147, 165], ["PEDV", "SPECIES", 147, 151], ["PEDV genome copies in colonoids", "PROBLEM", 14, 45], ["PEDV genome copies in ileal enteroids", "PROBLEM", 147, 184], ["substantially elevated", "PROBLEM", 189, 211], ["PEDV genome", "OBSERVATION", 14, 25], ["ileal", "ANATOMY", 169, 174], ["elevated", "OBSERVATION_MODIFIER", 203, 211]]], ["Consistent with the PEDV genome numbers, at 24 to 72 hpi at the same MOIs, ileal enteroids produced up to 44-fold more infectious particles than colonic enteroids (Fig. 4C).", [["ileal enteroids", "ANATOMY", 75, 90], ["colonic enteroids", "ANATOMY", 145, 162], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 75, 90], ["colonic enteroids", "CANCER", 145, 162], ["PEDV genome", "DNA", 20, 31], ["PEDV", "SPECIES", 20, 24], ["the PEDV genome numbers", "TEST", 16, 39], ["ileal enteroids", "TREATMENT", 75, 90], ["colonic enteroids", "TREATMENT", 145, 162], ["ileal", "ANATOMY", 75, 80], ["infectious", "OBSERVATION", 119, 129]]], ["The discrepancy in infection between ileal enteroids and colonoids was further confirmed by a PEDV N protein IFA (Fig. 4D), and the results were consistent with the in vivo results: PEDV infection did not cause prominent pathological injury to colonic villi, and only a limited number of PEDV antigen-positive cells was detected in the colonic villi (Fig. 4E).", [["ileal enteroids", "ANATOMY", 37, 52], ["colonoids", "ANATOMY", 57, 66], ["colonic villi", "ANATOMY", 244, 257], ["cells", "ANATOMY", 310, 315], ["colonic villi", "ANATOMY", 336, 349], ["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 187, 196], ["ileal enteroids", "CANCER", 37, 52], ["colonoids", "CANCER", 57, 66], ["PEDV", "SIMPLE_CHEMICAL", 182, 186], ["colonic villi", "MULTI-TISSUE_STRUCTURE", 244, 257], ["PEDV antigen", "GENE_OR_GENE_PRODUCT", 288, 300], ["colonic villi", "MULTI-TISSUE_STRUCTURE", 336, 349], ["PEDV N protein IFA", "PROTEIN", 94, 112], ["PEDV antigen-positive cells", "CELL_TYPE", 288, 315], ["PEDV", "SPECIES", 182, 186], ["The discrepancy in infection", "PROBLEM", 0, 28], ["ileal enteroids and colonoids", "PROBLEM", 37, 66], ["a PEDV N protein IFA", "TEST", 92, 112], ["PEDV infection", "PROBLEM", 182, 196], ["prominent pathological injury to colonic villi", "PROBLEM", 211, 257], ["PEDV antigen", "TEST", 288, 300], ["positive cells", "PROBLEM", 301, 315], ["discrepancy", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 19, 28], ["ileal enteroids", "ANATOMY", 37, 52], ["consistent with", "UNCERTAINTY", 145, 160], ["infection", "OBSERVATION", 187, 196], ["injury", "OBSERVATION", 234, 240], ["colonic villi", "ANATOMY", 244, 257], ["positive cells", "OBSERVATION", 301, 315], ["colonic villi", "ANATOMY", 336, 349]]], ["Our results suggest that enteroids retain the internal region-specific identity among intestine segments.", [["enteroids", "ANATOMY", 25, 34], ["intestine", "ANATOMY", 86, 95], ["enteroids", "CANCER", 25, 34], ["intestine segments", "MULTI-TISSUE_STRUCTURE", 86, 104], ["enteroids", "PROBLEM", 25, 34], ["the internal region", "PROBLEM", 42, 61], ["internal", "ANATOMY_MODIFIER", 46, 54], ["intestine", "ANATOMY", 86, 95], ["segments", "ANATOMY_MODIFIER", 96, 104]]], ["These data demonstrate that enteroid systems well mimic the events that occur during PEDV infection in vivo.A clinical PEDV isolate shows better propagation in ileal enteroids than the cell-adapted strain CV777. ::: RESULTSThe growth of clinical isolates of PEDV in cell lineages such as Vero E6 cells is typically challenging.", [["ileal enteroids", "ANATOMY", 160, 175], ["cell", "ANATOMY", 185, 189], ["cell", "ANATOMY", 266, 270], ["Vero E6 cells", "ANATOMY", 288, 301], ["infection", "DISEASE", 90, 99], ["PEDV", "CHEMICAL", 258, 262], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 160, 175], ["cell", "CELL", 185, 189], ["CV777", "CELL", 205, 210], ["PEDV", "CELL", 258, 262], ["cell", "CELL", 266, 270], ["Vero E6 cells", "CELL", 288, 301], ["Vero E6 cells", "CELL_LINE", 288, 301], ["PEDV", "SPECIES", 85, 89], ["PEDV", "SPECIES", 258, 262], ["Vero E6", "SPECIES", 288, 295], ["enteroid systems", "PROBLEM", 28, 44], ["PEDV infection", "PROBLEM", 85, 99], ["A clinical PEDV isolate", "TEST", 108, 131], ["ileal enteroids", "PROBLEM", 160, 175], ["PEDV in cell lineages", "TREATMENT", 258, 279], ["Vero E6 cells", "TREATMENT", 288, 301], ["infection", "OBSERVATION", 90, 99], ["ileal", "ANATOMY", 160, 165], ["cell lineages", "OBSERVATION", 266, 279], ["E6 cells", "OBSERVATION", 293, 301]]], ["Often, cell-adapted PEDV grows well in continuous cell lines, such as Vero E6 cells, after being subjected to multiple rounds of blind passaging in the cell line.", [["cell", "ANATOMY", 7, 11], ["cell lines", "ANATOMY", 50, 60], ["Vero E6 cells", "ANATOMY", 70, 83], ["cell line", "ANATOMY", 152, 161], ["cell", "CELL", 7, 11], ["PEDV", "CELL", 20, 24], ["cell lines", "CELL", 50, 60], ["Vero E6 cells", "CELL", 70, 83], ["cell line", "CELL", 152, 161], ["PEDV", "PROTEIN", 20, 24], ["continuous cell lines", "CELL_LINE", 39, 60], ["Vero E6 cells", "CELL_LINE", 70, 83], ["cell line", "CELL_LINE", 152, 161], ["Vero E6", "SPECIES", 70, 77], ["PEDV", "PROBLEM", 20, 24], ["continuous cell lines", "TREATMENT", 39, 60], ["Vero E6 cells", "TREATMENT", 70, 83], ["blind passaging in the cell line", "TREATMENT", 129, 161], ["cell lines", "OBSERVATION", 50, 60], ["cell line", "OBSERVATION", 152, 161]]], ["We subsequently compared the replication of the clinical isolate PEDV-JMS in porcine ileal enteroids with that of the cell-adapted strain PEDV-CV777.", [["ileal enteroids", "ANATOMY", 85, 100], ["cell", "ANATOMY", 118, 122], ["PEDV", "CHEMICAL", 65, 69], ["PEDV-CV777", "CHEMICAL", 138, 148], ["porcine", "ORGANISM", 77, 84], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 85, 100], ["cell", "CELL", 118, 122], ["PEDV-CV777", "CELL", 138, 148], ["porcine", "SPECIES", 77, 84], ["porcine", "SPECIES", 77, 84], ["PEDV-CV777", "SPECIES", 138, 148], ["porcine ileal enteroids", "TREATMENT", 77, 100], ["ileal", "ANATOMY", 85, 90]]], ["After infection at equivalent MOIs, PEDV-JMS in ileal enteroids produced up to 473-fold-higher levels of viral genomes than those obtained with PEDV-CV777 throughout the study period (Fig. 5A).", [["ileal enteroids", "ANATOMY", 48, 63], ["infection", "DISEASE", 6, 15], ["PEDV", "CHEMICAL", 36, 40], ["PEDV-CV777", "CHEMICAL", 144, 154], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 48, 63], ["PEDV-JMS", "DNA", 36, 44], ["viral genomes", "DNA", 105, 118], ["PEDV", "SPECIES", 36, 40], ["PEDV", "SPECIES", 144, 148], ["infection", "PROBLEM", 6, 15], ["PEDV", "PROBLEM", 36, 40], ["JMS", "PROBLEM", 41, 44], ["ileal enteroids", "PROBLEM", 48, 63], ["higher levels of viral genomes", "PROBLEM", 88, 118], ["PEDV", "TEST", 144, 148], ["infection", "OBSERVATION", 6, 15], ["ileal", "ANATOMY", 48, 53], ["viral genomes", "OBSERVATION", 105, 118]]], ["Consistent with the RNA results, PEDV-JMS produced higher viral titers in enteroids, yielding values that were 49- to 140-fold higher than those obtained with PEDV-CV777 (Fig. 5B), which indicated that the clinical isolate PEDV-JMS exhibits better infection in ileal enteroids than the cell-adapted strain CV777.", [["enteroids", "ANATOMY", 74, 83], ["ileal enteroids", "ANATOMY", 261, 276], ["cell", "ANATOMY", 286, 290], ["PEDV", "CHEMICAL", 33, 37], ["PEDV", "CHEMICAL", 223, 227], ["JMS", "CHEMICAL", 228, 231], ["infection", "DISEASE", 248, 257], ["PEDV-JMS", "GENE_OR_GENE_PRODUCT", 33, 41], ["enteroids", "PATHOLOGICAL_FORMATION", 74, 83], ["PEDV-CV777", "ORGANISM", 159, 169], ["Fig. 5B", "ORGANISM", 171, 178], ["PEDV-JMS", "ORGANISM", 223, 231], ["ileal enteroids", "PATHOLOGICAL_FORMATION", 261, 276], ["cell", "CELL", 286, 290], ["CV777", "CELL", 306, 311], ["PEDV", "PROTEIN", 33, 37], ["JMS", "PROTEIN", 38, 41], ["PEDV-CV777", "SPECIES", 159, 169], ["the RNA results", "TEST", 16, 31], ["PEDV", "TEST", 33, 37], ["JMS", "TEST", 38, 41], ["higher viral titers in enteroids", "PROBLEM", 51, 83], ["PEDV", "TEST", 159, 163], ["the clinical isolate PEDV", "PROBLEM", 202, 227], ["JMS", "PROBLEM", 228, 231], ["better infection in ileal enteroids", "PROBLEM", 241, 276], ["viral titers", "OBSERVATION", 58, 70], ["infection", "OBSERVATION", 248, 257], ["ileal", "ANATOMY", 261, 266]]], ["PEDV N protein IFAs further confirmed that PEDV-JMS propagated better in enteroids than PEDV-CV777, even though both viruses infected enteroids (Fig. 5C).", [["enteroids", "ANATOMY", 73, 82], ["PEDV", "CHEMICAL", 43, 47], ["PEDV N protein", "GENE_OR_GENE_PRODUCT", 0, 14], ["PEDV-JMS", "GENE_OR_GENE_PRODUCT", 43, 51], ["enteroids", "CANCER", 73, 82], ["PEDV-CV777", "CELL", 88, 98], ["PEDV N protein IFAs", "PROTEIN", 0, 19], ["PEDV", "PROTEIN", 43, 47], ["JMS", "PROTEIN", 48, 51], ["PEDV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 88, 92], ["PEDV N protein IFAs", "TEST", 0, 19], ["PEDV", "PROBLEM", 43, 47], ["JMS", "PROBLEM", 48, 51], ["PEDV", "TEST", 88, 92], ["both viruses infected enteroids", "PROBLEM", 112, 143], ["viruses", "OBSERVATION_MODIFIER", 117, 124], ["infected", "OBSERVATION", 125, 133]]], ["These data indicate that enteroids can be a good culture system for isolating clinical PEDV isolates.PEDV infection suppresses the induction of innate IFN responses in enteroids. ::: RESULTSRecent studies have shown that PEDV infection inhibits the production of type I and III IFN in IEC lines such as IPEC-J2 (21).", [["enteroids", "ANATOMY", 25, 34], ["IEC lines", "ANATOMY", 285, 294], ["PEDV", "CHEMICAL", 101, 105], ["infection", "DISEASE", 106, 115], ["PEDV", "CHEMICAL", 221, 225], ["infection", "DISEASE", 226, 235], ["PEDV", "ORGANISM", 87, 91], ["IFN", "GENE_OR_GENE_PRODUCT", 151, 154], ["PEDV", "ORGANISM", 221, 225], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 263, 281], ["IEC lines", "CELL", 285, 294], ["IPEC-J2", "CELL", 303, 310], ["IFN", "PROTEIN", 151, 154], ["type I and III IFN", "PROTEIN", 263, 281], ["IEC lines", "CELL_LINE", 285, 294], ["IPEC", "CELL_LINE", 303, 307], ["PEDV", "SPECIES", 87, 91], ["PEDV", "SPECIES", 101, 105], ["PEDV", "SPECIES", 221, 225], ["enteroids", "PROBLEM", 25, 34], ["isolating clinical PEDV isolates", "PROBLEM", 68, 100], ["PEDV infection", "PROBLEM", 101, 115], ["RESULTSRecent studies", "TEST", 183, 204], ["PEDV infection", "PROBLEM", 221, 235], ["type I and III IFN in IEC lines", "PROBLEM", 263, 294], ["IPEC", "TEST", 303, 307], ["infection", "OBSERVATION", 106, 115], ["PEDV", "OBSERVATION_MODIFIER", 221, 225], ["infection", "OBSERVATION", 226, 235], ["IEC lines", "OBSERVATION", 285, 294]]], ["To verify whether PEDV infection inhibits the innate IFN responses in enteroids, we monitored the mRNA transcripts of type I IFN (IFN alpha [IFN-\u03b1]) and type III IFN lambda 1 (IFN-L1) by reverse transcriptase quantitative PCR (RT-qPCR) in enteroids at various time points after infection with PEDV-JMS.", [["enteroids", "ANATOMY", 70, 79], ["enteroids", "ANATOMY", 239, 248], ["PEDV", "CHEMICAL", 18, 22], ["infection", "DISEASE", 23, 32], ["infection", "DISEASE", 278, 287], ["PEDV", "ORGANISM", 18, 22], ["IFN", "GENE_OR_GENE_PRODUCT", 53, 56], ["enteroids", "CANCER", 70, 79], ["type I IFN", "GENE_OR_GENE_PRODUCT", 118, 128], ["IFN alpha", "GENE_OR_GENE_PRODUCT", 130, 139], ["IFN-\u03b1]", "GENE_OR_GENE_PRODUCT", 141, 147], ["type III IFN lambda 1", "GENE_OR_GENE_PRODUCT", 153, 174], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 176, 182], ["enteroids", "PATHOLOGICAL_FORMATION", 239, 248], ["IFN", "PROTEIN", 53, 56], ["enteroids", "CELL_TYPE", 70, 79], ["mRNA transcripts", "RNA", 98, 114], ["type I IFN", "PROTEIN", 118, 128], ["IFN alpha", "PROTEIN", 130, 139], ["IFN", "PROTEIN", 141, 144], ["\u03b1]", "PROTEIN", 145, 147], ["type III IFN lambda 1", "PROTEIN", 153, 174], ["IFN", "PROTEIN", 176, 179], ["L1", "DNA", 180, 182], ["reverse transcriptase", "PROTEIN", 187, 208], ["PEDV", "SPECIES", 18, 22], ["PEDV", "SPECIES", 293, 297], ["PEDV infection", "PROBLEM", 18, 32], ["type I IFN", "PROBLEM", 118, 128], ["IFN alpha", "TEST", 130, 139], ["IFN", "TEST", 141, 144], ["type III IFN lambda", "PROBLEM", 153, 172], ["quantitative PCR", "TEST", 209, 225], ["RT-qPCR", "TEST", 227, 234], ["enteroids", "TREATMENT", 239, 248], ["infection", "PROBLEM", 278, 287], ["PEDV", "PROBLEM", 293, 297], ["infection", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 278, 287]]], ["Compared with the mock uninfected control, PEDV-JMS caused a rapid and substantial reduction in the expression of IFN-\u03b1 and IFN-L1 transcripts, as observed at 2 and 12 hpi, and this decrease was followed by the induction of IFN expression after 24 hpi, indicating that PEDV infection inhibits the induction of type I and III IFN at the early stage of infection.", [["PEDV", "CHEMICAL", 43, 47], ["JMS", "CHEMICAL", 48, 51], ["PEDV", "CHEMICAL", 269, 273], ["infection", "DISEASE", 274, 283], ["infection", "DISEASE", 351, 360], ["PEDV-JMS", "ORGANISM", 43, 51], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 114, 119], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 124, 130], ["IFN", "GENE_OR_GENE_PRODUCT", 224, 227], ["PEDV", "GENE_OR_GENE_PRODUCT", 269, 273], ["type I and III IFN", "GENE_OR_GENE_PRODUCT", 310, 328], ["IFN-\u03b1 and IFN-L1 transcripts", "RNA", 114, 142], ["IFN", "PROTEIN", 224, 227], ["type I and III IFN", "PROTEIN", 310, 328], ["PEDV", "SPECIES", 43, 47], ["PEDV", "SPECIES", 269, 273], ["PEDV", "PROBLEM", 43, 47], ["a rapid and substantial reduction", "PROBLEM", 59, 92], ["IFN", "PROBLEM", 114, 117], ["IFN-L1 transcripts", "TREATMENT", 124, 142], ["IFN expression", "TREATMENT", 224, 238], ["PEDV infection", "PROBLEM", 269, 283], ["type I and III IFN", "PROBLEM", 310, 328], ["infection", "PROBLEM", 351, 360], ["rapid", "OBSERVATION_MODIFIER", 61, 66], ["substantial", "OBSERVATION_MODIFIER", 71, 82], ["reduction", "OBSERVATION_MODIFIER", 83, 92], ["PEDV", "OBSERVATION_MODIFIER", 269, 273], ["infection", "OBSERVATION", 274, 283], ["early stage", "OBSERVATION_MODIFIER", 336, 347], ["infection", "OBSERVATION", 351, 360]]], ["However, the IFN-\u03b1 and IFN-L1 expression kinetics were not identical (Fig. 6A and B): IFN-\u03b1 expression peaked at 24 hpi, whereas IFN-L1 expression peaked at 48 hpi.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 13, 18], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 23, 29], ["B", "GENE_OR_GENE_PRODUCT", 82, 83], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 86, 91], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 129, 135], ["IFN", "PROTEIN", 13, 16], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 86, 89], ["\u03b1", "PROTEIN", 90, 91], ["IFN", "PROTEIN", 129, 132], ["the IFN", "TEST", 9, 16], ["IFN", "TEST", 23, 26], ["L1 expression kinetics", "PROBLEM", 27, 49], ["IFN", "PROBLEM", 86, 89], ["IFN", "TEST", 129, 132]]], ["To further verify that PEDV infection suppresses the induction of IFNs, we assessed IFN-L1 production after stimulating PEDV-infected enteroids at 12 hpi with poly(I\u00b7C) for 12 h.", [["enteroids", "ANATOMY", 134, 143], ["PEDV", "CHEMICAL", 23, 27], ["infection", "DISEASE", 28, 37], ["PEDV", "CHEMICAL", 120, 124], ["poly(I\u00b7C)", "CHEMICAL", 159, 168], ["PEDV", "ORGANISM", 23, 27], ["IFNs", "GENE_OR_GENE_PRODUCT", 66, 70], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 84, 90], ["PEDV", "SIMPLE_CHEMICAL", 120, 124], ["enteroids", "CELL", 134, 143], ["IFNs", "PROTEIN", 66, 70], ["IFN", "PROTEIN", 84, 87], ["PEDV", "PROTEIN", 120, 124], ["PEDV", "SPECIES", 23, 27], ["PEDV", "SPECIES", 120, 124], ["PEDV infection", "PROBLEM", 23, 37], ["the induction of IFNs", "TREATMENT", 49, 70], ["IFN", "TEST", 84, 87], ["L1 production", "PROBLEM", 88, 101], ["stimulating PEDV", "PROBLEM", 108, 124], ["infected enteroids", "PROBLEM", 125, 143], ["poly(I\u00b7C)", "TREATMENT", 159, 168], ["infection", "OBSERVATION", 28, 37]]], ["Stimulation with poly(I\u00b7C) substantially increased the expression of IFN-L1 in enteroids (Fig. 6C), which suggested that enteroids are capable of efficiently producing IFN-L1.", [["enteroids", "ANATOMY", 121, 130], ["poly(I\u00b7C", "CHEMICAL", 17, 25], ["poly(I\u00b7C)", "CHEMICAL", 17, 26], ["poly(I\u00b7C", "SIMPLE_CHEMICAL", 17, 25], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 69, 75], ["enteroids", "PATHOLOGICAL_FORMATION", 79, 88], ["enteroids", "CANCER", 121, 130], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 168, 174], ["IFN", "PROTEIN", 69, 72], ["L1", "PROTEIN", 73, 75], ["IFN", "PROTEIN", 168, 171], ["L1", "PROTEIN", 172, 174], ["Stimulation with poly(I\u00b7C)", "TREATMENT", 0, 26], ["IFN-L1 in enteroids", "TREATMENT", 69, 88], ["enteroids", "PROBLEM", 121, 130], ["L1", "ANATOMY", 172, 174]]], ["In contrast, PEDV infection for 12 hpi significantly reduced the poly(I\u00b7C)-elicited production of IFN-L1 (Fig. 6C), which suggested that PEDV suppresses IFN production in enteroids.", [["enteroids", "ANATOMY", 171, 180], ["PEDV", "CHEMICAL", 13, 17], ["infection", "DISEASE", 18, 27], ["poly", "CHEMICAL", 65, 69], ["PEDV", "CHEMICAL", 137, 141], ["poly(I\u00b7C)", "CHEMICAL", 65, 74], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 98, 104], ["PEDV", "SIMPLE_CHEMICAL", 137, 141], ["IFN", "GENE_OR_GENE_PRODUCT", 153, 156], ["enteroids", "CANCER", 171, 180], ["IFN", "PROTEIN", 98, 101], ["L1", "PROTEIN", 102, 104], ["IFN", "PROTEIN", 153, 156], ["PEDV", "SPECIES", 13, 17], ["PEDV", "SPECIES", 137, 141], ["PEDV infection", "PROBLEM", 13, 27], ["IFN", "PROBLEM", 98, 101], ["PEDV suppresses IFN production in enteroids", "PROBLEM", 137, 180], ["infection", "OBSERVATION", 18, 27]]], ["These findings indicate that intestinal enteroids are a suitable ex vivo model for the study of innate immunity in response to PEDV infection.IFN-L1 induces potent ISG expression and inhibits PEDV infection in ileal enteroids. ::: RESULTSWe and others have shown that compared with IFN-\u03b1, IFN-L1 selectively acts on IPEC-J2 cells and induces potent interferon-stimulated gene (ISG) expression (21, 28).", [["intestinal enteroids", "ANATOMY", 29, 49], ["ileal enteroids", "ANATOMY", 210, 225], ["IPEC-J2 cells", "ANATOMY", 316, 329], ["infection", "DISEASE", 132, 141], ["infection", "DISEASE", 197, 206], ["intestinal enteroids", "CELL", 29, 49], ["PEDV", "ORGANISM", 127, 131], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 142, 148], ["ISG", "GENE_OR_GENE_PRODUCT", 164, 167], ["PEDV", "SIMPLE_CHEMICAL", 192, 196], ["ileal enteroids", "CANCER", 210, 225], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 282, 287], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 289, 295], ["IPEC-J2 cells", "CELL", 316, 329], ["interferon-stimulated gene", "GENE_OR_GENE_PRODUCT", 349, 375], ["ISG", "GENE_OR_GENE_PRODUCT", 377, 380], ["IFN", "PROTEIN", 142, 145], ["L1", "PROTEIN", 146, 148], ["ISG", "PROTEIN", 164, 167], ["IFN", "PROTEIN", 282, 285], ["\u03b1", "PROTEIN", 286, 287], ["IFN", "PROTEIN", 289, 292], ["L1", "PROTEIN", 293, 295], ["IPEC-J2 cells", "CELL_LINE", 316, 329], ["interferon-stimulated gene", "DNA", 349, 375], ["ISG", "DNA", 377, 380], ["PEDV", "SPECIES", 127, 131], ["PEDV", "SPECIES", 192, 196], ["intestinal enteroids", "PROBLEM", 29, 49], ["the study", "TEST", 83, 92], ["innate immunity", "TREATMENT", 96, 111], ["PEDV infection", "PROBLEM", 127, 141], ["potent ISG expression", "PROBLEM", 157, 178], ["PEDV infection in ileal enteroids", "PROBLEM", 192, 225], ["IFN", "TEST", 282, 285], ["IFN", "TREATMENT", 289, 292], ["IPEC-J2 cells", "TREATMENT", 316, 329], ["potent interferon", "TREATMENT", 342, 359], ["intestinal", "ANATOMY", 29, 39], ["enteroids", "OBSERVATION", 40, 49], ["PEDV", "OBSERVATION_MODIFIER", 127, 131], ["infection", "OBSERVATION", 132, 141], ["L1", "ANATOMY", 146, 148], ["potent", "OBSERVATION_MODIFIER", 157, 163], ["ISG expression", "OBSERVATION", 164, 178], ["PEDV", "OBSERVATION_MODIFIER", 192, 196], ["infection", "OBSERVATION", 197, 206], ["ileal enteroids", "OBSERVATION", 210, 225]]], ["To gauge the antiviral activities of type III and I IFNs against virus infection in enteroids, we initially monitored ISG expression in enteroids that had been primed for 24 h with either IFN-L1 or IFN-\u03b1.", [["enteroids", "ANATOMY", 84, 93], ["enteroids", "ANATOMY", 136, 145], ["infection", "DISEASE", 71, 80], ["type III and I IFNs", "GENE_OR_GENE_PRODUCT", 37, 56], ["enteroids", "CANCER", 84, 93], ["ISG", "GENE_OR_GENE_PRODUCT", 118, 121], ["enteroids", "CANCER", 136, 145], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 188, 194], ["type III and I IFNs", "PROTEIN", 37, 56], ["IFN", "PROTEIN", 188, 191], ["IFN", "PROTEIN", 198, 201], ["type III", "PROBLEM", 37, 45], ["virus infection in enteroids", "PROBLEM", 65, 93]]], ["Both IFN-L1 and IFN-\u03b1 elicited potent expression of interferon-stimulated gene 15 (ISG15) (Fig. 7A), MxA (Fig. 7B), 2\u2032-5\u2032-oligoadenylate synthetase-like protein (OASL) (Fig. 7C), and interferon-induced transmembrane protein 1 (IFITM1) (Fig. 7D) in a dose-dependent manner after stimulation.", [["IFN-L1", "GENE_OR_GENE_PRODUCT", 5, 11], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["interferon-stimulated gene 15", "GENE_OR_GENE_PRODUCT", 52, 81], ["ISG15", "GENE_OR_GENE_PRODUCT", 83, 88], ["Fig. 7A", "GENE_OR_GENE_PRODUCT", 91, 98], ["MxA", "GENE_OR_GENE_PRODUCT", 101, 104], ["Fig. 7B", "GENE_OR_GENE_PRODUCT", 106, 113], ["2\u2032-5\u2032-oligoadenylate synthetase-like protein", "GENE_OR_GENE_PRODUCT", 116, 160], ["OASL", "GENE_OR_GENE_PRODUCT", 162, 166], ["Fig. 7C", "GENE_OR_GENE_PRODUCT", 169, 176], ["interferon-induced transmembrane protein 1", "GENE_OR_GENE_PRODUCT", 183, 225], ["IFITM1", "GENE_OR_GENE_PRODUCT", 227, 233], ["IFN", "PROTEIN", 5, 8], ["L1", "PROTEIN", 9, 11], ["IFN", "PROTEIN", 16, 19], ["interferon-stimulated gene 15", "DNA", 52, 81], ["ISG15", "DNA", 83, 88], ["MxA", "DNA", 101, 104], ["2\u2032", "DNA", 116, 118], ["5\u2032", "DNA", 119, 121], ["oligoadenylate synthetase", "PROTEIN", 122, 147], ["like protein", "PROTEIN", 148, 160], ["OASL", "PROTEIN", 162, 166], ["interferon-induced transmembrane protein 1", "PROTEIN", 183, 225], ["IFITM1", "PROTEIN", 227, 233], ["interferon", "TREATMENT", 52, 62], ["MxA", "TEST", 101, 104], ["2\u2032", "TEST", 116, 118], ["oligoadenylate synthetase", "TREATMENT", 122, 147], ["interferon", "TREATMENT", 183, 193], ["transmembrane protein", "TEST", 202, 223], ["L1", "ANATOMY", 9, 11]]], ["Consistent with the above-described results for IPEC-J2 cells, IFN-L1 induced significantly higher levels of ISG15, OASL, MxA, and IFITM1 in enteroids than IFN-\u03b1, regardless of the concentrations of IFNs (Fig. 7A to D).", [["IPEC-J2 cells", "ANATOMY", 48, 61], ["enteroids", "ANATOMY", 141, 150], ["IPEC-J2 cells", "CELL", 48, 61], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 63, 69], ["ISG15", "GENE_OR_GENE_PRODUCT", 109, 114], ["OASL", "GENE_OR_GENE_PRODUCT", 116, 120], ["MxA", "GENE_OR_GENE_PRODUCT", 122, 125], ["IFITM1", "GENE_OR_GENE_PRODUCT", 131, 137], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 156, 161], ["IFNs", "GENE_OR_GENE_PRODUCT", 199, 203], ["IPEC-J2 cells", "CELL_LINE", 48, 61], ["IFN", "PROTEIN", 63, 66], ["L1", "PROTEIN", 67, 69], ["ISG15", "PROTEIN", 109, 114], ["OASL", "PROTEIN", 116, 120], ["MxA", "PROTEIN", 122, 125], ["IFITM1", "PROTEIN", 131, 137], ["IFN", "PROTEIN", 156, 159], ["\u03b1", "PROTEIN", 160, 161], ["IFNs", "PROTEIN", 199, 203], ["IPEC", "TEST", 48, 52], ["J2 cells", "PROBLEM", 53, 61], ["IFN", "TEST", 63, 66], ["ISG15", "TEST", 109, 114], ["OASL", "TEST", 116, 120], ["MxA", "TEST", 122, 125], ["IFITM1 in enteroids", "PROBLEM", 131, 150], ["IFN", "TEST", 156, 159], ["J2 cells", "OBSERVATION", 53, 61]]], ["In agreement with the ISG expression profiles elicited by IFN-L1 and IFN-\u03b1, both IFN-L1 and IFN-\u03b1 inhibited PEDV infection in enteroids in a dose-dependent manner, although IFN-L1 showed stronger antiviral activity against PEDV than IFN-\u03b1 (Fig. 7E and F).", [["enteroids", "ANATOMY", 126, 135], ["PEDV", "CHEMICAL", 108, 112], ["infection", "DISEASE", 113, 122], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 58, 64], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 74], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 81, 87], ["IFN-\u03b1", "SIMPLE_CHEMICAL", 92, 97], ["PEDV", "SIMPLE_CHEMICAL", 108, 112], ["enteroids", "CANCER", 126, 135], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 173, 179], ["PEDV", "SIMPLE_CHEMICAL", 223, 227], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 233, 238], ["IFN", "PROTEIN", 58, 61], ["L1", "PROTEIN", 62, 64], ["IFN", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 81, 84], ["L1", "PROTEIN", 85, 87], ["IFN", "PROTEIN", 92, 95], ["IFN", "PROTEIN", 173, 176], ["L1", "PROTEIN", 177, 179], ["PEDV", "PROTEIN", 223, 227], ["IFN", "PROTEIN", 233, 236], ["PEDV", "SPECIES", 108, 112], ["PEDV", "SPECIES", 223, 227], ["the ISG expression profiles", "TEST", 18, 45], ["IFN", "TEST", 58, 61], ["IFN", "TEST", 69, 72], ["IFN", "PROBLEM", 92, 95], ["\u03b1", "PROBLEM", 96, 97], ["PEDV infection in enteroids", "PROBLEM", 108, 135], ["IFN", "TEST", 173, 176], ["PEDV", "PROBLEM", 223, 227], ["IFN", "TEST", 233, 236], ["L1", "ANATOMY", 85, 87], ["PEDV", "OBSERVATION_MODIFIER", 108, 112], ["infection", "OBSERVATION", 113, 122]]], ["These results demonstrate that IFN-L1 exhibits increased activity on enteroids compared to IFN-\u03b1.", [["enteroids", "ANATOMY", 69, 78], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 31, 37], ["enteroids", "CANCER", 69, 78], ["IFN", "PROTEIN", 31, 34], ["L1", "PROTEIN", 35, 37], ["IFN", "PROTEIN", 91, 94], ["IFN", "TEST", 31, 34], ["increased activity on enteroids", "PROBLEM", 47, 78], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["activity", "OBSERVATION_MODIFIER", 57, 65]]], ["In summary, intestinal enteroids present a good in vitro model for evaluating the innate response to PEDV infection.DISCUSSIONPEDV is primarily transmitted through the fecal-oral route and infects intestinal villous epithelial cells in vivo (12, 27).", [["intestinal enteroids", "ANATOMY", 12, 32], ["fecal", "ANATOMY", 168, 173], ["oral", "ANATOMY", 174, 178], ["intestinal villous epithelial cells", "ANATOMY", 197, 232], ["PEDV", "CHEMICAL", 101, 105], ["infection", "DISEASE", 106, 115], ["intestinal enteroids", "CELL", 12, 32], ["PEDV", "ORGANISM", 101, 105], ["fecal", "ORGANISM_SUBDIVISION", 168, 173], ["oral", "ORGANISM_SUBDIVISION", 174, 178], ["intestinal villous epithelial cells", "CELL", 197, 232], ["intestinal villous epithelial cells", "CELL_TYPE", 197, 232], ["PEDV", "SPECIES", 101, 105], ["intestinal enteroids", "PROBLEM", 12, 32], ["PEDV infection", "PROBLEM", 101, 115], ["intestinal", "ANATOMY", 12, 22], ["infection", "OBSERVATION", 106, 115], ["fecal", "ANATOMY", 168, 173], ["intestinal villous", "ANATOMY", 197, 215], ["epithelial cells", "OBSERVATION", 216, 232]]], ["Current in vitro cell culture models of PEDV include Vero cells (29), MARC-145 cells (another monkey kidney cell line), HEK293 cells (30), and IPEC-J2 cells (21, 31), and most of these are nonporcine intestinal epithelial cells and thus not the ideal in vitro cellular models for studying the interaction between PEDV infection and the host response due to interspecific variation.", [["cell", "ANATOMY", 17, 21], ["Vero cells", "ANATOMY", 53, 63], ["MARC-145 cells", "ANATOMY", 70, 84], ["kidney cell line", "ANATOMY", 101, 117], ["HEK293 cells", "ANATOMY", 120, 132], ["IPEC-J2 cells", "ANATOMY", 143, 156], ["intestinal epithelial cells", "ANATOMY", 200, 227], ["cellular", "ANATOMY", 260, 268], ["PEDV infection", "DISEASE", 313, 327], ["cell", "CELL", 17, 21], ["PEDV", "CELL", 40, 44], ["Vero cells", "CELL", 53, 63], ["29", "CELL", 65, 67], ["MARC-145 cells", "CELL", 70, 84], ["monkey", "ORGANISM", 94, 100], ["kidney cell line", "CELL", 101, 117], ["HEK293 cells", "CELL", 120, 132], ["IPEC-J2 cells", "CELL", 143, 156], ["intestinal epithelial cells", "CELL", 200, 227], ["cellular", "CELL", 260, 268], ["PEDV", "GENE_OR_GENE_PRODUCT", 313, 317], ["Vero cells", "CELL_LINE", 53, 63], ["MARC-145 cells", "CELL_LINE", 70, 84], ["monkey kidney cell line", "CELL_LINE", 94, 117], ["HEK293 cells", "CELL_LINE", 120, 132], ["IPEC-J2 cells", "CELL_LINE", 143, 156], ["nonporcine intestinal epithelial cells", "CELL_TYPE", 189, 227], ["monkey", "SPECIES", 94, 100], ["PEDV", "SPECIES", 40, 44], ["MARC-145", "SPECIES", 70, 78], ["Current in vitro cell culture models", "TEST", 0, 36], ["PEDV", "PROBLEM", 40, 44], ["Vero cells", "TEST", 53, 63], ["MARC", "TEST", 70, 74], ["monkey kidney cell line", "TEST", 94, 117], ["HEK293 cells", "TEST", 120, 132], ["IPEC-J2 cells", "TEST", 143, 156], ["nonporcine intestinal epithelial cells", "PROBLEM", 189, 227], ["PEDV infection", "PROBLEM", 313, 327], ["interspecific variation", "PROBLEM", 357, 380], ["vitro cell", "OBSERVATION", 11, 21], ["Vero cells", "OBSERVATION", 53, 63], ["145 cells", "OBSERVATION_MODIFIER", 75, 84], ["kidney", "ANATOMY", 101, 107], ["cell line", "OBSERVATION", 108, 117], ["J2 cells", "ANATOMY", 148, 156], ["intestinal", "ANATOMY", 200, 210], ["epithelial cells", "OBSERVATION", 211, 227], ["infection", "OBSERVATION", 318, 327], ["interspecific variation", "OBSERVATION", 357, 380]]], ["Although IPEC-J2 cells are a nontransformed porcine intestinal epithelial cell line, these cells lack the complexity of the cell types found in and the architecture of the intestinal epithelium and thus do not satisfactorily mimic the natural infection process.", [["IPEC-J2 cells", "ANATOMY", 9, 22], ["intestinal epithelial cell line", "ANATOMY", 52, 83], ["cells", "ANATOMY", 91, 96], ["cell", "ANATOMY", 124, 128], ["intestinal epithelium", "ANATOMY", 172, 193], ["infection", "DISEASE", 243, 252], ["IPEC-J2 cells", "CELL", 9, 22], ["porcine", "ORGANISM", 44, 51], ["intestinal epithelial cell line", "CELL", 52, 83], ["cells", "CELL", 91, 96], ["cell", "CELL", 124, 128], ["intestinal epithelium", "TISSUE", 172, 193], ["IPEC-J2 cells", "CELL_LINE", 9, 22], ["nontransformed porcine intestinal epithelial cell line", "CELL_LINE", 29, 83], ["porcine", "SPECIES", 44, 51], ["IPEC", "TEST", 9, 13], ["J2 cells", "PROBLEM", 14, 22], ["a nontransformed porcine intestinal epithelial cell line", "TREATMENT", 27, 83], ["these cells", "PROBLEM", 85, 96], ["the cell types", "PROBLEM", 120, 134], ["the natural infection process", "PROBLEM", 231, 260], ["J2 cells", "OBSERVATION", 14, 22], ["nontransformed", "OBSERVATION_MODIFIER", 29, 43], ["porcine", "OBSERVATION_MODIFIER", 44, 51], ["intestinal epithelial cell line", "OBSERVATION", 52, 83], ["complexity", "OBSERVATION_MODIFIER", 106, 116], ["cell types", "OBSERVATION", 124, 134], ["intestinal epithelium", "ANATOMY", 172, 193], ["natural", "OBSERVATION_MODIFIER", 235, 242], ["infection", "OBSERVATION", 243, 252]]], ["Intestinal enteroids represent a significant advantage over traditional in vitro models and provide a unique opportunity to explore host-pathogen interactions in an in vitro system that recapitulates the complicated cellularity of the GI tract.", [["Intestinal enteroids", "ANATOMY", 0, 20], ["GI tract", "ANATOMY", 235, 243], ["Intestinal enteroids", "CANCER", 0, 20], ["GI tract", "ORGANISM_SUBDIVISION", 235, 243], ["Intestinal enteroids", "PROBLEM", 0, 20], ["a significant advantage", "PROBLEM", 31, 54], ["host-pathogen interactions", "PROBLEM", 132, 158], ["the complicated cellularity of the GI tract", "PROBLEM", 200, 243], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["advantage", "OBSERVATION", 45, 54], ["complicated", "OBSERVATION_MODIFIER", 204, 215], ["cellularity", "OBSERVATION", 216, 227], ["GI tract", "ANATOMY", 235, 243]]], ["Although great progress has been achieved in generating human and mouse intestinal enteroids and using ex vivo systems to better understand the intestinal physiology and pathophysiology of enteric infection, previous studies have not investigated enteric viral infection in enteroids derived from porcine crypt stem cells.", [["intestinal enteroids", "ANATOMY", 72, 92], ["intestinal", "ANATOMY", 144, 154], ["enteroids", "ANATOMY", 274, 283], ["crypt stem cells", "ANATOMY", 305, 321], ["enteric infection", "DISEASE", 189, 206], ["viral infection", "DISEASE", 255, 270], ["human", "ORGANISM", 56, 61], ["mouse", "ORGANISM", 66, 71], ["intestinal enteroids", "CANCER", 72, 92], ["intestinal", "ORGAN", 144, 154], ["enteric", "ANATOMICAL_SYSTEM", 189, 196], ["enteroids", "CANCER", 274, 283], ["porcine", "ORGANISM", 297, 304], ["crypt stem cells", "CELL", 305, 321], ["porcine crypt stem cells", "CELL_TYPE", 297, 321], ["human", "SPECIES", 56, 61], ["mouse", "SPECIES", 66, 71], ["human", "SPECIES", 56, 61], ["mouse", "SPECIES", 66, 71], ["porcine", "SPECIES", 297, 304], ["mouse intestinal enteroids", "TREATMENT", 66, 92], ["ex vivo systems", "TREATMENT", 103, 118], ["the intestinal physiology", "PROBLEM", 140, 165], ["enteric infection", "PROBLEM", 189, 206], ["previous studies", "TEST", 208, 224], ["enteric viral infection in enteroids", "PROBLEM", 247, 283], ["intestinal", "ANATOMY", 72, 82], ["intestinal", "ANATOMY", 144, 154], ["enteric", "ANATOMY", 189, 196], ["infection", "OBSERVATION", 197, 206], ["viral", "OBSERVATION_MODIFIER", 255, 260], ["infection", "OBSERVATION", 261, 270], ["crypt stem cells", "OBSERVATION", 305, 321]]], ["Here, we established a porcine enteroid culture system from crypt cells that contains enterocytes, enteroendocrine cells, goblet cells, Paneth cells, and stem cells and found that the proposed system well recapitulates the complex intestinal epithelium in vivo (Fig. 1).", [["crypt cells", "ANATOMY", 60, 71], ["enterocytes", "ANATOMY", 86, 97], ["enteroendocrine cells", "ANATOMY", 99, 120], ["goblet cells", "ANATOMY", 122, 134], ["Paneth cells", "ANATOMY", 136, 148], ["stem cells", "ANATOMY", 154, 164], ["intestinal epithelium", "ANATOMY", 231, 252], ["porcine", "ORGANISM", 23, 30], ["crypt cells", "CELL", 60, 71], ["enterocytes", "CELL", 86, 97], ["enteroendocrine cells", "CELL", 99, 120], ["goblet cells", "CELL", 122, 134], ["Paneth cells", "CELL", 136, 148], ["stem cells", "CELL", 154, 164], ["intestinal epithelium", "TISSUE", 231, 252], ["porcine enteroid culture system", "CELL_LINE", 23, 54], ["crypt cells", "CELL_TYPE", 60, 71], ["enterocytes", "CELL_TYPE", 86, 97], ["enteroendocrine cells", "CELL_TYPE", 99, 120], ["goblet cells", "CELL_TYPE", 122, 134], ["Paneth cells", "CELL_TYPE", 136, 148], ["stem cells", "CELL_TYPE", 154, 164], ["a porcine enteroid culture system", "TEST", 21, 54], ["crypt cells", "PROBLEM", 60, 71], ["enteroendocrine cells", "TEST", 99, 120], ["goblet cells", "TEST", 122, 134], ["Paneth cells", "TEST", 136, 148], ["stem cells", "TEST", 154, 164], ["the complex intestinal epithelium", "PROBLEM", 219, 252], ["crypt cells", "OBSERVATION", 60, 71], ["enterocytes", "ANATOMY", 86, 97], ["enteroendocrine cells", "OBSERVATION", 99, 120], ["goblet cells", "OBSERVATION", 122, 134], ["Paneth cells", "OBSERVATION", 136, 148], ["stem cells", "OBSERVATION", 154, 164], ["intestinal epithelium", "ANATOMY", 231, 252]]], ["The porcine crypt enteroids derived from all three small intestinal regions were found to be permissive to infection by PEDV and provide a unique platform for studying intestinal physiology and a variety of biological aspects of porcine enteric pathogens.DISCUSSIONThe use of enteroids represents a significant advantage over traditional in vitro methods because they closely mimic the structure and function of the small intestine while maintaining the genetic identity of the host.", [["crypt enteroids", "ANATOMY", 12, 27], ["intestinal", "ANATOMY", 57, 67], ["intestinal", "ANATOMY", 168, 178], ["small intestine", "ANATOMY", 416, 431], ["infection", "DISEASE", 107, 116], ["porcine", "ORGANISM", 4, 11], ["crypt enteroids", "CANCER", 12, 27], ["intestinal", "ORGAN", 57, 67], ["intestinal", "ORGAN", 168, 178], ["porcine", "ORGANISM", 229, 236], ["small intestine", "ORGAN", 416, 431], ["PEDV", "SPECIES", 120, 124], ["The porcine crypt enteroids", "TREATMENT", 0, 27], ["infection", "PROBLEM", 107, 116], ["PEDV", "PROBLEM", 120, 124], ["porcine enteric pathogens", "PROBLEM", 229, 254], ["enteroids", "TREATMENT", 276, 285], ["a significant advantage", "PROBLEM", 297, 320], ["traditional in vitro methods", "TREATMENT", 326, 354], ["porcine crypt enteroids", "OBSERVATION", 4, 27], ["small", "OBSERVATION_MODIFIER", 51, 56], ["intestinal", "ANATOMY", 57, 67], ["infection", "OBSERVATION", 107, 116], ["porcine enteric pathogens", "OBSERVATION", 229, 254], ["significant", "OBSERVATION_MODIFIER", 299, 310], ["advantage", "OBSERVATION_MODIFIER", 311, 320], ["small intestine", "ANATOMY", 416, 431]]], ["Enteroids derived from crypt stem cells from different intestinal segments of the same donor allow assessment of the contributions of different intestinal segments to PEDV infection.", [["crypt stem cells", "ANATOMY", 23, 39], ["intestinal segments", "ANATOMY", 55, 74], ["intestinal", "ANATOMY", 144, 154], ["infection", "DISEASE", 172, 181], ["crypt stem cells", "CELL", 23, 39], ["intestinal segments", "MULTI-TISSUE_STRUCTURE", 55, 74], ["intestinal segments", "MULTI-TISSUE_STRUCTURE", 144, 163], ["PEDV", "GENE_OR_GENE_PRODUCT", 167, 171], ["crypt stem cells", "CELL_TYPE", 23, 39], ["PEDV", "SPECIES", 167, 171], ["Enteroids", "TREATMENT", 0, 9], ["crypt stem cells", "PROBLEM", 23, 39], ["different intestinal segments to PEDV infection", "PROBLEM", 134, 181], ["crypt stem cells", "OBSERVATION", 23, 39], ["intestinal segments", "ANATOMY_MODIFIER", 55, 74], ["intestinal segments", "ANATOMY", 144, 163], ["PEDV", "OBSERVATION_MODIFIER", 167, 171], ["infection", "OBSERVATION", 172, 181]]], ["Previous studies and our results have shown that PEDV largely infects the epithelial cells of the small intestine and occasionally infects colon epithelial cells (Fig. 2 to 4) (27, 32).", [["epithelial cells", "ANATOMY", 74, 90], ["small intestine", "ANATOMY", 98, 113], ["colon epithelial cells", "ANATOMY", 139, 161], ["PEDV", "CHEMICAL", 49, 53], ["PEDV", "GENE_OR_GENE_PRODUCT", 49, 53], ["epithelial cells", "CELL", 74, 90], ["small intestine", "ORGAN", 98, 113], ["colon epithelial cells", "CELL", 139, 161], ["PEDV", "PROTEIN", 49, 53], ["epithelial cells", "CELL_TYPE", 74, 90], ["colon epithelial cells", "CELL_TYPE", 139, 161], ["PEDV", "SPECIES", 49, 53], ["Previous studies", "TEST", 0, 16], ["PEDV", "PROBLEM", 49, 53], ["occasionally infects colon epithelial cells", "PROBLEM", 118, 161], ["PEDV", "OBSERVATION", 49, 53], ["infects", "OBSERVATION", 62, 69], ["epithelial cells", "OBSERVATION", 74, 90], ["small intestine", "ANATOMY", 98, 113], ["occasionally", "OBSERVATION_MODIFIER", 118, 130], ["infects", "OBSERVATION_MODIFIER", 131, 138], ["colon", "ANATOMY", 139, 144], ["epithelial cells", "OBSERVATION", 145, 161]]], ["In fact, we observed differential susceptibilities to PEDV infection between colonoids and ileal enteroids (Fig. 4B to D), indicating that the segment-specific difference is maintained ex vivo in enteroid cultures.", [["colonoids", "ANATOMY", 77, 86], ["ileal enteroids", "ANATOMY", 91, 106], ["enteroid cultures", "ANATOMY", 196, 213], ["PEDV", "CHEMICAL", 54, 58], ["infection", "DISEASE", 59, 68], ["PEDV", "SIMPLE_CHEMICAL", 54, 58], ["colonoids", "CANCER", 77, 86], ["ileal enteroids", "CANCER", 91, 106], ["enteroid cultures", "CELL", 196, 213], ["enteroid cultures", "CELL_LINE", 196, 213], ["PEDV", "SPECIES", 54, 58], ["PEDV infection between colonoids", "PROBLEM", 54, 86], ["ileal enteroids", "PROBLEM", 91, 106], ["enteroid cultures", "TEST", 196, 213], ["PEDV", "OBSERVATION_MODIFIER", 54, 58], ["infection", "OBSERVATION", 59, 68], ["ileal enteroids", "ANATOMY", 91, 106], ["segment", "ANATOMY_MODIFIER", 143, 150]]], ["These data illustrate the utility of the enteroid system for addressing fundamental aspects of PEDV that cannot be modeled using standard cell lines.DISCUSSIONDue to their unique features, enteroids better mimic the multiple cell types of the intestinal epithelium in vivo than traditional cell line models.", [["cell lines", "ANATOMY", 138, 148], ["enteroids", "ANATOMY", 189, 198], ["cell", "ANATOMY", 225, 229], ["intestinal epithelium", "ANATOMY", 243, 264], ["cell line", "ANATOMY", 290, 299], ["PEDV", "ORGANISM", 95, 99], ["cell lines", "CELL", 138, 148], ["enteroids", "CANCER", 189, 198], ["cell", "CELL", 225, 229], ["intestinal epithelium", "TISSUE", 243, 264], ["cell line", "CELL", 290, 299], ["standard cell lines", "CELL_LINE", 129, 148], ["PEDV", "SPECIES", 95, 99], ["the enteroid system", "TREATMENT", 37, 56], ["PEDV", "PROBLEM", 95, 99], ["standard cell lines", "TREATMENT", 129, 148], ["the intestinal epithelium", "PROBLEM", 239, 264], ["traditional cell line models", "TREATMENT", 278, 306], ["PEDV", "OBSERVATION", 95, 99], ["cell lines", "OBSERVATION", 138, 148], ["multiple", "OBSERVATION_MODIFIER", 216, 224], ["cell types", "OBSERVATION", 225, 235], ["intestinal epithelium", "ANATOMY", 243, 264], ["cell line", "OBSERVATION", 290, 299]]], ["We observed that PEDV was capable of infecting goblet cells and stem cells in addition to the primary cellular target, villous mature enterocytes, in the enteroids, and this finding was confirmed in vivo in the PEDV-infected ileum (Fig. 3C).", [["goblet cells", "ANATOMY", 47, 59], ["stem cells", "ANATOMY", 64, 74], ["cellular", "ANATOMY", 102, 110], ["villous", "ANATOMY", 119, 126], ["enterocytes", "ANATOMY", 134, 145], ["enteroids", "ANATOMY", 154, 163], ["ileum", "ANATOMY", 225, 230], ["PEDV", "CHEMICAL", 17, 21], ["PEDV", "SIMPLE_CHEMICAL", 17, 21], ["goblet cells", "CELL", 47, 59], ["stem cells", "CELL", 64, 74], ["cellular", "CELL", 102, 110], ["villous mature enterocytes", "CELL", 119, 145], ["PEDV", "ORGANISM", 211, 215], ["ileum", "MULTI-TISSUE_STRUCTURE", 225, 230], ["PEDV", "PROTEIN", 17, 21], ["goblet cells", "CELL_TYPE", 47, 59], ["stem cells", "CELL_TYPE", 64, 74], ["villous mature enterocytes", "CELL_TYPE", 119, 145], ["PEDV", "SPECIES", 17, 21], ["PEDV", "SPECIES", 211, 215], ["PEDV", "PROBLEM", 17, 21], ["infecting goblet cells", "PROBLEM", 37, 59], ["stem cells", "PROBLEM", 64, 74], ["villous mature enterocytes", "PROBLEM", 119, 145], ["PEDV", "OBSERVATION", 17, 21], ["goblet cells", "OBSERVATION", 47, 59], ["stem cells", "OBSERVATION", 64, 74], ["cellular target", "OBSERVATION", 102, 117], ["villous mature enterocytes", "OBSERVATION", 119, 145], ["infected", "OBSERVATION", 216, 224], ["ileum", "ANATOMY", 225, 230]]], ["The intestinal epithelium is a rapidly self-renewing tissue, and the turnover rate for complete renewal is approximately 3 to 5 days (33).", [["intestinal epithelium", "ANATOMY", 4, 25], ["tissue", "ANATOMY", 53, 59], ["intestinal epithelium", "TISSUE", 4, 25], ["tissue", "TISSUE", 53, 59], ["intestinal epithelium", "ANATOMY", 4, 25], ["rapidly", "OBSERVATION_MODIFIER", 31, 38], ["renewing tissue", "OBSERVATION_MODIFIER", 44, 59]]], ["The Lgr5+ stem cells in crypts are primarily responsible for replenishing the intestinal epithelium at a high rate of turnover.", [["Lgr5+ stem cells", "ANATOMY", 4, 20], ["crypts", "ANATOMY", 24, 30], ["intestinal epithelium", "ANATOMY", 78, 99], ["Lgr5+ stem cells", "CELL", 4, 20], ["crypts", "MULTI-TISSUE_STRUCTURE", 24, 30], ["intestinal epithelium", "TISSUE", 78, 99], ["Lgr5+ stem cells", "CELL_LINE", 4, 20], ["crypts", "PROBLEM", 24, 30], ["the intestinal epithelium", "PROBLEM", 74, 99], ["stem cells", "OBSERVATION", 10, 20], ["primarily responsible for", "UNCERTAINTY", 35, 60], ["intestinal epithelium", "ANATOMY", 78, 99]]], ["PEDV infection is cytolytic and causes acute necrosis of the infected enterocytes, leading to marked intestinal villous atrophy (12, 14, 15).", [["enterocytes", "ANATOMY", 70, 81], ["intestinal villous", "ANATOMY", 101, 119], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 5, 14], ["necrosis", "DISEASE", 45, 53], ["intestinal villous atrophy", "DISEASE", 101, 127], ["enterocytes", "CELL", 70, 81], ["intestinal villous", "MULTI-TISSUE_STRUCTURE", 101, 119], ["PEDV", "SPECIES", 0, 4], ["PEDV infection", "PROBLEM", 0, 14], ["cytolytic", "PROBLEM", 18, 27], ["acute necrosis of the infected enterocytes", "PROBLEM", 39, 81], ["marked intestinal villous atrophy", "PROBLEM", 94, 127], ["infection", "OBSERVATION", 5, 14], ["cytolytic", "OBSERVATION_MODIFIER", 18, 27], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["necrosis", "OBSERVATION", 45, 53], ["infected enterocytes", "OBSERVATION", 61, 81], ["marked", "OBSERVATION_MODIFIER", 94, 100], ["intestinal villous", "ANATOMY", 101, 119], ["atrophy", "OBSERVATION", 120, 127]]], ["Elucidating the effect of PEDV infection on crypt proliferation and differentiation has been a critical challenge.", [["crypt", "ANATOMY", 44, 49], ["PEDV", "CHEMICAL", 26, 30], ["infection", "DISEASE", 31, 40], ["PEDV", "GENE_OR_GENE_PRODUCT", 26, 30], ["crypt", "CELL", 44, 49], ["PEDV infection", "PROBLEM", 26, 40], ["crypt proliferation", "PROBLEM", 44, 63], ["PEDV", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 31, 40], ["crypt proliferation", "OBSERVATION", 44, 63]]], ["Only two previous reports have shown that PEDV infection causes a substantial increase in the number of Ki-67-positive cells and induces the localization of large numbers of Lgr5+ cells in the crypt niches of the intestine of PEDV-infected pigs (13, 15).", [["Ki-67-positive cells", "ANATOMY", 104, 124], ["Lgr5+ cells", "ANATOMY", 174, 185], ["crypt niches", "ANATOMY", 193, 205], ["intestine", "ANATOMY", 213, 222], ["PEDV", "CHEMICAL", 42, 46], ["infection", "DISEASE", 47, 56], ["PEDV", "GENE_OR_GENE_PRODUCT", 42, 46], ["Ki-67", "GENE_OR_GENE_PRODUCT", 104, 109], ["Lgr5", "GENE_OR_GENE_PRODUCT", 174, 178], ["crypt niches", "MULTI-TISSUE_STRUCTURE", 193, 205], ["intestine", "ORGAN", 213, 222], ["PEDV", "GENE_OR_GENE_PRODUCT", 226, 230], ["pigs", "ORGANISM", 240, 244], ["Ki-67-positive cells", "CELL_LINE", 104, 124], ["Lgr5", "PROTEIN", 174, 178], ["pigs", "SPECIES", 240, 244], ["PEDV", "SPECIES", 42, 46], ["PEDV infection", "PROBLEM", 42, 56], ["a substantial increase", "PROBLEM", 64, 86], ["positive cells", "PROBLEM", 110, 124], ["Lgr5+ cells", "PROBLEM", 174, 185], ["PEDV", "PROBLEM", 226, 230], ["PEDV", "OBSERVATION_MODIFIER", 42, 46], ["infection", "OBSERVATION", 47, 56], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["positive cells", "OBSERVATION", 110, 124], ["large", "OBSERVATION_MODIFIER", 157, 162], ["numbers", "OBSERVATION_MODIFIER", 163, 170], ["Lgr5+ cells", "OBSERVATION", 174, 185], ["crypt", "ANATOMY_MODIFIER", 193, 198], ["niches", "ANATOMY_MODIFIER", 199, 205], ["intestine", "ANATOMY", 213, 222], ["PEDV", "OBSERVATION", 226, 230], ["infected", "OBSERVATION_MODIFIER", 231, 239], ["pigs", "OBSERVATION_MODIFIER", 240, 244]]], ["A previous study conducted by Jung and Saif showed that the numbers of Lgr5+ cells and the proliferation of crypt cells are associated with piglet age, which is associated with susceptibility to PEDV infection (13).", [["Lgr5+ cells", "ANATOMY", 71, 82], ["crypt cells", "ANATOMY", 108, 119], ["piglet", "ANATOMY", 140, 146], ["infection", "DISEASE", 200, 209], ["Lgr5", "GENE_OR_GENE_PRODUCT", 71, 75], ["crypt cells", "CELL", 108, 119], ["piglet", "ORGAN", 140, 146], ["Lgr5", "PROTEIN", 71, 75], ["crypt cells", "CELL_TYPE", 108, 119], ["PEDV", "SPECIES", 195, 199], ["A previous study", "TEST", 0, 16], ["Lgr5+ cells", "PROBLEM", 71, 82], ["crypt cells", "PROBLEM", 108, 119], ["PEDV infection", "PROBLEM", 195, 209], ["Lgr5+ cells", "OBSERVATION", 71, 82], ["proliferation", "OBSERVATION_MODIFIER", 91, 104], ["crypt cells", "OBSERVATION", 108, 119], ["associated with", "UNCERTAINTY", 161, 176], ["PEDV", "OBSERVATION_MODIFIER", 195, 199], ["infection", "OBSERVATION", 200, 209]]], ["These results indicate that crypt stem cells are involved in the pathogenesis of PEDV infection.", [["crypt stem cells", "ANATOMY", 28, 44], ["PEDV infection", "DISEASE", 81, 95], ["crypt stem cells", "CELL", 28, 44], ["PEDV", "ORGANISM", 81, 85], ["crypt stem cells", "CELL_TYPE", 28, 44], ["PEDV", "SPECIES", 81, 85], ["crypt stem cells", "PROBLEM", 28, 44], ["PEDV infection", "PROBLEM", 81, 95], ["crypt stem cells", "OBSERVATION", 28, 44], ["PEDV", "OBSERVATION_MODIFIER", 81, 85], ["infection", "OBSERVATION", 86, 95]]], ["However, whether PEDV directly infects Lgr5+ stem cells is unknown.", [["Lgr5+ stem cells", "ANATOMY", 39, 55], ["PEDV", "CHEMICAL", 17, 21], ["PEDV", "GENE_OR_GENE_PRODUCT", 17, 21], ["Lgr5+ stem cells", "CELL", 39, 55], ["PEDV", "PROTEIN", 17, 21], ["Lgr5+ stem cells", "CELL_LINE", 39, 55], ["PEDV", "SPECIES", 17, 21], ["PEDV", "PROBLEM", 17, 21], ["stem cells", "OBSERVATION", 45, 55]]], ["Madson et al. previously visualized PEDV protein at the villus-crypt interface of the distal jejunum and ileum early during the infection process (32).", [["villus-crypt", "ANATOMY", 56, 68], ["distal jejunum", "ANATOMY", 86, 100], ["ileum", "ANATOMY", 105, 110], ["infection", "DISEASE", 128, 137], ["PEDV protein", "GENE_OR_GENE_PRODUCT", 36, 48], ["villus-crypt", "TISSUE", 56, 68], ["jejunum", "MULTI-TISSUE_STRUCTURE", 93, 100], ["ileum", "ORGAN", 105, 110], ["PEDV protein", "PROTEIN", 36, 48], ["previously visualized PEDV protein", "PROBLEM", 14, 48], ["the infection process", "PROBLEM", 124, 145], ["PEDV protein", "OBSERVATION", 36, 48], ["villus", "ANATOMY_MODIFIER", 56, 62], ["crypt", "ANATOMY_MODIFIER", 63, 68], ["interface", "ANATOMY_MODIFIER", 69, 78], ["distal", "ANATOMY_MODIFIER", 86, 92], ["jejunum", "ANATOMY", 93, 100], ["ileum", "ANATOMY", 105, 110], ["infection", "OBSERVATION", 128, 137]]], ["Here, we directly observed PEDV proteins in Lgr5+ cells and Ki-67+ transit-amplifying cells in both ileal enteroids and infected ileal tissue.", [["Lgr5+ cells", "ANATOMY", 44, 55], ["Ki-67+ transit-amplifying cells", "ANATOMY", 60, 91], ["ileal enteroids", "ANATOMY", 100, 115], ["ileal tissue", "ANATOMY", 129, 141], ["PEDV", "GENE_OR_GENE_PRODUCT", 27, 31], ["Lgr5+ cells", "CELL", 44, 55], ["Ki-67", "GENE_OR_GENE_PRODUCT", 60, 65], ["cells", "CELL", 86, 91], ["ileal enteroids", "MULTI-TISSUE_STRUCTURE", 100, 115], ["ileal tissue", "TISSUE", 129, 141], ["PEDV proteins", "PROTEIN", 27, 40], ["Lgr5+ cells", "CELL_LINE", 44, 55], ["Ki-67+ transit-amplifying cells", "CELL_LINE", 60, 91], ["PEDV proteins", "TEST", 27, 40], ["Ki", "TEST", 60, 62], ["transit-amplifying cells", "PROBLEM", 67, 91], ["infected ileal tissue", "PROBLEM", 120, 141], ["both", "ANATOMY_MODIFIER", 95, 99], ["ileal", "ANATOMY", 100, 105], ["enteroids", "OBSERVATION", 106, 115], ["infected", "OBSERVATION", 120, 128], ["ileal tissue", "ANATOMY", 129, 141]]], ["Enterocytes move on luminal surfaces from the bottom crypt area as they differentiate and mature, but further studies are needed to clarify whether the location and maturity of enterocytes influence the susceptibility of these cells to PEDV infection.", [["Enterocytes", "ANATOMY", 0, 11], ["luminal surfaces", "ANATOMY", 20, 36], ["crypt area", "ANATOMY", 53, 63], ["enterocytes", "ANATOMY", 177, 188], ["cells", "ANATOMY", 227, 232], ["luminal", "CHEMICAL", 20, 27], ["infection", "DISEASE", 241, 250], ["Enterocytes", "CELL", 0, 11], ["luminal surfaces", "TISSUE", 20, 36], ["crypt area", "TISSUE", 53, 63], ["enterocytes", "CELL", 177, 188], ["cells", "CELL", 227, 232], ["PEDV", "GENE_OR_GENE_PRODUCT", 236, 240], ["Enterocytes", "CELL_TYPE", 0, 11], ["PEDV", "SPECIES", 236, 240], ["further studies", "TEST", 102, 117], ["these cells", "PROBLEM", 221, 232], ["PEDV infection", "PROBLEM", 236, 250], ["luminal surfaces", "OBSERVATION_MODIFIER", 20, 36], ["bottom", "ANATOMY_MODIFIER", 46, 52], ["crypt", "ANATOMY", 53, 58], ["mature", "OBSERVATION_MODIFIER", 90, 96], ["enterocytes", "ANATOMY", 177, 188], ["infection", "OBSERVATION", 241, 250]]], ["In contrast to the previous in vivo study (27), we did not observe a significant increase in the number of Ki-67+ epithelial cells following PEDV infection in enteroids.", [["Ki-67+ epithelial cells", "ANATOMY", 107, 130], ["enteroids", "ANATOMY", 159, 168], ["infection", "DISEASE", 146, 155], ["Ki-67", "GENE_OR_GENE_PRODUCT", 107, 112], ["enteroids", "CANCER", 159, 168], ["Ki-67+ epithelial cells", "CELL_LINE", 107, 130], ["PEDV", "SPECIES", 141, 145], ["vivo study", "TEST", 31, 41], ["a significant increase", "PROBLEM", 67, 89], ["Ki", "TEST", 107, 109], ["epithelial cells", "PROBLEM", 114, 130], ["PEDV infection in enteroids", "PROBLEM", 141, 168], ["significant", "OBSERVATION_MODIFIER", 69, 80], ["increase", "OBSERVATION_MODIFIER", 81, 89], ["epithelial cells", "OBSERVATION", 114, 130], ["infection", "OBSERVATION", 146, 155]]], ["Other factors might be involved in the increase in the number of Ki-67+ epithelial cells during in vivo PEDV infection, and enteroids provide a good in vitro model to further address this question.DISCUSSIONGoblet cells are simple columnar epithelial cells that constitute the primary cellular source of Muc2 mucins (34, 35).", [["Ki-67+ epithelial cells", "ANATOMY", 65, 88], ["DISCUSSIONGoblet cells", "ANATOMY", 197, 219], ["columnar epithelial cells", "ANATOMY", 231, 256], ["cellular", "ANATOMY", 285, 293], ["infection", "DISEASE", 109, 118], ["Ki-67", "GENE_OR_GENE_PRODUCT", 65, 70], ["DISCUSSIONGoblet cells", "CELL", 197, 219], ["columnar epithelial cells", "CELL", 231, 256], ["cellular", "CELL", 285, 293], ["Muc2 mucins", "GENE_OR_GENE_PRODUCT", 304, 315], ["Ki-67+ epithelial cells", "CELL_LINE", 65, 88], ["DISCUSSIONGoblet cells", "CELL_LINE", 197, 219], ["columnar epithelial cells", "CELL_TYPE", 231, 256], ["Muc2 mucins", "PROTEIN", 304, 315], ["PEDV", "SPECIES", 104, 108], ["Ki", "TEST", 65, 67], ["epithelial cells", "PROBLEM", 72, 88], ["vivo PEDV infection", "PROBLEM", 99, 118], ["enteroids", "TREATMENT", 124, 133], ["DISCUSSIONGoblet cells", "PROBLEM", 197, 219], ["simple columnar epithelial cells", "PROBLEM", 224, 256], ["Muc2 mucins", "TEST", 304, 315], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["epithelial cells", "OBSERVATION", 72, 88], ["PEDV", "OBSERVATION_MODIFIER", 104, 108], ["infection", "OBSERVATION", 109, 118], ["columnar epithelial cells", "OBSERVATION", 231, 256], ["Muc2 mucins", "OBSERVATION", 304, 315]]], ["Mucins form an intestinal inner mucus layer, which serves as a physical barrier that effectively separates the commensal microbiota from the single epithelial cell layer and plays crucial roles in the maintenance of microbial homeostasis and the protection of epithelial cells from infection (36, 37).", [["intestinal inner mucus layer", "ANATOMY", 15, 43], ["epithelial cell layer", "ANATOMY", 148, 169], ["epithelial cells", "ANATOMY", 260, 276], ["infection", "DISEASE", 282, 291], ["Mucins", "GENE_OR_GENE_PRODUCT", 0, 6], ["intestinal inner mucus layer", "TISSUE", 15, 43], ["epithelial cell layer", "TISSUE", 148, 169], ["epithelial cells", "CELL", 260, 276], ["epithelial cells", "CELL_TYPE", 260, 276], ["an intestinal inner mucus layer", "PROBLEM", 12, 43], ["a physical barrier", "TREATMENT", 61, 79], ["microbial homeostasis", "TREATMENT", 216, 237], ["epithelial cells", "PROBLEM", 260, 276], ["infection", "PROBLEM", 282, 291], ["intestinal", "ANATOMY", 15, 25], ["inner", "ANATOMY_MODIFIER", 26, 31], ["mucus layer", "OBSERVATION", 32, 43], ["commensal microbiota", "OBSERVATION_MODIFIER", 111, 131], ["epithelial cell layer", "OBSERVATION", 148, 169], ["crucial", "OBSERVATION_MODIFIER", 180, 187], ["microbial homeostasis", "OBSERVATION", 216, 237], ["epithelial cells", "OBSERVATION", 260, 276], ["infection", "OBSERVATION", 282, 291]]], ["Jung et al. previously detected a PEDV antigen in goblet cells and demonstrated that PEDV infection caused a substantial reduction in the number of goblet cells in the small intestine (27, 38).", [["goblet cells", "ANATOMY", 50, 62], ["goblet cells", "ANATOMY", 148, 160], ["small intestine", "ANATOMY", 168, 183], ["PEDV", "CHEMICAL", 85, 89], ["infection", "DISEASE", 90, 99], ["PEDV antigen", "GENE_OR_GENE_PRODUCT", 34, 46], ["goblet cells", "CELL", 50, 62], ["goblet cells", "CELL", 148, 160], ["small intestine", "ORGAN", 168, 183], ["PEDV antigen", "PROTEIN", 34, 46], ["goblet cells", "CELL_TYPE", 50, 62], ["goblet cells", "CELL_TYPE", 148, 160], ["PEDV", "SPECIES", 34, 38], ["PEDV", "SPECIES", 85, 89], ["a PEDV antigen in goblet cells", "PROBLEM", 32, 62], ["PEDV infection", "PROBLEM", 85, 99], ["a substantial reduction", "PROBLEM", 107, 130], ["goblet cells", "OBSERVATION", 50, 62], ["PEDV", "OBSERVATION_MODIFIER", 85, 89], ["infection", "OBSERVATION", 90, 99], ["substantial", "OBSERVATION_MODIFIER", 109, 120], ["reduction", "OBSERVATION_MODIFIER", 121, 130], ["number", "OBSERVATION_MODIFIER", 138, 144], ["goblet cells", "OBSERVATION", 148, 160], ["small intestine", "ANATOMY", 168, 183]]], ["In agreement with the previous in vivo results, we observed that PEDV infected goblet cells of enteroids in vitro.", [["goblet cells", "ANATOMY", 79, 91], ["enteroids", "ANATOMY", 95, 104], ["PEDV", "SIMPLE_CHEMICAL", 65, 69], ["goblet cells", "CELL", 79, 91], ["enteroids", "CELL", 95, 104], ["PEDV infected goblet cells", "CELL_TYPE", 65, 91], ["PEDV", "SPECIES", 65, 69], ["PEDV infected goblet cells of enteroids", "PROBLEM", 65, 104], ["goblet cells", "OBSERVATION", 79, 91]]], ["Another porcine alphacoronavirus, transmissible gastroenteritis virus (TGEV), reportedly binds to mucin on the apical membrane of intestinal cells, which allows TGEV to stay longer in the intestine and facilitates intestinal infection (39).", [["apical membrane", "ANATOMY", 111, 126], ["intestinal cells", "ANATOMY", 130, 146], ["intestine", "ANATOMY", 188, 197], ["intestinal", "ANATOMY", 214, 224], ["transmissible gastroenteritis", "DISEASE", 34, 63], ["intestinal infection", "DISEASE", 214, 234], ["porcine", "ORGANISM", 8, 15], ["alphacoronavirus, transmissible gastroenteritis virus", "ORGANISM", 16, 69], ["TGEV", "ORGANISM", 71, 75], ["mucin", "GENE_OR_GENE_PRODUCT", 98, 103], ["apical membrane", "CELLULAR_COMPONENT", 111, 126], ["intestinal cells", "CELL", 130, 146], ["TGEV", "ORGANISM", 161, 165], ["intestine", "ORGAN", 188, 197], ["intestinal", "ORGAN", 214, 224], ["mucin", "PROTEIN", 98, 103], ["intestinal cells", "CELL_TYPE", 130, 146], ["transmissible gastroenteritis virus", "SPECIES", 34, 69], ["transmissible gastroenteritis virus", "SPECIES", 34, 69], ["TGEV", "SPECIES", 71, 75], ["TGEV", "SPECIES", 161, 165], ["Another porcine alphacoronavirus", "PROBLEM", 0, 32], ["transmissible gastroenteritis virus", "PROBLEM", 34, 69], ["intestinal cells", "PROBLEM", 130, 146], ["TGEV", "PROBLEM", 161, 165], ["intestinal infection", "PROBLEM", 214, 234], ["porcine alphacoronavirus", "OBSERVATION", 8, 32], ["transmissible", "OBSERVATION_MODIFIER", 34, 47], ["gastroenteritis virus", "OBSERVATION", 48, 69], ["apical", "ANATOMY_MODIFIER", 111, 117], ["membrane", "ANATOMY_MODIFIER", 118, 126], ["intestinal cells", "ANATOMY", 130, 146], ["intestine", "ANATOMY", 188, 197], ["intestinal", "ANATOMY", 214, 224], ["infection", "OBSERVATION", 225, 234]]], ["However, whether PEDV takes advantage of mucin to facilitate the infection of goblet cells and the effect of PEDV infection on the functions of goblet cells remain unclear.", [["goblet cells", "ANATOMY", 78, 90], ["goblet cells", "ANATOMY", 144, 156], ["PEDV", "CHEMICAL", 17, 21], ["infection", "DISEASE", 65, 74], ["PEDV", "CHEMICAL", 109, 113], ["infection", "DISEASE", 114, 123], ["PEDV", "GENE_OR_GENE_PRODUCT", 17, 21], ["mucin", "GENE_OR_GENE_PRODUCT", 41, 46], ["goblet cells", "CELL", 78, 90], ["PEDV", "GENE_OR_GENE_PRODUCT", 109, 113], ["goblet cells", "CELL", 144, 156], ["PEDV", "PROTEIN", 17, 21], ["goblet cells", "CELL_TYPE", 78, 90], ["goblet cells", "CELL_TYPE", 144, 156], ["PEDV", "SPECIES", 109, 113], ["PEDV", "PROBLEM", 17, 21], ["mucin", "TREATMENT", 41, 46], ["the infection of goblet cells", "PROBLEM", 61, 90], ["PEDV infection", "PROBLEM", 109, 123], ["goblet cells", "PROBLEM", 144, 156], ["goblet cells", "OBSERVATION", 78, 90], ["PEDV", "OBSERVATION_MODIFIER", 109, 113], ["infection", "OBSERVATION", 114, 123], ["goblet cells", "OBSERVATION", 144, 156]]], ["In addition to the secretion of mucins, goblet cells play crucial roles in the presentation of oral antigens to the immune system (34).", [["goblet cells", "ANATOMY", 40, 52], ["oral", "ANATOMY", 95, 99], ["immune system", "ANATOMY", 116, 129], ["mucins", "GENE_OR_GENE_PRODUCT", 32, 38], ["goblet cells", "CELL", 40, 52], ["oral", "ORGANISM_SUBDIVISION", 95, 99], ["immune system", "ANATOMICAL_SYSTEM", 116, 129], ["goblet cells", "CELL_TYPE", 40, 52], ["oral antigens", "PROTEIN", 95, 108], ["goblet cells", "PROBLEM", 40, 52], ["goblet cells", "OBSERVATION", 40, 52]]], ["In the future, it will be very interesting to further explore the effect of PEDV infection on the functions of goblet cells by taking advantage of the enteroid model.DISCUSSIONIn summary, we show that porcine enteroids can be used to model the multicellular phenotype of the intestinal epithelium, which serves as the primary portal through which enteric viruses enter the hosts.", [["goblet cells", "ANATOMY", 111, 123], ["enteroids", "ANATOMY", 209, 218], ["intestinal epithelium", "ANATOMY", 275, 296], ["PEDV", "CHEMICAL", 76, 80], ["infection", "DISEASE", 81, 90], ["PEDV", "SIMPLE_CHEMICAL", 76, 80], ["goblet cells", "CELL", 111, 123], ["porcine", "ORGANISM", 201, 208], ["enteroids", "GENE_OR_GENE_PRODUCT", 209, 218], ["intestinal epithelium", "TISSUE", 275, 296], ["enteric viruses", "ORGANISM", 347, 362], ["goblet cells", "CELL_TYPE", 111, 123], ["PEDV", "SPECIES", 76, 80], ["porcine", "SPECIES", 201, 208], ["PEDV infection", "PROBLEM", 76, 90], ["goblet cells", "TREATMENT", 111, 123], ["the enteroid model", "TREATMENT", 147, 165], ["porcine enteroids", "TREATMENT", 201, 218], ["infection", "OBSERVATION", 81, 90], ["multicellular phenotype", "OBSERVATION", 244, 267], ["intestinal epithelium", "ANATOMY", 275, 296], ["portal", "ANATOMY", 326, 332], ["viruses", "OBSERVATION", 355, 362]]], ["Our findings provide important insights into events associated with PEDV infection and demonstrate that swine enteroids can be used as a unique model to define the complicated cross talk that exists between PEDV and the intestinal epithelium, which would undoubtedly have profound impacts on the clarification of PEDV pathogenesis.", [["intestinal epithelium", "ANATOMY", 220, 241], ["infection", "DISEASE", 73, 82], ["PEDV", "GENE_OR_GENE_PRODUCT", 68, 72], ["swine enteroids", "ORGANISM", 104, 119], ["PEDV", "GENE_OR_GENE_PRODUCT", 207, 211], ["intestinal epithelium", "TISSUE", 220, 241], ["PEDV", "CANCER", 313, 317], ["swine", "SPECIES", 104, 109], ["PEDV", "SPECIES", 68, 72], ["swine", "SPECIES", 104, 109], ["PEDV", "SPECIES", 207, 211], ["PEDV", "SPECIES", 313, 317], ["PEDV infection", "PROBLEM", 68, 82], ["swine enteroids", "TREATMENT", 104, 119], ["the complicated cross talk", "PROBLEM", 160, 186], ["PEDV", "PROBLEM", 207, 211], ["PEDV pathogenesis", "PROBLEM", 313, 330], ["infection", "OBSERVATION", 73, 82], ["intestinal epithelium", "ANATOMY", 220, 241], ["PEDV", "OBSERVATION", 313, 317]]], ["Intestinal enteroids also provide a platform for exploring the role of additional host factors in cellular tropism and can be used to isolate and grow previously uncultivable enteric viruses.Cell cultures. ::: MATERIALS AND METHODSAfrican green monkey kidney cells (Vero E6) were grown and maintained in Dulbecco\u2019s modified Eagle\u2019s medium (DMEM) supplemented with antibiotics (100 U/ml penicillin and 100 \u03bcg/ml streptomycin) and 10% heat-inactivated fetal bovine serum (FBS) (Gibco).Virus stocks, titration, and infection of cells. ::: MATERIALS AND METHODSThe Vero cell-adapted PEDV-CV777 strain (GenBank accession no. KT323979) was propagated as previously described (40, 41).", [["Intestinal", "ANATOMY", 0, 10], ["cellular", "ANATOMY", 98, 106], ["Cell cultures", "ANATOMY", 191, 204], ["kidney cells", "ANATOMY", 252, 264], ["Vero", "ANATOMY", 266, 270], ["fetal bovine serum", "ANATOMY", 450, 468], ["FBS", "ANATOMY", 470, 473], ["cells", "ANATOMY", 525, 530], ["cell", "ANATOMY", 566, 570], ["penicillin", "CHEMICAL", 386, 396], ["streptomycin", "CHEMICAL", 411, 423], ["infection", "DISEASE", 512, 521], ["KT323979", "CHEMICAL", 620, 628], ["penicillin", "CHEMICAL", 386, 396], ["streptomycin", "CHEMICAL", 411, 423], ["KT323979", "CHEMICAL", 620, 628], ["cellular", "CELL", 98, 106], ["Cell cultures", "CELL", 191, 204], ["monkey", "ORGANISM", 245, 251], ["kidney cells", "CELL", 252, 264], ["Vero E6", "CELL", 266, 273], ["penicillin", "SIMPLE_CHEMICAL", 386, 396], ["streptomycin", "SIMPLE_CHEMICAL", 411, 423], ["bovine", "ORGANISM", 456, 462], ["serum", "ORGANISM_SUBSTANCE", 463, 468], ["FBS", "ORGANISM_SUBSTANCE", 470, 473], ["Virus", "ORGANISM", 483, 488], ["cells", "CELL", 525, 530], ["Vero cell", "CELL", 561, 570], ["PEDV-CV777 strain", "CELL", 579, 596], ["KT323979", "SIMPLE_CHEMICAL", 620, 628], ["METHODSAfrican green monkey kidney cells", "CELL_LINE", 224, 264], ["Vero E6", "CELL_LINE", 266, 273], ["monkey", "SPECIES", 245, 251], ["bovine", "SPECIES", 456, 462], ["green monkey", "SPECIES", 239, 251], ["Vero E6", "SPECIES", 266, 273], ["bovine", "SPECIES", 456, 462], ["Intestinal enteroids", "PROBLEM", 0, 20], ["cellular tropism", "PROBLEM", 98, 114], ["previously uncultivable enteric viruses", "PROBLEM", 151, 190], ["Cell cultures", "TEST", 191, 204], ["Vero E6)", "TEST", 266, 274], ["antibiotics", "TREATMENT", 364, 375], ["penicillin", "TREATMENT", 386, 396], ["streptomycin", "TREATMENT", 411, 423], ["fetal bovine serum", "TEST", 450, 468], ["Virus stocks", "TREATMENT", 483, 495], ["titration", "TREATMENT", 497, 506], ["infection of cells", "PROBLEM", 512, 530], ["PEDV", "PROBLEM", 579, 583], ["cellular tropism", "OBSERVATION", 98, 114], ["viruses", "OBSERVATION", 183, 190], ["Vero cell", "OBSERVATION", 561, 570]]], ["The PEDV-JMS strain (passage 6) was isolated and stocked by our laboratory, and the PEDV stock was prepared and titrated as described previously (22, 40).", [["PEDV-JMS", "CHEMICAL", 4, 12], ["PEDV", "ORGANISM", 84, 88], ["PEDV", "SPECIES", 84, 88], ["The PEDV", "PROBLEM", 0, 8], ["JMS strain", "PROBLEM", 9, 19], ["the PEDV stock", "TREATMENT", 80, 94], ["PEDV", "OBSERVATION", 4, 8]]], ["To assess the anti-PEDV activity of IFN-\u03b1 and IFN-L1, cells were infected with PEDV after being primed with the indicated concentrations of IFN for 24 h.", [["cells", "ANATOMY", 54, 59], ["PEDV", "CHEMICAL", 79, 83], ["IFN", "CHEMICAL", 140, 143], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["IFN-L1", "GENE_OR_GENE_PRODUCT", 46, 52], ["cells", "CELL", 54, 59], ["PEDV", "ORGANISM", 79, 83], ["IFN", "PROTEIN", 36, 39], ["IFN", "PROTEIN", 46, 49], ["L1", "PROTEIN", 50, 52], ["IFN", "PROTEIN", 140, 143], ["PEDV", "SPECIES", 79, 83], ["IFN", "TEST", 36, 39], ["IFN", "TREATMENT", 46, 49], ["PEDV", "PROBLEM", 79, 83], ["IFN", "TREATMENT", 140, 143], ["L1", "ANATOMY", 50, 52]]], ["Samples were collected at the indicated times postinfection for the quantification of PEDV infection.Porcine intestinal crypt isolation and 3D enteroid culture. ::: MATERIALS AND METHODSPorcine intestinal crypts were prepared from specific-pathogen-free (SPF) 2- to 10-day-old piglets using previously described protocols, with minor modifications (11, 23).", [["Samples", "ANATOMY", 0, 7], ["intestinal crypt", "ANATOMY", 109, 125], ["intestinal crypts", "ANATOMY", 194, 211], ["PEDV", "CHEMICAL", 86, 90], ["infection", "DISEASE", 91, 100], ["PEDV", "ORGANISM", 86, 90], ["Porcine", "ORGANISM", 101, 108], ["intestinal crypt", "CELL", 109, 125], ["intestinal crypts", "TISSUE", 194, 211], ["piglets", "ORGANISM", 277, 284], ["3D enteroid culture", "CELL_LINE", 140, 159], ["Porcine", "SPECIES", 101, 108], ["piglets", "SPECIES", 277, 284], ["PEDV", "SPECIES", 86, 90], ["Porcine", "SPECIES", 101, 108], ["Samples", "TEST", 0, 7], ["PEDV infection", "PROBLEM", 86, 100], ["Porcine intestinal crypt isolation", "TREATMENT", 101, 135], ["3D enteroid culture", "TEST", 140, 159], ["METHODSPorcine intestinal crypts", "PROBLEM", 179, 211], ["previously described protocols", "TREATMENT", 291, 321], ["PEDV", "OBSERVATION_MODIFIER", 86, 90], ["infection", "OBSERVATION", 91, 100], ["intestinal", "ANATOMY", 109, 119], ["crypt isolation", "OBSERVATION", 120, 135], ["intestinal crypts", "ANATOMY", 194, 211]]], ["Briefly, the intestine was opened lengthwise and cut into 2-mm segments.", [["intestine", "ANATOMY", 13, 22], ["intestine", "ORGAN", 13, 22], ["intestine", "ANATOMY", 13, 22], ["mm", "ANATOMY_MODIFIER", 60, 62], ["segments", "ANATOMY_MODIFIER", 63, 71]]], ["The intestinal pieces were washed several times until the supernatant was clear, and the washed intestinal pieces were then suspended in gentle cell dissociation reagent (Stemcell, Canada) to disassociate the crypts.", [["intestinal pieces", "ANATOMY", 4, 21], ["supernatant", "ANATOMY", 58, 69], ["intestinal pieces", "ANATOMY", 96, 113], ["cell", "ANATOMY", 144, 148], ["crypts", "ANATOMY", 209, 215], ["intestinal pieces", "MULTI-TISSUE_STRUCTURE", 4, 21], ["intestinal", "ORGAN", 96, 106], ["cell", "CELL", 144, 148], ["crypts", "TISSUE", 209, 215], ["The intestinal pieces", "TREATMENT", 0, 21], ["the washed intestinal pieces", "TREATMENT", 85, 113], ["gentle cell dissociation reagent", "TREATMENT", 137, 169], ["the crypts", "PROBLEM", 205, 215], ["intestinal", "ANATOMY", 4, 14], ["pieces", "OBSERVATION", 15, 21], ["clear", "OBSERVATION", 74, 79], ["crypts", "OBSERVATION", 209, 215]]], ["The pellets of the intestinal pieces were suspended in 10 ml of cold phosphate-buffered saline (PBS) with 0.1% bovine serum albumin (BSA) and antibiotics (penicillin-streptomycin) and passed through a 70-\u03bcm filter.", [["intestinal pieces", "ANATOMY", 19, 36], ["serum", "ANATOMY", 118, 123], ["phosphate", "CHEMICAL", 69, 78], ["BSA", "CHEMICAL", 133, 136], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 166, 178], ["phosphate", "CHEMICAL", 69, 78], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 166, 178], ["intestinal pieces", "MULTI-TISSUE_STRUCTURE", 19, 36], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 69, 94], ["bovine", "ORGANISM", 111, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["albumin", "SIMPLE_CHEMICAL", 124, 131], ["BSA", "SIMPLE_CHEMICAL", 133, 136], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 155, 178], ["bovine", "SPECIES", 111, 117], ["bovine", "SPECIES", 111, 117], ["the intestinal pieces", "TREATMENT", 15, 36], ["cold phosphate-buffered saline (PBS", "TREATMENT", 64, 99], ["0.1% bovine serum albumin (BSA", "TREATMENT", 106, 136], ["antibiotics", "TREATMENT", 142, 153], ["penicillin", "TREATMENT", 155, 165], ["streptomycin", "TREATMENT", 166, 178], ["a 70-\u03bcm filter", "TREATMENT", 199, 213], ["pellets", "OBSERVATION_MODIFIER", 4, 11], ["intestinal pieces", "ANATOMY", 19, 36]]], ["The crypt pellets were harvested by centrifugation at 200 \u00d7 g at 4\u00b0C for 5 min and resuspended in 10 ml of cold DMEM\u2013F-12 medium.", [["crypt pellets", "ANATOMY", 4, 17], ["crypt pellets", "CELL", 4, 17], ["The crypt pellets", "TREATMENT", 0, 17], ["cold DMEM\u2013F", "TREATMENT", 107, 118], ["crypt", "ANATOMY", 4, 9]]], ["After counting, the intestinal crypts were resuspended with IntestiCult organoid growth medium (Stemcell, Canada) and Matrigel (BD Biosciences, USA) and seeded into a 48-well plate at a density of 50 crypts per well.", [["intestinal crypts", "ANATOMY", 20, 37], ["crypts", "ANATOMY", 200, 206], ["intestinal crypts", "MULTI-TISSUE_STRUCTURE", 20, 37], ["the intestinal crypts", "PROBLEM", 16, 37], ["intestinal crypts", "ANATOMY", 20, 37]]], ["The plate was incubated at 37\u00b0C for 10 min until the Matrigel solidified, and 300 \u03bcl of IntestiCult organoid growth medium was then added to each well.", [["IntestiCult organoid growth medium", "TREATMENT", 88, 122], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The plate was subsequently incubated at 37\u00b0C in a 5% CO2 incubator, and the culture medium was exchanged every 3 to 4 days.", [["CO2", "CHEMICAL", 53, 56], ["CO2", "CHEMICAL", 53, 56], ["CO2", "SIMPLE_CHEMICAL", 53, 56], ["a 5% CO2 incubator", "TREATMENT", 48, 66], ["the culture medium", "TREATMENT", 72, 90], ["plate", "OBSERVATION_MODIFIER", 4, 9]]], ["The Institutional Animal Care and Use Committee of the Harbin Veterinary Research Institute approved all the protocols used for animal experiments in this study.2D monolayer enteroid culture. ::: MATERIALS AND METHODSExpanded 3D enteroids were recovered from Matrigel after 7 to 14 days of growth by the addition of ice-cold DMEM\u2013F-12 medium, transferred into 15-ml tubes, and centrifuged at 250 \u00d7 g at 4\u00b0C for 5 min.", [["3D enteroids", "CANCER", 226, 238], ["2D monolayer enteroid culture", "CELL_LINE", 161, 190], ["this study", "TEST", 150, 160], ["2D monolayer enteroid culture", "TEST", 161, 190], ["METHODSExpanded 3D enteroids", "TREATMENT", 210, 238], ["ice-cold DMEM\u2013F", "TREATMENT", 316, 331]]], ["The enteroid pellet was incubated in 0.25% trypsin-EDTA (Gibco) for 5 min at 37\u00b0C and dissociated by repeated pipetting to obtain a single-cell suspension.", [["enteroid pellet", "ANATOMY", 4, 19], ["cell", "ANATOMY", 139, 143], ["trypsin-EDTA", "CHEMICAL", 43, 55], ["EDTA", "CHEMICAL", 51, 55], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 43, 55], ["C", "GENE_OR_GENE_PRODUCT", 80, 81], ["cell", "CELL", 139, 143], ["The enteroid pellet", "TREATMENT", 0, 19], ["repeated pipetting", "TREATMENT", 101, 119], ["a single-cell suspension", "TREATMENT", 130, 154]]], ["DMEM\u2013F-12 medium with 10% (vol/vol) FBS was added to the single-cell suspension, and the mixture was centrifuged at 800 \u00d7 g for 5 min.", [["FBS", "ANATOMY", 36, 39], ["cell", "ANATOMY", 64, 68], ["DMEM\u2013F-12", "CHEMICAL", 0, 9], ["FBS", "ORGANISM_SUBSTANCE", 36, 39], ["single-cell", "CELL", 57, 68], ["DMEM\u2013F", "TEST", 0, 6], ["10% (vol/vol) FBS", "TREATMENT", 22, 39], ["the single-cell suspension", "TREATMENT", 53, 79]]], ["The cell pellets were resuspended in complete IntestiCult organoid growth medium at room temperature (RT) and seeded at 50 enteroid cells per well in a Matrigel-precoated 96-well plate.", [["cell", "ANATOMY", 4, 8], ["enteroid cells", "ANATOMY", 123, 137], ["cell", "CELL", 4, 8], ["enteroid cells", "CELL", 123, 137], ["The cell pellets", "TREATMENT", 0, 16], ["a Matrigel", "TREATMENT", 150, 160], ["cell pellets", "OBSERVATION", 4, 16]]], ["After 3 days of differentiation, the planner monolayer 2D enteroids were ready for experiments.Experimental infection of piglets. ::: MATERIALS AND METHODSFour 10-day-old SPF piglets were randomly divided into two groups.", [["infection", "DISEASE", 108, 117], ["monolayer 2D enteroids", "CELL", 45, 67], ["piglets", "ORGANISM", 121, 128], ["SPF", "ORGANISM", 171, 174], ["piglets", "ORGANISM", 175, 182], ["piglets", "SPECIES", 121, 128], ["piglets", "SPECIES", 175, 182], ["the planner monolayer 2D enteroids", "TREATMENT", 33, 67], ["Experimental infection of piglets", "PROBLEM", 95, 128], ["SPF piglets", "TREATMENT", 171, 182], ["infection", "OBSERVATION", 108, 117]]], ["The SPF piglets in group 1 were orally inoculated with 1.0 ml of 4.5 \u00d7 105 50% tissue culture infective doses (TCID50) of the PEDV-JMS strain, and the SPF piglets in group 2 were inoculated with 1.0 ml of DMEM and served as uninfected controls.", [["tissue", "ANATOMY", 79, 85], ["SPF piglets", "ORGANISM", 4, 15], ["tissue", "TISSUE", 79, 85], ["SPF piglets", "ORGANISM", 151, 162], ["piglets", "SPECIES", 8, 15], ["piglets", "SPECIES", 155, 162], ["SPF", "SPECIES", 151, 154], ["The SPF piglets", "TREATMENT", 0, 15], ["the PEDV", "TEST", 122, 130], ["JMS strain", "PROBLEM", 131, 141], ["the SPF piglets in group 2", "TREATMENT", 147, 173], ["DMEM", "TREATMENT", 205, 209], ["SPF piglets", "OBSERVATION", 4, 15]]], ["All clinical signs were recorded on a daily basis after virus infection, and all the piglets were euthanized at 4 days postinfection.", [["infection", "DISEASE", 62, 71], ["piglets", "ORGANISM", 85, 92], ["piglets", "SPECIES", 85, 92], ["All clinical signs", "TEST", 0, 18], ["virus infection", "PROBLEM", 56, 71], ["infection", "OBSERVATION", 62, 71]]], ["The Animal Ethics Committee approved the protocol under approval no. Heilongjiang-SYXK-2006-032.", [["Heilongjiang-SYXK-2006-032", "CHEMICAL", 69, 95], ["Heilongjiang-SYXK-2006-032", "SPECIES", 69, 95]]], ["Intestinal samples from the piglets were collected for pathological evaluation and assessment of PEDV infection.RNA isolation and reverse transcriptase quantitative PCR. ::: MATERIALS AND METHODSTotal cellular mRNA was extracted using the Simply P total RNA extraction kit (BioFlux, China) according to the manufacturer\u2019s instructions.", [["Intestinal samples", "ANATOMY", 0, 18], ["cellular", "ANATOMY", 201, 209], ["infection", "DISEASE", 102, 111], ["Intestinal samples", "CANCER", 0, 18], ["piglets", "ORGANISM", 28, 35], ["PEDV", "ORGANISM", 97, 101], ["METHODSTotal cellular", "CELL", 188, 209], ["reverse transcriptase", "PROTEIN", 130, 151], ["METHODSTotal cellular mRNA", "RNA", 188, 214], ["piglets", "SPECIES", 28, 35], ["PEDV", "SPECIES", 97, 101], ["Intestinal samples", "TEST", 0, 18], ["pathological evaluation", "TEST", 55, 78], ["assessment", "TEST", 83, 93], ["PEDV infection", "PROBLEM", 97, 111], ["RNA isolation", "TEST", 112, 125], ["reverse transcriptase quantitative PCR", "PROBLEM", 130, 168], ["METHODSTotal cellular mRNA", "TREATMENT", 188, 214], ["the Simply P total RNA extraction kit", "TREATMENT", 235, 272], ["PEDV", "OBSERVATION_MODIFIER", 97, 101], ["infection", "OBSERVATION", 102, 111], ["cellular mRNA", "OBSERVATION", 201, 214]]], ["Total mRNA (1 \u03bcg) was reverse transcribed to cDNA using the PrimeScript II first-strand cDNA synthesis kit (TaKaRa, China), and relative gene expression levels were quantified by qPCR using SYBR green PCR mix (Life Technologies, USA) based on the cycle threshold (\u0394\u0394CT) method (42).", [["mRNA", "RNA", 6, 10], ["cDNA", "DNA", 45, 49], ["PrimeScript II first-strand cDNA", "DNA", 60, 92], ["Total mRNA", "TREATMENT", 0, 10]]], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as the internal control.", [["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate", "CHEMICAL", 0, 26], ["Glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 40], ["GAPDH", "GENE_OR_GENE_PRODUCT", 42, 47], ["Glyceraldehyde-3-phosphate dehydrogenase", "PROTEIN", 0, 40], ["GAPDH", "PROTEIN", 42, 47], ["Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)", "TREATMENT", 0, 48], ["the internal control", "TREATMENT", 59, 79]]], ["The primers were designed using Primer Premier 5 software and are listed in Table 1.H&E staining. ::: MATERIALS AND METHODSFormalin-fixed ileum sections were serially dehydrated with 70%, 95%, and 100% ethanol; cleared in xylene; embedded in paraffin wax; and sectioned at a 4- to 6-\u03bcm thickness.", [["ileum sections", "ANATOMY", 138, 152], ["ethanol", "CHEMICAL", 202, 209], ["ethanol", "CHEMICAL", 202, 209], ["xylene", "CHEMICAL", 222, 228], ["paraffin", "CHEMICAL", 242, 250], ["ileum sections", "MULTI-TISSUE_STRUCTURE", 138, 152], ["ethanol", "SIMPLE_CHEMICAL", 202, 209], ["xylene", "SIMPLE_CHEMICAL", 222, 228], ["H&E staining", "PROBLEM", 84, 96], ["METHODSFormalin", "TEST", 116, 131], ["fixed ileum sections", "TEST", 132, 152], ["staining", "OBSERVATION", 88, 96], ["ileum", "ANATOMY", 138, 143]]], ["After dewaxing in xylene and serially rehydration with 100%, 95%, and 70% ethanol, the ileum sections were stained with hematoxylin and eosin (H&E; Sigma-Aldrich) for histopathological evaluation and observed using a light microscope.Immunohistochemistry. ::: MATERIALS AND METHODSIleum or colon tissue sections were deparaffinized in xylene and rehydrated with water containing descending concentrations (100%, 95%, and 70%) of ethanol.", [["ileum sections", "ANATOMY", 87, 101], ["colon tissue sections", "ANATOMY", 290, 311], ["xylene", "CHEMICAL", 18, 24], ["ethanol", "CHEMICAL", 74, 81], ["xylene", "CHEMICAL", 335, 341], ["ethanol", "CHEMICAL", 429, 436], ["xylene", "CHEMICAL", 18, 24], ["ethanol", "CHEMICAL", 74, 81], ["hematoxylin", "CHEMICAL", 120, 131], ["eosin", "CHEMICAL", 136, 141], ["xylene", "CHEMICAL", 335, 341], ["ethanol", "CHEMICAL", 429, 436], ["xylene", "SIMPLE_CHEMICAL", 18, 24], ["ethanol", "SIMPLE_CHEMICAL", 74, 81], ["ileum sections", "MULTI-TISSUE_STRUCTURE", 87, 101], ["hematoxylin", "SIMPLE_CHEMICAL", 120, 131], ["eosin", "SIMPLE_CHEMICAL", 136, 141], ["colon tissue sections", "CANCER", 290, 311], ["xylene", "SIMPLE_CHEMICAL", 335, 341], ["water", "SIMPLE_CHEMICAL", 362, 367], ["ethanol", "SIMPLE_CHEMICAL", 429, 436], ["hematoxylin", "TREATMENT", 120, 131], ["histopathological evaluation", "TEST", 167, 195], ["a light microscope", "TEST", 215, 233], ["Immunohistochemistry", "TEST", 234, 254], ["METHODSIleum", "TREATMENT", 274, 286], ["colon tissue sections", "TREATMENT", 290, 311], ["xylene", "TREATMENT", 335, 341], ["ileum", "ANATOMY", 87, 92], ["colon tissue", "ANATOMY", 290, 302]]], ["The slide was immersed in a citric acid (pH 7.4)\u2013sodium citrate buffer solution (pH 8.0) at 121\u00b0C for 30 min for antigen retrieval.", [["citric acid", "CHEMICAL", 28, 39], ["\u2013sodium citrate", "CHEMICAL", 48, 63], ["citric acid", "CHEMICAL", 28, 39], ["\u2013sodium citrate", "CHEMICAL", 48, 63], ["citric acid", "SIMPLE_CHEMICAL", 28, 39], ["a citric acid", "TREATMENT", 26, 39], ["pH", "TEST", 41, 43], ["\u2013sodium citrate buffer solution", "TREATMENT", 48, 79], ["pH", "TEST", 81, 83], ["antigen retrieval", "TREATMENT", 113, 130]]], ["The tissues were rinsed with running tap water for 5 min and in PBS (Gibco) for 5 min, immersed in a 3% (vol/vol) H2O2\u2013methanol solution for 30 min to block endogenous peroxidase activity, rinsed with running tap water for 5 min, and then blocked with 5% skim milk (Sigma-Aldrich, USA) in PBS for 30 min at room temperature.", [["tissues", "ANATOMY", 4, 11], ["milk", "ANATOMY", 260, 264], ["H2O2\u2013methanol", "CHEMICAL", 114, 127], ["H2O2\u2013methanol", "CHEMICAL", 114, 127], ["tissues", "TISSUE", 4, 11], ["peroxidase", "GENE_OR_GENE_PRODUCT", 168, 178], ["milk", "ORGANISM_SUBSTANCE", 260, 264], ["endogenous peroxidase", "PROTEIN", 157, 178], ["running tap water", "TREATMENT", 29, 46], ["a 3% (vol/vol) H2O2\u2013methanol solution", "TREATMENT", 99, 136], ["block endogenous peroxidase activity", "TREATMENT", 151, 187], ["running tap water", "TREATMENT", 201, 218], ["tissues", "ANATOMY", 4, 11], ["peroxidase activity", "OBSERVATION", 168, 187]]], ["Mouse anti-PEDV spike protein monoclonal antibody (mAb) 6E5 (stocked in our laboratory) was diluted 1:200 in PBS.", [["Mouse", "ORGANISM", 0, 5], ["Mouse anti-PEDV spike protein monoclonal antibody (mAb) 6E5", "PROTEIN", 0, 59], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-PEDV", "TEST", 0, 15], ["protein monoclonal antibody", "TEST", 22, 49]]], ["After overnight incubation at 4\u00b0C, the tissue sections were subjected to three 10-min washes with PBS.", [["tissue sections", "ANATOMY", 39, 54], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 39, 54], ["the tissue sections", "TEST", 35, 54], ["PBS", "TREATMENT", 98, 101]]], ["Subsequently, the slides were incubated with goat anti-rabbit secondary antibody in the dark for 30 min at room temperature, subjected to three 5-min washes with PBS, visualized rapidly using diaminobenzidine (DAB) (Sigma-Aldrich, USA), and counterstained with hematoxylin.", [["DAB", "CHEMICAL", 210, 213], ["diaminobenzidine", "CHEMICAL", 192, 208], ["DAB", "CHEMICAL", 210, 213], ["hematoxylin", "CHEMICAL", 261, 272], ["goat", "ORGANISM", 45, 49], ["diaminobenzidine", "SIMPLE_CHEMICAL", 192, 208], ["DAB", "SIMPLE_CHEMICAL", 210, 213], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 216, 229], ["hematoxylin", "SIMPLE_CHEMICAL", 261, 272], ["goat anti-rabbit secondary antibody", "PROTEIN", 45, 80], ["goat", "SPECIES", 45, 49], ["anti-rabbit", "SPECIES", 50, 61], ["goat", "SPECIES", 45, 49], ["the slides", "TEST", 14, 24], ["goat anti-rabbit secondary antibody", "TREATMENT", 45, 80], ["PBS", "TREATMENT", 162, 165], ["diaminobenzidine", "TREATMENT", 192, 208], ["hematoxylin", "TREATMENT", 261, 272]]], ["The slides were then dehydrated with ascending concentrations (70%, 95%, and 100%) of ethanol, clarified in xylene, and mounted with Entellan mounting medium (Sigma-Aldrich, USA).", [["ethanol", "CHEMICAL", 86, 93], ["ethanol", "CHEMICAL", 86, 93], ["xylene", "CHEMICAL", 108, 114], ["ethanol", "SIMPLE_CHEMICAL", 86, 93], ["xylene", "SIMPLE_CHEMICAL", 108, 114], ["ascending concentrations", "TREATMENT", 37, 61], ["ethanol", "TREATMENT", 86, 93], ["ascending", "ANATOMY_MODIFIER", 37, 46]]], ["Staining was observed using an optical microscope.Immunofluorescence assay. ::: MATERIALS AND METHODSPorcine intestinal enteroid monolayers were infected with PEDV-JMS at an MOI of 5.", [["intestinal enteroid monolayers", "ANATOMY", 109, 139], ["PEDV", "CHEMICAL", 159, 163], ["METHODSPorcine intestinal enteroid monolayers", "CELL", 94, 139], ["METHODSPorcine intestinal enteroid monolayers", "CELL_LINE", 94, 139], ["an optical microscope", "TEST", 28, 49], ["Immunofluorescence assay", "TEST", 50, 74], ["METHODSPorcine intestinal enteroid monolayers", "TREATMENT", 94, 139], ["PEDV", "PROBLEM", 159, 163], ["intestinal", "ANATOMY", 109, 119], ["enteroid monolayers", "OBSERVATION", 120, 139]]], ["The level of PEDV infection at 48 h postinfection and the expression of differentiation markers were analyzed by an IFA as described previously (22).", [["infection", "DISEASE", 18, 27], ["PEDV", "GENE_OR_GENE_PRODUCT", 13, 17], ["differentiation markers", "PROTEIN", 72, 95], ["PEDV", "SPECIES", 13, 17], ["PEDV infection", "PROBLEM", 13, 27], ["differentiation markers", "TEST", 72, 95], ["an IFA", "TEST", 113, 119], ["PEDV", "OBSERVATION_MODIFIER", 13, 17], ["infection", "OBSERVATION", 18, 27]]], ["Briefly, porcine intestinal enteroid monolayers were fixed with 4% paraformaldehyde (PFA) for 30 min at RT.", [["intestinal enteroid monolayers", "ANATOMY", 17, 47], ["paraformaldehyde", "CHEMICAL", 67, 83], ["PFA", "CHEMICAL", 85, 88], ["porcine", "ORGANISM", 9, 16], ["intestinal enteroid monolayers", "CELL", 17, 47], ["paraformaldehyde", "SIMPLE_CHEMICAL", 67, 83], ["PFA", "SIMPLE_CHEMICAL", 85, 88], ["porcine intestinal enteroid monolayers", "CELL_LINE", 9, 47], ["porcine", "SPECIES", 9, 16], ["porcine", "SPECIES", 9, 16], ["porcine intestinal enteroid monolayers", "TREATMENT", 9, 47], ["4% paraformaldehyde (PFA", "TREATMENT", 64, 88], ["intestinal", "ANATOMY", 17, 27], ["enteroid monolayers", "OBSERVATION", 28, 47]]], ["After permeabilization with 0.2% Triton X-100, the cells were blocked with blocking buffer (PBS with 5% FBS and 5% skim milk), incubated with the primary antibodies for 2 h at 37\u00b0C, and stained with the secondary antibodies for 1 h at 37\u00b0C. The surface differentiation markers of intestinal epithelial cells were detected using primary anti-Ki-67 (1 \u03bcg/ml; Abcam, USA) for proliferative cells, anti-Lgr5 (1:50; Novus Biologicals, USA) for stem cells, anti-mucin 2 (1:50; Abcam, USA) for goblet cells, antivillin (1:100; Abcam, USA) and anti-chromogranin A (1:100; Santa Cruz, USA) for enteroendocrine cells, and antilysozyme (1:50; Santa Cruz, USA) for Paneth cells.", [["cells", "ANATOMY", 51, 56], ["FBS", "ANATOMY", 104, 107], ["milk", "ANATOMY", 120, 124], ["surface", "ANATOMY", 245, 252], ["intestinal epithelial cells", "ANATOMY", 280, 307], ["cells", "ANATOMY", 387, 392], ["stem cells", "ANATOMY", 439, 449], ["goblet cells", "ANATOMY", 487, 499], ["enteroendocrine cells", "ANATOMY", 585, 606], ["Paneth cells", "ANATOMY", 653, 665], ["Triton X-100", "CHEMICAL", 33, 45], ["Triton X-100", "SIMPLE_CHEMICAL", 33, 45], ["cells", "CELL", 51, 56], ["FBS", "ORGANISM_SUBSTANCE", 104, 107], ["milk", "ORGANISM_SUBSTANCE", 120, 124], ["intestinal epithelial cells", "CELL", 280, 307], ["anti-Ki-67", "SIMPLE_CHEMICAL", 336, 346], ["proliferative cells", "CELL", 373, 392], ["Lgr5", "GENE_OR_GENE_PRODUCT", 399, 403], ["stem cells", "CELL", 439, 449], ["anti-mucin 2", "CELL", 451, 463], ["Abcam", "GENE_OR_GENE_PRODUCT", 471, 476], ["USA", "GENE_OR_GENE_PRODUCT", 478, 481], ["goblet cells", "CELL", 487, 499], ["antivillin", "SIMPLE_CHEMICAL", 501, 511], ["Abcam", "GENE_OR_GENE_PRODUCT", 520, 525], ["USA", "GENE_OR_GENE_PRODUCT", 527, 530], ["anti-chromogranin A", "SIMPLE_CHEMICAL", 536, 555], ["enteroendocrine cells", "CELL", 585, 606], ["antilysozyme", "SIMPLE_CHEMICAL", 612, 624], ["Paneth cells", "CELL", 653, 665], ["primary antibodies", "PROTEIN", 146, 164], ["secondary antibodies", "PROTEIN", 203, 223], ["intestinal epithelial cells", "CELL_TYPE", 280, 307], ["primary anti-Ki-67", "PROTEIN", 328, 346], ["proliferative cells", "CELL_TYPE", 373, 392], ["Lgr5", "PROTEIN", 399, 403], ["stem cells", "CELL_TYPE", 439, 449], ["Abcam", "PROTEIN", 471, 476], ["goblet cells", "CELL_TYPE", 487, 499], ["enteroendocrine cells", "CELL_TYPE", 585, 606], ["Paneth cells", "CELL_TYPE", 653, 665], ["permeabilization", "TREATMENT", 6, 22], ["0.2% Triton", "TREATMENT", 28, 39], ["the cells", "TREATMENT", 47, 56], ["blocking buffer (PBS", "TREATMENT", 75, 95], ["5% FBS", "TREATMENT", 101, 107], ["5% skim milk", "TREATMENT", 112, 124], ["intestinal epithelial cells", "PROBLEM", 280, 307], ["primary anti-Ki-67", "TREATMENT", 328, 346], ["proliferative cells", "PROBLEM", 373, 392], ["anti-Lgr5", "TEST", 394, 403], ["stem cells", "TEST", 439, 449], ["anti-mucin", "TEST", 451, 461], ["goblet cells", "TEST", 487, 499], ["antivillin", "TEST", 501, 511], ["enteroendocrine cells", "TEST", 585, 606], ["antilysozyme", "TEST", 612, 624], ["Paneth cells", "PROBLEM", 653, 665], ["surface", "OBSERVATION_MODIFIER", 245, 252], ["differentiation", "OBSERVATION_MODIFIER", 253, 268], ["intestinal epithelial cells", "OBSERVATION", 280, 307], ["proliferative cells", "OBSERVATION", 373, 392], ["goblet cells", "OBSERVATION", 487, 499], ["Paneth cells", "OBSERVATION", 653, 665]]], ["Mouse anti-PEDV nucleocapsid mAb 2G3 was stocked in our laboratory (1:180 dilution).", [["Mouse", "ORGANISM", 0, 5], ["Mouse anti-PEDV nucleocapsid mAb 2G3", "PROTEIN", 0, 36], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-PEDV nucleocapsid mAb", "TREATMENT", 0, 32]]], ["The cells were then labeled with secondary antibody conjugated to Alexa Fluor 488 donkey polyclonal antibody against rabbit IgG (1:1,000; Thermo Fisher Scientific, USA) or Alexa Fluor 546 goat anti-mouse IgG antibody (1:500; Thermo Fisher Scientific, USA).", [["cells", "ANATOMY", 4, 9], ["Alexa Fluor 488", "CHEMICAL", 66, 81], ["cells", "CELL", 4, 9], ["Alexa Fluor", "SIMPLE_CHEMICAL", 66, 77], ["rabbit", "ORGANISM", 117, 123], ["Alexa Fluor", "SIMPLE_CHEMICAL", 172, 183], ["secondary antibody", "PROTEIN", 33, 51], ["Alexa Fluor 488 donkey polyclonal antibody", "PROTEIN", 66, 108], ["rabbit IgG", "PROTEIN", 117, 127], ["Alexa Fluor 546 goat anti-mouse IgG antibody", "PROTEIN", 172, 216], ["donkey", "SPECIES", 82, 88], ["rabbit", "SPECIES", 117, 123], ["goat", "SPECIES", 188, 192], ["anti-mouse", "SPECIES", 193, 203], ["Alexa Fluor 488 donkey", "SPECIES", 66, 88], ["rabbit", "SPECIES", 117, 123], ["Alexa Fluor 546", "SPECIES", 172, 187], ["goat", "SPECIES", 188, 192], ["secondary antibody", "TEST", 33, 51], ["Alexa Fluor", "TEST", 66, 77], ["donkey polyclonal antibody", "TEST", 82, 108], ["rabbit IgG", "TEST", 117, 127], ["Alexa Fluor", "TEST", 172, 183], ["anti-mouse IgG antibody", "TEST", 193, 216]]], ["DAPI (4\u2032,6-diamidino-2-phenylindole) (1:100; Sigma, USA) was used to stain cellular nuclei.", [["cellular nuclei", "ANATOMY", 75, 90], ["DAPI", "CHEMICAL", 0, 4], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 6, 35], ["DAPI", "CHEMICAL", 0, 4], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 6, 35], ["DAPI", "SIMPLE_CHEMICAL", 0, 4], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 6, 35], ["cellular nuclei", "CELL", 75, 90], ["DAPI", "TEST", 0, 4], ["diamidino", "TREATMENT", 11, 20], ["cellular nuclei", "OBSERVATION", 75, 90]]], ["The stained cells were visualized using an Evos FL Auto2 fluorescence microscope.Immunofluorescence assay. ::: MATERIALS AND METHODSRepresentative sections of ileum or colon tissues were deparaffinized, rehydrated, heated for antigen retrieval, and blocked with 5% skim milk.", [["cells", "ANATOMY", 12, 17], ["sections", "ANATOMY", 147, 155], ["ileum", "ANATOMY", 159, 164], ["colon tissues", "ANATOMY", 168, 181], ["milk", "ANATOMY", 270, 274], ["cells", "CELL", 12, 17], ["ileum", "MULTI-TISSUE_STRUCTURE", 159, 164], ["colon tissues", "TISSUE", 168, 181], ["milk", "ORGANISM_SUBSTANCE", 270, 274], ["The stained cells", "TEST", 0, 17], ["Immunofluorescence assay", "TEST", 81, 105], ["colon tissues", "PROBLEM", 168, 181], ["antigen retrieval", "TREATMENT", 226, 243], ["5% skim milk", "TREATMENT", 262, 274], ["stained cells", "OBSERVATION", 4, 17], ["ileum", "ANATOMY", 159, 164], ["colon tissues", "ANATOMY", 168, 181]]], ["Mouse anti-PEDV spike protein mAb 6E5 (1:200 dilution) was stocked in our laboratory.", [["Mouse", "ORGANISM", 0, 5], ["Mouse anti-PEDV spike protein mAb 6E5", "PROTEIN", 0, 37], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-PEDV spike protein mAb", "TREATMENT", 0, 33]]], ["The surface differentiation markers of intestinal epithelial cells were stained as described above.", [["surface", "ANATOMY", 4, 11], ["intestinal epithelial cells", "ANATOMY", 39, 66], ["intestinal epithelial cells", "CELL", 39, 66], ["intestinal epithelial cells", "CELL_TYPE", 39, 66], ["intestinal epithelial cells", "PROBLEM", 39, 66], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["differentiation", "OBSERVATION_MODIFIER", 12, 27], ["markers", "OBSERVATION_MODIFIER", 28, 35], ["intestinal epithelial cells", "OBSERVATION", 39, 66]]], ["The tissue sections were then rapidly washed three times in PBS, incubated with DAPI for 10 min at room temperature, and mounted.", [["tissue sections", "ANATOMY", 4, 19], ["DAPI", "CHEMICAL", 80, 84], ["tissue sections", "CANCER", 4, 19], ["DAPI", "SIMPLE_CHEMICAL", 80, 84], ["The tissue sections", "TEST", 0, 19], ["DAPI", "TREATMENT", 80, 84]]], ["The slides were imaged using a Carl Zeiss microscope (LSM700; Carl Zeiss, Heidenheim, Germany) with the appropriate filter set.Statistical analysis. ::: MATERIALS AND METHODSAll the results in the figures are presented, wherever appropriate, as the means \u00b1 the standard errors of the mean (SEMs) from three independent experiments and were analyzed using GraphPad Prism (GraphPad Software, Inc.).", [["the appropriate filter set", "TREATMENT", 100, 126], ["Statistical analysis", "TEST", 127, 147], ["the mean (SEMs", "TREATMENT", 280, 294], ["filter", "OBSERVATION", 116, 122]]], ["Differences were considered significant if the P value was <0.05.", [["the P value", "TEST", 43, 54]]]], "e5b976b6fac012ad3dae65faec97311c374cbbdf": [["IntroductionAngiotensin-converting enzyme (ACE) 2 is present in mammalian tissues and plays an important role in the resolution of inflammation and cellular homeostasis under inflammatory conditions.", [["tissues", "ANATOMY", 74, 81], ["cellular", "ANATOMY", 148, 156], ["IntroductionAngiotensin-converting enzyme (ACE) 2", "CHEMICAL", 0, 49], ["inflammation", "DISEASE", 131, 143], ["IntroductionAngiotensin-converting enzyme (ACE) 2", "GENE_OR_GENE_PRODUCT", 0, 49], ["mammalian tissues", "TISSUE", 64, 81], ["cellular", "CELL", 148, 156], ["IntroductionAngiotensin-converting enzyme (ACE) 2", "PROTEIN", 0, 49], ["IntroductionAngiotensin-converting enzyme (ACE)", "TREATMENT", 0, 47], ["inflammation", "PROBLEM", 131, 143], ["cellular homeostasis under inflammatory conditions", "PROBLEM", 148, 198], ["mammalian tissues", "ANATOMY", 64, 81], ["inflammation", "OBSERVATION", 131, 143], ["cellular homeostasis", "OBSERVATION", 148, 168], ["inflammatory", "OBSERVATION_MODIFIER", 175, 187]]], ["The stimulation of ACE2 with specific activators is protective in specific diseases, such as brain injury induced by an ischemic stroke (Bennion et al., 2015; Mecca et al., 2011) .", [["brain", "ANATOMY", 93, 98], ["brain injury", "DISEASE", 93, 105], ["ischemic stroke", "DISEASE", 120, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 19, 23], ["brain", "ORGAN", 93, 98], ["ACE2", "PROTEIN", 19, 23], ["ACE2 with specific activators", "TREATMENT", 19, 48], ["specific diseases", "PROBLEM", 66, 83], ["brain injury", "PROBLEM", 93, 105], ["an ischemic stroke", "PROBLEM", 117, 135], ["brain", "ANATOMY", 93, 98], ["injury", "OBSERVATION", 99, 105], ["ischemic", "OBSERVATION_MODIFIER", 120, 128], ["stroke", "OBSERVATION", 129, 135]]], ["However, recent data have demonstrated that SARS-CoV-2, the coronavirus causing COVID-19, utilizes ACE2 for entering into the epithelial cells (Hoffmann et al., 2020) .", [["epithelial cells", "ANATOMY", 126, 142], ["SARS-CoV-2", "ORGANISM", 44, 54], ["coronavirus", "ORGANISM", 60, 71], ["COVID-19", "GENE_OR_GENE_PRODUCT", 80, 88], ["ACE2", "GENE_OR_GENE_PRODUCT", 99, 103], ["epithelial cells", "CELL", 126, 142], ["COVID-19", "DNA", 80, 88], ["ACE2", "PROTEIN", 99, 103], ["epithelial cells", "CELL_TYPE", 126, 142], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["the coronavirus", "PROBLEM", 56, 71], ["COVID", "TEST", 80, 85], ["ACE2", "TREATMENT", 99, 103], ["epithelial cells", "ANATOMY", 126, 142]]], ["The ensuing infection is accompanied by inflammatory lung injury and death and has caused a world-wide epidemic since its start at the end of 2019 (Pedersen and Ho, 2020) .IntroductionStroke-induced immune activation can affect multiple vital organs and augment the progression of specific inflammatory diseases.", [["lung", "ANATOMY", 53, 57], ["organs", "ANATOMY", 243, 249], ["infection", "DISEASE", 12, 21], ["lung injury", "DISEASE", 53, 64], ["death", "DISEASE", 69, 74], ["Stroke", "DISEASE", 184, 190], ["lung", "ORGAN", 53, 57], ["organs", "ORGAN", 243, 249], ["The ensuing infection", "PROBLEM", 0, 21], ["inflammatory lung injury", "PROBLEM", 40, 64], ["death", "PROBLEM", 69, 74], ["IntroductionStroke-induced immune activation", "TREATMENT", 172, 216], ["specific inflammatory diseases", "PROBLEM", 281, 311], ["infection", "OBSERVATION", 12, 21], ["accompanied by", "UNCERTAINTY", 25, 39], ["inflammatory", "OBSERVATION_MODIFIER", 40, 52], ["lung", "ANATOMY", 53, 57], ["injury", "OBSERVATION", 58, 64], ["progression", "OBSERVATION_MODIFIER", 266, 277], ["specific", "OBSERVATION_MODIFIER", 281, 289], ["inflammatory", "OBSERVATION", 290, 302]]], ["Previous findings have shown that the induction of stroke in murine models of brain ischemia can activate immune cells and promote the progression of inflammatory heart disease .", [["brain", "ANATOMY", 78, 83], ["immune cells", "ANATOMY", 106, 118], ["heart", "ANATOMY", 163, 168], ["stroke", "DISEASE", 51, 57], ["brain ischemia", "DISEASE", 78, 92], ["heart disease", "DISEASE", 163, 176], ["murine", "ORGANISM", 61, 67], ["brain", "ORGAN", 78, 83], ["immune cells", "CELL", 106, 118], ["heart", "ORGAN", 163, 168], ["immune cells", "CELL_TYPE", 106, 118], ["murine", "SPECIES", 61, 67], ["stroke", "PROBLEM", 51, 57], ["brain ischemia", "PROBLEM", 78, 92], ["immune cells", "PROBLEM", 106, 118], ["inflammatory heart disease", "PROBLEM", 150, 176], ["stroke", "OBSERVATION", 51, 57], ["brain", "ANATOMY", 78, 83], ["ischemia", "OBSERVATION", 84, 92], ["immune cells", "OBSERVATION", 106, 118], ["progression", "OBSERVATION_MODIFIER", 135, 146], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["heart", "ANATOMY", 163, 168], ["disease", "OBSERVATION", 169, 176]]], ["Moreover, brain injury can modulate the functions of the intestine and its immune components, supporting the hypothesis of multi-organ failure after stroke (Singh et al., 2016a; Singh et al., 2018) .", [["brain", "ANATOMY", 10, 15], ["intestine", "ANATOMY", 57, 66], ["multi-organ", "ANATOMY", 123, 134], ["brain injury", "DISEASE", 10, 22], ["multi-organ failure", "DISEASE", 123, 142], ["stroke", "DISEASE", 149, 155], ["brain", "ORGAN", 10, 15], ["intestine", "ORGAN", 57, 66], ["multi-organ", "ORGAN", 123, 134], ["brain injury", "PROBLEM", 10, 22], ["multi-organ failure", "PROBLEM", 123, 142], ["stroke", "PROBLEM", 149, 155], ["brain", "ANATOMY", 10, 15], ["injury", "OBSERVATION", 16, 22], ["intestine", "ANATOMY", 57, 66], ["multi-organ", "ANATOMY", 123, 134], ["failure", "OBSERVATION", 135, 142]]], ["In addition, stroke patients may present signs of severe immunosuppression and inflammation that often lead to hospital-acquired respiratory infections (Shi et al., 2018) .", [["respiratory", "ANATOMY", 129, 140], ["stroke", "DISEASE", 13, 19], ["inflammation", "DISEASE", 79, 91], ["respiratory infections", "DISEASE", 129, 151], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["stroke", "PROBLEM", 13, 19], ["severe immunosuppression", "PROBLEM", 50, 74], ["inflammation", "PROBLEM", 79, 91], ["acquired respiratory infections", "PROBLEM", 120, 151], ["stroke", "OBSERVATION", 13, 19], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["immunosuppression", "OBSERVATION", 57, 74], ["inflammation", "OBSERVATION", 79, 91], ["respiratory", "ANATOMY", 129, 140], ["infections", "OBSERVATION", 141, 151]]], ["A recent study by Austin et al. has demonstrated an increased number of mononuclear granulocytes in bronchoalveolar lavage fluid and higher IL-1\uf062 expression in lung tissue of mice that were subjected to ischemia-induced brain injury (Austin et al., 2019) .", [["mononuclear granulocytes", "ANATOMY", 72, 96], ["bronchoalveolar lavage fluid", "ANATOMY", 100, 128], ["lung tissue", "ANATOMY", 160, 171], ["brain", "ANATOMY", 220, 225], ["brain injury", "DISEASE", 220, 232], ["mononuclear granulocytes", "CELL", 72, 96], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 100, 128], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 140, 145], ["lung tissue", "TISSUE", 160, 171], ["mice", "ORGANISM", 175, 179], ["brain", "ORGAN", 220, 225], ["mononuclear granulocytes", "CELL_TYPE", 72, 96], ["IL", "PROTEIN", 140, 142], ["mice", "SPECIES", 175, 179], ["mice", "SPECIES", 175, 179], ["A recent study", "TEST", 0, 14], ["mononuclear granulocytes", "PROBLEM", 72, 96], ["bronchoalveolar lavage fluid", "TEST", 100, 128], ["higher IL", "TREATMENT", 133, 142], ["brain injury", "PROBLEM", 220, 232], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["number", "OBSERVATION_MODIFIER", 62, 68], ["mononuclear granulocytes", "OBSERVATION", 72, 96], ["bronchoalveolar lavage fluid", "OBSERVATION", 100, 128], ["higher", "OBSERVATION_MODIFIER", 133, 139], ["IL", "OBSERVATION_MODIFIER", 140, 142], ["lung", "ANATOMY", 160, 164], ["tissue", "ANATOMY_MODIFIER", 165, 171], ["brain", "ANATOMY", 220, 225], ["injury", "OBSERVATION", 226, 232]]], ["In this respect, it is highly conspicuous that a plethora of clinical studies identified stroke as one of the most significant risk factors for a severe course of COVID-19 in humans (Bravi, 2020; Khawaja, 2020; Pigoga, 2020; Ssentongo, 2020) .", [["stroke", "DISEASE", 89, 95], ["COVID-19", "CHEMICAL", 163, 171], ["humans", "ORGANISM", 175, 181], ["humans", "SPECIES", 175, 181], ["humans", "SPECIES", 175, 181], ["clinical studies", "TEST", 61, 77], ["stroke", "PROBLEM", 89, 95], ["COVID", "TEST", 163, 168], ["stroke", "OBSERVATION", 89, 95], ["severe", "OBSERVATION_MODIFIER", 146, 152]]], ["The reasons for this connection are currently enigmatic.IntroductionHence, we hypothesized that brain injury-induced immunological alterations and systemic inflammatory conditions may enhance the expression of alveolar ACE2 and thereby, make stroke patients more susceptible to a lethal SARS-CoV-2 infection.", [["brain", "ANATOMY", 96, 101], ["alveolar", "ANATOMY", 210, 218], ["brain injury", "DISEASE", 96, 108], ["stroke", "DISEASE", 242, 248], ["SARS-CoV-2 infection", "DISEASE", 287, 307], ["brain", "ORGAN", 96, 101], ["alveolar ACE2", "GENE_OR_GENE_PRODUCT", 210, 223], ["patients", "ORGANISM", 249, 257], ["SARS-CoV-2", "ORGANISM", 287, 297], ["alveolar ACE2", "PROTEIN", 210, 223], ["patients", "SPECIES", 249, 257], ["brain injury", "PROBLEM", 96, 108], ["immunological alterations", "PROBLEM", 117, 142], ["systemic inflammatory conditions", "PROBLEM", 147, 179], ["alveolar ACE2", "PROBLEM", 210, 223], ["stroke", "PROBLEM", 242, 248], ["a lethal SARS", "PROBLEM", 278, 291], ["CoV-2 infection", "PROBLEM", 292, 307], ["brain", "ANATOMY", 96, 101], ["injury", "OBSERVATION", 102, 108], ["systemic", "OBSERVATION_MODIFIER", 147, 155], ["inflammatory", "OBSERVATION", 156, 168], ["alveolar ACE2", "OBSERVATION", 210, 223], ["infection", "OBSERVATION", 298, 307]]], ["At present, there is no data available demonstrating the dynamics of alveolar ACE2 and its functional role in lung inflammation after brain injury.", [["alveolar", "ANATOMY", 69, 77], ["lung", "ANATOMY", 110, 114], ["brain", "ANATOMY", 134, 139], ["lung inflammation", "DISEASE", 110, 127], ["brain injury", "DISEASE", 134, 146], ["alveolar", "MULTI-TISSUE_STRUCTURE", 69, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["lung", "ORGAN", 110, 114], ["brain", "ORGAN", 134, 139], ["alveolar ACE2", "PROTEIN", 69, 82], ["alveolar ACE2", "PROBLEM", 69, 82], ["lung inflammation", "PROBLEM", 110, 127], ["brain injury", "PROBLEM", 134, 146], ["alveolar", "ANATOMY_MODIFIER", 69, 77], ["lung", "ANATOMY", 110, 114], ["inflammation", "OBSERVATION", 115, 127], ["brain", "ANATOMY", 134, 139], ["injury", "OBSERVATION", 140, 146]]], ["Here, using an experimental murine model of stroke we found that focal cerebral ischemia indeed sharply increased the expression of ACE2 and pro-inflammatory cytokines IL-1\uf062 and IL-6 in the lungs.AnimalsAll animal experiments were performed following ethical guidelines and were approved by the local authorities (Landesamt f\u00fcr Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Essen, Germany).", [["cerebral", "ANATOMY", 71, 79], ["lungs", "ANATOMY", 190, 195], ["stroke", "DISEASE", 44, 50], ["cerebral ischemia", "DISEASE", 71, 88], ["murine", "ORGANISM", 28, 34], ["cerebral", "ORGAN", 71, 79], ["ACE2", "GENE_OR_GENE_PRODUCT", 132, 136], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 168, 173], ["IL-6", "GENE_OR_GENE_PRODUCT", 178, 182], ["lungs", "ORGAN", 190, 195], ["ACE2", "PROTEIN", 132, 136], ["pro-inflammatory cytokines", "PROTEIN", 141, 167], ["IL-1\uf062 and IL-6", "PROTEIN", 168, 182], ["murine", "SPECIES", 28, 34], ["stroke", "PROBLEM", 44, 50], ["focal cerebral ischemia", "PROBLEM", 65, 88], ["ACE2", "TEST", 132, 136], ["pro-inflammatory cytokines IL", "TEST", 141, 170], ["IL", "TEST", 178, 180], ["ethical guidelines", "TREATMENT", 251, 269], ["focal", "OBSERVATION_MODIFIER", 65, 70], ["cerebral", "ANATOMY", 71, 79], ["ischemia", "OBSERVATION", 80, 88], ["pro-inflammatory", "OBSERVATION_MODIFIER", 141, 157], ["lungs", "ANATOMY", 190, 195]]], ["The C57BL/6Hsd wild type male mice are received from Envigo, Netherlands.", [["C57BL/6Hsd wild type male mice", "ORGANISM", 4, 34], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34]]], ["In all experiments, mice of age between 8 and 10 weeks were used.Mouse model of middle cerebral artery occlusionTransient middle cerebral artery (MCA) occlusion (MCAO) was induced during anesthesia with 1% isoflurane in 100% oxygen.", [["middle cerebral artery", "ANATOMY", 80, 102], ["middle cerebral artery", "ANATOMY", 122, 144], ["MCA", "ANATOMY", 146, 149], ["isoflurane", "CHEMICAL", 206, 216], ["oxygen", "CHEMICAL", 225, 231], ["isoflurane", "CHEMICAL", 206, 216], ["oxygen", "CHEMICAL", 225, 231], ["mice", "ORGANISM", 20, 24], ["Mouse", "ORGANISM", 65, 70], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 87, 102], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 129, 144], ["MCA", "MULTI-TISSUE_STRUCTURE", 146, 149], ["isoflurane", "SIMPLE_CHEMICAL", 206, 216], ["oxygen", "SIMPLE_CHEMICAL", 225, 231], ["mice", "SPECIES", 20, 24], ["Mouse", "SPECIES", 65, 70], ["mice", "SPECIES", 20, 24], ["middle cerebral artery occlusion", "PROBLEM", 80, 112], ["Transient middle cerebral artery (MCA) occlusion", "PROBLEM", 112, 160], ["anesthesia", "TREATMENT", 187, 197], ["1% isoflurane", "TREATMENT", 203, 216], ["100% oxygen", "TREATMENT", 220, 231], ["middle cerebral artery", "ANATOMY", 80, 102], ["occlusion", "OBSERVATION", 103, 112], ["middle cerebral artery", "ANATOMY", 122, 144], ["MCA", "ANATOMY", 146, 149], ["occlusion", "OBSERVATION", 151, 160]]], ["Mice were injected with the analgetic buprenorphine (0.1 mg/Kg, s.c.) and the anti-inflammatory drug carprofen (4-5 mg/Kg, s.c.).", [["buprenorphine", "CHEMICAL", 38, 51], ["carprofen", "CHEMICAL", 101, 110], ["buprenorphine", "CHEMICAL", 38, 51], ["carprofen", "CHEMICAL", 101, 110], ["Mice", "ORGANISM", 0, 4], ["buprenorphine", "SIMPLE_CHEMICAL", 38, 51], ["carprofen", "SIMPLE_CHEMICAL", 101, 110], ["Mice", "SPECIES", 0, 4], ["the analgetic buprenorphine", "TREATMENT", 24, 51], ["the anti-inflammatory drug carprofen", "TREATMENT", 74, 110]]], ["An eye ointment (bepanthen) was applied to avoid any harm to mouse eyes during the surgical procedures.", [["eye", "ANATOMY", 3, 6], ["eyes", "ANATOMY", 67, 71], ["eye", "ORGAN", 3, 6], ["mouse", "ORGANISM", 61, 66], ["eyes", "ORGAN", 67, 71], ["mouse", "SPECIES", 61, 66], ["mouse", "SPECIES", 61, 66], ["An eye ointment (bepanthen)", "TREATMENT", 0, 27], ["any harm to mouse eyes", "PROBLEM", 49, 71], ["the surgical procedures", "TREATMENT", 79, 102], ["eye", "ANATOMY", 3, 6]]], ["A small incision was made between the ear and the eye to expose the temporal bone and a laser Doppler flow probe was attached to the skull above the core of the MCA territory.", [["ear", "ANATOMY", 38, 41], ["eye", "ANATOMY", 50, 53], ["temporal bone", "ANATOMY", 68, 81], ["skull", "ANATOMY", 133, 138], ["MCA", "ANATOMY", 161, 164], ["ear", "ORGAN", 38, 41], ["eye", "ORGAN", 50, 53], ["bone", "TISSUE", 77, 81], ["skull", "ORGAN", 133, 138], ["MCA territory", "MULTI-TISSUE_STRUCTURE", 161, 174], ["A small incision", "PROBLEM", 0, 16], ["a laser Doppler flow probe", "TEST", 86, 112], ["small", "OBSERVATION_MODIFIER", 2, 7], ["incision", "OBSERVATION", 8, 16], ["ear", "ANATOMY", 38, 41], ["eye", "ANATOMY", 50, 53], ["temporal bone", "ANATOMY", 68, 81], ["flow probe", "OBSERVATION", 102, 112], ["skull", "ANATOMY", 133, 138], ["core", "ANATOMY_MODIFIER", 149, 153], ["MCA", "ANATOMY", 161, 164], ["territory", "ANATOMY_MODIFIER", 165, 174]]], ["Mice were then placed in a supine position on a feedbackcontrolled heat pad and the midline neck region was exposed with a small incision.", [["midline neck region", "ANATOMY", 84, 103], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["a feedbackcontrolled heat pad", "TREATMENT", 46, 75], ["a small incision", "PROBLEM", 121, 137], ["midline", "ANATOMY_MODIFIER", 84, 91], ["neck", "ANATOMY", 92, 96], ["small", "OBSERVATION_MODIFIER", 123, 128], ["incision", "OBSERVATION", 129, 137]]], ["The common carotid artery (CCA) and left external carotid arteries were identified and ligated.", [["common carotid artery", "ANATOMY", 4, 25], ["CCA", "ANATOMY", 27, 30], ["left external carotid arteries", "ANATOMY", 36, 66], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 11, 25], ["CCA", "MULTI-TISSUE_STRUCTURE", 27, 30], ["external carotid arteries", "MULTI-TISSUE_STRUCTURE", 41, 66], ["common carotid artery", "ANATOMY", 4, 25], ["CCA", "ANATOMY", 27, 30], ["left external carotid arteries", "ANATOMY", 36, 66], ["ligated", "OBSERVATION", 87, 94]]], ["A 2 mm silicon-coated filament (catalog #701912PKRe; Doccol) was inserted into the internal carotid artery to occlude the MCA.", [["internal carotid artery", "ANATOMY", 83, 106], ["MCA", "ANATOMY", 122, 125], ["silicon", "CHEMICAL", 7, 14], ["internal carotid artery", "MULTI-TISSUE_STRUCTURE", 83, 106], ["MCA", "MULTI-TISSUE_STRUCTURE", 122, 125], ["A 2 mm silicon-coated filament", "TREATMENT", 0, 30], ["Doccol)", "TREATMENT", 53, 60], ["internal carotid artery", "ANATOMY", 83, 106], ["MCA", "ANATOMY", 122, 125]]], ["MCAO was verified by a stable reduction of blood flow to \u226420% of baseline that was observed on the laser Doppler flow device.", [["blood", "ANATOMY", 43, 48], ["reduction of blood flow", "DISEASE", 30, 53], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["blood flow", "TEST", 43, 53], ["the laser Doppler flow device", "TREATMENT", 95, 124], ["stable", "OBSERVATION_MODIFIER", 23, 29], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["blood flow", "OBSERVATION", 43, 53], ["flow device", "OBSERVATION", 113, 124]]], ["Mouse wounds were sutured and mice inserted into a recovery box with a constant temperature of 37\u00b0C. After 45 min of MCAO, mice were anesthetized with isoflurane in 100% oxygen and the filament was removed for the reestablishment of the blood flow.", [["wounds", "ANATOMY", 6, 12], ["filament", "ANATOMY", 185, 193], ["blood", "ANATOMY", 237, 242], ["isoflurane", "CHEMICAL", 151, 161], ["oxygen", "CHEMICAL", 170, 176], ["isoflurane", "CHEMICAL", 151, 161], ["oxygen", "CHEMICAL", 170, 176], ["Mouse", "ORGANISM", 0, 5], ["wounds", "PATHOLOGICAL_FORMATION", 6, 12], ["mice", "ORGANISM", 30, 34], ["mice", "ORGANISM", 123, 127], ["isoflurane", "SIMPLE_CHEMICAL", 151, 161], ["oxygen", "SIMPLE_CHEMICAL", 170, 176], ["filament", "CELLULAR_COMPONENT", 185, 193], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 123, 127], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 123, 127], ["Mouse wounds", "PROBLEM", 0, 12], ["a recovery box", "TREATMENT", 49, 63], ["a constant temperature", "TEST", 69, 91], ["isoflurane", "TREATMENT", 151, 161], ["100% oxygen", "TREATMENT", 165, 176], ["the filament", "TREATMENT", 181, 193], ["the blood flow", "TEST", 233, 247], ["wounds", "OBSERVATION", 6, 12], ["blood flow", "OBSERVATION", 237, 247]]], ["Mouse wounds were again sutured and mice returned to their cages with free access to the food and water.", [["wounds", "ANATOMY", 6, 12], ["Mouse", "ORGANISM", 0, 5], ["wounds", "PATHOLOGICAL_FORMATION", 6, 12], ["mice", "ORGANISM", 36, 40], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 36, 40], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 36, 40], ["Mouse wounds", "PROBLEM", 0, 12], ["wounds", "OBSERVATION", 6, 12]]], ["Sham-operated mice underwent the same surgical protocol except the filament was inserted into the CCA and immediately removed.", [["filament", "ANATOMY", 67, 75], ["mice", "ORGANISM", 14, 18], ["filament", "CELLULAR_COMPONENT", 67, 75], ["CCA", "DNA", 98, 101], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["the same surgical protocol", "TREATMENT", 29, 55], ["the filament", "TREATMENT", 63, 75], ["CCA", "ANATOMY", 98, 101]]], ["For experiments with 3 days survival, mice were daily injected with carprofen (4-5 mg/Kg, s.c.).", [["carprofen", "CHEMICAL", 68, 77], ["carprofen", "CHEMICAL", 68, 77], ["mice", "ORGANISM", 38, 42], ["carprofen", "SIMPLE_CHEMICAL", 68, 77], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["carprofen", "TREATMENT", 68, 77]]], ["The overall mortality rate of MCAO mice was ~5% and that of sham mice was 0%.", [["mice", "ORGANISM", 35, 39], ["mice", "ORGANISM", 65, 69], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 65, 69]]], ["The exclusion criteria of experimental mice were as follows: inadequate MCAO (a reduction in blood flow to >20% of the baseline value), weight loss >20% of baseline body weight during the study, and spontaneous animal death.Quantitative PCRMouse brain and lungs were processed to isolate total RNA using PureLink RNA Mini Kit (Invitrogen).", [["blood", "ANATOMY", 93, 98], ["body", "ANATOMY", 165, 169], ["PCRMouse brain", "ANATOMY", 237, 251], ["lungs", "ANATOMY", 256, 261], ["weight loss", "DISEASE", 136, 147], ["death", "DISEASE", 218, 223], ["mice", "ORGANISM", 39, 43], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["body", "ORGANISM_SUBDIVISION", 165, 169], ["brain", "ORGAN", 246, 251], ["lungs", "ORGAN", 256, 261], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 327, 337], ["mice", "SPECIES", 39, 43], ["mice", "SPECIES", 39, 43], ["inadequate MCAO", "PROBLEM", 61, 76], ["blood flow", "TEST", 93, 103], ["the baseline value", "TEST", 115, 133], ["weight loss", "PROBLEM", 136, 147], ["baseline body weight", "TEST", 156, 176], ["the study", "TEST", 184, 193], ["spontaneous animal death", "PROBLEM", 199, 223], ["total RNA", "TREATMENT", 288, 297], ["PureLink RNA Mini Kit (Invitrogen)", "TREATMENT", 304, 338], ["brain", "ANATOMY", 246, 251], ["lungs", "ANATOMY", 256, 261]]], ["An equal amount of total RNA was used to synthesize cDNA with a High-Capacity cDNA reverse transcription kit (ThermoFisher Scientific).", [["cDNA", "DNA", 52, 56], ["total RNA", "TREATMENT", 19, 28], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["amount", "OBSERVATION_MODIFIER", 9, 15], ["total RNA", "OBSERVATION_MODIFIER", 19, 28]]], ["Quantitative PCR was performed using a Q-Rex thermal cycler using the Rotor-Gene SYBR green PCR kit (Qiagen).", [["Quantitative PCR", "TEST", 0, 16], ["a Q-Rex thermal cycler", "TREATMENT", 37, 59], ["the Rotor", "TREATMENT", 66, 75]]], ["Primer sequences were: ACE2 5\" TGGGCAAACTCTATGCTG 3\" and 5\" TTCATTGGCTCCGTTTCTTA 3\"; ACE 5\" GTTCGTGGAAGAGTATGACCG 3\" and 5\" CCATTGAGCTTGGCGAGCTTG 3\"; IL-6 5\" CAG TTG CCT TCT TGG GAC TGA 3\" and 5\" GGG AGT GGT ATC CTC TGT GAA GTC 3\"; IL-1\uf062 5\" TGTAATGAAAGACGGCACACC 3\" and 5\" TCTTCTTTGGGTATTGCTTGG 3\"; GAPDH 5\" AACTTTGGCATTGTGGAAGG 3\" and 5\" ACACATTGGGGGTAGGAACA 3\".", [["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["IL-6", "GENE_OR_GENE_PRODUCT", 150, 154], ["IL-1", "GENE_OR_GENE_PRODUCT", 232, 236], ["Primer sequences", "DNA", 0, 16], ["ACE2", "PROTEIN", 23, 27], ["TTCATTGGCTCCGTTTCTTA 3", "DNA", 60, 82], ["ACE 5", "DNA", 85, 90], ["GTTCGTGGAAGAGTATGACCG 3", "DNA", 92, 115], ["CCATTGAGCTTGGCGAGCTTG 3", "DNA", 124, 147], ["IL-6 5", "DNA", 150, 156], ["TCTTCTTTGGGTATTGCTTGG 3", "DNA", 273, 296], ["GAPDH 5", "DNA", 299, 306], ["ACACATTGGGGGTAGGAACA 3", "DNA", 339, 361], ["Primer sequences", "TEST", 0, 16], ["ACE2", "TEST", 23, 27], ["TGGGCAAACTCTATGCTG", "TEST", 31, 49], ["\"", "TEST", 51, 52], ["TTCATTGGCTCCGTTTCTTA", "TEST", 60, 80], ["ACE", "TEST", 85, 88], ["GTTCGTGGAAGAGTATGACCG", "TEST", 92, 113], ["\"", "TEST", 115, 116], ["CCATTGAGCTTGGCGAGCTTG", "TEST", 124, 145], ["IL", "TEST", 150, 152], ["CAG", "TEST", 158, 161], ["TTG", "TEST", 162, 165], ["CCT", "TEST", 166, 169], ["TCT", "TEST", 170, 173], ["TGG", "TEST", 174, 177], ["TGA", "TEST", 182, 185], ["GGG AGT GGT ATC CTC TGT GAA GTC", "TREATMENT", 196, 227]]], ["The relative quantification was performed by the \u0394\u0394CT method.Western blottingMice were perfused with phosphate-buffered saline (PBS) and isolated lung tissues were prepared in lysis buffer (42 mM Tris-HCl, 1.3% sodium dodecyl sulfate (SDS), 6.5% glycerin and 2% protease and phosphatase inhibitors).", [["lung tissues", "ANATOMY", 146, 158], ["phosphate", "CHEMICAL", 101, 110], ["Tris-HCl", "CHEMICAL", 196, 204], ["sodium dodecyl sulfate", "CHEMICAL", 211, 233], ["glycerin", "CHEMICAL", 246, 254], ["phosphate", "CHEMICAL", 101, 110], ["Tris-HCl", "CHEMICAL", 196, 204], ["sodium dodecyl sulfate", "CHEMICAL", 211, 233], ["SDS", "CHEMICAL", 235, 238], ["glycerin", "CHEMICAL", 246, 254], ["Mice", "ORGANISM", 77, 81], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 101, 126], ["lung tissues", "TISSUE", 146, 158], ["Tris-HCl", "SIMPLE_CHEMICAL", 196, 204], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 211, 233], ["glycerin", "SIMPLE_CHEMICAL", 246, 254], ["protease", "PROTEIN", 262, 270], ["Mice", "SPECIES", 77, 81], ["The relative quantification", "TEST", 0, 27], ["the \u0394\u0394CT method", "TEST", 45, 60], ["phosphate-buffered saline (PBS", "TREATMENT", 101, 131], ["isolated lung tissues", "PROBLEM", 137, 158], ["lysis buffer", "TREATMENT", 176, 188], ["1.3% sodium dodecyl sulfate", "TREATMENT", 206, 233], ["SDS", "TEST", 235, 238], ["6.5% glycerin", "TREATMENT", 241, 254], ["2% protease", "TREATMENT", 259, 270], ["phosphatase inhibitors", "TREATMENT", 275, 297], ["lung tissues", "ANATOMY", 146, 158]]], ["The protein concentration of the samples was measured using the bicinchoninic acid protein assay kit (ThermoFisher Scientific).", [["samples", "ANATOMY", 33, 40], ["bicinchoninic acid", "CHEMICAL", 64, 82], ["bicinchoninic acid", "CHEMICAL", 64, 82], ["the samples", "TEST", 29, 40], ["the bicinchoninic acid protein", "TREATMENT", 60, 90]]], ["For immunoblotting, 20 \uf06dg of protein from each sample was subjected to SDS-polyacrylamide gel electrophoresis (PAGE) on a 10% gel under reducing conditions.", [["sample", "ANATOMY", 47, 53], ["SDS-polyacrylamide", "CHEMICAL", 71, 89], ["SDS", "CHEMICAL", 71, 74], ["polyacrylamide", "CHEMICAL", 75, 89], ["immunoblotting", "TREATMENT", 4, 18], ["polyacrylamide gel electrophoresis", "TREATMENT", 75, 109], ["a 10% gel", "TREATMENT", 120, 129]]], ["Proteins were then transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore).", [["polyvinylidene fluoride", "CHEMICAL", 38, 61], ["polyvinylidene fluoride", "CHEMICAL", 38, 61], ["PVDF", "CHEMICAL", 63, 67], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 38, 61], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["a polyvinylidene fluoride (PVDF) membrane (Millipore", "TREATMENT", 36, 88]]], ["After blocking with 5% milk solution, the membrane was incubated overnight at 4\u00b0C with the primary antibody.", [["membrane", "ANATOMY", 42, 50], ["milk", "ORGANISM_SUBSTANCE", 23, 27], ["membrane", "CELLULAR_COMPONENT", 42, 50], ["primary antibody", "PROTEIN", 91, 107], ["5% milk solution", "TREATMENT", 20, 36]]], ["Primary antibodies used were goat anti-mouse ACE2 (AF3437, R and D Systems), goat anti-mouse ACE (AF1513, R&D Systems), and rabbit anti-mouse actin (4967, Cell Signaling).", [["Cell", "ANATOMY", 155, 159], ["ACE2", "GENE_OR_GENE_PRODUCT", 45, 49], ["goat anti-mouse ACE", "GENE_OR_GENE_PRODUCT", 77, 96], ["AF1513", "SIMPLE_CHEMICAL", 98, 104], ["rabbit", "ORGANISM", 124, 130], ["anti-mouse actin", "GENE_OR_GENE_PRODUCT", 131, 147], ["Cell", "CELL", 155, 159], ["goat anti-mouse ACE2", "PROTEIN", 29, 49], ["AF3437", "PROTEIN", 51, 57], ["R", "PROTEIN", 59, 60], ["D Systems", "PROTEIN", 65, 74], ["goat anti-mouse ACE", "PROTEIN", 77, 96], ["AF1513", "PROTEIN", 98, 104], ["R&D", "PROTEIN", 106, 109], ["rabbit anti-mouse actin", "PROTEIN", 124, 147], ["4967", "PROTEIN", 149, 153], ["goat", "SPECIES", 29, 33], ["anti-mouse", "SPECIES", 34, 44], ["goat", "SPECIES", 77, 81], ["anti-mouse", "SPECIES", 82, 92], ["rabbit", "SPECIES", 124, 130], ["goat", "SPECIES", 29, 33], ["goat", "SPECIES", 77, 81], ["rabbit", "SPECIES", 124, 130], ["Primary antibodies", "TEST", 0, 18], ["anti-mouse ACE2", "TEST", 34, 49], ["AF3437", "TEST", 51, 57], ["R and D Systems", "TREATMENT", 59, 74], ["goat anti-mouse ACE", "TREATMENT", 77, 96], ["rabbit anti-mouse actin", "TREATMENT", 124, 147]]], ["After extensive washing (three times for 15 min each in TBS containing 0.1% Tween 20), proteins were detected with horseradish peroxidase-coupled anti-goat or anti-rabbit antibody.", [["Tween 20", "CHEMICAL", 76, 84], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 115, 137], ["anti-goat", "GENE_OR_GENE_PRODUCT", 146, 155], ["horseradish peroxidase", "PROTEIN", 115, 137], ["coupled anti-goat", "PROTEIN", 138, 155], ["anti-rabbit antibody", "PROTEIN", 159, 179], ["horseradish", "SPECIES", 115, 126], ["anti-rabbit", "SPECIES", 159, 170], ["anti-rabbit", "SPECIES", 159, 170], ["extensive washing", "TREATMENT", 6, 23], ["TBS", "TEST", 56, 59], ["proteins", "TEST", 87, 95], ["horseradish peroxidase", "TEST", 115, 137], ["anti-rabbit antibody", "PROBLEM", 159, 179]]], ["Densitometry analysis was performed using ImageJ software (NIH, USA), and a \uf062-actin control was used to confirm equal sample loading and normalization of the data.Flow cytometry analysisMice were sacrificed and blood was collected via cardiac puncture and added to EDTA containing tubes.", [["sample", "ANATOMY", 118, 124], ["blood", "ANATOMY", 211, 216], ["cardiac", "ANATOMY", 235, 242], ["EDTA", "CHEMICAL", 265, 269], ["blood", "ORGANISM_SUBSTANCE", 211, 216], ["cardiac", "ORGAN", 235, 242], ["EDTA", "SIMPLE_CHEMICAL", 265, 269], ["Densitometry analysis", "TEST", 0, 21], ["ImageJ software", "TEST", 42, 57], ["a \uf062-actin control", "TREATMENT", 74, 91], ["the data", "TEST", 154, 162], ["Flow cytometry analysisMice", "TEST", 163, 190], ["blood", "TEST", 211, 216], ["cardiac puncture", "TEST", 235, 251], ["EDTA containing tubes", "TREATMENT", 265, 286], ["cardiac", "ANATOMY", 235, 242], ["puncture", "OBSERVATION", 243, 251], ["tubes", "OBSERVATION", 281, 286]]], ["Mice were then perfused with PBS and spleens were collected in cold PBS.", [["spleens", "ANATOMY", 37, 44], ["Mice", "ORGANISM", 0, 4], ["spleens", "ORGAN", 37, 44], ["Mice", "SPECIES", 0, 4], ["Mice", "SPECIES", 0, 4], ["PBS and spleens", "TREATMENT", 29, 44], ["spleens", "ANATOMY", 37, 44]]], ["Single-cell suspensions were prepared by mincing the spleens in PBS and filtered through 70 \uf06dm cell filters.", [["cell", "ANATOMY", 7, 11], ["spleens", "ANATOMY", 53, 60], ["cell", "ANATOMY", 95, 99], ["Single-cell", "CELL", 0, 11], ["spleens", "ORGAN", 53, 60], ["cell", "CELL", 95, 99], ["Single-cell suspensions", "TREATMENT", 0, 23], ["70 \uf06dm cell filters", "TREATMENT", 89, 107], ["-cell", "OBSERVATION_MODIFIER", 6, 11], ["spleens", "ANATOMY", 53, 60], ["\uf06dm cell filters", "OBSERVATION", 92, 107]]], ["Blood and spleen samples were treated with RBC lysis buffer and washed in PBS.", [["Blood", "ANATOMY", 0, 5], ["spleen samples", "ANATOMY", 10, 24], ["RBC", "ANATOMY", 43, 46], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["spleen samples", "ORGANISM_SUBSTANCE", 10, 24], ["RBC", "CELL", 43, 46], ["Blood and spleen samples", "TEST", 0, 24], ["RBC lysis buffer", "TREATMENT", 43, 59], ["spleen", "ANATOMY", 10, 16]]], ["Total cell counts in samples were measured using an automated cell counter (Nexcelom Bioscience).", [["cell", "ANATOMY", 6, 10], ["samples", "ANATOMY", 21, 28], ["cell", "ANATOMY", 62, 66], ["cell", "CELL", 6, 10], ["cell", "CELL", 62, 66], ["Total cell counts", "TEST", 0, 17], ["samples", "TEST", 21, 28], ["cell counts", "OBSERVATION", 6, 17]]], ["An equal amount of cells from each sample was used to stain with antibodies purchased from Biolegend: CD45 FITC (30-F11), CD3 APC (17A2).", [["cells", "ANATOMY", 19, 24], ["sample", "ANATOMY", 35, 41], ["FITC", "CHEMICAL", 107, 111], ["cells", "CELL", 19, 24], ["Biolegend", "GENE_OR_GENE_PRODUCT", 91, 100], ["CD45", "GENE_OR_GENE_PRODUCT", 102, 106], ["CD3 APC", "GENE_OR_GENE_PRODUCT", 122, 129], ["antibodies", "PROTEIN", 65, 75], ["Biolegend", "PROTEIN", 91, 100], ["CD45 FITC", "PROTEIN", 102, 111], ["F11", "PROTEIN", 116, 119], ["CD3 APC", "PROTEIN", 122, 129], ["17A2", "PROTEIN", 131, 135], ["each sample", "TEST", 30, 41], ["antibodies", "TEST", 65, 75], ["CD45 FITC", "TEST", 102, 111], ["CD3 APC", "TEST", 122, 129], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["amount", "OBSERVATION_MODIFIER", 9, 15]]], ["Stained samples were measured on BD FACSAria TM flow cytometer and analyzed using FlowJo software (BD Biosciences).Statistical analysisData were analyzed using GraphPad Prism version 6.0.", [["samples", "ANATOMY", 8, 15], ["Stained samples", "TEST", 0, 15], ["flow cytometer", "TEST", 48, 62], ["Statistical analysisData", "TEST", 115, 139], ["GraphPad Prism version", "TEST", 160, 182]]], ["All datasets were tested for normality using the Shapiro-Wilk normality test.", [["All datasets", "TEST", 0, 12], ["the Shapiro-Wilk normality test", "TEST", 45, 76]]], ["The comparisons between two groups were analyzed using the Mann-Whitney U test.", [["the Mann-Whitney U test", "TEST", 55, 78]]], ["Differences with p-values\u22640.05 were considered to be statistically significant.ResultsTo understand the impact of stroke on lung ACE2 levels and inflammation, we utilized a wellestablished mouse model of focal cerebral ischemia, that is, transient MCAO.", [["lung", "ANATOMY", 124, 128], ["cerebral", "ANATOMY", 210, 218], ["stroke", "DISEASE", 114, 120], ["inflammation", "DISEASE", 145, 157], ["cerebral ischemia", "DISEASE", 210, 227], ["lung", "ORGAN", 124, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["mouse", "ORGANISM", 189, 194], ["cerebral", "ORGAN", 210, 218], ["ACE2", "PROTEIN", 129, 133], ["mouse", "SPECIES", 189, 194], ["mouse", "SPECIES", 189, 194], ["p-values", "TEST", 17, 25], ["stroke", "PROBLEM", 114, 120], ["lung ACE2 levels", "TEST", 124, 140], ["inflammation", "PROBLEM", 145, 157], ["focal cerebral ischemia", "PROBLEM", 204, 227], ["stroke", "OBSERVATION", 114, 120], ["lung", "ANATOMY", 124, 128], ["inflammation", "OBSERVATION", 145, 157], ["focal", "OBSERVATION_MODIFIER", 204, 209], ["cerebral", "ANATOMY", 210, 218], ["ischemia", "OBSERVATION", 219, 227], ["transient", "OBSERVATION_MODIFIER", 238, 247], ["MCAO", "OBSERVATION", 248, 252]]], ["Induction of 45 min of MCAO in mice leads to focal brain infarcts that cover the striatum and overlying parietal cortex (Fig. 1a) .", [["brain", "ANATOMY", 51, 56], ["striatum", "ANATOMY", 81, 89], ["parietal cortex", "ANATOMY", 104, 119], ["brain infarcts", "DISEASE", 51, 65], ["mice", "ORGANISM", 31, 35], ["brain", "ORGAN", 51, 56], ["striatum", "MULTI-TISSUE_STRUCTURE", 81, 89], ["parietal cortex", "MULTI-TISSUE_STRUCTURE", 104, 119], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["MCAO in mice", "TREATMENT", 23, 35], ["focal brain infarcts", "PROBLEM", 45, 65], ["focal", "OBSERVATION_MODIFIER", 45, 50], ["brain", "ANATOMY", 51, 56], ["infarcts", "OBSERVATION", 57, 65], ["striatum", "ANATOMY", 81, 89], ["overlying", "ANATOMY_MODIFIER", 94, 103], ["parietal cortex", "ANATOMY", 104, 119]]], ["Our results showed increased gene expression of pro-inflammatory cytokines IL-6 and IL-1\uf062 in the ipsilateral compared to contralateral brain hemispheres (Fig. 1b, c) .", [["contralateral brain hemispheres", "ANATOMY", 121, 152], ["IL-6", "GENE_OR_GENE_PRODUCT", 75, 79], ["IL-1", "GENE_OR_GENE_PRODUCT", 84, 88], ["brain hemispheres", "MULTI-TISSUE_STRUCTURE", 135, 152], ["pro-inflammatory cytokines", "PROTEIN", 48, 74], ["IL-6", "PROTEIN", 75, 79], ["IL", "PROTEIN", 84, 86], ["pro-inflammatory cytokines IL", "TEST", 48, 77], ["IL", "TEST", 84, 86], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["pro-inflammatory cytokines", "OBSERVATION", 48, 74], ["ipsilateral", "ANATOMY_MODIFIER", 97, 108], ["contralateral", "ANATOMY_MODIFIER", 121, 134], ["brain hemispheres", "ANATOMY", 135, 152]]], ["In addition, mice subjected to stroke had a reduced number of circulating and splenic T lymphocytes which is an indicator of strokeinduced systemic immunosuppression (Fig. 1d, e) .Figure 1.", [["splenic T lymphocytes", "ANATOMY", 78, 99], ["stroke", "DISEASE", 31, 37], ["mice", "ORGANISM", 13, 17], ["splenic T lymphocytes", "CELL", 78, 99], ["splenic T lymphocytes", "CELL_TYPE", 78, 99], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["stroke", "PROBLEM", 31, 37], ["a reduced number of circulating and splenic T lymphocytes", "PROBLEM", 42, 99], ["strokeinduced systemic immunosuppression", "TREATMENT", 125, 165], ["reduced", "OBSERVATION_MODIFIER", 44, 51], ["number", "OBSERVATION_MODIFIER", 52, 58], ["splenic", "ANATOMY", 78, 85], ["T lymphocytes", "OBSERVATION", 86, 99], ["systemic", "OBSERVATION_MODIFIER", 139, 147], ["immunosuppression", "OBSERVATION", 148, 165]]], ["Sterile brain injury induces inflammation and lymphopenia. a) Brain serial sections stained with cresyl violet to visualize infarcts 24 h after transient MCAO. b, c)Increased gene expression of brain IL-6 and IL-1\uf062 in ischemic (Ipsi) hemispheres compared to non-ischemic hemispheres (Contra). d, e) Reduced number of T lymphocytes in blood and spleen of MCAO mice.", [["brain", "ANATOMY", 8, 13], ["Brain", "ANATOMY", 62, 67], ["sections", "ANATOMY", 75, 83], ["infarcts", "ANATOMY", 124, 132], ["brain", "ANATOMY", 194, 199], ["Ipsi) hemispheres", "ANATOMY", 228, 245], ["non-ischemic hemispheres", "ANATOMY", 258, 282], ["T lymphocytes", "ANATOMY", 317, 330], ["blood", "ANATOMY", 334, 339], ["spleen", "ANATOMY", 344, 350], ["brain injury", "DISEASE", 8, 20], ["inflammation", "DISEASE", 29, 41], ["lymphopenia", "DISEASE", 46, 57], ["cresyl violet", "CHEMICAL", 97, 110], ["infarcts", "DISEASE", 124, 132], ["cresyl violet", "CHEMICAL", 97, 110], ["brain", "ORGAN", 8, 13], ["cresyl violet", "SIMPLE_CHEMICAL", 97, 110], ["brain", "ORGAN", 194, 199], ["IL-6", "GENE_OR_GENE_PRODUCT", 200, 204], ["IL-1", "GENE_OR_GENE_PRODUCT", 209, 213], ["hemispheres", "MULTI-TISSUE_STRUCTURE", 271, 282], ["T lymphocytes", "CELL", 317, 330], ["blood", "ORGANISM_SUBSTANCE", 334, 339], ["spleen", "ORGAN", 344, 350], ["MCAO mice", "ORGANISM", 354, 363], ["brain IL-6", "PROTEIN", 194, 204], ["IL", "PROTEIN", 209, 211], ["T lymphocytes", "CELL_TYPE", 317, 330], ["mice", "SPECIES", 359, 363], ["mice", "SPECIES", 359, 363], ["Sterile brain injury", "PROBLEM", 0, 20], ["inflammation", "PROBLEM", 29, 41], ["lymphopenia", "PROBLEM", 46, 57], ["Brain serial sections", "TEST", 62, 83], ["cresyl violet", "TEST", 97, 110], ["infarcts", "PROBLEM", 124, 132], ["transient MCAO", "TREATMENT", 144, 158], ["brain IL", "TEST", 194, 202], ["ischemic (Ipsi) hemispheres", "PROBLEM", 218, 245], ["T lymphocytes in blood", "PROBLEM", 317, 339], ["brain", "ANATOMY", 8, 13], ["injury", "OBSERVATION", 14, 20], ["inflammation", "OBSERVATION", 29, 41], ["lymphopenia", "OBSERVATION", 46, 57], ["Brain", "ANATOMY", 62, 67], ["infarcts", "OBSERVATION", 124, 132], ["brain", "ANATOMY", 194, 199], ["ischemic", "OBSERVATION", 218, 226], ["non-ischemic hemispheres", "ANATOMY", 258, 282], ["T lymphocytes", "OBSERVATION", 317, 330], ["blood", "ANATOMY", 334, 339], ["spleen", "ANATOMY", 344, 350], ["MCAO mice", "OBSERVATION", 354, 363]]], ["Ipsi=ipsilateral; contra=contralateral.", [["Ipsi", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ipsi", "TEST", 0, 4]]], ["Data are means \u00b1 SEM. **p<0.05, Mann-Whitney U test, N=8 per group.Figure 1.", [["Whitney U test", "TEST", 37, 51]]], ["Sterile brain injury induces inflammation and lymphopenia. a) Brain serial sections stained with cresyl violet to visualize infarcts 24 h after transient MCAO. b, c)To test our hypothesis that stroke can increase the expression of ACE2 in the lungs, we performed quantitative PCR analysis on lung tissues 24 h after transient MCAO or sham surgery.", [["brain", "ANATOMY", 8, 13], ["Brain", "ANATOMY", 62, 67], ["sections", "ANATOMY", 75, 83], ["infarcts", "ANATOMY", 124, 132], ["lungs", "ANATOMY", 243, 248], ["lung tissues", "ANATOMY", 292, 304], ["brain injury", "DISEASE", 8, 20], ["inflammation", "DISEASE", 29, 41], ["lymphopenia", "DISEASE", 46, 57], ["cresyl violet", "CHEMICAL", 97, 110], ["infarcts", "DISEASE", 124, 132], ["stroke", "DISEASE", 193, 199], ["cresyl violet", "CHEMICAL", 97, 110], ["brain", "ORGAN", 8, 13], ["cresyl violet", "SIMPLE_CHEMICAL", 97, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 231, 235], ["lungs", "ORGAN", 243, 248], ["lung tissues", "TISSUE", 292, 304], ["ACE2", "PROTEIN", 231, 235], ["Sterile brain injury", "PROBLEM", 0, 20], ["inflammation", "PROBLEM", 29, 41], ["lymphopenia", "PROBLEM", 46, 57], ["Brain serial sections", "TEST", 62, 83], ["cresyl violet", "TEST", 97, 110], ["infarcts", "PROBLEM", 124, 132], ["transient MCAO", "TREATMENT", 144, 158], ["stroke", "PROBLEM", 193, 199], ["ACE2 in the lungs", "PROBLEM", 231, 248], ["quantitative PCR analysis", "TEST", 263, 288], ["transient MCAO", "TREATMENT", 316, 330], ["sham surgery", "TREATMENT", 334, 346], ["brain", "ANATOMY", 8, 13], ["injury", "OBSERVATION", 14, 20], ["inflammation", "OBSERVATION", 29, 41], ["lymphopenia", "OBSERVATION", 46, 57], ["infarcts", "OBSERVATION", 124, 132], ["stroke", "OBSERVATION", 193, 199], ["lungs", "ANATOMY", 243, 248], ["lung", "ANATOMY", 292, 296]]], ["Strikingly, the induction of transient MCAO significantly increased the level of ACE2 mRNA in the lungs compared to sham-operated mice (Fig. 2a) .", [["lungs", "ANATOMY", 98, 103], ["ACE2", "GENE_OR_GENE_PRODUCT", 81, 85], ["lungs", "ORGAN", 98, 103], ["mice", "ORGANISM", 130, 134], ["ACE2 mRNA", "RNA", 81, 90], ["mice", "SPECIES", 130, 134], ["transient MCAO", "PROBLEM", 29, 43], ["ACE2 mRNA in the lungs", "PROBLEM", 81, 103], ["transient", "OBSERVATION_MODIFIER", 29, 38], ["MCAO", "OBSERVATION", 39, 43], ["ACE2 mRNA", "OBSERVATION", 81, 90], ["lungs", "ANATOMY", 98, 103]]], ["However, the expression of ACE mRNA was not changed between sham and transient MCAO (Fig. 2b) .", [["ACE", "GENE_OR_GENE_PRODUCT", 27, 30], ["ACE mRNA", "RNA", 27, 35], ["ACE mRNA", "TREATMENT", 27, 35]]], ["Interestingly, we also found an increased expression of the inflammatory cytokines IL-6 and IL-1\uf062 mRNAs in murine lungs after transient MCAO (Fig. 2c, d) .", [["lungs", "ANATOMY", 114, 119], ["IL-6", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-1", "GENE_OR_GENE_PRODUCT", 92, 96], ["murine", "ORGANISM", 107, 113], ["lungs", "ORGAN", 114, 119], ["inflammatory cytokines IL-6 and IL-1\uf062 mRNAs", "RNA", 60, 103], ["murine", "SPECIES", 107, 113], ["the inflammatory cytokines IL", "TREATMENT", 56, 85], ["IL", "TREATMENT", 92, 94], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["inflammatory", "OBSERVATION_MODIFIER", 60, 72], ["lungs", "ANATOMY", 114, 119]]], ["These data suggest that stroke-induced peripheral signals can increase ACE2, but not ACE levels and generate an inflammatory milieu in the lungs of affected mice.", [["lungs", "ANATOMY", 139, 144], ["stroke", "DISEASE", 24, 30], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["ACE", "GENE_OR_GENE_PRODUCT", 85, 88], ["lungs", "ORGAN", 139, 144], ["mice", "ORGANISM", 157, 161], ["ACE2", "PROTEIN", 71, 75], ["ACE", "PROTEIN", 85, 88], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 157, 161], ["These data", "TEST", 0, 10], ["stroke", "PROBLEM", 24, 30], ["peripheral signals", "PROBLEM", 39, 57], ["ACE2", "TEST", 71, 75], ["ACE levels", "TEST", 85, 95], ["an inflammatory milieu", "PROBLEM", 109, 131], ["stroke", "OBSERVATION", 24, 30], ["inflammatory", "OBSERVATION", 112, 124], ["lungs", "ANATOMY", 139, 144]]], ["To verify that the increased mRNA expression was also mirrored on the level of expressed protein, we investigated the impact of transient MCAO on the abundance of ACE2 and ACE proteins in murine lungs by Western blotting.", [["lungs", "ANATOMY", 195, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 163, 167], ["ACE", "GENE_OR_GENE_PRODUCT", 172, 175], ["murine", "ORGANISM", 188, 194], ["lungs", "ORGAN", 195, 200], ["ACE2", "PROTEIN", 163, 167], ["ACE proteins", "PROTEIN", 172, 184], ["murine", "SPECIES", 188, 194], ["the increased mRNA expression", "PROBLEM", 15, 44], ["transient MCAO", "PROBLEM", 128, 142], ["ACE2 and ACE proteins", "TREATMENT", 163, 184], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["mRNA expression", "OBSERVATION", 29, 44], ["transient MCAO", "OBSERVATION", 128, 142], ["lungs", "ANATOMY", 195, 200]]], ["Indeed, we found that transient MCAO led to a 2-fold increase in ACE2 protein abundance compared to the sham controls 24 h post-ischemic-reperfusion injury.", [["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE2", "PROTEIN", 65, 69], ["transient MCAO", "PROBLEM", 22, 36], ["a 2-fold increase in ACE2 protein abundance", "PROBLEM", 44, 87], ["post-ischemic-reperfusion injury", "PROBLEM", 123, 155], ["transient", "OBSERVATION_MODIFIER", 22, 31], ["MCAO", "OBSERVATION", 32, 36], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["post-ischemic", "OBSERVATION_MODIFIER", 123, 136], ["reperfusion injury", "OBSERVATION", 137, 155]]], ["However, again, ACE protein abundance remained unchanged (Fig. 3a, b, c) .", [["ACE", "GENE_OR_GENE_PRODUCT", 16, 19], ["ACE", "PROTEIN", 16, 19], ["ACE protein abundance", "TEST", 16, 37], ["unchanged", "OBSERVATION_MODIFIER", 47, 56]]], ["We further extended our experiments to investigate the levels of ACE2 and ACE at a later time point of 72 h after transient MCAO or sham surgery.", [["ACE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["ACE", "GENE_OR_GENE_PRODUCT", 74, 77], ["ACE2", "PROTEIN", 65, 69], ["ACE", "PROTEIN", 74, 77], ["ACE2", "TREATMENT", 65, 69], ["ACE", "TREATMENT", 74, 77], ["sham surgery", "TREATMENT", 132, 144]]], ["Again, we found increased levels of ACE2 but not ACE protein in lungs of MCAO mice compared to sham-operated mice (Fig. 3d, e) .", [["lungs", "ANATOMY", 64, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ACE", "GENE_OR_GENE_PRODUCT", 49, 52], ["lungs", "ORGAN", 64, 69], ["MCAO mice", "ORGANISM", 73, 82], ["mice", "ORGANISM", 109, 113], ["ACE2", "PROTEIN", 36, 40], ["ACE protein", "PROTEIN", 49, 60], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 78, 82], ["increased levels of ACE2", "PROBLEM", 16, 40], ["ACE protein", "TEST", 49, 60], ["sham", "TEST", 95, 99], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["lungs", "ANATOMY", 64, 69]]], ["These results further indicate the longlasting impact of systemic immune alterations and inflammation on ACE2 in lungs after sterile brain injury.DiscussionACE and ACE2 are the key enzymes of the renin-angiotensin system which regulate blood pressure and salt-fluid balance in the body (Donoghue et al., 2000) .", [["lungs", "ANATOMY", 113, 118], ["brain", "ANATOMY", 133, 138], ["blood", "ANATOMY", 236, 241], ["body", "ANATOMY", 281, 285], ["inflammation", "DISEASE", 89, 101], ["brain injury", "DISEASE", 133, 145], ["angiotensin", "CHEMICAL", 202, 213], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["lungs", "ORGAN", 113, 118], ["brain", "ORGAN", 133, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 196, 213], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["salt", "SIMPLE_CHEMICAL", 255, 259], ["body", "ORGANISM_SUBDIVISION", 281, 285], ["ACE2", "PROTEIN", 105, 109], ["DiscussionACE", "PROTEIN", 146, 159], ["ACE2", "PROTEIN", 164, 168], ["renin", "PROTEIN", 196, 201], ["systemic immune alterations", "PROBLEM", 57, 84], ["inflammation on ACE2 in lungs", "PROBLEM", 89, 118], ["sterile brain injury", "PROBLEM", 125, 145], ["the renin-angiotensin system", "TREATMENT", 192, 220], ["blood pressure", "TEST", 236, 250], ["salt-fluid balance", "TEST", 255, 273], ["systemic immune alterations", "OBSERVATION", 57, 84], ["inflammation", "OBSERVATION", 89, 101], ["lungs", "ANATOMY", 113, 118], ["brain", "ANATOMY", 133, 138], ["injury", "OBSERVATION", 139, 145], ["fluid balance", "OBSERVATION", 260, 273]]], ["ACE2 is a homolog of ACE and counterbalances pathways of inflammation in specific tissue injuries (Rodrigues Prestes et al., 2017) .", [["tissue", "ANATOMY", 82, 88], ["inflammation", "DISEASE", 57, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ACE", "GENE_OR_GENE_PRODUCT", 21, 24], ["tissue", "TISSUE", 82, 88], ["ACE2", "PROTEIN", 0, 4], ["ACE", "PROTEIN", 21, 24], ["ACE and counterbalances pathways", "TREATMENT", 21, 53], ["inflammation in specific tissue injuries", "PROBLEM", 57, 97], ["inflammation", "OBSERVATION", 57, 69], ["specific tissue", "OBSERVATION_MODIFIER", 73, 88]]], ["A higher expression of ACE2 is protective in lung injury, and the stimulation of this pathway with chemical activators has been shown to reduce LPS-induced lung edema and inflammatory tissue damage (Li et al., 2016) .", [["lung", "ANATOMY", 45, 49], ["lung", "ANATOMY", 156, 160], ["tissue", "ANATOMY", 184, 190], ["lung injury", "DISEASE", 45, 56], ["LPS", "CHEMICAL", 144, 147], ["lung edema", "DISEASE", 156, 166], ["ACE2", "GENE_OR_GENE_PRODUCT", 23, 27], ["lung", "ORGAN", 45, 49], ["LPS", "SIMPLE_CHEMICAL", 144, 147], ["lung", "ORGAN", 156, 160], ["tissue", "TISSUE", 184, 190], ["ACE2", "PROTEIN", 23, 27], ["lung injury", "PROBLEM", 45, 56], ["chemical activators", "TREATMENT", 99, 118], ["LPS", "PROBLEM", 144, 147], ["lung edema", "PROBLEM", 156, 166], ["inflammatory tissue damage", "PROBLEM", 171, 197], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["protective", "OBSERVATION_MODIFIER", 31, 41], ["lung", "ANATOMY", 45, 49], ["injury", "OBSERVATION", 50, 56], ["lung", "ANATOMY", 156, 160], ["edema", "OBSERVATION", 161, 166], ["inflammatory tissue", "OBSERVATION", 171, 190]]], ["A recent study by Imai et al. suggested that the loss of ACE2 in a mouse model of acid-induced lung injury leads to the worsening of lung inflammation and increased lung edema (Imai et al., 2005) .DiscussionACE2 is utilized as a binding receptor by SARS-CoV2 for its entry into nasal and lung epithelial cells and the infection can induce acute respiratory distress syndrome (ARDS) in affected patients (Hoffmann et al., 2020; Ziegler et al., 2020) .", [["lung", "ANATOMY", 95, 99], ["lung", "ANATOMY", 133, 137], ["lung", "ANATOMY", 165, 169], ["nasal", "ANATOMY", 278, 283], ["lung epithelial cells", "ANATOMY", 288, 309], ["respiratory", "ANATOMY", 345, 356], ["lung injury", "DISEASE", 95, 106], ["lung inflammation", "DISEASE", 133, 150], ["lung edema", "DISEASE", 165, 175], ["DiscussionACE2", "CHEMICAL", 197, 211], ["infection", "DISEASE", 318, 327], ["acute respiratory distress syndrome", "DISEASE", 339, 374], ["ARDS", "DISEASE", 376, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 57, 61], ["mouse", "ORGANISM", 67, 72], ["lung", "ORGAN", 95, 99], ["lung", "ORGAN", 133, 137], ["lung", "ORGAN", 165, 169], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 249, 258], ["nasal", "CELL", 278, 283], ["lung epithelial cells", "CELL", 288, 309], ["patients", "ORGANISM", 394, 402], ["ACE2", "PROTEIN", 57, 61], ["DiscussionACE2", "PROTEIN", 197, 211], ["binding receptor", "PROTEIN", 229, 245], ["CoV2", "PROTEIN", 254, 258], ["nasal and lung epithelial cells", "CELL_TYPE", 278, 309], ["mouse", "SPECIES", 67, 72], ["patients", "SPECIES", 394, 402], ["mouse", "SPECIES", 67, 72], ["A recent study", "TEST", 0, 14], ["the loss of ACE2", "PROBLEM", 45, 61], ["acid-induced lung injury", "PROBLEM", 82, 106], ["lung inflammation", "PROBLEM", 133, 150], ["increased lung edema", "PROBLEM", 155, 175], ["nasal and lung epithelial cells", "PROBLEM", 278, 309], ["the infection", "PROBLEM", 314, 327], ["acute respiratory distress syndrome", "PROBLEM", 339, 374], ["ARDS", "PROBLEM", 376, 380], ["acid-induced", "OBSERVATION_MODIFIER", 82, 94], ["lung", "ANATOMY", 95, 99], ["injury", "OBSERVATION", 100, 106], ["worsening", "OBSERVATION_MODIFIER", 120, 129], ["lung", "ANATOMY", 133, 137], ["inflammation", "OBSERVATION", 138, 150], ["increased", "OBSERVATION_MODIFIER", 155, 164], ["lung", "ANATOMY", 165, 169], ["edema", "OBSERVATION", 170, 175], ["nasal", "ANATOMY", 278, 283], ["lung", "ANATOMY", 288, 292], ["epithelial cells", "OBSERVATION", 293, 309], ["infection", "OBSERVATION", 318, 327], ["acute", "OBSERVATION_MODIFIER", 339, 344], ["respiratory distress", "OBSERVATION", 345, 365]]], ["Based on the fact that SARS-CoV2 infection co-exists with reported cases of cardiac disease and stroke patients (Pan Zhai 2020; Shi et al., 2020) , we hypothesized that brain injury may also increase ACE2 expression in the lungs.", [["cardiac", "ANATOMY", 76, 83], ["brain", "ANATOMY", 169, 174], ["lungs", "ANATOMY", 223, 228], ["SARS-CoV2 infection", "DISEASE", 23, 42], ["cardiac disease", "DISEASE", 76, 91], ["stroke", "DISEASE", 96, 102], ["brain injury", "DISEASE", 169, 181], ["SARS-CoV2", "ORGANISM", 23, 32], ["cardiac", "ORGAN", 76, 83], ["patients", "ORGANISM", 103, 111], ["brain", "ORGAN", 169, 174], ["ACE2", "GENE_OR_GENE_PRODUCT", 200, 204], ["lungs", "ORGAN", 223, 228], ["ACE2", "PROTEIN", 200, 204], ["patients", "SPECIES", 103, 111], ["SARS", "PROBLEM", 23, 27], ["CoV2 infection", "PROBLEM", 28, 42], ["cardiac disease", "PROBLEM", 76, 91], ["stroke", "PROBLEM", 96, 102], ["brain injury", "PROBLEM", 169, 181], ["ACE2 expression in the lungs", "PROBLEM", 200, 228], ["SARS", "OBSERVATION", 23, 27], ["cardiac", "ANATOMY", 76, 83], ["disease", "OBSERVATION", 84, 91], ["brain", "ANATOMY", 169, 174], ["injury", "OBSERVATION", 175, 181], ["increase", "OBSERVATION_MODIFIER", 191, 199], ["ACE2 expression", "OBSERVATION", 200, 215], ["lungs", "ANATOMY", 223, 228]]], ["Indeed, our results suggest a rapid increase of ACE2 expression and pro-inflammatory cytokines in murine lungs after ischemic brain injury.", [["lungs", "ANATOMY", 105, 110], ["brain", "ANATOMY", 126, 131], ["ischemic brain injury", "DISEASE", 117, 138], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["murine", "ORGANISM", 98, 104], ["lungs", "ORGAN", 105, 110], ["brain", "ORGAN", 126, 131], ["ACE2", "PROTEIN", 48, 52], ["pro-inflammatory cytokines", "PROTEIN", 68, 94], ["murine", "SPECIES", 98, 104], ["a rapid increase of ACE2 expression", "PROBLEM", 28, 63], ["pro-inflammatory cytokines in murine lungs", "PROBLEM", 68, 110], ["ischemic brain injury", "PROBLEM", 117, 138], ["rapid", "OBSERVATION_MODIFIER", 30, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["ACE2 expression", "OBSERVATION", 48, 63], ["pro-inflammatory cytokines", "OBSERVATION", 68, 94], ["lungs", "ANATOMY", 105, 110], ["ischemic", "OBSERVATION_MODIFIER", 117, 125], ["brain", "ANATOMY", 126, 131], ["injury", "OBSERVATION", 132, 138]]], ["The increase of ACE2 levels within 24 h of brain injury suggests fast kinetics of signaling to induce protein expression changes in the lungs.", [["brain", "ANATOMY", 43, 48], ["lungs", "ANATOMY", 136, 141], ["brain injury", "DISEASE", 43, 55], ["ACE2", "GENE_OR_GENE_PRODUCT", 16, 20], ["brain", "ORGAN", 43, 48], ["lungs", "ORGAN", 136, 141], ["ACE2", "PROTEIN", 16, 20], ["ACE2 levels", "TEST", 16, 27], ["brain injury", "PROBLEM", 43, 55], ["fast kinetics of signaling", "PROBLEM", 65, 91], ["protein expression changes in the lungs", "PROBLEM", 102, 141], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["brain", "ANATOMY", 43, 48], ["injury", "OBSERVATION", 49, 55], ["fast kinetics", "OBSERVATION", 65, 78], ["protein expression", "OBSERVATION", 102, 120], ["lungs", "ANATOMY", 136, 141]]], ["The molecular mechanisms underlying this response in the lungs after transient MCAO are currently unclear, but, based on our data and related studies of others increased post-stroke lung inflammation might be a possible explanation (Austin et al., 2019) .", [["lungs", "ANATOMY", 57, 62], ["lung", "ANATOMY", 182, 186], ["MCAO", "DISEASE", 79, 83], ["stroke", "DISEASE", 175, 181], ["inflammation", "DISEASE", 187, 199], ["lungs", "ORGAN", 57, 62], ["lung", "ORGAN", 182, 186], ["transient MCAO", "PROBLEM", 69, 83], ["our data", "TEST", 121, 129], ["related studies", "TEST", 134, 149], ["stroke lung inflammation", "PROBLEM", 175, 199], ["lungs", "ANATOMY", 57, 62], ["transient", "OBSERVATION_MODIFIER", 69, 78], ["MCAO", "OBSERVATION", 79, 83], ["increased", "OBSERVATION_MODIFIER", 160, 169], ["lung", "ANATOMY", 182, 186], ["inflammation", "OBSERVATION", 187, 199]]], ["Physiologically, the augmented ACE2 levels in inflamed lungs after brain ischemia may help to counterbalance the subsequent inflammatory lung injury (Imai et al., 2005) .", [["lungs", "ANATOMY", 55, 60], ["brain", "ANATOMY", 67, 72], ["lung", "ANATOMY", 137, 141], ["brain ischemia", "DISEASE", 67, 81], ["lung injury", "DISEASE", 137, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 31, 35], ["lungs", "ORGAN", 55, 60], ["brain", "ORGAN", 67, 72], ["lung", "ORGAN", 137, 141], ["ACE2", "PROTEIN", 31, 35], ["the augmented ACE2 levels", "TEST", 17, 42], ["inflamed lungs", "PROBLEM", 46, 60], ["brain ischemia", "PROBLEM", 67, 81], ["the subsequent inflammatory lung injury", "PROBLEM", 109, 148], ["inflamed", "ANATOMY_MODIFIER", 46, 54], ["lungs", "ANATOMY", 55, 60], ["brain", "ANATOMY", 67, 72], ["ischemia", "OBSERVATION", 73, 81], ["inflammatory", "OBSERVATION_MODIFIER", 124, 136], ["lung", "ANATOMY", 137, 141], ["injury", "OBSERVATION", 142, 148]]], ["But in the presence of a virus that exploits this anti-inflammatory enzyme for cell entry and infection, this protective mechanism might prove fatal.DiscussionOne of the clinical features of SARS-CoV-2-infected patients is the ensuing cytokine storm that leads to ARDS (Mehta et al., 2020) .", [["cell", "ANATOMY", 79, 83], ["infection", "DISEASE", 94, 103], ["SARS-CoV-2-infected", "DISEASE", 191, 210], ["ARDS", "DISEASE", 264, 268], ["cell", "CELL", 79, 83], ["SARS-CoV-2", "ORGANISM", 191, 201], ["patients", "ORGANISM", 211, 219], ["anti-inflammatory enzyme", "PROTEIN", 50, 74], ["cytokine", "PROTEIN", 235, 243], ["CoV-2", "SPECIES", 196, 201], ["patients", "SPECIES", 211, 219], ["a virus", "PROBLEM", 23, 30], ["this anti-inflammatory enzyme", "TREATMENT", 45, 74], ["cell entry", "PROBLEM", 79, 89], ["infection", "PROBLEM", 94, 103], ["SARS", "PROBLEM", 191, 195], ["CoV", "TEST", 196, 199], ["the ensuing cytokine storm", "PROBLEM", 223, 249], ["ARDS", "PROBLEM", 264, 268], ["virus", "OBSERVATION", 25, 30], ["infection", "OBSERVATION", 94, 103], ["cytokine storm", "OBSERVATION", 235, 249]]], ["In the last months, several clinical studies have shown a higher serum level of cytokines such as IL-1\uf062\uf02c IL-6 and TNF-\uf061 in virus-infected patients compared to the healthy controls (Conti et al., 2020; Han et al., 2020) .", [["serum", "ANATOMY", 65, 70], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["IL-1", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL-6", "GENE_OR_GENE_PRODUCT", 105, 109], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 114, 119], ["patients", "ORGANISM", 138, 146], ["cytokines", "PROTEIN", 80, 89], ["TNF", "PROTEIN", 114, 117], ["patients", "SPECIES", 138, 146], ["several clinical studies", "TEST", 20, 44], ["a higher serum level of cytokines", "PROBLEM", 56, 89], ["IL", "TEST", 98, 100], ["IL", "TEST", 105, 107], ["TNF", "TEST", 114, 117], ["virus", "PROBLEM", 123, 128]]], ["Our results show that brain injury can also increase the expression of the pro-inflammatory cytokines IL-1\uf062\uf020and IL-6 in the injured brain hemispheres and the lungs.", [["brain", "ANATOMY", 22, 27], ["brain hemispheres", "ANATOMY", 132, 149], ["lungs", "ANATOMY", 158, 163], ["brain injury", "DISEASE", 22, 34], ["brain", "ORGAN", 22, 27], ["IL-1\uf062\uf020and", "GENE_OR_GENE_PRODUCT", 102, 111], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["brain hemispheres", "MULTI-TISSUE_STRUCTURE", 132, 149], ["lungs", "ORGAN", 158, 163], ["pro-inflammatory cytokines", "PROTEIN", 75, 101], ["IL-1\uf062\uf020and IL-6", "PROTEIN", 102, 116], ["brain injury", "PROBLEM", 22, 34], ["the pro-inflammatory cytokines IL", "TEST", 71, 104], ["brain", "ANATOMY", 22, 27], ["injury", "OBSERVATION", 28, 34], ["pro-inflammatory", "OBSERVATION_MODIFIER", 75, 91], ["injured", "ANATOMY_MODIFIER", 124, 131], ["brain", "ANATOMY", 132, 137], ["hemispheres", "ANATOMY_MODIFIER", 138, 149], ["lungs", "ANATOMY", 158, 163]]], ["In addition, sterile tissue injury can initiate the release of damage-associated molecular patterns (DAMPs) and thereby propagate parenchymal and systemic inflammation (Singh et al., 2016b) .", [["tissue", "ANATOMY", 21, 27], ["parenchymal", "ANATOMY", 130, 141], ["tissue injury", "DISEASE", 21, 34], ["inflammation", "DISEASE", 155, 167], ["tissue", "TISSUE", 21, 27], ["damage-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 63, 99], ["DAMPs", "GENE_OR_GENE_PRODUCT", 101, 106], ["parenchymal", "TISSUE", 130, 141], ["sterile tissue injury", "PROBLEM", 13, 34], ["damage", "PROBLEM", 63, 69], ["propagate parenchymal and systemic inflammation", "PROBLEM", 120, 167], ["sterile tissue", "OBSERVATION_MODIFIER", 13, 27], ["injury", "OBSERVATION", 28, 34], ["parenchymal", "ANATOMY_MODIFIER", 130, 141], ["systemic", "OBSERVATION_MODIFIER", 146, 154], ["inflammation", "OBSERVATION", 155, 167]]], ["These DAMPs might serve as activation signals for lung epithelial and immune cells.", [["lung epithelial", "ANATOMY", 50, 65], ["immune cells", "ANATOMY", 70, 82], ["DAMPs", "GENE_OR_GENE_PRODUCT", 6, 11], ["lung epithelial", "CELL", 50, 65], ["immune cells", "CELL", 70, 82], ["DAMPs", "PROTEIN", 6, 11], ["lung epithelial and immune cells", "CELL_TYPE", 50, 82], ["These DAMPs", "PROBLEM", 0, 11], ["activation signals", "TEST", 27, 45], ["lung epithelial and immune cells", "PROBLEM", 50, 82], ["lung", "ANATOMY", 50, 54], ["epithelial", "ANATOMY_MODIFIER", 55, 65], ["immune cells", "OBSERVATION", 70, 82]]], ["However, which specific molecules modulate ACE2 expression in the lungs after stroke is an open question and requires further research.DiscussionThe potential role of soluble ACE2 as a therapeutic target for SARS-CoV-2 infection is intensively discussed in the scientific community (Tang et al., 2020) .", [["lungs", "ANATOMY", 66, 71], ["stroke", "DISEASE", 78, 84], ["SARS", "DISEASE", 208, 212], ["infection", "DISEASE", 219, 228], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["lungs", "ORGAN", 66, 71], ["ACE2", "GENE_OR_GENE_PRODUCT", 175, 179], ["SARS-CoV-2", "ORGANISM", 208, 218], ["ACE2", "PROTEIN", 43, 47], ["ACE2", "PROTEIN", 175, 179], ["SARS-CoV", "SPECIES", 208, 216], ["stroke", "PROBLEM", 78, 84], ["soluble ACE2", "TREATMENT", 167, 179], ["SARS", "PROBLEM", 208, 212], ["CoV-2 infection", "PROBLEM", 213, 228], ["ACE2 expression", "OBSERVATION", 43, 58], ["lungs", "ANATOMY", 66, 71], ["stroke", "OBSERVATION", 78, 84], ["infection", "OBSERVATION", 219, 228]]], ["Recent experimental data have demonstrated the effectiveness of recombinant human ACE2 in blocking SARS-CoV-2 binding to membrane ACE2 and thereby blocking virus invasion (Vanessa Monteil et al., 2020) .", [["membrane", "ANATOMY", 121, 129], ["human", "ORGANISM", 76, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 82, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 99, 109], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["recombinant human ACE2", "PROTEIN", 64, 86], ["membrane ACE2", "PROTEIN", 121, 134], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81], ["Recent experimental data", "TEST", 0, 24], ["recombinant human ACE2", "TREATMENT", 64, 86], ["blocking SARS", "PROBLEM", 90, 103], ["membrane ACE2", "TREATMENT", 121, 134], ["thereby blocking virus invasion", "TREATMENT", 139, 170]]], ["The safety and use of soluble ACE2 therapy in humans has been successfully tested in a phase 1 clinical trial (Haschke et al., 2013) and is now examined in a clinical trial to treat COVID-19 patients (Clinicaltrials.gov #NCT04335136).", [["COVID", "DISEASE", 182, 187], ["ACE2", "GENE_OR_GENE_PRODUCT", 30, 34], ["humans", "ORGANISM", 46, 52], ["patients", "ORGANISM", 191, 199], ["ACE2", "PROTEIN", 30, 34], ["humans", "SPECIES", 46, 52], ["patients", "SPECIES", 191, 199], ["humans", "SPECIES", 46, 52], ["soluble ACE2 therapy", "TREATMENT", 22, 42], ["COVID", "TEST", 182, 187]]], ["In this respect, it is very important to note that decreased circulating levels of soluble ACE2 in stroke patients (Bennion et al., 2016) may further increase their susceptibility to SARS-CoV-2 infection in the light of increased levels of ACE2 in lung epithelial cells.", [["lung epithelial cells", "ANATOMY", 248, 269], ["stroke", "DISEASE", 99, 105], ["SARS", "DISEASE", 183, 187], ["infection", "DISEASE", 194, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["patients", "ORGANISM", 106, 114], ["SARS-CoV-2", "ORGANISM", 183, 193], ["ACE2", "GENE_OR_GENE_PRODUCT", 240, 244], ["lung epithelial cells", "CELL", 248, 269], ["ACE2", "PROTEIN", 91, 95], ["ACE2", "PROTEIN", 240, 244], ["lung epithelial cells", "CELL_TYPE", 248, 269], ["patients", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 183, 191], ["decreased circulating levels", "PROBLEM", 51, 79], ["SARS", "PROBLEM", 183, 187], ["CoV-2 infection", "PROBLEM", 188, 203], ["increased levels of ACE2 in lung epithelial cells", "PROBLEM", 220, 269], ["infection", "OBSERVATION", 194, 203], ["increased", "OBSERVATION_MODIFIER", 220, 229], ["lung", "ANATOMY", 248, 252], ["epithelial cells", "OBSERVATION", 253, 269]]], ["Moreover, post-stroke immunosuppression is a key co-morbidity factor contributing to lung infections and leading to poor outcomes and increased mortality in affected individuals (Kalra et al., 2015) .", [["lung", "ANATOMY", 85, 89], ["stroke", "DISEASE", 15, 21], ["lung infections", "DISEASE", 85, 100], ["lung", "ORGAN", 85, 89], ["stroke immunosuppression", "TREATMENT", 15, 39], ["a key co-morbidity factor", "PROBLEM", 43, 68], ["lung infections", "PROBLEM", 85, 100], ["poor outcomes", "PROBLEM", 116, 129], ["increased mortality in affected individuals", "PROBLEM", 134, 177], ["lung", "ANATOMY", 85, 89], ["infections", "OBSERVATION", 90, 100], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["mortality", "OBSERVATION_MODIFIER", 144, 153]]], ["The mouse model of stroke used in our study also indicated a pronounced post-stroke lymphopenia similar to what is commonly observed after human stroke.", [["stroke", "DISEASE", 19, 25], ["stroke", "DISEASE", 77, 83], ["lymphopenia", "DISEASE", 84, 95], ["stroke", "DISEASE", 145, 151], ["mouse", "ORGANISM", 4, 9], ["human", "ORGANISM", 139, 144], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 139, 144], ["mouse", "SPECIES", 4, 9], ["human", "SPECIES", 139, 144], ["stroke", "PROBLEM", 19, 25], ["our study", "TEST", 34, 43], ["a pronounced post-stroke lymphopenia", "PROBLEM", 59, 95], ["human stroke", "PROBLEM", 139, 151], ["stroke", "OBSERVATION", 19, 25], ["stroke lymphopenia", "OBSERVATION", 77, 95], ["stroke", "OBSERVATION", 145, 151]]], ["Collectively, we suggest that increased ACE2 levels in lungs, systemic immunosuppression a reduced circulating ACE2 levels may act together to increase the prevalence of severe courses of COVID-19 in patients with preexisting brain injuries.DiscussionIn conclusion, our results demonstrate that in the lungs of stroke mice ACE2 is rapidly upregulated and accompanied by increased inflammatory responses.", [["lungs", "ANATOMY", 55, 60], ["brain", "ANATOMY", 226, 231], ["lungs", "ANATOMY", 302, 307], ["COVID-19", "CHEMICAL", 188, 196], ["brain injuries", "DISEASE", 226, 240], ["stroke", "DISEASE", 311, 317], ["COVID-19", "CHEMICAL", 188, 196], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["lungs", "ORGAN", 55, 60], ["ACE2", "GENE_OR_GENE_PRODUCT", 111, 115], ["patients", "ORGANISM", 200, 208], ["brain", "ORGAN", 226, 231], ["lungs", "ORGAN", 302, 307], ["mice", "ORGANISM", 318, 322], ["ACE2", "GENE_OR_GENE_PRODUCT", 323, 327], ["ACE2", "PROTEIN", 40, 44], ["ACE2", "PROTEIN", 111, 115], ["ACE2", "PROTEIN", 323, 327], ["patients", "SPECIES", 200, 208], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 318, 322], ["increased ACE2 levels in lungs", "PROBLEM", 30, 60], ["systemic immunosuppression", "TREATMENT", 62, 88], ["a reduced circulating ACE2 levels", "TREATMENT", 89, 122], ["COVID", "TEST", 188, 193], ["preexisting brain injuries", "PROBLEM", 214, 240], ["increased inflammatory responses", "PROBLEM", 370, 402], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["ACE2 levels", "OBSERVATION", 40, 51], ["lungs", "ANATOMY", 55, 60], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["brain", "ANATOMY", 226, 231], ["injuries", "OBSERVATION", 232, 240], ["lungs", "ANATOMY", 302, 307], ["stroke", "OBSERVATION", 311, 317], ["increased", "OBSERVATION_MODIFIER", 370, 379], ["inflammatory", "OBSERVATION", 380, 392]]], ["The results described in this study may help to design new therapeutic strategies to reduce SARS-CoV-2 infections or ameliorate clinical courses of COVID-19 in stroke patients by targeting the ACE2 axis.", [["infections", "DISEASE", 103, 113], ["COVID-19", "CHEMICAL", 148, 156], ["stroke", "DISEASE", 160, 166], ["COVID-19", "CHEMICAL", 148, 156], ["SARS-CoV-2", "ORGANISM", 92, 102], ["patients", "ORGANISM", 167, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 193, 197], ["ACE2", "PROTEIN", 193, 197], ["patients", "SPECIES", 167, 175], ["SARS-CoV", "SPECIES", 92, 100], ["this study", "TEST", 25, 35], ["new therapeutic strategies", "TREATMENT", 55, 81], ["SARS", "PROBLEM", 92, 96], ["CoV-2 infections", "PROBLEM", 97, 113], ["COVID", "TEST", 148, 153], ["ACE2 axis", "ANATOMY", 193, 202]]]], "0caed0cc529aec82cac8958df5dcb5f9f0c795b2": [["INTRODUCTIONThe genome of RNA virus can easily generate mutations as virus spreads.", [["RNA virus", "PROBLEM", 26, 35], ["mutations as virus spreads", "PROBLEM", 56, 82], ["RNA virus", "OBSERVATION", 26, 35]]], ["Genetic studies showed that SARS-CoV has 18-fold increases in mutation rates compared to other RNA viruses (16) .", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "ORGANISM", 28, 36], ["SARS-CoV", "SPECIES", 28, 36], ["Genetic studies", "TEST", 0, 15], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["18-fold increases in mutation rates", "PROBLEM", 41, 76], ["other RNA viruses", "PROBLEM", 89, 106], ["SARS", "OBSERVATION", 28, 32], ["18-fold", "OBSERVATION_MODIFIER", 41, 48], ["increases", "OBSERVATION_MODIFIER", 49, 58]]], ["SARS-CoV-2 spreads rapidly worldwide and accumulates many mutations.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["many mutations", "OBSERVATION", 53, 67]]], ["The constant emergence of new mutations in SARS-CoV-2 is the major challenge for the ongoing development of antiviral drug and broad neutralizing antibodies.", [["SARS", "DISEASE", 43, 47], ["SARS-CoV-2", "ORGANISM", 43, 53], ["neutralizing antibodies", "PROTEIN", 133, 156], ["SARS-CoV", "SPECIES", 43, 51], ["new mutations in SARS", "PROBLEM", 26, 47], ["antiviral drug", "TREATMENT", 108, 122], ["broad neutralizing antibodies", "PROBLEM", 127, 156], ["constant", "OBSERVATION_MODIFIER", 4, 12], ["antiviral drug", "OBSERVATION", 108, 122], ["neutralizing antibodies", "OBSERVATION", 133, 156]]], ["The in silico methods can readily quantify the effects of coding mutations on protein function and structure.", [["coding mutations", "PROBLEM", 58, 74]]], ["A bioinformatics analysis based on the homology modelling of SARS-CoV-2 predicted that the mutations in the RBD region reduce the binding energy between the RBD and the ACE2 (10).", [["ACE2", "GENE_OR_GENE_PRODUCT", 169, 173], ["SARS-CoV-2", "DNA", 61, 71], ["RBD region", "DNA", 108, 118], ["RBD", "PROTEIN", 157, 160], ["ACE2", "PROTEIN", 169, 173], ["A bioinformatics analysis", "TEST", 0, 25], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["the mutations in the RBD region", "PROBLEM", 87, 118], ["RBD", "ANATOMY", 108, 111], ["binding energy", "OBSERVATION", 130, 144], ["RBD", "ANATOMY", 157, 160]]], ["However, a comprehensive effect map of SARS-CoV-2 S mutations still lacks for identifying the target sites for vaccine design.", [["SARS", "DISEASE", 39, 43], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 39, 51], ["SARS-CoV-2 S mutations", "DNA", 39, 61], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["S mutations", "PROBLEM", 50, 61], ["vaccine design", "TREATMENT", 111, 125]]], ["In-silico saturation mutagenesis provides a fast methodology to investigate all possible mutations and identify the potential functional sites.", [["a fast methodology", "TREATMENT", 42, 60], ["mutations", "PROBLEM", 89, 98]]], ["It has been applied to Mycobacterium research to determine the effects of missense mutations on thermostability, affinity, conformational changes and proteinprotein interaction (17) .", [["Mycobacterium research", "TEST", 23, 45], ["missense mutations", "PROBLEM", 74, 92], ["conformational changes and proteinprotein interaction", "PROBLEM", 123, 176], ["Mycobacterium", "OBSERVATION", 23, 36]]], ["The infection of SARS-CoV-2 in permissive cells is largely depending on the interaction of the viral S protein and ACE2.", [["cells", "ANATOMY", 42, 47], ["infection", "DISEASE", 4, 13], ["SARS", "DISEASE", 17, 21], ["SARS-CoV-2", "ORGANISM", 17, 27], ["cells", "CELL", 42, 47], ["viral S protein", "GENE_OR_GENE_PRODUCT", 95, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["permissive cells", "CELL_TYPE", 31, 47], ["viral S protein", "PROTEIN", 95, 110], ["ACE2", "PROTEIN", 115, 119], ["SARS-CoV", "SPECIES", 17, 25], ["The infection of SARS", "PROBLEM", 0, 21], ["CoV", "TEST", 22, 25], ["permissive cells", "PROBLEM", 31, 47], ["the viral S protein", "TEST", 91, 110], ["ACE2", "TEST", 115, 119], ["infection", "OBSERVATION", 4, 13], ["permissive cells", "OBSERVATION", 31, 47]]], ["The affinity of the S and ACE2 and the stability of RBD-ACE2 complex are hence important to be investigated.", [["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 52, 60], ["S", "PROTEIN", 20, 21], ["ACE2", "PROTEIN", 26, 30], ["RBD", "PROTEIN", 52, 55], ["ACE2 complex", "PROTEIN", 56, 68], ["ACE2", "TREATMENT", 26, 30], ["RBD", "PROBLEM", 52, 55], ["ACE2 complex", "TREATMENT", 56, 68]]], ["We have applied the structure-based tools to quantitatively assess the effects of damaging mutations on protein stability and proteinprotein interaction (18) (19) (20) .", [["damaging mutations", "PROBLEM", 82, 100], ["protein stability", "TEST", 104, 121], ["proteinprotein interaction", "TEST", 126, 152]]], ["In the present study, we applied saturation mutagenesis to investigate 18 ,354 missense mutations in SARS-CoV-2 S, 3,705 mutations in SARS-CoV-2 RBD, and 11,324 mutations in hACE2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 134, 144], ["SARS-CoV-2 S", "DNA", 101, 113], ["SARS-CoV-2 RBD", "DNA", 134, 148], ["hACE2", "DNA", 174, 179], ["SARS-CoV", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 134, 142], ["saturation mutagenesis", "TREATMENT", 33, 55], ["missense mutations", "PROBLEM", 79, 97], ["SARS", "TEST", 101, 105], ["CoV", "TEST", 106, 109], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["mutations in hACE2", "PROBLEM", 161, 179]]], ["We applied structure-based energy calculations to quantify the systemic effects of missense mutations on the stability of and binding affinity of the S and hACE2 proteins.INTRODUCTIONWe studied the mutations involved in N-linked glycosylation which is important for the stability of SARS-CoV-2 S protein (21) .", [["N", "CHEMICAL", 220, 221], ["hACE2", "GENE_OR_GENE_PRODUCT", 156, 161], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["S and hACE2 proteins", "PROTEIN", 150, 170], ["SARS-CoV-2 S protein", "PROTEIN", 283, 303], ["structure-based energy calculations", "TREATMENT", 11, 46], ["missense mutations", "PROBLEM", 83, 101], ["the S and hACE2 proteins", "PROBLEM", 146, 170], ["N-linked glycosylation", "TREATMENT", 220, 242], ["SARS", "TEST", 283, 287], ["CoV", "TEST", 288, 291]]], ["We identified the potential target sites critical for the designs of antiviral drugs and vaccines against COVID-19.Structure preparationAll structures are collected from Protein Data Bank (PDB) (22) .", [["antiviral drugs", "TREATMENT", 69, 84], ["vaccines", "TREATMENT", 89, 97], ["COVID", "TEST", 106, 111], ["Structure preparation", "TREATMENT", 115, 136]]], ["We collected the structure of the SARS-CoV-2 2P (P980-P987) spike (S) ectodomain glycoprotein in the open state (PDB ID: 6VYB).", [["SARS-CoV-2 2P (P980-P987) spike (S) ectodomain glycoprotein", "PROTEIN", 34, 93], ["6VYB", "PROTEIN", 121, 125], ["the SARS", "TEST", 30, 38], ["CoV", "TEST", 39, 42], ["P980", "TEST", 49, 53], ["spike (S) ectodomain glycoprotein", "PROBLEM", 60, 93]]], ["To study the protein stability of wide type SARS-CoV-2 S, we separated the A chain of 6VYB and introduced P986K and P987V mutations using FoldX (23) .", [["SARS", "DISEASE", 44, 48], ["6VYB", "GENE_OR_GENE_PRODUCT", 86, 90], ["P986K", "GENE_OR_GENE_PRODUCT", 106, 111], ["A chain", "PROTEIN", 75, 82], ["6VYB", "PROTEIN", 86, 90], ["wide type SARS", "PROBLEM", 34, 48], ["CoV", "TEST", 49, 52]]], ["The S receptor-binding domain (RBD) complexed with its receptor ACE2 (PDB ID: 6LZG) was used to investigate the RBD-ACE2 binding affinity and protein stability of SARS-CoV-2 RBD and hACE2.", [["ACE2", "GENE_OR_GENE_PRODUCT", 64, 68], ["PDB ID: 6LZG", "GENE_OR_GENE_PRODUCT", 70, 82], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["hACE2", "GENE_OR_GENE_PRODUCT", 182, 187], ["S receptor-binding domain", "PROTEIN", 4, 29], ["RBD", "PROTEIN", 31, 34], ["ACE2", "PROTEIN", 64, 68], ["PDB ID: 6LZG", "PROTEIN", 70, 82], ["RBD", "PROTEIN", 112, 115], ["ACE2", "PROTEIN", 116, 120], ["SARS-CoV-2 RBD", "PROTEIN", 163, 177], ["hACE2", "PROTEIN", 182, 187], ["The S receptor-binding domain (RBD)", "TREATMENT", 0, 35], ["its receptor ACE2 (PDB ID: 6LZG)", "TREATMENT", 51, 83], ["the RBD", "TEST", 108, 115], ["ACE2 binding affinity", "TEST", 116, 137], ["protein stability", "TEST", 142, 159], ["SARS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171], ["hACE2", "TREATMENT", 182, 187]]], ["The SARS-CoV-2 S structure in closed state (6vxx), SARS-CoV S glycoprotein (6acg) and RBD-ACE2 complex (2ajf), and MERS-COV S protein (5w9j) were collected for the comparison studies.", [["SARS-CoV S glycoprotein", "GENE_OR_GENE_PRODUCT", 51, 74], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 86, 94], ["MERS-COV S", "GENE_OR_GENE_PRODUCT", 115, 125], ["SARS-CoV-2 S structure", "DNA", 4, 26], ["6vxx", "PROTEIN", 44, 48], ["SARS-CoV S glycoprotein", "PROTEIN", 51, 74], ["6acg", "PROTEIN", 76, 80], ["RBD", "PROTEIN", 86, 89], ["ACE2 complex", "PROTEIN", 90, 102], ["2ajf", "PROTEIN", 104, 108], ["MERS-COV S protein", "PROTEIN", 115, 133], ["5w9j", "PROTEIN", 135, 139], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["SARS", "PROBLEM", 51, 55], ["CoV S glycoprotein", "TEST", 56, 74], ["RBD", "TEST", 86, 89], ["ACE2 complex", "PROBLEM", 90, 102], ["MERS-COV S protein", "TREATMENT", 115, 133], ["the comparison studies", "TEST", 160, 182], ["SARS", "OBSERVATION", 4, 8], ["closed", "OBSERVATION", 30, 36]]], ["The PyMOL (http://www.pymol.org/) was used to generate protein structural images and perform structure alignments.Mutation collectionTo determine the effects of the mutations on protein structure, we collected all mutations that canSequence Analysis and Mutation PathogenicityThe amino acid sequences of S protein of SARS-CoV-2 (Entry: P0DTC2), SARS-CoV (Entry: P59594) and MERS-CoV (Entry: K9N5Q8) and human ACE2 (Entry: Q9BYF1) were downloaded from UniProt (24) .", [["amino acid", "CHEMICAL", 280, 290], ["amino acid", "CHEMICAL", 280, 290], ["PyMOL", "GENE_OR_GENE_PRODUCT", 4, 9], ["amino acid", "AMINO_ACID", 280, 290], ["SARS-CoV-2", "ORGANISM", 317, 327], ["P0DTC2", "GENE_OR_GENE_PRODUCT", 336, 342], ["SARS-CoV", "ORGANISM", 345, 353], ["MERS-CoV", "ORGANISM", 374, 382], ["human", "ORGANISM", 403, 408], ["ACE2", "GENE_OR_GENE_PRODUCT", 409, 413], ["amino acid sequences", "PROTEIN", 280, 300], ["S protein", "PROTEIN", 304, 313], ["P0DTC2", "PROTEIN", 336, 342], ["MERS-CoV", "PROTEIN", 374, 382], ["K9N5Q8", "PROTEIN", 391, 397], ["human ACE2", "PROTEIN", 403, 413], ["Q9BYF1", "PROTEIN", 422, 428], ["human", "SPECIES", 403, 408], ["SARS-CoV", "SPECIES", 317, 325], ["SARS-CoV", "SPECIES", 345, 353], ["MERS-CoV", "SPECIES", 374, 382], ["human", "SPECIES", 403, 408], ["protein structural images", "TEST", 55, 80], ["Mutation collection", "PROBLEM", 114, 133], ["the mutations on protein structure", "PROBLEM", 161, 195], ["Analysis", "TEST", 241, 249], ["Mutation Pathogenicity", "TEST", 254, 276], ["The amino acid sequences", "TEST", 276, 300], ["S protein", "TEST", 304, 313], ["SARS", "TEST", 317, 321], ["CoV", "TEST", 322, 325], ["SARS", "PROBLEM", 345, 349]]], ["The pairwise sequence alignment was carried out using EMBOSS Water multiple sequence alignment was performed using Clustal Omega and (25) .Sequence Analysis and Mutation PathogenicityThe protein sequences were submitted to SNAP (26) to predicts the effect of mutations on protein function for SARS-CoV-2 S and hACE2.", [["SNAP", "CHEMICAL", 223, 227], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 293, 305], ["hACE2", "GENE_OR_GENE_PRODUCT", 310, 315], ["SARS-CoV-2 S and hACE2", "PROTEIN", 293, 315], ["The pairwise sequence alignment", "TEST", 0, 31], ["Clustal Omega", "TREATMENT", 115, 128], ["Sequence Analysis", "TEST", 139, 156], ["Mutation Pathogenicity", "TEST", 161, 183], ["The protein sequences", "TEST", 183, 204], ["SNAP", "TEST", 223, 227], ["mutations", "PROBLEM", 259, 268], ["protein function", "TEST", 272, 288], ["SARS", "TEST", 293, 297], ["CoV", "TEST", 298, 301], ["hACE2", "TREATMENT", 310, 315]]], ["SNAP uses neural networks to integrate many sequencebased bioinformatics tools to analyze the mutation pathogenicity.", [["neural networks", "ANATOMY", 10, 25], ["SNAP", "CHEMICAL", 0, 4], ["SNAP", "SIMPLE_CHEMICAL", 0, 4], ["neural networks", "MULTI-TISSUE_STRUCTURE", 10, 25], ["SNAP", "PROTEIN", 0, 4], ["the mutation pathogenicity", "PROBLEM", 90, 116]]], ["It takes a protein sequence as input and gives a reliability index (RI) as a measure of the prediction accuracy.", [["the prediction accuracy", "TEST", 88, 111]]], ["The prediction scores range from -100 (neutral) to 100 (effect).", [["The prediction scores", "TEST", 0, 21]]], ["Positive scores indicate that the mutations have damaging effects on protein function.Free Energy Changes CalculationsThe effects of mutations on protein stability of S proteins and binding affinity of RBD with hACE2 were estimated by the change of the folding free energy (\u2206\u2206G) and the change of the binding free energy (\u2206\u2206\u2206G) between the mutant structure (MUT) and wild-type (WT) structure, respectively.", [["RBD", "GENE_OR_GENE_PRODUCT", 202, 205], ["hACE2", "GENE_OR_GENE_PRODUCT", 211, 216], ["S proteins", "PROTEIN", 167, 177], ["RBD", "PROTEIN", 202, 205], ["hACE2", "PROTEIN", 211, 216], ["mutant structure", "PROTEIN", 340, 356], ["MUT", "PROTEIN", 358, 361], ["the mutations", "PROBLEM", 30, 43], ["protein function", "TEST", 69, 85], ["mutations", "PROBLEM", 133, 142], ["S proteins", "PROBLEM", 167, 177], ["binding affinity of RBD", "PROBLEM", 182, 205], ["hACE2", "TREATMENT", 211, 216]]], ["FoldX (23) was used for energy calculations.", [["FoldX", "CHEMICAL", 0, 5], ["energy calculations", "TEST", 24, 43]]], ["It can be used to perform mutagenesis and predict protein stability and biding changes as well as calculate energy contributions of total energy, electrostatic, Van der Waals interactions and other energy terms.", [["mutagenesis", "TEST", 26, 37], ["total energy", "PROBLEM", 132, 144]]], ["Before performing any Foldx analysis, all protein structures were repaired using the 'RepairPdb' command, which works by mutating certain residues to themselves to reduce the overall free energy of the protein structure.Free Energy Changes CalculationsFor stability analysis, the 'BuildModel' command was used.", [["Foldx", "DNA", 22, 27], ["protein structure", "PROTEIN", 202, 219], ["any Foldx analysis", "TEST", 18, 36]]], ["This command takes as input, both repaired protein structure and a list of point mutations.", [["point mutations", "PROBLEM", 75, 90]]], ["The output computes energy changes brought about by each point mutation.", [["The output computes energy changes", "PROBLEM", 0, 34], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["The advantage of the reference wildtype model is that it considers the neighboring side chains that are moved in the process of generating the mutant protein.", [["mutant protein", "PROTEIN", 143, 157], ["the neighboring side chains", "PROBLEM", 67, 94]]], ["The change of the folding free energy (\u2206\u2206G) introduced by an amino acid substitution is an indicator of how this mutation affects the stability of the structure.", [["amino acid", "CHEMICAL", 61, 71], ["amino acid", "CHEMICAL", 61, 71], ["amino acid", "AMINO_ACID", 61, 71], ["the folding free energy (\u2206\u2206G)", "TREATMENT", 14, 43], ["an amino acid substitution", "TREATMENT", 58, 84], ["this mutation", "PROBLEM", 108, 121], ["stability", "OBSERVATION_MODIFIER", 134, 143]]], ["It was calculated using:\u0394\u0394G(stability)= \u0394G(folding)MUT -\u0394G(folding)WTA negative \u2206\u2206G value suggests that the mutation can stabilize the monomer protein and a positive value of \u2206\u2206G indicates that it makes the protein unstable.\u0394\u0394G(stability)= \u0394G(folding)MUT -\u0394G(folding)WTFor interaction analysis, the 'AnalyseComplex' command was carried out, where the user can calculate the binding affinity of a protein structure.", [["\u2206\u2206G", "GENE_OR_GENE_PRODUCT", 80, 83], ["\u2206\u2206G", "GENE_OR_GENE_PRODUCT", 175, 178], ["MUT", "PROTEIN", 51, 54], ["\u0394G", "PROTEIN", 56, 58], ["monomer protein", "PROTEIN", 135, 150], ["\u2206\u2206G", "PROTEIN", 175, 178], ["MUT", "PROTEIN", 251, 254], ["\u0394G", "PROTEIN", 256, 258], ["WTFor", "PROTEIN", 267, 272], ["protein structure", "PROTEIN", 396, 413], ["\u0394G", "TEST", 40, 42], ["WTA", "TEST", 67, 70], ["G value", "TEST", 82, 89], ["the mutation", "PROBLEM", 104, 116], ["the monomer protein", "TEST", 131, 150], ["a positive value of \u2206\u2206G", "PROBLEM", 155, 178], ["the protein unstable", "PROBLEM", 203, 223], ["\u0394\u0394G", "TEST", 224, 227], ["\u0394G", "TEST", 240, 242], ["interaction analysis", "TEST", 273, 293], ["stability", "OBSERVATION_MODIFIER", 228, 237]]], ["The program then subtracts the individual protein energies from the energy of the bound proteins or protein complex.\u0394\u0394G(stability)= \u0394G(folding)MUT -\u0394G(folding)WTThe change of binding energy (\u2206\u2206\u2206G) between the mutant and wild-type structures was used to estimate the effect of the missense mutations on the binding affinity of RBD-ACE2 protein complex.", [["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 326, 334], ["bound proteins", "PROTEIN", 82, 96], ["protein complex", "PROTEIN", 100, 115], ["MUT", "PROTEIN", 143, 146], ["\u0394G", "PROTEIN", 148, 150], ["RBD", "PROTEIN", 326, 329], ["ACE2 protein complex", "PROTEIN", 330, 350], ["\u0394\u0394G", "TEST", 116, 119], ["\u0394G", "TEST", 132, 134], ["binding energy (\u2206\u2206\u2206G)", "TREATMENT", 175, 196], ["the mutant and wild-type structures", "TREATMENT", 205, 240], ["the missense mutations", "PROBLEM", 276, 298], ["ACE2 protein complex", "PROBLEM", 330, 350], ["stability", "OBSERVATION_MODIFIER", 120, 129]]], ["It was computed by:\u0394\u0394\u0394G(binding)= \u0394\u0394G(binding)MUT -\u0394\u0394G(binding)WTA negative \u2206\u2206\u2206G value suggests that the mutation strengthens the binding affinity, whereas a positive value indicates that the mutation weakens the protein-protein interaction.Effects of mutations on SARS-CoV-2 full-length S protein stability (\u0394\u0394G)Since S protein is critical for SARS-CoV-2 infection, we want to anatomize its amino acids that affect its stability.", [["infection", "DISEASE", 356, 365], ["amino acids", "CHEMICAL", 392, 403], ["amino acids", "CHEMICAL", 392, 403], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 265, 275], ["SARS-CoV-2", "ORGANISM", 345, 355], ["amino acids", "AMINO_ACID", 392, 403], ["MUT", "PROTEIN", 46, 49], ["S protein", "PROTEIN", 288, 297], ["S protein", "PROTEIN", 319, 328], ["SARS-CoV", "SPECIES", 265, 273], ["SARS-CoV-2", "SPECIES", 345, 355], ["WTA", "TEST", 63, 66], ["G value", "TEST", 79, 86], ["the mutation strengthens the binding affinity", "PROBLEM", 101, 146], ["a positive value", "PROBLEM", 156, 172], ["the mutation", "PROBLEM", 188, 200], ["mutations", "PROBLEM", 252, 261], ["SARS", "TEST", 265, 269], ["CoV", "TEST", 270, 273], ["length S protein stability", "TEST", 281, 307], ["S protein", "TEST", 319, 328], ["SARS", "PROBLEM", 345, 349], ["CoV", "PROBLEM", 350, 353], ["2 infection", "PROBLEM", 354, 365], ["its amino acids", "TEST", 388, 403], ["infection", "OBSERVATION", 356, 365], ["stability", "OBSERVATION_MODIFIER", 420, 429]]], ["We used the cryo-EM structure of the SARS-CoV-2 spike ectodomain structure in the open state (PDB ID: 6vyb) as the SARS-CoV-2 full-length S structure.", [["SARS-CoV-2 spike ectodomain structure", "PROTEIN", 37, 74], ["6vyb", "PROTEIN", 102, 106], ["SARS-CoV-2 full-length S structure", "DNA", 115, 149], ["the SARS", "TEST", 33, 41], ["CoV", "TEST", 42, 45], ["2 spike ectodomain structure", "PROBLEM", 46, 74], ["the SARS", "TEST", 111, 119], ["CoV", "TEST", 120, 123]]], ["This structure covers 27-1141 amino acid region and includes 966 residues (76%) of SARS-CoV-2 full-length S protein.Effects of mutations on SARS-CoV-2 full-length S protein stability (\u0394\u0394G)To determine the effects of the systematic mutations on SARS-CoV-2 S stability, we generated We present the key residues and mutations with significant effects on SARS-CoV-2 S protein stability in Table 1 and Figure 2 .", [["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "AMINO_ACID", 30, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["S protein", "GENE_OR_GENE_PRODUCT", 106, 115], ["SARS-CoV-2 full-length S protein", "PROTEIN", 83, 115], ["S protein", "PROTEIN", 163, 172], ["SARS-CoV", "SPECIES", 140, 148], ["This structure", "TEST", 0, 14], ["amino acid region", "TEST", 30, 47], ["residues", "TEST", 65, 73], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["mutations", "PROBLEM", 127, 136], ["SARS", "TEST", 140, 144], ["CoV", "TEST", 145, 148], ["length S protein stability", "TEST", 156, 182], ["the systematic mutations", "PROBLEM", 216, 240], ["SARS", "TEST", 244, 248], ["CoV", "TEST", 249, 252], ["significant effects", "PROBLEM", 328, 347], ["SARS", "TEST", 351, 355], ["CoV", "TEST", 356, 359]]], ["As the line chart shown in Figure 2A , the mean value of folding change (\u0394\u0394G) in protein stability at each SARS-CoV-2 full-length S residue position ranged from 29.41 kcal/mol in G431 to -1.54 kcal/mol in S514.", [["SARS-CoV-2 full-length S residue position", "DNA", 107, 148], ["the mean value", "TEST", 39, 53], ["folding change (\u0394\u0394G) in protein stability", "PROBLEM", 57, 98], ["each SARS", "TEST", 102, 111], ["CoV", "TEST", 112, 115], ["stability", "OBSERVATION_MODIFIER", 89, 98]]], ["We listed the amino acid positions that strongly stabilize or destabilize spike protein in the Table 1 according to the mean values of \u0394\u0394G of mutations in each position.", [["amino acid", "CHEMICAL", 14, 24], ["amino acid", "CHEMICAL", 14, 24], ["amino acid", "AMINO_ACID", 14, 24], ["spike protein", "PROTEIN", 74, 87], ["Table 1", "PROTEIN", 95, 102], ["the amino acid positions", "TREATMENT", 10, 34], ["spike protein", "PROBLEM", 74, 87]]], ["The mutations at glycine residues G431, G648 and G35 residues have maximum destabilizing effects on the full-length S protein.", [["glycine", "CHEMICAL", 17, 24], ["glycine", "CHEMICAL", 17, 24], ["G431", "CHEMICAL", 34, 38], ["G648", "CHEMICAL", 40, 44], ["G35", "CHEMICAL", 49, 52], ["glycine", "AMINO_ACID", 17, 24], ["G431", "AMINO_ACID", 34, 38], ["G648", "AMINO_ACID", 40, 44], ["G35", "AMINO_ACID", 49, 52], ["full-length S protein", "PROTEIN", 104, 125], ["The mutations at glycine residues", "TREATMENT", 0, 33], ["maximum destabilizing effects", "PROBLEM", 67, 96], ["the full-length S protein", "TREATMENT", 100, 125]]], ["In contrast, the mutations at serine residues S514, S735 and S50 residues have induced highly stabilizing effects on the overall protein.", [["serine", "CHEMICAL", 30, 36], ["S514", "CHEMICAL", 46, 50], ["S735", "CHEMICAL", 52, 56], ["S50", "CHEMICAL", 61, 64], ["serine", "AMINO_ACID", 30, 36], ["S514", "AMINO_ACID", 46, 50], ["S735", "AMINO_ACID", 52, 56], ["S50", "AMINO_ACID", 61, 64], ["the mutations at serine residues", "PROBLEM", 13, 45], ["highly", "OBSERVATION_MODIFIER", 87, 93], ["stabilizing", "OBSERVATION", 94, 105]]], ["Noteworthily, both G431 with maximum \u0394\u0394G and S514 with minimum \u0394\u0394G are located in the RBD region.", [["G431", "DNA", 19, 23], ["\u0394\u0394G", "DNA", 63, 66], ["RBD region", "DNA", 86, 96], ["RBD", "ANATOMY", 86, 89], ["region", "ANATOMY_MODIFIER", 90, 96]]], ["Moreover, residues G526 (\u0394\u0394G mean = 18.364 kcal/mol) and T385 (\u0394\u0394G mean = -0.431 kcal/mol) in RBD have significant effects on the stability of full-length S protein.Effects of mutations on SARS-CoV-2 full-length S protein stability (\u0394\u0394G)The mutations with maximum and minimum \u0394\u0394G values are listed in Table 1 .", [["S protein", "GENE_OR_GENE_PRODUCT", 155, 164], ["RBD", "PROTEIN", 94, 97], ["full-length S protein", "PROTEIN", 143, 164], ["S protein", "PROTEIN", 212, 221], ["SARS-CoV", "SPECIES", 189, 197], ["mean", "TEST", 67, 71], ["RBD", "PROBLEM", 94, 97], ["mutations", "PROBLEM", 176, 185], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["length S protein stability", "TEST", 205, 231], ["maximum and minimum \u0394\u0394G values", "TEST", 256, 286], ["significant", "OBSERVATION_MODIFIER", 103, 114]]], ["Among all mutations destabilizing full-length S protein, the glycine mutation G431W has introduced the largest positive folding energy at \u0394\u0394G = 59.92 kcal/mol.", [["glycine", "CHEMICAL", 61, 68], ["G431W", "CHEMICAL", 78, 83], ["glycine", "CHEMICAL", 61, 68], ["glycine", "AMINO_ACID", 61, 68], ["full-length S protein", "PROTEIN", 34, 55], ["the glycine mutation", "TEST", 57, 77]]], ["However, V976D has the minimum \u0394\u0394G at -4.014 kcal/mol and most of the mutations in V976 (\u0394\u0394G mean = -0.562 kcal/mol) can increase the stability of full-length S protein (Figure 2a ).SARS-CoV-2 RBD mutations important for domain stabilityThe full-length S protein is cleaved to S1 and S2 by cellular protease, furin.", [["cellular", "ANATOMY", 290, 298], ["S1", "GENE_OR_GENE_PRODUCT", 277, 279], ["S2", "GENE_OR_GENE_PRODUCT", 284, 286], ["cellular protease", "GENE_OR_GENE_PRODUCT", 290, 307], ["furin", "GENE_OR_GENE_PRODUCT", 309, 314], ["full-length S protein", "PROTEIN", 147, 168], ["Figure 2a", "PROTEIN", 170, 179], ["RBD", "PROTEIN", 193, 196], ["full-length S protein", "PROTEIN", 241, 262], ["S1", "PROTEIN", 277, 279], ["S2", "PROTEIN", 284, 286], ["cellular protease", "PROTEIN", 290, 307], ["furin", "PROTEIN", 309, 314], ["the mutations", "TEST", 66, 79], ["full-length S protein", "TREATMENT", 147, 168], ["SARS", "TEST", 182, 186], ["RBD mutations", "PROBLEM", 193, 206], ["The full-length S protein", "TEST", 237, 262], ["cellular protease", "TREATMENT", 290, 307], ["stability", "OBSERVATION_MODIFIER", 134, 143]]], ["S1 binds to ACE2 through its RBD.", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["ACE2", "GENE_OR_GENE_PRODUCT", 12, 16], ["S1", "PROTEIN", 0, 2], ["ACE2", "PROTEIN", 12, 16], ["RBD", "PROTEIN", 29, 32], ["RBD", "OBSERVATION", 29, 32]]], ["Hence, we wonder whether S1 RBD stability could be affected by amino acid substitutions.", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["S1", "GENE_OR_GENE_PRODUCT", 25, 27], ["amino acid", "AMINO_ACID", 63, 73], ["RBD", "PROTEIN", 28, 31], ["S1 RBD stability", "PROBLEM", 25, 41], ["amino acid substitutions", "PROBLEM", 63, 87], ["acid substitutions", "OBSERVATION", 69, 87]]], ["In doing so, we used the crystal structure of SARS-CoV-2 S RBD complexed with its receptor ACE2 (PDB ID: 6lzg) and analyzed a total of 3,705 mutations generated from 195 residues of its RBD chain.", [["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["PDB ID: 6lzg", "GENE_OR_GENE_PRODUCT", 97, 109], ["SARS-CoV-2 S RBD", "PROTEIN", 46, 62], ["ACE2", "PROTEIN", 91, 95], ["PDB ID: 6lzg", "PROTEIN", 97, 109], ["RBD chain", "PROTEIN", 186, 195], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["its receptor ACE2", "TREATMENT", 78, 95], ["a total of 3,705 mutations", "TREATMENT", 124, 150], ["RBD", "ANATOMY", 186, 189], ["chain", "ANATOMY_MODIFIER", 190, 195]]], ["The top RBD residues and mutations with maximum and minimum \u0394\u0394G values are shown in Table 1 and Figure 2B .", [["top RBD residues", "PROTEIN", 4, 20], ["The top RBD residues and mutations", "PROBLEM", 0, 34], ["maximum and minimum \u0394\u0394G values", "TEST", 40, 70], ["top", "OBSERVATION_MODIFIER", 4, 7], ["RBD residues", "OBSERVATION", 8, 20]]], ["The average change in protein stability at each SARS-CoV-2 S residue position ranged from 26.266 kcal/mol in G431 to -1.658 kcal/mol in S514.", [["The average change in protein stability", "PROBLEM", 0, 39], ["each SARS", "TEST", 43, 52], ["CoV", "TEST", 53, 56], ["average", "OBSERVATION_MODIFIER", 4, 11], ["change", "OBSERVATION_MODIFIER", 12, 18], ["protein stability", "OBSERVATION", 22, 39]]], ["Notably, G431 and S514 are also the top residues altering the full-length S stability.", [["S514", "CHEMICAL", 18, 22], ["G431", "GENE_OR_GENE_PRODUCT", 9, 13], ["S514", "GENE_OR_GENE_PRODUCT", 18, 22]]], ["Interestingly, G431A has the maximum \u0394\u0394G values among all substitutions to alanine in both full-length S and RBD, and S514A has the minimum \u0394\u0394G value among all substitutions to alanine in RBD.", [["G431A", "CHEMICAL", 15, 20], ["alanine", "CHEMICAL", 75, 82], ["alanine", "CHEMICAL", 177, 184], ["RBD", "DISEASE", 188, 191], ["alanine", "CHEMICAL", 75, 82], ["alanine", "CHEMICAL", 177, 184], ["G431A", "GENE_OR_GENE_PRODUCT", 15, 20], ["alanine", "AMINO_ACID", 75, 82], ["RBD", "GENE_OR_GENE_PRODUCT", 109, 112], ["S514A", "GENE_OR_GENE_PRODUCT", 118, 123], ["alanine", "AMINO_ACID", 177, 184], ["RBD", "PROTEIN", 109, 112], ["RBD", "PROTEIN", 188, 191], ["the maximum \u0394\u0394G values", "TEST", 25, 47], ["alanine", "TEST", 75, 82], ["RBD", "TEST", 109, 112], ["alanine in RBD", "PROBLEM", 177, 191]]], ["These results indicate that the side-chains of G431 and S514 have important contributions to the RBD stability ( Figure 2 ).", [["G431", "CHEMICAL", 47, 51], ["S514", "CHEMICAL", 56, 60], ["RBD", "DISEASE", 97, 100], ["G431", "CHEMICAL", 47, 51], ["S514", "CHEMICAL", 56, 60], ["G431", "GENE_OR_GENE_PRODUCT", 47, 51], ["S514", "SIMPLE_CHEMICAL", 56, 60], ["RBD", "PROTEIN", 97, 100]]], ["Other residues strongly destabilizing RBD include G526 (\u0394\u0394G mean = 16.502 kcal/mol) and P507 (\u0394\u0394G mean = 14.592 kcal/mol).", [["RBD", "PROTEIN", 38, 41], ["G526", "PROTEIN", 50, 54]]], ["In contrast, the mutations at residue positions T385 (\u0394\u0394G mean = -0.967 kcal/mol) and N394 (\u0394\u0394G mean = -0.616 kcal/mol) induce strongly stabilizing effects on the SARS-Cov-2 RBD (Table1 and Figure 2B ).", [["Cov", "PROTEIN", 168, 171], ["RBD", "PROTEIN", 174, 177], ["Table1", "PROTEIN", 179, 185], ["Figure 2B", "PROTEIN", 190, 199], ["strongly stabilizing effects", "PROBLEM", 127, 155], ["the SARS", "TEST", 159, 167], ["Cov", "TEST", 168, 171]]], ["In all RBD mutations, G431W introduced the highest positive folding energy change at 55.323 kcal/mol, and all mutations in G431 could highly reduce the protein stabilities of RBD and full-length S ( Figure 2 ).", [["G431", "CHEMICAL", 123, 127], ["G431", "SIMPLE_CHEMICAL", 123, 127], ["RBD", "PROTEIN", 7, 10], ["RBD", "PROTEIN", 175, 178], ["all mutations", "PROBLEM", 106, 119], ["the protein stabilities of RBD", "PROBLEM", 148, 178], ["RBD mutations", "OBSERVATION", 7, 20]]], ["A397L has the smallest folding free energy change at -3.582 kcal/mol and can increase RBD stability.", [["A397L", "CHEMICAL", 0, 5], ["A397L", "PROTEIN", 0, 5], ["RBD", "PROTEIN", 86, 89], ["smallest", "OBSERVATION_MODIFIER", 14, 22], ["folding", "OBSERVATION_MODIFIER", 23, 30], ["free energy", "OBSERVATION", 31, 42], ["RBD stability", "OBSERVATION", 86, 99]]], ["But many mutations in A397 (\u0394\u0394G mean = 1.563 kcal/mol) have positive \u0394\u0394G values and can decrease RBD stability ( Figure 2B ).Effects of RBD Mutations on RBD-ACE2 binding affinity (\u0394\u0394\u0394G)Missense mutations in RBD region could change the key interaction site and affect the binding affinity of RBD and ACE2.", [["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 153, 161], ["RBD", "GENE_OR_GENE_PRODUCT", 291, 294], ["ACE2", "GENE_OR_GENE_PRODUCT", 299, 303], ["\u0394\u0394G", "PROTEIN", 69, 72], ["RBD", "PROTEIN", 97, 100], ["RBD", "PROTEIN", 136, 139], ["RBD", "PROTEIN", 153, 156], ["ACE2", "PROTEIN", 157, 161], ["RBD region", "DNA", 207, 217], ["RBD", "PROTEIN", 291, 294], ["ACE2", "PROTEIN", 299, 303], ["many mutations", "PROBLEM", 4, 18], ["positive \u0394\u0394G values", "PROBLEM", 60, 79], ["RBD Mutations", "PROBLEM", 136, 149], ["RBD", "TEST", 153, 156], ["ACE2 binding affinity (\u0394\u0394\u0394G)", "TREATMENT", 157, 185], ["Missense mutations in RBD region", "PROBLEM", 185, 217], ["ACE2", "TEST", 299, 303], ["RBD Mutations", "OBSERVATION", 136, 149]]], ["We calculated the binding energy changes (\u0394\u0394\u0394G) of total RBD The key residues and mutations on RBD-ACE2 binding affinity are listed in Figure 3 and Table 2.", [["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 95, 103], ["RBD", "PROTEIN", 95, 98], ["ACE2", "PROTEIN", 99, 103], ["the binding energy changes", "PROBLEM", 14, 40], ["total RBD", "PROBLEM", 51, 60], ["The key residues", "PROBLEM", 61, 77], ["mutations on RBD", "PROBLEM", 82, 98], ["ACE2 binding affinity", "TREATMENT", 99, 120]]], ["G496 has the maximum \u0394\u0394\u0394G mean in RBD-ACE2 binding affinity at 4.694 kcal/mol.", [["G496", "CHEMICAL", 0, 4], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 34, 42], ["RBD", "PROTEIN", 34, 37], ["ACE2", "PROTEIN", 38, 42]]], ["The mutations in this site, such as G496W and G496Y induced the first largest and second-largest binding energy change at 17.418 kcal/mol and 13.420 kcal/mol in all RBD mutations, respectively.Effects of RBD Mutations on RBD-ACE2 binding affinity (\u0394\u0394\u0394G)Interestingly, G496's neighbor residues F497 has minimum \u0394\u0394\u0394G mean at -0.476 kcal/mol.", [["G496", "CHEMICAL", 268, 272], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 221, 229], ["RBD", "PROTEIN", 204, 207], ["RBD", "PROTEIN", 221, 224], ["ACE2", "PROTEIN", 225, 229], ["The mutations in this site", "PROBLEM", 0, 26], ["RBD Mutations", "PROBLEM", 204, 217], ["RBD", "TEST", 221, 224], ["mutations", "OBSERVATION", 4, 13], ["RBD Mutations", "OBSERVATION", 204, 217]]], ["Many mutations including F497W (\u0394\u0394\u0394G = -0.976 kcal/mol) can reduce the RBD-ACE2 interaction.Effects of RBD Mutations on RBD-ACE2 binding affinity (\u0394\u0394\u0394G)These two residues are located in a 10-residues sequence Y495GFQPTNGVG504.", [["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 120, 128], ["RBD", "PROTEIN", 71, 74], ["ACE2", "PROTEIN", 75, 79], ["RBD", "PROTEIN", 103, 106], ["RBD", "PROTEIN", 120, 123], ["ACE2", "PROTEIN", 124, 128], ["Many mutations", "PROBLEM", 0, 14], ["RBD Mutations", "PROBLEM", 103, 116], ["RBD", "TEST", 120, 123], ["ACE2 binding affinity", "TREATMENT", 124, 145], ["RBD", "OBSERVATION", 71, 74], ["RBD Mutations", "OBSERVATION", 103, 116]]], ["Many mutations and residues in this short motif have significant effects on RBD-ACE2 binding affinity.", [["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 76, 84], ["RBD", "PROTEIN", 76, 79], ["ACE2", "PROTEIN", 80, 84], ["Many mutations", "PROBLEM", 0, 14], ["this short motif", "PROBLEM", 31, 47], ["significant effects on RBD", "PROBLEM", 53, 79], ["ACE2 binding affinity", "TREATMENT", 80, 101]]], ["The largest negative binding free energy change is introduced by N501E at -2.490 kcal/mol.", [["largest", "OBSERVATION_MODIFIER", 4, 11], ["negative", "OBSERVATION", 12, 20], ["binding", "OBSERVATION_MODIFIER", 21, 28], ["free energy", "OBSERVATION", 29, 40]]], ["Mutations N501L (\u0394\u0394\u0394G = -2.397 kcal/mol), N501M (\u0394\u0394\u0394G = -2.273 kcal/mol), N501K (\u0394\u0394\u0394G = -2.134, kcal/mol) in the same position can increase the RBD-ACE2 binding affinity.", [["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["RBD", "PROTEIN", 144, 147], ["ACE2", "PROTEIN", 148, 152], ["Mutations", "TEST", 0, 9], ["ACE2 binding affinity", "TREATMENT", 148, 169]]], ["In contrast, G502 has the second largest positive \u0394\u0394\u0394G mean at 2.922 kcal/mol and G502P (\u0394\u0394\u0394G = 11.767 kcal/mol) has the highest destabilizing effect on RBD-ACE2 complex.Effects of ACE2 Mutations on RBD-ACE2 InteractionThe human ACE2 mutations located in RBD-ACE2 interface could affect ACE2 interaction with SARS-Cov-2 RBD.", [["G502", "CHEMICAL", 13, 17], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 153, 161], ["ACE2", "GENE_OR_GENE_PRODUCT", 181, 185], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 199, 207], ["human", "ORGANISM", 223, 228], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 255, 263], ["ACE2", "GENE_OR_GENE_PRODUCT", 287, 291], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 309, 319], ["RBD", "PROTEIN", 153, 156], ["ACE2 complex", "PROTEIN", 157, 169], ["ACE2", "PROTEIN", 181, 185], ["RBD", "PROTEIN", 199, 202], ["ACE2", "PROTEIN", 203, 207], ["ACE2", "PROTEIN", 229, 233], ["RBD", "PROTEIN", 255, 258], ["ACE2", "PROTEIN", 259, 263], ["ACE2", "PROTEIN", 287, 291], ["SARS-Cov-2 RBD", "PROTEIN", 309, 323], ["human", "SPECIES", 223, 228], ["human", "SPECIES", 223, 228], ["ACE2 Mutations", "PROBLEM", 181, 195], ["RBD", "PROBLEM", 199, 202], ["ACE2 Interaction", "PROBLEM", 203, 219], ["The human ACE2 mutations", "TREATMENT", 219, 243], ["SARS", "TEST", 309, 313], ["Cov", "TEST", 314, 317], ["RBD", "OBSERVATION", 153, 156]]], ["We then scrutinized the effects of total 11,324 mutations in ACE2 chain of crystal structure of RBD-ACE2 complex (PDB ID: 6lzg).", [["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 96, 104], ["ACE2 chain", "PROTEIN", 61, 71], ["RBD", "PROTEIN", 96, 99], ["ACE2 complex", "PROTEIN", 100, 112], ["PDB ID: 6lzg", "PROTEIN", 114, 126], ["total 11,324 mutations", "TREATMENT", 35, 57]]], ["10 As shown in Table 2 , the mutations at residues D355, D38 and Q42 induce strong destabilizing effects on RBD-ACE2 binding affinity.", [["Q42", "AMINO_ACID", 65, 68], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 108, 116], ["RBD", "PROTEIN", 108, 111], ["ACE2", "PROTEIN", 112, 116], ["the mutations at residues D355", "TREATMENT", 25, 55], ["D38", "TREATMENT", 57, 60], ["RBD", "TEST", 108, 111], ["ACE2 binding affinity", "TREATMENT", 112, 133]]], ["Residue D355 (\u0394\u0394\u0394G mean = 2.031 kcal/mol) and mutation D355Y (\u0394\u0394\u0394G = 7.284 kcal/mol) in this position have maximum effects on destabilizing the RBD-ACE2 complex.", [["ACE2", "GENE_OR_GENE_PRODUCT", 148, 152], ["RBD", "PROTEIN", 144, 147], ["ACE2 complex", "PROTEIN", 148, 160], ["mutation D355Y (\u0394\u0394\u0394G", "TREATMENT", 46, 66], ["RBD", "OBSERVATION", 144, 147]]], ["However, the mutations at residues Y41, K353 and N330 can increase the RBD-ACE2 binding affinity.", [["N330", "CHEMICAL", 49, 53], ["N330", "AMINO_ACID", 49, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 75, 79], ["RBD", "PROTEIN", 71, 74], ["ACE2", "PROTEIN", 75, 79], ["the mutations at residues Y41", "PROBLEM", 9, 38], ["K353", "TEST", 40, 44], ["the RBD", "TEST", 67, 74]]], ["Residue Y41 (\u0394\u0394\u0394G mean = -0.742 kcal/mol) and mutation D355Y (\u0394\u0394\u0394G = -1.808 kcal/mol) can increase the RBD-ACE2 interaction.", [["ACE2", "GENE_OR_GENE_PRODUCT", 107, 111], ["RBD", "PROTEIN", 103, 106], ["ACE2", "PROTEIN", 107, 111], ["Residue", "TEST", 0, 7]]], ["K353F has the smallest binding free energy change at -1.937 kcal/mol, and K353C and K353Y can also increase the binding affinity of the RBD-ACE2 complex.", [["K353F", "CHEMICAL", 0, 5], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["RBD", "PROTEIN", 136, 139], ["ACE2 complex", "PROTEIN", 140, 152], ["smallest", "OBSERVATION_MODIFIER", 14, 22], ["RBD", "OBSERVATION", 136, 139]]], ["Overall, many mutations have been identified by our studies to either enhance or attenuate the interaction between ACE2 and RBD.Effects of viral variations on spike protein stability and RBD-ACE2 binding affinityWe also searched and listed the viral mutations that occurred naturally in the strains of SRS-CoV- Figure 1B , we observed less viral mutations (2.3%) can reduce the RBD-ACE2 binding affinity (\u0394\u0394\u0394G > 0.5 kcal/mol) on RBD, compare to those of all mutations (7.1%).", [["RBD", "DISEASE", 124, 127], ["ACE2", "GENE_OR_GENE_PRODUCT", 115, 119], ["RBD", "GENE_OR_GENE_PRODUCT", 124, 127], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 187, 195], ["SRS-CoV- Figure 1B", "ORGANISM", 302, 320], ["ACE2", "GENE_OR_GENE_PRODUCT", 382, 386], ["ACE2", "PROTEIN", 115, 119], ["RBD", "PROTEIN", 124, 127], ["RBD", "PROTEIN", 187, 190], ["ACE2", "PROTEIN", 191, 195], ["RBD", "PROTEIN", 378, 381], ["ACE2", "PROTEIN", 382, 386], ["RBD", "PROTEIN", 429, 432], ["many mutations", "PROBLEM", 9, 23], ["our studies", "TEST", 48, 59], ["the interaction between ACE2 and RBD", "PROBLEM", 91, 127], ["viral variations", "PROBLEM", 139, 155], ["spike protein stability", "PROBLEM", 159, 182], ["RBD", "TEST", 187, 190], ["ACE2 binding affinity", "PROBLEM", 191, 212], ["the viral mutations", "PROBLEM", 240, 259], ["SRS", "TEST", 302, 305], ["CoV", "TEST", 306, 309], ["less viral mutations", "PROBLEM", 335, 355], ["the RBD", "TEST", 374, 381], ["ACE2 binding affinity", "TEST", 382, 403], ["\u0394\u0394\u0394G", "TEST", 405, 409], ["RBD", "PROBLEM", 429, 432], ["all mutations", "TEST", 454, 467], ["RBD", "OBSERVATION", 124, 127], ["viral variations", "OBSERVATION", 139, 155], ["viral mutations", "OBSERVATION", 244, 259]]], ["We did not find viral mutations with \u0394\u0394\u0394G < -0.5 kcal/mol.", [["viral mutations", "PROBLEM", 16, 31], ["\u0394\u0394\u0394G", "TEST", 37, 41]]], ["However, there are more viral mutations (9.3%) that have small effects (-0.1 < \u0394\u0394G <= -0.5 kcal/mol) on stabilizing RBD-ACE2 complex, compared to those of all mutations (3.4%).Effects of viral variations on spike protein stability and RBD-ACE2 binding affinityWe investigated the effects of common viral variations and the mutations with significant effects (Table 3)Mutation Pathogenicity of SARS-Cov-2 S and ACE2We applied SNAP (26) to analyze the mutation pathogenicity of all mutations of S and ACE2 proteins based their protein sequences.", [["SNAP", "CHEMICAL", 425, 429], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 116, 124], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 235, 243], ["ACE2", "GENE_OR_GENE_PRODUCT", 499, 503], ["RBD", "PROTEIN", 116, 119], ["ACE2 complex", "PROTEIN", 120, 132], ["RBD", "PROTEIN", 235, 238], ["ACE2", "PROTEIN", 239, 243], ["SARS-Cov-2 S", "DNA", 393, 405], ["ACE2We", "DNA", 410, 416], ["S and ACE2 proteins", "PROTEIN", 493, 512], ["more viral mutations", "PROBLEM", 19, 39], ["small effects", "PROBLEM", 57, 70], ["\u0394\u0394G", "TEST", 79, 82], ["ACE2 complex", "PROBLEM", 120, 132], ["all mutations", "TEST", 155, 168], ["viral variations", "PROBLEM", 187, 203], ["spike protein stability", "PROBLEM", 207, 230], ["RBD", "TEST", 235, 238], ["ACE2 binding affinity", "PROBLEM", 239, 260], ["common viral variations", "PROBLEM", 291, 314], ["the mutations", "PROBLEM", 319, 332], ["Mutation Pathogenicity of SARS", "PROBLEM", 367, 397], ["Cov", "TEST", 398, 401], ["ACE2We applied SNAP", "TREATMENT", 410, 429], ["the mutation pathogenicity", "TEST", 446, 472], ["ACE2 proteins", "TEST", 499, 512], ["their protein sequences", "TEST", 519, 542], ["viral mutations", "OBSERVATION", 24, 39], ["small", "OBSERVATION_MODIFIER", 57, 62], ["RBD", "OBSERVATION", 116, 119], ["viral variations", "OBSERVATION", 187, 203]]], ["We generated predictions for 15,295 mutations in human ACE2 and 24,187 mutations in SARS-Cov-2 full-length S including 4,237 mutations in its RBD region.", [["human", "ORGANISM", 49, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["human ACE2", "PROTEIN", 49, 59], ["SARS-Cov-2 full-length S", "DNA", 84, 108], ["RBD region", "DNA", 142, 152], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["human ACE2", "TEST", 49, 59], ["SARS", "TEST", 84, 88], ["Cov", "TEST", 89, 92], ["RBD", "ANATOMY", 142, 145], ["region", "ANATOMY_MODIFIER", 146, 152]]], ["As shown in Figure 4A Protein destabilization is a common mechanism by which mutations cause human diseases.Mutation Pathogenicity of SARS-Cov-2 S and ACE2Studies suggested that up to 80% of the disease-causing missense mutations may lead to protein destabilization (27) .", [["human", "ORGANISM", 93, 98], ["SARS-Cov-2 S", "GENE_OR_GENE_PRODUCT", 134, 146], ["ACE2Studies", "GENE_OR_GENE_PRODUCT", 151, 162], ["SARS-Cov-2 S", "DNA", 134, 146], ["ACE2Studies", "DNA", 151, 162], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["Protein destabilization", "PROBLEM", 22, 45], ["human diseases", "PROBLEM", 93, 107], ["Mutation Pathogenicity of SARS", "PROBLEM", 108, 138], ["Cov", "TEST", 139, 142], ["ACE2Studies", "TEST", 151, 162], ["the disease", "PROBLEM", 191, 202], ["missense mutations", "PROBLEM", 211, 229], ["protein destabilization", "PROBLEM", 242, 265], ["disease", "OBSERVATION", 195, 202]]], ["The effect of a mutation on protein function can be related to its impact on protein stability changes (28) .", [["a mutation on protein function", "PROBLEM", 14, 44]]], ["As shown in Figure 4C , we observed the SNAP scores of mutations with strong effects (\u0394\u0394G > 2.5 or \u0394\u0394G < -2.5 kcal/mol) on the stabilities of full-length S and RBD are higher than the mutations with moderate effects (0.5 2.5 kcal/mol), 3 mutations have the moderate destabilizing effects (2.5 => \u0394\u0394\u0394G > 0.5 kcal/mol) and only 1 mutation G496P has small stabilizing effect (\u0394\u0394\u0394G = -0.119 kcal/mol) on RBD-ACE2 complex (Figure 3 ).", [["SNAP", "GENE_OR_GENE_PRODUCT", 40, 44], ["RBD", "GENE_OR_GENE_PRODUCT", 160, 163], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 400, 408], ["SNAP", "PROTEIN", 40, 44], ["RBD", "PROTEIN", 160, 163], ["RBD", "PROTEIN", 400, 403], ["ACE2 complex", "PROTEIN", 404, 416], ["the SNAP scores of mutations", "PROBLEM", 36, 64], ["\u0394\u0394G", "TEST", 86, 89], ["\u0394\u0394G", "TEST", 99, 102], ["RBD", "PROBLEM", 160, 163], ["the moderate destabilizing effects", "PROBLEM", 253, 287], ["small stabilizing effect", "PROBLEM", 347, 371], ["\u0394\u0394\u0394G", "TEST", 373, 377], ["RBD", "TEST", 400, 403], ["moderate", "OBSERVATION_MODIFIER", 199, 207], ["moderate", "OBSERVATION_MODIFIER", 257, 265], ["destabilizing", "OBSERVATION", 266, 279], ["small", "OBSERVATION_MODIFIER", 347, 352], ["stabilizing", "OBSERVATION", 353, 364]]], ["The substitutions from small glycine to other large amino acids will lead to an unfavorable change in protein interface and reduce the binding of complex.", [["glycine", "CHEMICAL", 29, 36], ["amino acids", "CHEMICAL", 52, 63], ["glycine", "CHEMICAL", 29, 36], ["amino acids", "CHEMICAL", 52, 63], ["glycine", "AMINO_ACID", 29, 36], ["amino acids", "AMINO_ACID", 52, 63], ["The substitutions", "PROBLEM", 0, 17], ["small glycine to other large amino acids", "TREATMENT", 23, 63], ["an unfavorable change in protein interface", "PROBLEM", 77, 119], ["small", "OBSERVATION_MODIFIER", 23, 28], ["glycine", "OBSERVATION_MODIFIER", 29, 36], ["unfavorable", "OBSERVATION_MODIFIER", 80, 91], ["change", "OBSERVATION", 92, 98], ["protein interface", "OBSERVATION", 102, 119], ["complex", "OBSERVATION_MODIFIER", 146, 153]]], ["In G496's contact residue K353 of ACE2, mutation K353F has the minimum \u0394\u0394\u0394G at -1.937 kcal/mol.", [["ACE2", "GENE_OR_GENE_PRODUCT", 34, 38], ["ACE2", "PROTEIN", 34, 38]]], ["Most mutation in RBD residue F497 can increase the RBD-ACE binding, and mutation F497W has the minimum \u0394\u0394\u0394G at -0.978 kcal/mol in this position.", [["F497", "CHEMICAL", 29, 33], ["F497", "AMINO_ACID", 29, 33], ["RBD-ACE", "GENE_OR_GENE_PRODUCT", 51, 58], ["RBD", "PROTEIN", 17, 20], ["RBD", "PROTEIN", 51, 54], ["ACE", "PROTEIN", 55, 58], ["Most mutation in RBD residue", "PROBLEM", 0, 28], ["ACE binding", "TREATMENT", 55, 66], ["RBD", "OBSERVATION", 51, 54]]], ["Both phenylalanine (F) and tryptophan (W) are aromatic amino acids which include delocalized \u03c0 electrons that interact with other aromatic residues as well as with positively charged residues such as lysine (K).", [["phenylalanine", "CHEMICAL", 5, 18], ["tryptophan", "CHEMICAL", 27, 37], ["amino acids", "CHEMICAL", 55, 66], ["lysine", "CHEMICAL", 200, 206], ["K", "CHEMICAL", 208, 209], ["phenylalanine", "CHEMICAL", 5, 18], ["tryptophan", "CHEMICAL", 27, 37], ["amino acids", "CHEMICAL", 55, 66], ["lysine", "CHEMICAL", 200, 206], ["phenylalanine (F)", "SIMPLE_CHEMICAL", 5, 22], ["tryptophan", "SIMPLE_CHEMICAL", 27, 37], ["aromatic", "SIMPLE_CHEMICAL", 46, 54], ["amino acids", "AMINO_ACID", 55, 66], ["lysine", "AMINO_ACID", 200, 206], ["Both phenylalanine (F)", "TREATMENT", 0, 22], ["tryptophan (W)", "TREATMENT", 27, 41], ["aromatic amino acids", "TREATMENT", 46, 66], ["delocalized \u03c0 electrons", "TREATMENT", 81, 104], ["other aromatic residues", "TREATMENT", 124, 147]]], ["SARS-Cov RBD residues G482 and F483 are in the equivalent positions of G496 and F497 of SARS-Cov-2 in the sequence and structure alignments ( Figure 6A and 6C ).", [["SARS", "DISEASE", 0, 4], ["SARS-Cov-2", "DNA", 88, 98], ["SARS", "PROBLEM", 0, 4], ["Cov RBD residues", "TEST", 5, 21], ["SARS", "TEST", 88, 92], ["Cov", "TEST", 93, 96]]], ["All mutations in SARS-Cov RBD residue G482 can reduce the RBD-ACE2 binding affinity but the \u0394\u0394\u0394G values are relatively small compared with those changes in G496 of SARS-Cov-2.", [["G482", "CHEMICAL", 38, 42], ["G482", "AMINO_ACID", 38, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["RBD", "PROTEIN", 58, 61], ["ACE2", "PROTEIN", 62, 66], ["All mutations in SARS", "PROBLEM", 0, 21], ["Cov RBD residue", "TEST", 22, 37], ["the RBD", "TEST", 54, 61], ["ACE2 binding affinity", "TEST", 62, 83], ["the \u0394\u0394\u0394G values", "TEST", 88, 103], ["SARS", "TEST", 164, 168], ["Cov", "TEST", 169, 172], ["relatively", "OBSERVATION_MODIFIER", 108, 118], ["small", "OBSERVATION_MODIFIER", 119, 124]]], ["This may be explained by that the distances from SARS-Cov residue G482 to ACE2 residues D38 and K353 are increased to 7.5 \u00c5 and 10.0 \u00c5, compared to the distances from SARS-Cov-2 residue G496 to ACE2 residues D38 and K353 are 6.3 \u00c5 and 9.0 \u00c5 ( Figure 6C ).", [["SARS", "DISEASE", 49, 53], ["ACE2", "GENE_OR_GENE_PRODUCT", 74, 78], ["K353", "AMINO_ACID", 96, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 194, 198], ["ACE2", "PROTEIN", 74, 78], ["K353", "PROTEIN", 96, 100], ["ACE2", "PROTEIN", 194, 198], ["SARS", "PROBLEM", 49, 53], ["Cov residue", "PROBLEM", 54, 65], ["ACE2 residues D38", "TREATMENT", 74, 91], ["K353", "TEST", 96, 100], ["SARS", "TEST", 167, 171], ["Cov", "TEST", 172, 175], ["ACE2 residues D38", "TEST", 194, 211], ["K353", "TEST", 216, 220]]], ["Interestingly, even though the F483 of SARS-Cov can be superimposed to F497 of SARS-Cov-2, F483 shows the different effects on RBD-ACE2 interaction.", [["SARS", "DISEASE", 39, 43], ["SARS-Cov", "GENE_OR_GENE_PRODUCT", 39, 47], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["F483", "SIMPLE_CHEMICAL", 91, 95], ["RBD", "GENE_OR_GENE_PRODUCT", 127, 130], ["ACE2", "GENE_OR_GENE_PRODUCT", 131, 135], ["F483", "DNA", 31, 35], ["SARS-Cov", "DNA", 39, 47], ["F497", "DNA", 71, 75], ["F483", "DNA", 91, 95], ["RBD", "PROTEIN", 127, 130], ["ACE2", "PROTEIN", 131, 135], ["SARS", "PROBLEM", 39, 43], ["SARS", "TEST", 79, 83], ["Cov", "TEST", 84, 87]]], ["Most of the mutations in F483 of SARS-Cov have not effects on binding affinity and F483R can weaken the interaction.", [["SARS", "DISEASE", 33, 37], ["SARS-Cov", "GENE_OR_GENE_PRODUCT", 33, 41], ["F483R", "GENE_OR_GENE_PRODUCT", 83, 88], ["F483", "DNA", 25, 29], ["SARS-Cov", "DNA", 33, 41], ["F483R", "PROTEIN", 83, 88], ["the mutations", "PROBLEM", 8, 21], ["SARS", "PROBLEM", 33, 37]]], ["However, most of mutations in F497 of SARS-Cov-2 can enhance (\u0394\u0394\u0394G < -0.5 kcal/mol) the RBD-ACE2 binding affinity.", [["SARS", "DISEASE", 38, 42], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 38, 48], ["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 88, 96], ["SARS-Cov-2", "DNA", 38, 48], ["RBD", "PROTEIN", 88, 91], ["ACE2", "PROTEIN", 92, 96], ["mutations", "TEST", 17, 26], ["SARS", "TEST", 38, 42], ["Cov", "TEST", 43, 46], ["\u0394\u0394\u0394G", "TEST", 62, 66], ["the RBD", "TEST", 84, 91], ["ACE2 binding affinity", "PROBLEM", 92, 113]]], ["Previous studies suggest that SARS-Cov-2 S protein has a higher RBD-ACE2 binding affinity compared to those of SARS-CoV S (5, 10, 14) .", [["SARS", "DISEASE", 30, 34], ["SARS-Cov-2 S", "GENE_OR_GENE_PRODUCT", 30, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 68, 72], ["SARS-CoV S", "GENE_OR_GENE_PRODUCT", 111, 121], ["SARS-Cov-2 S protein", "PROTEIN", 30, 50], ["RBD", "PROTEIN", 64, 67], ["ACE2", "PROTEIN", 68, 72], ["SARS-CoV", "SPECIES", 111, 119], ["Previous studies", "TEST", 0, 16], ["SARS", "TEST", 30, 34], ["Cov", "TEST", 35, 38], ["S protein", "TEST", 41, 50], ["a higher RBD", "PROBLEM", 55, 67], ["ACE2 binding affinity", "PROBLEM", 68, 89], ["SARS", "TEST", 111, 115], ["CoV S", "TEST", 116, 121], ["SARS", "OBSERVATION", 30, 34]]], ["F497 may play important roles for enhancing the RBD-ACE2 interaction for SARS-Cov-2.", [["F497", "CHEMICAL", 0, 4], ["F497", "SIMPLE_CHEMICAL", 0, 4], ["ACE2", "GENE_OR_GENE_PRODUCT", 52, 56], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 73, 83], ["F497", "PROTEIN", 0, 4], ["RBD", "PROTEIN", 48, 51], ["ACE2", "PROTEIN", 52, 56], ["SARS-Cov-2", "DNA", 73, 83], ["SARS", "PROBLEM", 73, 77]]], ["Our binding energy calculations suggest that these residues are potential binding sites for spike protein and its receptor, any alterations in these sites may significantly change the binding affinity of RBD-ACE2 complex.Common viral variations tend to increase spike protein stabilityWe found that the most common variants D614G in 5703 strains can induce the stabilizing effects on SARS-Cov-2 full-length S at -0.7838 kcal/mol.", [["RBD-ACE2", "GENE_OR_GENE_PRODUCT", 204, 212], ["spike protein", "PROTEIN", 92, 105], ["RBD", "PROTEIN", 204, 207], ["ACE2 complex", "PROTEIN", 208, 220], ["SARS-Cov-2 full-length S", "DNA", 384, 408], ["Our binding energy calculations", "TEST", 0, 31], ["these residues", "PROBLEM", 45, 59], ["potential binding sites", "PROBLEM", 64, 87], ["spike protein and its receptor", "PROBLEM", 92, 122], ["any alterations in these sites", "PROBLEM", 124, 154], ["ACE2 complex", "PROBLEM", 208, 220], ["Common viral variations", "PROBLEM", 221, 244], ["increase spike protein stability", "PROBLEM", 253, 285], ["Cov", "TEST", 389, 392], ["stability", "OBSERVATION_MODIFIER", 276, 285]]], ["Particularly, D614G becomes the dominant pandemic form worldwide (33).", [["D614G", "CHEMICAL", 14, 19], ["dominant", "OBSERVATION_MODIFIER", 32, 40], ["pandemic", "OBSERVATION", 41, 49]]], ["D614 form is in the Wuhan reference strain and a G-to-A base substitution result in the G614 form.", [["D614 form", "RNA", 0, 9], ["G614 form", "PROTEIN", 88, 97], ["A base substitution", "TREATMENT", 54, 73]]], ["The D614 mutation was first found in the strains in Germany.Common viral variations tend to increase spike protein stabilityKorber et al. found that G614 form started its expansion in Europe and then spread quickly to many other countries in the world (33).", [["G614", "CHEMICAL", 149, 153], ["D614", "GENE_OR_GENE_PRODUCT", 4, 8], ["D614", "DNA", 4, 8], ["The D614 mutation", "PROBLEM", 0, 17], ["Common viral variations", "PROBLEM", 60, 83], ["expansion", "OBSERVATION_MODIFIER", 171, 180]]], ["They showed that the patients with D614G strain had higher viral loads and suggested this mutation is important for RBD binding and enhance viral infection and production.", [["viral infection", "DISEASE", 140, 155], ["patients", "ORGANISM", 21, 29], ["RBD", "PROTEIN", 116, 119], ["patients", "SPECIES", 21, 29], ["D614G strain", "PROBLEM", 35, 47], ["higher viral loads", "PROBLEM", 52, 70], ["this mutation", "PROBLEM", 85, 98], ["RBD binding", "PROBLEM", 116, 127], ["enhance viral infection", "PROBLEM", 132, 155], ["viral", "OBSERVATION_MODIFIER", 140, 145], ["infection", "OBSERVATION", 146, 155]]], ["Based on our calculations of folding energy changes, D614G has the minimum \u0394\u0394G at -0.7838 kcal/mol among all 19 possible mutations in this position (Figure 2 ).", [["folding energy changes", "PROBLEM", 29, 51], ["D614G", "TREATMENT", 53, 58]]], ["This suggests that G614 is the most stable form compared to other possible mutations.", [["G614", "CHEMICAL", 19, 23], ["G614", "GENE_OR_GENE_PRODUCT", 19, 23], ["G614", "DNA", 19, 23], ["mutations", "PROBLEM", 75, 84], ["most stable", "OBSERVATION_MODIFIER", 31, 42]]], ["In addition, D614G is predicted to have neutral effect (SNAP score = -52) on protein function, which would benefit the viral S protein function (Table 3) .", [["D614G", "GENE_OR_GENE_PRODUCT", 13, 18], ["D614G", "PROTEIN", 13, 18], ["viral S protein", "PROTEIN", 119, 134], ["neutral effect", "PROBLEM", 40, 54], ["SNAP score", "TEST", 56, 66], ["protein function", "TEST", 77, 93], ["the viral S protein function", "TEST", 115, 143]]], ["Interestingly, we also found D614 is very closed to N-linked glycosylation site N616 ( Figure 5C ).", [["D614", "CHEMICAL", 29, 33], ["N-", "CHEMICAL", 52, 54], ["D614", "SIMPLE_CHEMICAL", 29, 33], ["D614", "PROTEIN", 29, 33], ["N-linked glycosylation site", "PROTEIN", 52, 79], ["N-linked glycosylation site", "PROBLEM", 52, 79]]], ["Many mutations in N616 can also induce the stabilizing effects (Figure 7) .", [["N616", "CHEMICAL", 18, 22], ["N616", "SIMPLE_CHEMICAL", 18, 22], ["Many mutations", "PROBLEM", 0, 14]]], ["Thus, D614G may enhance the fitness of SARS-Cov-2 through increasing S protein stability and participating in the N-linked glycosylation.", [["D614G", "CHEMICAL", 6, 11], ["SARS", "DISEASE", 39, 43], ["N", "CHEMICAL", 114, 115], ["D614G", "GENE_OR_GENE_PRODUCT", 6, 11], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["S protein", "PROTEIN", 69, 78], ["D614G", "TREATMENT", 6, 11], ["SARS", "PROBLEM", 39, 43], ["Cov", "TEST", 44, 47], ["increasing S protein stability", "PROBLEM", 58, 88], ["the N-linked glycosylation", "TREATMENT", 110, 136]]], ["In addition, common viral mutations D936Y in 37 strains, V483A in 24 strains and V367F in 24 strains can also induce the stabilizing effects on SARS-Cov-2 full-length S or RBD (Table 3) .", [["SARS-Cov-2 full-length S", "DNA", 144, 168], ["RBD", "DNA", 172, 175], ["common viral mutations", "PROBLEM", 13, 35], ["SARS", "TEST", 144, 148], ["Cov", "TEST", 149, 152], ["RBD", "PROBLEM", 172, 175], ["common", "ANATOMY", 13, 19], ["viral mutations", "OBSERVATION", 20, 35], ["stabilizing", "OBSERVATION", 121, 132]]], ["S50L in 7 strains and V341L have the minimum \u0394\u0394G among all other possible mutations in their positions (Supplementary Figure 4) .", [["S50L", "GENE_OR_GENE_PRODUCT", 0, 4], ["V341L", "CANCER", 22, 27], ["S50L", "PROTEIN", 0, 4], ["the minimum \u0394\u0394G", "TREATMENT", 33, 48]]], ["Moreover, we observed the percentage of mutations with stabilizing effects is higher in viral mutations (18.9%), compared to the one in all computationally predicted mutations (10.6%) ( Figure 1) .", [["mutations", "PROBLEM", 40, 49], ["stabilizing effects", "PROBLEM", 55, 74], ["viral mutations", "PROBLEM", 88, 103], ["higher", "OBSERVATION_MODIFIER", 78, 84], ["viral mutations", "OBSERVATION", 88, 103]]], ["These results indicate that the mutations with stabilizing effects can make S protein remain sufficiently stable for its function and enhance the resistance of SARS-CoV-2.", [["SARS", "DISEASE", 160, 164], ["S protein", "GENE_OR_GENE_PRODUCT", 76, 85], ["SARS-CoV-2", "ORGANISM", 160, 170], ["S protein", "PROTEIN", 76, 85], ["SARS-CoV", "SPECIES", 160, 168], ["the mutations", "PROBLEM", 28, 41], ["S protein", "TEST", 76, 85], ["SARS", "TEST", 160, 164], ["CoV", "TEST", 165, 168]]], ["We noticed that most of the viral mutations are not substitutions with minimum and maximum folding or binding energy changes (Supplementary Figure 4) .", [["the viral mutations", "PROBLEM", 24, 43], ["binding energy changes", "PROBLEM", 102, 124], ["viral mutations", "OBSERVATION", 28, 43]]], ["As shown in Supplementary Figure 5 , the |\u0394\u0394G| mean of residues with viral mutations is lower than those without viral mutations (P < 2.2e- 16) , and |\u0394\u0394G| of viral mutations is also smaller than other computational predicted mutations (P = 0.00016) in the same positions.", [["viral mutations", "PROBLEM", 69, 84], ["viral mutations", "PROBLEM", 113, 128], ["viral mutations", "PROBLEM", 159, 174], ["P", "TEST", 237, 238], ["viral mutations", "OBSERVATION", 69, 84], ["viral mutations", "OBSERVATION", 159, 174], ["smaller", "OBSERVATION_MODIFIER", 183, 190]]], ["The mutations with significant stabilizing or destabilizing effects may interfere with the S protein function ( Figure 4C ).", [["S protein", "PROTEIN", 91, 100], ["The mutations", "PROBLEM", 0, 13], ["significant stabilizing", "PROBLEM", 19, 42], ["destabilizing effects", "PROBLEM", 46, 67], ["the S protein function", "TEST", 87, 109], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["stabilizing", "OBSERVATION", 31, 42]]], ["The selection pressure makes the viral mutations occurred in the residues with small effects on protein stability and maintain SARS-Cov-2 S at its normal functions for transmission.CONCLUSIONThe emergence of the pathogenic betacoronavirus SARS-CoV-2 poses a serious threat to global health.", [["SARS", "DISEASE", 239, 243], ["betacoronavirus SARS-CoV-2", "ORGANISM", 223, 249], ["SARS-CoV-2", "SPECIES", 239, 249], ["The selection pressure", "TREATMENT", 0, 22], ["the viral mutations", "PROBLEM", 29, 48], ["protein stability", "TEST", 96, 113], ["SARS", "TEST", 127, 131], ["Cov", "TEST", 132, 135], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["viral mutations", "OBSERVATION", 33, 48], ["small", "OBSERVATION_MODIFIER", 79, 84], ["normal functions", "OBSERVATION", 147, 163]]], ["SARS-CoV-2 S protein and its RBD and human ACE2 are critical for viral success to infection.", [["infection", "DISEASE", 82, 91], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 0, 12], ["RBD", "GENE_OR_GENE_PRODUCT", 29, 32], ["human", "ORGANISM", 37, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 43, 47], ["SARS-CoV-2 S protein", "PROTEIN", 0, 20], ["RBD", "PROTEIN", 29, 32], ["human ACE2", "PROTEIN", 37, 47], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["S protein", "TEST", 11, 20], ["its RBD", "PROBLEM", 25, 32], ["human ACE2", "TREATMENT", 37, 47], ["viral success to infection", "PROBLEM", 65, 91], ["infection", "OBSERVATION", 82, 91]]], ["In this study, we applied the computational saturation mutagenesis to mutate all residues in the S and ACE2 proteins to all other 19 amino acid types.", [["amino acid", "CHEMICAL", 133, 143], ["amino acid", "CHEMICAL", 133, 143], ["ACE2", "GENE_OR_GENE_PRODUCT", 103, 107], ["amino acid", "AMINO_ACID", 133, 143], ["S and ACE2 proteins", "PROTEIN", 97, 116], ["this study", "TEST", 3, 13], ["the computational saturation mutagenesis", "TREATMENT", 26, 66], ["the S and ACE2 proteins", "TREATMENT", 93, 116]]], ["We used structure-based energy calculations and sequence-based bioinformatics tools to quantify the systemic effects of missense mutations on the protein structure and function.", [["energy calculations", "TEST", 24, 43], ["bioinformatics tools", "TEST", 63, 83], ["missense mutations", "PROBLEM", 120, 138], ["missense", "OBSERVATION", 120, 128]]], ["A total of 18,354 mutations in SARS-CoV-2 spike protein were analyzed and we discovered that the majority of these mutations could destabilize the entire S protein including its RBD region.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["SARS-CoV-2 spike protein", "PROTEIN", 31, 55], ["S protein", "PROTEIN", 154, 163], ["RBD region", "PROTEIN", 178, 188], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["spike protein", "TEST", 42, 55], ["these mutations", "PROBLEM", 109, 124]]], ["Remarkably, the amino acid substitutions in SARS-CoV-2 RBD residue G431 can decrease the spike protein stability, but the mutations in its spatial residue S514 can make the spike and RBD more stable.", [["amino acid", "CHEMICAL", 16, 26], ["G431", "CHEMICAL", 67, 71], ["amino acid", "CHEMICAL", 16, 26], ["amino acid", "AMINO_ACID", 16, 26], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["G431", "AMINO_ACID", 67, 71], ["SARS-CoV-2 RBD residue G431", "PROTEIN", 44, 71], ["RBD", "PROTEIN", 183, 186], ["the amino acid substitutions", "PROBLEM", 12, 40], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["the spike protein stability", "PROBLEM", 85, 112], ["the mutations", "PROBLEM", 118, 131], ["the spike and RBD", "PROBLEM", 169, 186], ["stability", "OBSERVATION_MODIFIER", 103, 112], ["stable", "OBSERVATION_MODIFIER", 192, 198]]], ["We analyzed 384 experimentally verified spike missense variations and identified that D614G in 5,703 virus strains can stabilize SARS-Cov-2 entire spike protein.", [["SARS", "DISEASE", 129, 133], ["5,703 virus", "ORGANISM", 95, 106], ["Cov-2", "GENE_OR_GENE_PRODUCT", 134, 139], ["SARS-Cov-2 entire spike protein", "PROTEIN", 129, 160], ["spike missense variations", "PROBLEM", 40, 65], ["D614G", "TREATMENT", 86, 91], ["SARS", "PROBLEM", 129, 133], ["Cov", "TEST", 134, 137], ["entire spike protein", "PROBLEM", 140, 160]]], ["Moreover, we showed that many mutations in Nlinked glycosylation sites can increase the stability of the spike protein.", [["Nlinked glycosylation sites", "PROTEIN", 43, 70], ["spike protein", "PROTEIN", 105, 118], ["many mutations in Nlinked glycosylation sites", "PROBLEM", 25, 70], ["the spike protein", "PROBLEM", 101, 118], ["many", "OBSERVATION_MODIFIER", 25, 29], ["mutations", "OBSERVATION", 30, 39], ["stability", "OBSERVATION_MODIFIER", 88, 97]]], ["In addition, we investigated 3,705 mutations in SARS-CoV-2 RBD and 11,324 mutations in human ACE2 and found that the mutations located in the interface of RBD-ACE2 complex can alter its binding affinity.CONCLUSIONInterestingly, SARS-CoV-2 neighbor residues G496 and F497 have different effects on RBD- The key residues G431 and K514 are marked in the line charts and heatmaps.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["human", "ORGANISM", 87, 92], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["RBD", "GENE_OR_GENE_PRODUCT", 155, 158], ["ACE2", "GENE_OR_GENE_PRODUCT", 159, 163], ["F497", "AMINO_ACID", 266, 270], ["SARS-CoV-2 RBD", "DNA", 48, 62], ["human ACE2", "PROTEIN", 87, 97], ["RBD", "PROTEIN", 155, 158], ["ACE2 complex", "PROTEIN", 159, 171], ["RBD", "PROTEIN", 297, 300], ["human", "SPECIES", 87, 92], ["SARS-CoV", "SPECIES", 48, 56], ["human", "SPECIES", 87, 92], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["human ACE2", "TEST", 87, 97], ["the mutations", "PROBLEM", 113, 126], ["ACE2 complex", "PROBLEM", 159, 171], ["SARS", "PROBLEM", 228, 232], ["different effects on RBD", "PROBLEM", 276, 300], ["K514", "TREATMENT", 328, 332], ["heatmaps", "TEST", 367, 375], ["RBD", "OBSERVATION", 155, 158], ["marked", "OBSERVATION_MODIFIER", 337, 343]]], ["Heatmap and structural representation of SARS-CoV-2 residues G431 (red) and S514 (blue) and SARS-CoV residues G418 (magenta) and S500 (marine).", [["G418", "CHEMICAL", 110, 114], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["SARS-CoV", "SPECIES", 92, 100], ["Heatmap", "TREATMENT", 0, 7], ["SARS", "PROBLEM", 41, 45], ["CoV", "TEST", 46, 49], ["SARS", "PROBLEM", 92, 96], ["magenta", "TEST", 116, 123], ["SARS", "OBSERVATION", 41, 45]]], ["(C) Superimposition of the SARS-CoV-2 RBD (orange) with its ACE2 (green) and SARS-CoV RBD (yellow) with its RBD.", [["SARS", "DISEASE", 27, 31], ["RBD", "DISEASE", 108, 111], ["orange", "ORGANISM_SUBDIVISION", 43, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV RBD", "GENE_OR_GENE_PRODUCT", 77, 89], ["RBD", "PROTEIN", 38, 41], ["ACE2", "PROTEIN", 60, 64], ["CoV RBD", "PROTEIN", 82, 89], ["RBD", "PROTEIN", 108, 111], ["SARS-CoV", "SPECIES", 77, 85], ["the SARS", "TEST", 23, 31], ["CoV", "TEST", 32, 35], ["its ACE2", "TEST", 56, 64], ["SARS", "PROBLEM", 77, 81], ["CoV RBD (yellow) with its RBD", "PROBLEM", 82, 111], ["SARS", "OBSERVATION", 27, 31], ["RBD", "OBSERVATION", 108, 111]]], ["Heatmap and structural representation of SARS-CoV-2 residues G496 (red) and F497 (blue) and SARS-CoV residues G482 (magenta) and F482 (marine).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["SARS-CoV", "SPECIES", 92, 100], ["Heatmap", "TREATMENT", 0, 7], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["SARS", "PROBLEM", 92, 96], ["CoV residues", "TEST", 97, 109], ["magenta", "TEST", 116, 123], ["SARS", "OBSERVATION", 41, 45]]], ["The distances to ACE2 residues D38 (hot pink) and K353 (sky blue) are measured. (blue) are located in the interacting motif Y495GFQPTNGVG504 (brown) and form an interaction network with ACE2 residues D355 (hot pink) and Y41 (marine).", [["ACE2", "GENE_OR_GENE_PRODUCT", 17, 21], ["Y495GFQPTNGVG504", "GENE_OR_GENE_PRODUCT", 124, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 186, 190], ["ACE2", "PROTEIN", 17, 21], ["K353", "PROTEIN", 50, 54], ["ACE2", "PROTEIN", 186, 190], ["ACE2 residues", "TEST", 17, 30], ["ACE2 residues D355", "TREATMENT", 186, 204]]], ["(C) RBD residue G496 with has vdw contacts with ACE2 residues D38 (pink) and K353 (sky blue).", [["G496", "CHEMICAL", 16, 20], ["ACE2", "GENE_OR_GENE_PRODUCT", 48, 52], ["ACE2", "PROTEIN", 48, 52], ["RBD residue", "PROBLEM", 4, 15], ["ACE2 residues D38", "TREATMENT", 48, 65]]], ["(D) Q498 has contacts with residues D38, Q42, L45 (pink) as well as Y41 (marine).", [["Q498", "CHEMICAL", 4, 8], ["(D) Q498", "CHEMICAL", 0, 8]]], ["(E) RBD residues T500 (magenta) and N501 (cyan) interact with ACE2 residues K353 (sky blue) and Y41(marine).", [["N501", "AMINO_ACID", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["ACE2", "PROTEIN", 62, 66], ["RBD residues", "PROBLEM", 4, 16], ["ACE2 residues", "TEST", 62, 75], ["sky blue", "TEST", 82, 90]]], ["(F) RBD residue G502 (magenta) have vdw contacts with D355 (hot pink) and K353 (sky blue) in ACE2.", [["D355", "SIMPLE_CHEMICAL", 54, 58], ["K353", "SIMPLE_CHEMICAL", 74, 78], ["ACE2", "GENE_OR_GENE_PRODUCT", 93, 97], ["D355", "PROTEIN", 54, 58], ["K353", "PROTEIN", 74, 78], ["ACE2", "PROTEIN", 93, 97]]]], "PMC6501061": [["One-health and viral diseaseThe burden of viral disease is a global concern.", [["viral disease", "DISEASE", 15, 28], ["viral disease", "DISEASE", 42, 55], ["One-health and viral disease", "PROBLEM", 0, 28], ["viral disease", "PROBLEM", 42, 55], ["viral disease", "OBSERVATION", 15, 28], ["viral disease", "OBSERVATION", 42, 55], ["global", "OBSERVATION_MODIFIER", 61, 67]]], ["Due to their unique properties, viruses have a particular relevance when analyzing the interaction among humans, animals, and the environment.", [["humans", "ORGANISM", 105, 111], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["viruses", "PROBLEM", 32, 39]]], ["Viruses are small compared to other pathogens, facilitating transport in the environment.", [["Viruses", "PROBLEM", 0, 7], ["small", "OBSERVATION_MODIFIER", 12, 17], ["pathogens", "OBSERVATION", 36, 45]]], ["Moreover, their resistance to disinfection and ability to survive for prolonged periods in water and solids make their transmission from the environment to suitable hosts likely.", [["disinfection", "TREATMENT", 30, 42], ["prolonged periods in water and solids", "TREATMENT", 70, 107]]], ["This is compounded by their low infectious dose, inability to be treated by antibiotics, and their proclivity for adaptive mutation.", [["antibiotics", "TREATMENT", 76, 87], ["adaptive mutation", "PROBLEM", 114, 131], ["low", "OBSERVATION_MODIFIER", 28, 31], ["infectious", "OBSERVATION", 32, 42]]], ["Additionally, viruses do not replicate outside their host cells, therefore detection in environmental samples can be directly related to the human or animal population that excreted these viruses.One-health and viral diseaseFig.", [["cells", "ANATOMY", 58, 63], ["samples", "ANATOMY", 102, 109], ["viral disease", "DISEASE", 211, 224], ["host cells", "CELL", 53, 63], ["human", "ORGANISM", 141, 146], ["host cells", "CELL_TYPE", 53, 63], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["viruses", "PROBLEM", 14, 21], ["viral diseaseFig", "PROBLEM", 211, 227], ["viruses", "OBSERVATION", 14, 21], ["host cells", "OBSERVATION", 53, 63], ["viral disease", "OBSERVATION", 211, 224]]], ["1 summarizes viral exposure pathways and the relevance of the One-Health approach.", [["the One-Health approach", "TREATMENT", 58, 81], ["viral exposure", "OBSERVATION", 13, 27]]], ["Formally put forth by the One Health Commission in 2007, the concept is defined as \u201cthe collaborative effort of multiple disciplines \u2013 working locally, nationally, and globally \u2013 to attain optimal health for people, animals and our environment [1].\u201d", [["people", "ORGANISM", 208, 214], ["people", "SPECIES", 208, 214]]], ["Consequently, a key component to the One-Health approach is the notion that human health, animal health, and environmental health are all innately interrelated.", [["human", "ORGANISM", 76, 81], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 76, 81]]], ["By taking all three aspects of health into account, solutions can be generated that not only address the health problems of a specific group but mitigate the source of those problems as well.One-health and viral diseaseMuch of the current work using the One-Health approach is focused upon the exposure pathway between humans and animals, while the water-related exposure pathway has not been thoroughly investigated from a One-Health perspective.", [["humans", "ORGANISM", 319, 325], ["humans", "SPECIES", 319, 325], ["humans", "SPECIES", 319, 325], ["those problems", "PROBLEM", 168, 182], ["the One-Health approach", "TREATMENT", 250, 273], ["viral diseaseMuch", "OBSERVATION", 206, 223]]], ["The purpose of this paper is to explore water-related exposure pathways as they relate to human, animal, and environmental health, to explore the possibility of surveillance of water and wastewater systems as means of identification of endemic disease and potential outbreaks at a population level, and to develop a framework with which to apply the One-Health methodology for early detection and management of water-related viral outbreaks.Burden of viral diseaseCommunicable disease is one of the leading causes of death worldwide.", [["viral diseaseCommunicable disease", "DISEASE", 451, 484], ["death", "DISEASE", 517, 522], ["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["endemic disease", "PROBLEM", 236, 251], ["management", "TREATMENT", 397, 407], ["viral outbreaks", "PROBLEM", 425, 440], ["viral diseaseCommunicable disease", "PROBLEM", 451, 484], ["death", "PROBLEM", 517, 522], ["endemic disease", "OBSERVATION", 236, 251], ["viral diseaseCommunicable disease", "OBSERVATION", 451, 484]]], ["Lower respiratory infections were responsible for 3.0 million deaths in 2016 according to the World Health Organization (WHO), and diarrheal infections contributed to another 1.4 million deaths in the same year [2].", [["respiratory", "ANATOMY", 6, 17], ["Lower respiratory infections", "DISEASE", 0, 28], ["deaths", "DISEASE", 62, 68], ["diarrheal infections", "DISEASE", 131, 151], ["deaths", "DISEASE", 187, 193], ["Lower respiratory infections", "PROBLEM", 0, 28], ["diarrheal infections", "PROBLEM", 131, 151], ["respiratory", "ANATOMY", 6, 17], ["infections", "OBSERVATION", 18, 28]]], ["Viral diseases contribute to these categories; influenza, coronavirus, and adenovirus are all considered lower respiratory infections, and viruses such as rotavirus can cause diarrheal disease.", [["respiratory", "ANATOMY", 111, 122], ["Viral diseases", "DISEASE", 0, 14], ["influenza, coronavirus", "DISEASE", 47, 69], ["respiratory infections", "DISEASE", 111, 133], ["rotavirus", "DISEASE", 155, 164], ["diarrheal disease", "DISEASE", 175, 192], ["coronavirus", "ORGANISM", 58, 69], ["adenovirus", "ORGANISM", 75, 85], ["rotavirus", "ORGANISM", 155, 164], ["adenovirus", "SPECIES", 75, 85], ["rotavirus", "SPECIES", 155, 164], ["Viral diseases", "PROBLEM", 0, 14], ["these categories", "PROBLEM", 29, 45], ["influenza", "PROBLEM", 47, 56], ["coronavirus", "PROBLEM", 58, 69], ["adenovirus", "PROBLEM", 75, 85], ["lower respiratory infections", "PROBLEM", 105, 133], ["viruses", "PROBLEM", 139, 146], ["rotavirus", "PROBLEM", 155, 164], ["diarrheal disease", "PROBLEM", 175, 192], ["respiratory", "ANATOMY", 111, 122], ["infections", "OBSERVATION", 123, 133]]], ["Viral disease outbreaks occur often, with WHO reporting outbreaks of influenza, coronavirus, hepatitis E, yellow fever, Ebola virus, Zika virus, poliovirus, dengue fever, and chikungunya in 2017 alone, located in countries all over the world such as Brazil, Chad, China, France, Italy, Saudi Arabia, and Sri Lanka [3].", [["Viral disease", "DISEASE", 0, 13], ["influenza, coronavirus, hepatitis E", "DISEASE", 69, 104], ["yellow fever", "DISEASE", 106, 118], ["Ebola virus, Zika virus", "DISEASE", 120, 143], ["poliovirus", "DISEASE", 145, 155], ["dengue fever", "DISEASE", 157, 169], ["chikungunya", "DISEASE", 175, 186], ["coronavirus", "ORGANISM", 80, 91], ["hepatitis E", "ORGANISM", 93, 104], ["yellow fever", "ORGANISM", 106, 118], ["Ebola virus", "ORGANISM", 120, 131], ["Zika virus", "ORGANISM", 133, 143], ["coronavirus", "SPECIES", 80, 91], ["yellow fever", "SPECIES", 106, 118], ["Ebola virus", "SPECIES", 120, 131], ["Zika virus", "SPECIES", 133, 143], ["dengue fever", "SPECIES", 157, 169], ["Ebola virus", "SPECIES", 120, 131], ["Zika virus", "SPECIES", 133, 143], ["Viral disease outbreaks", "PROBLEM", 0, 23], ["influenza", "PROBLEM", 69, 78], ["coronavirus", "PROBLEM", 80, 91], ["hepatitis E", "PROBLEM", 93, 104], ["yellow fever", "PROBLEM", 106, 118], ["Ebola virus", "PROBLEM", 120, 131], ["Zika virus", "PROBLEM", 133, 143], ["poliovirus", "PROBLEM", 145, 155], ["dengue fever", "PROBLEM", 157, 169], ["chikungunya", "PROBLEM", 175, 186], ["disease", "OBSERVATION", 6, 13]]], ["Moreover, environmental factors such as water, soil, and zoonotic vectors such as mosquitos and animals have been cited as important contributing factors to viral outbreaks [4].Burden of viral diseaseWHO gathers surveillance statistics for specific viruses and estimates between 290,000 to 650,000 annual deaths from influenza, greater than previous estimates [5].", [["deaths", "DISEASE", 305, 311], ["influenza", "DISEASE", 317, 326], ["zoonotic vectors", "TREATMENT", 57, 73], ["surveillance statistics", "TEST", 212, 235], ["specific viruses", "PROBLEM", 240, 256], ["influenza", "PROBLEM", 317, 326], ["viral diseaseWHO", "OBSERVATION", 187, 203], ["influenza", "OBSERVATION", 317, 326]]], ["Data from February 2018 indicated that the disease burden of influenza was highest in north and east Africa, South America, and Europe [6].", [["influenza", "DISEASE", 61, 70], ["the disease burden", "PROBLEM", 39, 57], ["influenza", "PROBLEM", 61, 70], ["influenza", "OBSERVATION", 61, 70]]], ["Data from the WHO Mortality Database shows over 100,000 deaths from viral hepatitis since 2012 throughout the world [7].", [["deaths", "DISEASE", 56, 62], ["viral hepatitis", "DISEASE", 68, 83], ["Mortality Database", "TEST", 18, 36], ["viral hepatitis", "PROBLEM", 68, 83], ["viral hepatitis", "OBSERVATION", 68, 83]]], ["Outbreaks of gastrointestinal disease are also common around the world.", [["gastrointestinal", "ANATOMY", 13, 29], ["gastrointestinal disease", "DISEASE", 13, 37], ["gastrointestinal", "ORGAN", 13, 29], ["gastrointestinal disease", "PROBLEM", 13, 37], ["gastrointestinal", "ANATOMY", 13, 29], ["disease", "OBSERVATION", 30, 37]]], ["Rotavirus, for example, is associated with high rates of pediatric mortality; rotavirus infection was found to be responsible for approximately 453,000 pediatric deaths in 2008 worldwide, accounting for 5% of all deaths in children younger than five years [8].", [["Rotavirus", "DISEASE", 0, 9], ["rotavirus infection", "DISEASE", 78, 97], ["deaths", "DISEASE", 162, 168], ["deaths", "DISEASE", 213, 219], ["rotavirus", "ORGANISM", 78, 87], ["children", "ORGANISM", 223, 231], ["children", "SPECIES", 223, 231], ["rotavirus", "SPECIES", 78, 87], ["Rotavirus", "PROBLEM", 0, 9], ["high rates of pediatric mortality", "PROBLEM", 43, 76], ["rotavirus infection", "PROBLEM", 78, 97], ["infection", "OBSERVATION", 88, 97]]], ["Viral disease also disproportionately impacts poorer communities around the world.", [["Viral disease", "DISEASE", 0, 13], ["Viral disease", "PROBLEM", 0, 13], ["disease", "OBSERVATION", 6, 13], ["disproportionately", "OBSERVATION_MODIFIER", 19, 37], ["impacts", "OBSERVATION_MODIFIER", 38, 45], ["poorer", "OBSERVATION_MODIFIER", 46, 52], ["communities", "OBSERVATION_MODIFIER", 53, 64]]], ["The aforementioned rotavirus study determined that over half of the pediatric rotavirus deaths worldwide occurred in just five developing nations (Democratic Republic of the Congo, Ethiopia, India, Nigeria, and Pakistan) [8].", [["rotavirus deaths", "DISEASE", 78, 94], ["rotavirus", "ORGANISM", 78, 87], ["rotavirus", "SPECIES", 78, 87], ["The aforementioned rotavirus study", "TEST", 0, 34], ["the pediatric rotavirus deaths", "PROBLEM", 64, 94], ["rotavirus", "OBSERVATION", 19, 28]]], ["Academic studies assessing global disease burden also report substantial burden due to viral disease.", [["viral disease", "DISEASE", 87, 100], ["Academic studies", "TEST", 0, 16], ["global disease burden", "PROBLEM", 27, 48], ["substantial burden", "PROBLEM", 61, 79], ["viral disease", "PROBLEM", 87, 100], ["global", "OBSERVATION_MODIFIER", 27, 33], ["disease", "OBSERVATION", 34, 41], ["substantial", "OBSERVATION_MODIFIER", 61, 72], ["viral disease", "OBSERVATION", 87, 100]]], ["One study investigating global foodborne disease burden reported approximately 684 million disease cases and 212,000 deaths due to norovirus globally for the year 2010, the largest for any pathogen studied [9].", [["foodborne disease", "DISEASE", 31, 48], ["deaths", "DISEASE", 117, 123], ["norovirus", "DISEASE", 131, 140], ["One study", "TEST", 0, 9], ["global foodborne disease burden", "PROBLEM", 24, 55], ["norovirus", "PROBLEM", 131, 140], ["global", "OBSERVATION_MODIFIER", 24, 30], ["foodborne disease", "OBSERVATION", 31, 48]]], ["The same study found hepatitis A virus responsible for approximately 47 million illnesses and 94,000 deaths in 2010 [9].Burden of viral diseaseBeyond diseases arising from direct infection, there are other secondary diseases associated with viruses, such as cervical cancer, which is strongly associated with papillomavirus [10].", [["cervical cancer", "ANATOMY", 258, 273], ["hepatitis A virus", "DISEASE", 21, 38], ["deaths", "DISEASE", 101, 107], ["viral diseaseBeyond diseases", "DISEASE", 130, 158], ["infection", "DISEASE", 179, 188], ["cervical cancer", "DISEASE", 258, 273], ["hepatitis A virus", "ORGANISM", 21, 38], ["cervical cancer", "CANCER", 258, 273], ["papillomavirus", "ORGANISM", 309, 323], ["hepatitis A virus", "SPECIES", 21, 38], ["The same study", "TEST", 0, 14], ["hepatitis A virus", "PROBLEM", 21, 38], ["viral diseaseBeyond diseases", "PROBLEM", 130, 158], ["direct infection", "PROBLEM", 172, 188], ["other secondary diseases", "PROBLEM", 200, 224], ["viruses", "PROBLEM", 241, 248], ["cervical cancer", "PROBLEM", 258, 273], ["papillomavirus", "PROBLEM", 309, 323], ["hepatitis", "OBSERVATION", 21, 30], ["viral diseaseBeyond diseases", "OBSERVATION", 130, 158], ["infection", "OBSERVATION", 179, 188], ["secondary", "OBSERVATION_MODIFIER", 206, 215], ["diseases", "OBSERVATION", 216, 224], ["viruses", "OBSERVATION", 241, 248], ["cervical", "ANATOMY", 258, 266], ["cancer", "OBSERVATION", 267, 273]]], ["Other viruses have also been linked to increased incidences of heart disease [11,12] and kidney disease [13], particularly in immunocompromised patients.", [["heart", "ANATOMY", 63, 68], ["kidney", "ANATOMY", 89, 95], ["heart disease", "DISEASE", 63, 76], ["kidney disease", "DISEASE", 89, 103], ["heart", "ORGAN", 63, 68], ["kidney", "ORGAN", 89, 95], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["Other viruses", "PROBLEM", 0, 13], ["heart disease", "PROBLEM", 63, 76], ["kidney disease", "PROBLEM", 89, 103], ["viruses", "OBSERVATION", 6, 13], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["heart", "ANATOMY", 63, 68], ["disease", "OBSERVATION", 69, 76], ["kidney", "ANATOMY", 89, 95], ["disease", "OBSERVATION", 96, 103], ["immunocompromised", "OBSERVATION", 126, 143]]], ["Additionally, it is thought that the true impact of viral disease is underestimated.", [["viral disease", "DISEASE", 52, 65], ["viral disease", "PROBLEM", 52, 65], ["viral disease", "OBSERVATION", 52, 65]]], ["Many disease outbreaks are reported to be caused by agents of unknown etiology, and some of these outbreaks are suspected to be viral in origin [14].", [["Many disease outbreaks", "PROBLEM", 0, 22], ["disease", "OBSERVATION", 5, 12]]], ["A One-Health approach could assist in discovering the origin of these disease outbreaks.Burden of viral diseaseIn the United States, the Centers for Disease Control (CDC) publish surveillance statistics regarding the rate and occurrence of disease for a number of human viruses, including influenza [15], adenovirus [16], hepatitis A virus [17], rotavirus [18], and West Nile virus [19].", [["influenza", "DISEASE", 289, 298], ["hepatitis A", "DISEASE", 322, 333], ["human", "ORGANISM", 264, 269], ["influenza [15", "ORGANISM", 289, 302], ["adenovirus [16],", "ORGANISM", 305, 321], ["hepatitis A virus", "ORGANISM", 322, 339], ["rotavirus", "ORGANISM", 346, 355], ["West Nile virus", "ORGANISM", 366, 381], ["human", "SPECIES", 264, 269], ["hepatitis A virus", "SPECIES", 322, 339], ["West Nile virus", "SPECIES", 366, 381], ["human viruses", "SPECIES", 264, 277], ["adenovirus", "SPECIES", 305, 315], ["hepatitis A virus", "SPECIES", 322, 339], ["West Nile virus", "SPECIES", 366, 381], ["these disease outbreaks", "PROBLEM", 64, 87], ["the rate", "TEST", 213, 221], ["disease", "PROBLEM", 240, 247], ["human viruses", "PROBLEM", 264, 277], ["influenza", "PROBLEM", 289, 298], ["adenovirus", "PROBLEM", 305, 315], ["hepatitis A virus", "PROBLEM", 322, 339], ["rotavirus", "PROBLEM", 346, 355], ["disease", "OBSERVATION", 70, 77], ["viral diseaseIn", "OBSERVATION", 98, 113], ["disease", "OBSERVATION", 240, 247]]], ["Annual summaries of these surveillance statistics are published in various forms from the CDC.", [["these surveillance statistics", "TEST", 20, 49]]], ["The Summary of Notifiable Diseases (SoND) is an annual report containing information on those diseases for which \u201cregular, frequent, and timely information regarding individual cases is considered necessary for the prevention and control of the disease or condition\u201d, a list of which is updated regularly by the CDC.", [["the disease or condition", "PROBLEM", 241, 265]]], ["Viruses reported in the SoND include hepatitis A virus, West Nile virus, and Dengue virus [20].", [["hepatitis A", "DISEASE", 37, 48], ["Dengue virus", "DISEASE", 77, 89], ["SoND", "ORGANISM", 24, 28], ["hepatitis A virus", "ORGANISM", 37, 54], ["West Nile virus", "ORGANISM", 56, 71], ["Dengue virus", "ORGANISM", 77, 89], ["hepatitis A virus", "SPECIES", 37, 54], ["West Nile virus", "SPECIES", 56, 71], ["Dengue virus", "SPECIES", 77, 89], ["hepatitis A virus", "SPECIES", 37, 54], ["West Nile virus", "SPECIES", 56, 71], ["Dengue virus", "SPECIES", 77, 89], ["Viruses", "PROBLEM", 0, 7], ["hepatitis A virus", "PROBLEM", 37, 54], ["West Nile virus", "PROBLEM", 56, 71], ["Dengue virus", "PROBLEM", 77, 89], ["hepatitis", "OBSERVATION", 37, 46]]], ["The CDC also maintains the National Outbreak Reporting System (NORS), which includes information on the number of disease cases and outbreaks for a number of infectious agents, including norovirus, rotavirus, and sapovirus.", [["norovirus, rotavirus, and sapovirus", "DISEASE", 187, 222], ["norovirus", "ORGANISM", 187, 196], ["rotavirus", "ORGANISM", 198, 207], ["rotavirus", "SPECIES", 198, 207], ["infectious agents", "TREATMENT", 158, 175], ["norovirus", "PROBLEM", 187, 196], ["rotavirus", "PROBLEM", 198, 207], ["sapovirus", "PROBLEM", 213, 222]]], ["Influenza statistics are reported most frequently by the CDC via published FluView Weekly Influenza Surveillance Reports, documenting the number of cases of influenza and influenza-like illnesses in the United States.", [["Influenza", "DISEASE", 90, 99], ["influenza", "DISEASE", 157, 166], ["influenza-like illnesses", "DISEASE", 171, 195], ["Influenza statistics", "PROBLEM", 0, 20], ["influenza", "PROBLEM", 157, 166], ["influenza", "PROBLEM", 171, 180], ["influenza", "OBSERVATION", 157, 166]]], ["Each of these sources includes both monthly and geographic data regarding disease cases.", [["disease cases", "PROBLEM", 74, 87]]], ["This allows for the analysis of viral disease trends on both a temporal and spatial basis, many of which are unique from one virus to another [[20], [21], [22], [23], [24], [25], [26]].Viruses of concernViruses that infect humans can be both specific to humans and zoonotic in nature.", [["[[20], [21], [22], [23], [24], [25], [26]]", "SIMPLE_CHEMICAL", 142, 184], ["concernViruses", "GENE_OR_GENE_PRODUCT", 196, 210], ["humans", "ORGANISM", 223, 229], ["humans", "ORGANISM", 254, 260], ["humans", "SPECIES", 223, 229], ["humans", "SPECIES", 254, 260], ["humans", "SPECIES", 223, 229], ["humans", "SPECIES", 254, 260], ["the analysis", "TEST", 16, 28], ["viral disease trends", "PROBLEM", 32, 52], ["Viruses of concernViruses", "PROBLEM", 185, 210], ["viral disease", "OBSERVATION", 32, 45], ["zoonotic", "OBSERVATION_MODIFIER", 265, 273]]], ["Human viruses are categorized as those that exclusively infect humans and are transmissible from the environment to humans or from human to human.", [["Human", "ORGANISM", 0, 5], ["humans", "ORGANISM", 63, 69], ["humans", "ORGANISM", 116, 122], ["human", "ORGANISM", 131, 136], ["human", "ORGANISM", 140, 145], ["Human", "SPECIES", 0, 5], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 116, 122], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 140, 145], ["Human viruses", "SPECIES", 0, 13], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 116, 122], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 140, 145], ["Human viruses", "TREATMENT", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["Zoonotic viruses, meanwhile, are defined as viruses \u201cwhich are naturally transmitted between vertebrate animals and man\u201d [27].", [["man", "SPECIES", 116, 119], ["Zoonotic viruses", "PROBLEM", 0, 16]]], ["Zoonotic viruses can also be further split into direct and indirect categories.", [["Zoonotic viruses", "TREATMENT", 0, 16]]], ["Direct zoonoses involve infection via direct contact between humans and animals, such as skin contact, a bite, or ingestion of tissue.", [["skin", "ANATOMY", 89, 93], ["tissue", "ANATOMY", 127, 133], ["zoonoses", "DISEASE", 7, 15], ["infection", "DISEASE", 24, 33], ["humans", "ORGANISM", 61, 67], ["skin", "ORGAN", 89, 93], ["tissue", "TISSUE", 127, 133], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67], ["infection", "PROBLEM", 24, 33], ["ingestion of tissue", "PROBLEM", 114, 133], ["infection", "OBSERVATION", 24, 33], ["skin", "ANATOMY", 89, 93]]], ["Indirect zoonoses, meanwhile, require a vector or vehicle for transmission of the virus between humans and animals [27].Viruses of concernViruses can also be divided to categories based on their water-related transmission potential.", [["zoonoses", "DISEASE", 9, 17], ["humans", "ORGANISM", 96, 102], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["a vector or vehicle", "TREATMENT", 38, 57], ["Viruses of concernViruses", "PROBLEM", 120, 145], ["zoonoses", "OBSERVATION", 9, 17]]], ["This classification was put forth by Bradley (1977), splitting water-related infections into four main categories: water-washed infections (diseases arising from poor hygiene) and water-based infections (infections from worm parasites that spend their life cycle in an aquatic environment), as well as waterborne infections and infections with water-related insect vectors, the latter two designations being most relevant when discussing water-related viruses [[27], [28], [29]].", [["infections", "DISEASE", 77, 87], ["infections", "DISEASE", 128, 138], ["infections", "DISEASE", 192, 202], ["infections", "DISEASE", 204, 214], ["waterborne infections", "DISEASE", 302, 323], ["infections", "DISEASE", 328, 338], ["[27], [28]", "SIMPLE_CHEMICAL", 461, 471], ["washed infections (diseases", "PROBLEM", 121, 148], ["water-based infections (infections", "PROBLEM", 180, 214], ["worm parasites", "PROBLEM", 220, 234], ["waterborne infections", "PROBLEM", 302, 323], ["infections", "PROBLEM", 328, 338], ["water-related insect vectors", "TREATMENT", 344, 372], ["infections", "OBSERVATION", 192, 202], ["infections", "OBSERVATION", 313, 323]]], ["The foremost category is that of waterborne viruses, in which a virus is present in water and infection occurs via ingestion of the contaminated water source.", [["waterborne viruses", "DISEASE", 33, 51], ["infection", "DISEASE", 94, 103], ["waterborne viruses", "PROBLEM", 33, 51], ["a virus", "PROBLEM", 62, 69], ["infection", "PROBLEM", 94, 103], ["waterborne viruses", "OBSERVATION", 33, 51], ["virus", "OBSERVATION", 64, 69], ["infection", "OBSERVATION", 94, 103]]], ["Waterborne viruses will often enter the water source due to fecal contamination, making waste and wastewater management a critical pathway for tracking the spread of viral waterborne disease.", [["viral waterborne disease", "DISEASE", 166, 190], ["fecal", "ORGANISM_SUBSTANCE", 60, 65], ["Waterborne viruses", "PROBLEM", 0, 18], ["fecal contamination", "PROBLEM", 60, 79], ["wastewater management", "TREATMENT", 98, 119], ["a critical pathway", "TREATMENT", 120, 138], ["viral waterborne disease", "PROBLEM", 166, 190], ["viruses", "OBSERVATION", 11, 18], ["fecal", "ANATOMY", 60, 65], ["contamination", "OBSERVATION", 66, 79], ["viral waterborne disease", "OBSERVATION", 166, 190]]], ["The second important category of water-related viruses are those with water-related insect vectors [27].", [["related viruses", "PROBLEM", 39, 54], ["water-related insect vectors", "TREATMENT", 70, 98]]], ["This includes viruses transmitted by insects that breed in water, such as mosquitos, which carry numerous significant human viruses, such as Zika virus and West Nile virus.", [["mosquitos", "GENE_OR_GENE_PRODUCT", 74, 83], ["human", "ORGANISM", 118, 123], ["Zika virus", "ORGANISM", 141, 151], ["West Nile virus", "ORGANISM", 156, 171], ["human", "SPECIES", 118, 123], ["Zika virus", "SPECIES", 141, 151], ["West Nile virus", "SPECIES", 156, 171], ["human viruses", "SPECIES", 118, 131], ["Zika virus", "SPECIES", 141, 151], ["West Nile virus", "SPECIES", 156, 171], ["viruses", "PROBLEM", 14, 21], ["numerous significant human viruses", "PROBLEM", 97, 131], ["Zika virus", "PROBLEM", 141, 151], ["West Nile virus", "PROBLEM", 156, 171], ["viruses", "OBSERVATION", 14, 21], ["significant", "OBSERVATION_MODIFIER", 106, 117], ["human viruses", "OBSERVATION", 118, 131]]], ["In areas where primary water sources may be infested with these insect vectors, this is critical pathway for the spread of viral disease.", [["viral disease", "DISEASE", 123, 136], ["these insect vectors", "TREATMENT", 58, 78], ["viral disease", "PROBLEM", 123, 136], ["viral disease", "OBSERVATION", 123, 136]]], ["Finally, another potential transmission pathway for water-related disease is the aerosolization of contaminated water [27,30], in which viruses capable of respiratory transmission are inhaled following aerosolization.Viruses of concernWith these categories of zoonotic and water-related viruses in place, there is potential for crossover among them; some viruses may be both zoonotic and water-related.", [["respiratory", "ANATOMY", 155, 166], ["zoonotic and water-related viruses", "DISEASE", 260, 294], ["water-related disease", "PROBLEM", 52, 73], ["the aerosolization of contaminated water", "TREATMENT", 77, 117], ["respiratory transmission", "TREATMENT", 155, 179], ["some viruses", "PROBLEM", 350, 362], ["respiratory transmission", "OBSERVATION", 155, 179], ["zoonotic", "OBSERVATION_MODIFIER", 260, 268], ["viruses", "OBSERVATION", 355, 362]]], ["In a report on waterborne zoonoses in 2004, WHO put forth criteria for determining if a pathogen meets these qualifications: the pathogen must spend part of its life cycle within animal species, it is probable the pathogen will have a life stage that will enter water, and transmission of the pathogen between humans and animals must be through a water-related route.", [["waterborne zoonoses", "DISEASE", 15, 34], ["humans", "ORGANISM", 310, 316], ["humans", "SPECIES", 310, 316], ["humans", "SPECIES", 310, 316], ["a pathogen", "PROBLEM", 86, 96], ["the pathogen", "PROBLEM", 125, 137], ["the pathogen", "PROBLEM", 210, 222]]], ["If a virus meets all of these, it can be classified as a zoonotic water-related virus.Viruses of concernTable 1 lists several human viruses of concern (including all viruses included in SoND) and classifies them according to the aforementioned categories.", [["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["a virus", "PROBLEM", 3, 10], ["a zoonotic water-related virus", "PROBLEM", 55, 85]]], ["As mentioned above, a primary exposure pathway to viral disease for humans is wastewater.", [["viral disease", "DISEASE", 50, 63], ["humans", "ORGANISM", 68, 74], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["a primary exposure pathway", "TREATMENT", 20, 46], ["viral disease", "PROBLEM", 50, 63], ["viral disease", "OBSERVATION", 50, 63]]], ["The ability to detect viruses in wastewater is therefore critical for investigation via One-Health, and this information is also summarized in Table 1.", [["viruses", "PROBLEM", 22, 29], ["viruses", "OBSERVATION", 22, 29]]], ["As noted in the table, several of these viruses fall under multiple categories, being both water-related and zoonotic.", [["these viruses fall", "PROBLEM", 34, 52], ["viruses", "OBSERVATION", 40, 47]]], ["For instance, enteroviruses, hepatitis E virus, and rotaviruses are all classified as waterborne viruses, and each of them has been reported to have potential zoonotic properties as well, as cases of these viruses have been observed in animals [27].", [["enteroviruses", "DISEASE", 14, 27], ["hepatitis E", "DISEASE", 29, 40], ["waterborne viruses", "DISEASE", 86, 104], ["enteroviruses", "ORGANISM", 14, 27], ["hepatitis E virus", "ORGANISM", 29, 46], ["hepatitis E virus", "SPECIES", 29, 46], ["hepatitis E virus", "SPECIES", 29, 46], ["enteroviruses", "PROBLEM", 14, 27], ["hepatitis E virus", "PROBLEM", 29, 46], ["rotaviruses", "PROBLEM", 52, 63], ["these viruses", "PROBLEM", 200, 213], ["enteroviruses", "OBSERVATION", 14, 27]]], ["Additionally, a number of viruses are zoonotic due to their transmission between mosquitos and humans, such as West Nile virus, Zika virus, and Dengue virus [[31], [32], [33]].", [["Dengue virus", "DISEASE", 144, 156], ["mosquitos", "CANCER", 81, 90], ["humans", "ORGANISM", 95, 101], ["West Nile virus", "ORGANISM", 111, 126], ["Zika virus", "ORGANISM", 128, 138], ["Dengue virus", "ORGANISM", 144, 156], ["humans", "SPECIES", 95, 101], ["West Nile virus", "SPECIES", 111, 126], ["Zika virus", "SPECIES", 128, 138], ["Dengue virus", "SPECIES", 144, 156], ["humans", "SPECIES", 95, 101], ["West Nile virus", "SPECIES", 111, 126], ["Zika virus", "SPECIES", 128, 138], ["Dengue virus", "SPECIES", 144, 156], ["viruses", "PROBLEM", 26, 33], ["zoonotic", "PROBLEM", 38, 46], ["their transmission between mosquitos and humans", "PROBLEM", 54, 101], ["West Nile virus", "PROBLEM", 111, 126], ["Zika virus", "PROBLEM", 128, 138], ["Dengue virus", "PROBLEM", 144, 156], ["viruses", "OBSERVATION", 26, 33]]], ["Zoonotic diseases comprise approximately 64% of all human pathogens, with viruses accounting for 5% of pathogens [34].", [["Zoonotic diseases", "DISEASE", 0, 17], ["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Zoonotic diseases", "PROBLEM", 0, 17], ["all human pathogens", "PROBLEM", 48, 67], ["viruses", "PROBLEM", 74, 81], ["pathogens", "PROBLEM", 103, 112]]], ["Zoonoses are also responsible for 26% of the disease burden in low-income countries, whereas they only account for 0.7% in wealthier nations [35].Viruses of concernMoreover, many of the viruses listed in Table 1 have been reported as detected in wastewater or human excrement.", [["Zoonoses", "DISEASE", 0, 8], ["human", "ORGANISM", 260, 265], ["human", "SPECIES", 260, 265], ["human", "SPECIES", 260, 265], ["Zoonoses", "TREATMENT", 0, 8], ["the disease burden", "PROBLEM", 41, 59], ["disease", "OBSERVATION", 45, 52], ["viruses", "OBSERVATION", 186, 193]]], ["This is important as it signifies that these viruses are present or potentially present in aquatic pathways.", [["these viruses", "PROBLEM", 39, 52], ["viruses", "OBSERVATION", 45, 52]]], ["This is true even for viruses that are not typically designated as waterborne or water-related, such as influenza, herpesvirus, and papillomavirus.Viruses of concernRegarding animal viruses of concern, the U.S. Department of Agriculture (USDA) issues annual reports of the domestic status of reportable diseases put forth by the World Organization for Animal Health (OIE) [53].", [["influenza, herpesvirus, and papillomavirus", "DISEASE", 104, 146], ["herpesvirus", "ORGANISM", 115, 126], ["papillomavirus", "ORGANISM", 132, 146], ["viruses", "PROBLEM", 22, 29], ["influenza", "PROBLEM", 104, 113], ["herpesvirus", "PROBLEM", 115, 126], ["papillomavirus", "PROBLEM", 132, 146], ["reportable diseases", "PROBLEM", 292, 311], ["viruses", "OBSERVATION", 22, 29], ["viruses", "OBSERVATION", 182, 189]]], ["Table 2 summarizes livestock viral diseases that were reported as present in the United States by the USDA.", [["viral diseases", "DISEASE", 29, 43], ["livestock viral diseases", "PROBLEM", 19, 43], ["viral diseases", "OBSERVATION", 29, 43]]], ["Many of the same viral families that affect humans are represented in this list, including Coronaviridae, Flaviviridae, Herpesviridae, Orthomyxoviridae, and Reoviridae.", [["humans", "ORGANISM", 44, 50], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 91, 104], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 120, 133], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 135, 151], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 157, 167], ["humans", "SPECIES", 44, 50], ["humans", "SPECIES", 44, 50], ["Coronaviridae", "TREATMENT", 91, 104], ["Flaviviridae", "TREATMENT", 106, 118], ["Herpesviridae", "TREATMENT", 120, 133], ["Orthomyxoviridae", "TREATMENT", 135, 151], ["Reoviridae", "TREATMENT", 157, 167]]], ["A few of the reportable viral animal diseases are also considered zoonotic, which are of even greater significance to human health.Viruses of concernThe USDA also collects and maintains disease data for domesticated, agricultural, and wild animals, primarily via the National Animal Health Surveillance System (NAHSS).", [["viral animal diseases", "DISEASE", 24, 45], ["human", "ORGANISM", 118, 123], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 118, 123], ["the reportable viral animal diseases", "PROBLEM", 9, 45], ["zoonotic", "PROBLEM", 66, 74], ["few", "OBSERVATION_MODIFIER", 2, 5], ["viral animal diseases", "OBSERVATION", 24, 45], ["disease", "OBSERVATION", 186, 193]]], ["A number of viruses are investigated via NAHSS for various animals, including influenza A virus in swine [64], and herpesvirus and West Nile virus in horses [65,66].", [["influenza A virus", "DISEASE", 78, 95], ["influenza A virus", "ORGANISM", 78, 95], ["swine", "ORGANISM", 99, 104], ["herpesvirus", "ORGANISM", 115, 126], ["West Nile virus", "ORGANISM", 131, 146], ["horses", "ORGANISM", 150, 156], ["influenza A virus", "SPECIES", 78, 95], ["swine", "SPECIES", 99, 104], ["West Nile virus", "SPECIES", 131, 146], ["influenza A virus", "SPECIES", 78, 95], ["swine", "SPECIES", 99, 104], ["West Nile virus", "SPECIES", 131, 146], ["viruses", "PROBLEM", 12, 19], ["various animals", "PROBLEM", 51, 66], ["influenza A virus", "PROBLEM", 78, 95], ["herpesvirus", "PROBLEM", 115, 126], ["viruses", "OBSERVATION", 12, 19]]], ["Annual reports regarding cases of equine West Nile virus in domesticated horses are published via NAHSS, making them a useful comparison to reported human cases of West Nile virus [66].", [["equine", "ORGANISM", 34, 40], ["West Nile virus", "ORGANISM", 41, 56], ["horses", "ORGANISM", 73, 79], ["human", "ORGANISM", 149, 154], ["West Nile virus", "ORGANISM", 164, 179], ["equine", "SPECIES", 34, 40], ["West Nile virus", "SPECIES", 41, 56], ["human", "SPECIES", 149, 154], ["West Nile virus", "SPECIES", 164, 179], ["West Nile virus", "SPECIES", 41, 56], ["human", "SPECIES", 149, 154], ["West Nile virus", "SPECIES", 164, 179]]], ["In addition to domesticated animals, wild animals are also an important consideration, as wildlife has been shown to be a source of disease to both livestock and humans [62].One-health methodology: current statusThe One-Health approach has recently been applied to combat zoonotic viral disease, spearheaded by the veterinary community.", [["zoonotic viral disease", "DISEASE", 272, 294], ["humans", "ORGANISM", 162, 168], ["humans", "SPECIES", 162, 168], ["humans", "SPECIES", 162, 168], ["disease", "PROBLEM", 132, 139], ["The One-Health approach", "TREATMENT", 212, 235], ["zoonotic viral disease", "PROBLEM", 272, 294], ["viral disease", "OBSERVATION", 281, 294]]], ["Viral infection in humans can be prevented with the use of vaccinations, a common practice for a number of viruses for which vaccines have been developed, including influenza [67], poliovirus [68], and rotavirus [18,69].", [["Viral infection", "DISEASE", 0, 15], ["influenza", "DISEASE", 165, 174], ["Viral", "ORGANISM", 0, 5], ["humans", "ORGANISM", 19, 25], ["influenza [67]", "ORGANISM", 165, 179], ["poliovirus", "ORGANISM", 181, 191], ["rotavirus", "ORGANISM", 202, 211], ["humans", "SPECIES", 19, 25], ["humans", "SPECIES", 19, 25], ["Viral infection in humans", "PROBLEM", 0, 25], ["vaccinations", "TREATMENT", 59, 71], ["viruses", "PROBLEM", 107, 114], ["vaccines", "TREATMENT", 125, 133], ["influenza", "PROBLEM", 165, 174], ["poliovirus", "TEST", 181, 191], ["rotavirus", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 6, 15]]], ["Vaccines are known to lessen the disease burden in a population both by preventing infection and promoting herd immunity [70].One-health methodology: current statusIn cases for which the pathway to human infection has an intermediary animal vector between the host organism and humans, the vaccination of the intermediary animal could also prove vital.", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 204, 213], ["herd", "ORGANISM_SUBDIVISION", 107, 111], ["human", "ORGANISM", 198, 203], ["humans", "ORGANISM", 278, 284], ["human", "SPECIES", 198, 203], ["humans", "SPECIES", 278, 284], ["human", "SPECIES", 198, 203], ["humans", "SPECIES", 278, 284], ["Vaccines", "TREATMENT", 0, 8], ["the disease burden", "PROBLEM", 29, 47], ["infection", "PROBLEM", 83, 92], ["human infection", "PROBLEM", 198, 213], ["disease", "OBSERVATION", 33, 40], ["infection", "OBSERVATION", 83, 92], ["infection", "OBSERVATION", 204, 213], ["host organism", "OBSERVATION", 260, 273]]], ["This was performed in one of the most successful One-Health implementations to date, for a Hendra virus outbreak in Australia.", [["Hendra virus", "DISEASE", 91, 103], ["Hendra virus", "ORGANISM", 91, 103], ["Hendra virus", "SPECIES", 91, 103], ["a Hendra virus outbreak", "PROBLEM", 89, 112]]], ["Hendra virus is one of several zoonotic viruses, including Nipah virus, Tioman virus, and lyssavirus, that originate in bats.", [["Hendra virus", "DISEASE", 0, 12], ["zoonotic viruses", "DISEASE", 31, 47], ["Nipah virus", "DISEASE", 59, 70], ["Hendra virus", "ORGANISM", 0, 12], ["Nipah virus", "ORGANISM", 59, 70], ["Tioman virus", "ORGANISM", 72, 84], ["Hendra virus", "SPECIES", 0, 12], ["Nipah virus", "SPECIES", 59, 70], ["Tioman virus", "SPECIES", 72, 84], ["Hendra virus", "SPECIES", 0, 12], ["Nipah virus", "SPECIES", 59, 70], ["Tioman virus", "SPECIES", 72, 84], ["Hendra virus", "PROBLEM", 0, 12], ["several zoonotic viruses", "PROBLEM", 23, 47], ["Nipah virus", "PROBLEM", 59, 70], ["Tioman virus", "TREATMENT", 72, 84], ["lyssavirus", "TREATMENT", 90, 100], ["virus", "OBSERVATION", 7, 12], ["several", "OBSERVATION_MODIFIER", 23, 30], ["zoonotic", "OBSERVATION_MODIFIER", 31, 39], ["viruses", "OBSERVATION", 40, 47], ["Nipah virus", "OBSERVATION", 59, 70]]], ["It was determined that Hendra virus is first transmitted from bats to horses before being transmitted to humans, and no direct infection between bats and humans was observed.", [["Hendra virus", "DISEASE", 23, 35], ["infection", "DISEASE", 127, 136], ["Hendra virus", "ORGANISM", 23, 35], ["horses", "ORGANISM", 70, 76], ["humans", "ORGANISM", 105, 111], ["bats", "ORGANISM", 145, 149], ["humans", "ORGANISM", 154, 160], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 154, 160], ["Hendra virus", "SPECIES", 23, 35], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 154, 160], ["Hendra virus", "PROBLEM", 23, 35], ["direct infection between bats and humans", "PROBLEM", 120, 160], ["Hendra virus", "OBSERVATION", 23, 35], ["infection", "OBSERVATION", 127, 136]]], ["Therefore, a Hendra virus vaccine was developed for horses in order to eliminate the transmission route to humans [71].One-health methodology: current statusOn different occasions the strategy is to eliminate or lessen the disease vector responsible for transmission of the disease to humans; for example, mosquito control strategies can be utilized to lessen the burden of West Nile virus, Zika virus, and other viruses for which mosquitos are the primary transmission vector.", [["Hendra virus", "ORGANISM", 13, 25], ["horses", "ORGANISM", 52, 58], ["humans", "ORGANISM", 107, 113], ["humans", "ORGANISM", 285, 291], ["West Nile virus", "ORGANISM", 374, 389], ["Zika virus", "ORGANISM", 391, 401], ["mosquitos", "CANCER", 431, 440], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 285, 291], ["West Nile virus", "SPECIES", 374, 389], ["Zika virus", "SPECIES", 391, 401], ["Hendra virus", "SPECIES", 13, 25], ["horses", "SPECIES", 52, 58], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 285, 291], ["West Nile virus", "SPECIES", 374, 389], ["Zika virus", "SPECIES", 391, 401], ["a Hendra virus vaccine", "TREATMENT", 11, 33], ["the disease vector", "PROBLEM", 219, 237], ["the disease to humans", "PROBLEM", 270, 291], ["mosquito control strategies", "TREATMENT", 306, 333], ["West Nile virus", "PROBLEM", 374, 389], ["Zika virus", "PROBLEM", 391, 401], ["other viruses", "PROBLEM", 407, 420], ["disease", "OBSERVATION", 274, 281]]], ["Chemical methods of mosquito control (such as insecticides, insect growth regulators, and sprays) are commonly used, though these methods could also have an adverse effect on the health of humans, animals, and the surrounding environment, which are of important consideration to the One-Health approach.", [["humans", "ORGANISM", 189, 195], ["humans", "SPECIES", 189, 195], ["humans", "SPECIES", 189, 195], ["mosquito control", "TREATMENT", 20, 36]]], ["More \u201ceco-friendly\u201d options are also recently in use, such as sterile insect techniques and plant-based non-harmful mosquitocidals [72].", [["sterile insect techniques", "TREATMENT", 62, 87]]], ["A One-Health approach has been shown in the past to be effective at reducing costs and improving efficiency in the mitigation of Rift Valley fever virus to improve public health [73].One-health methodology: current statusSmaller-scale policy changes that focus on particular viruses could also help to curb the spread of viral disease.", [["Rift Valley fever", "DISEASE", 129, 146], ["viral disease", "DISEASE", 321, 334], ["Rift Valley fever virus", "ORGANISM", 129, 152], ["Rift Valley fever virus", "SPECIES", 129, 152], ["Rift Valley fever virus", "SPECIES", 129, 152], ["improving efficiency", "PROBLEM", 87, 107], ["Rift Valley fever virus", "PROBLEM", 129, 152], ["particular viruses", "PROBLEM", 264, 282], ["viral disease", "PROBLEM", 321, 334], ["viral disease", "OBSERVATION", 321, 334]]], ["For example, after it was determined that bats were the host species and civets the transmittance vector species for SARS coronavirus, affected areas (such as China) enacted bans on civet trading and the mixing of bats with other species in local markets [71].", [["SARS coronavirus", "DISEASE", 117, 133], ["SARS coronavirus", "ORGANISM", 117, 133], ["SARS coronavirus", "SPECIES", 117, 133], ["the host species", "PROBLEM", 52, 68], ["the transmittance vector species", "PROBLEM", 80, 112], ["SARS coronavirus", "PROBLEM", 117, 133], ["affected areas", "PROBLEM", 135, 149], ["civet trading", "TREATMENT", 182, 195]]], ["This shows that policies can be created to require the use of interventions to block exposure pathways for particular viruses.", [["interventions to block exposure pathways", "TREATMENT", 62, 102], ["particular viruses", "PROBLEM", 107, 125]]], ["Public education is also a useful approach, utilized with outbreaks of Nipah virus in Malaysia and Bangladesh, in which people were encouraged to avoid direct contact with bats and taking preventative measures to minimize the chances of viral transmission [71].Identification of critical pathways ::: One-health methodology: proposed approach for water-related virusesTo determine critical pathways of exposure the following should be identified: 1) potential sources/reservoirs of viruses in environmental, human and animal systems; 2) natural processes that affect transport within and between systems; 3) human behaviors that affect exposure to viruses, such as management practices for water, wastewater, agricultural waste, human disease determinants, and animal disease determinants.", [["Nipah virus", "DISEASE", 71, 82], ["Nipah virus", "ORGANISM", 71, 82], ["people", "ORGANISM", 120, 126], ["human", "ORGANISM", 508, 513], ["human", "ORGANISM", 608, 613], ["human", "ORGANISM", 729, 734], ["Nipah virus", "SPECIES", 71, 82], ["people", "SPECIES", 120, 126], ["human", "SPECIES", 508, 513], ["human", "SPECIES", 608, 613], ["human", "SPECIES", 729, 734], ["Nipah virus", "SPECIES", 71, 82], ["human", "SPECIES", 508, 513], ["human", "SPECIES", 608, 613], ["human", "SPECIES", 729, 734], ["Nipah virus", "PROBLEM", 71, 82], ["preventative measures", "TREATMENT", 188, 209], ["related viruses", "PROBLEM", 353, 368], ["viruses", "PROBLEM", 482, 489], ["human disease determinants", "PROBLEM", 729, 755], ["animal disease determinants", "PROBLEM", 761, 788], ["Nipah virus", "OBSERVATION", 71, 82], ["viruses", "OBSERVATION", 361, 368], ["animal disease", "OBSERVATION", 761, 775]]], ["The goal of this step is to prioritize the most critical reservoirs and exposure pathways for viruses.", [["viruses", "PROBLEM", 94, 101]]], ["Fig. 3 presents an example of water-related pathways that include urban and rural areas in the US.Identification of critical pathways ::: One-health methodology: proposed approach for water-related virusesThere are several potential pathways by which humans are exposed to waterborne or water-related viruses.", [["humans", "ORGANISM", 251, 257], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["related viruses", "PROBLEM", 190, 205], ["viruses", "OBSERVATION", 198, 205], ["viruses", "OBSERVATION", 301, 308]]], ["Surface water, treated or untreated, may be used as a drinking water source, and there are a number of pathways for viral contamination of surface water.", [["surface", "ANATOMY", 139, 146], ["Surface water", "TREATMENT", 0, 13], ["viral contamination of surface water", "TREATMENT", 116, 152]]], ["In urban areas, combined sewer overflows during high rainfall events can introduce untreated wastewater into surface water bodies.", [["combined sewer overflows", "PROBLEM", 16, 40], ["high rainfall events", "PROBLEM", 48, 68], ["sewer overflows", "OBSERVATION", 25, 40]]], ["In impoverished areas, people often dispose untreated wastewater into surface water bodies that are used elsewhere for drinking water, for example downstream of a river.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["impoverished", "OBSERVATION_MODIFIER", 3, 15], ["areas", "OBSERVATION_MODIFIER", 16, 21]]], ["Even treated wastewater effluent, which is often released into surface water, can contain detectable concentrations of human viruses [75].", [["human", "ORGANISM", 119, 124], ["human", "SPECIES", 119, 124], ["human viruses", "SPECIES", 119, 132], ["human viruses", "PROBLEM", 119, 132], ["wastewater effluent", "OBSERVATION", 13, 32]]], ["Treated or untreated livestock waste and wildlife waste is also washed off the land during precipitation events and can be carried into surface water bodies via runoff, and animal wastes have been shown to be a potential exposure pathway of disease to humans [76].", [["humans", "ORGANISM", 252, 258], ["humans", "SPECIES", 252, 258], ["humans", "SPECIES", 252, 258], ["animal wastes", "TREATMENT", 173, 186]]], ["In addition to ingestion of water, recreational exposure to contaminated surface water, for example in public swimming pools or on public beaches, can be a pathway of viral infection via surface water [77,78].", [["surface", "ANATOMY", 73, 80], ["surface", "ANATOMY", 187, 194], ["viral infection", "DISEASE", 167, 182], ["viral infection", "PROBLEM", 167, 182], ["viral", "OBSERVATION_MODIFIER", 167, 172], ["infection", "OBSERVATION", 173, 182]]], ["For example, in rural areas which dispose of wastewater in private septic systems, the leakage of these septic tanks may allow for the leaching of contaminated wastewater into a groundwater source [79,80].", [["septic", "DISEASE", 67, 73], ["septic", "DISEASE", 104, 110], ["private septic systems", "PROBLEM", 59, 81], ["the leakage", "PROBLEM", 83, 94], ["these septic tanks", "TREATMENT", 98, 116], ["wastewater", "OBSERVATION_MODIFIER", 45, 55], ["septic systems", "OBSERVATION", 67, 81], ["leakage", "OBSERVATION_MODIFIER", 87, 94], ["septic tanks", "OBSERVATION", 104, 116]]], ["Another pathway for exposure to waterborne disease is the consumption of food that has been contaminated during the agricultural process.", [["waterborne disease", "DISEASE", 32, 50], ["waterborne disease", "PROBLEM", 32, 50]]], ["This could be due to irrigation using contaminated water as well as uptake from contaminated soil or sediment.", [["irrigation", "TREATMENT", 21, 31], ["contaminated water", "TREATMENT", 38, 56], ["could be due to", "UNCERTAINTY", 5, 20], ["irrigation", "OBSERVATION", 21, 31], ["sediment", "OBSERVATION", 101, 109]]], ["Biosolids (treated wastewater sludge) are often used as an agricultural soil amendment, and viruses are known to have been detected in these biosolids [14,81].", [["Biosolids", "CHEMICAL", 0, 9], ["Biosolids", "CHEMICAL", 0, 9], ["Biosolids", "SIMPLE_CHEMICAL", 0, 9], ["Biosolids (treated wastewater sludge", "TREATMENT", 0, 36], ["an agricultural soil amendment", "TREATMENT", 56, 86], ["viruses", "PROBLEM", 92, 99]]], ["Manure or livestock is a possible source of contamination, whether it is used as a fertilizer or transported in the agricultural environment [82].", [["Manure", "CHEMICAL", 0, 6], ["contamination", "PROBLEM", 44, 57], ["a fertilizer", "TREATMENT", 81, 93]]], ["Wildlife waste could also contaminate soils and sediments, just as it can contaminate surface water [83].Identification of critical pathways ::: One-health methodology: proposed approach for water-related virusesData collection is crucial to attain preliminary information for the identification of critical pathways for viral transmission.", [["surface", "ANATOMY", 86, 93], ["Wildlife waste", "TREATMENT", 0, 14], ["water-related virusesData collection", "PROBLEM", 191, 227], ["viral transmission", "PROBLEM", 321, 339]]], ["Numerous governmental agencies publish data regarding clinical cases of disease both spatially and temporally.", [["disease", "PROBLEM", 72, 79], ["disease", "OBSERVATION", 72, 79]]], ["Animal disease data can also be collected and analyzed in this manner, but there is a need for an integrated human-animal disease surveillance to assess zoonotic disease occurrence [84].", [["zoonotic disease", "DISEASE", 153, 169], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["Animal disease data", "PROBLEM", 0, 19], ["animal disease surveillance", "TEST", 115, 142], ["zoonotic disease occurrence", "PROBLEM", 153, 180], ["disease", "OBSERVATION", 7, 14]]], ["Numerous factors may contribute to the likelihood of infectious disease in certain areas or time periods, including but not limited to hydrological patterns (e.g. precipitation) [85], land use [86], human/livestock/wildlife population density [87], and others.", [["infectious disease", "DISEASE", 53, 71], ["human", "ORGANISM", 199, 204], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["Numerous factors", "PROBLEM", 0, 16], ["infectious disease", "PROBLEM", 53, 71], ["may contribute to", "UNCERTAINTY", 17, 34], ["infectious", "OBSERVATION", 53, 63]]], ["Potential pathways can be prioritized to determine which are most relevant to the region being studied.", [["Potential pathways", "PROBLEM", 0, 18]]], ["A system of weight factors could be developed to perform prioritization quantitatively with the use of a statistical model.", [["weight factors", "PROTEIN", 12, 26], ["weight factors", "PROBLEM", 12, 26]]], ["For example, the degree of regulation of wastewater, storm-water, and livestock waste could impact the importance placed upon the potential pathways associated to the impact of waste disposal systems.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesThe second step in the framework is to design surveillance systems of the critical environmental reservoirs and pathways that will allow for early detection of outbreaks.", [["livestock waste", "TREATMENT", 70, 85], ["surveillance systems", "TEST", 210, 230], ["related viruses", "PROBLEM", 287, 302], ["surveillance systems", "TEST", 348, 368], ["outbreaks", "PROBLEM", 462, 471], ["degree", "OBSERVATION_MODIFIER", 17, 23], ["wastewater", "OBSERVATION_MODIFIER", 41, 51], ["waste disposal", "OBSERVATION", 177, 191], ["viruses", "OBSERVATION", 295, 302]]], ["The objective is to identify critical times and critical locations for the onset of viral outbreaks.", [["viral outbreaks", "PROBLEM", 84, 99], ["viral outbreaks", "OBSERVATION", 84, 99]]], ["This can be achieved by monitoring viral disease indicators (such as concentrations of viruses or other indicators) in critical reservoirs identified in the previous step.", [["viral disease indicators", "PROBLEM", 35, 59], ["viruses", "PROBLEM", 87, 94]]], ["The approach includes environmental sampling (such as polluted wastewater from a particular population), as well as clinical samples from infected people, livestock and wildlife.", [["people", "ORGANISM", 147, 153], ["people", "SPECIES", 147, 153], ["environmental sampling", "TREATMENT", 22, 44]]], ["Regular monitoring of critical reservoirs will identify peaks in viral concentrations or indicators that in turn can be related to early signals of disease outbreaks.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesThe central premise of the proposed surveillance approach is that community fecal pollution represents a snapshot of the status of public health or livestock health.", [["fecal pollution", "DISEASE", 344, 359], ["fecal", "ORGANISM_SUBSTANCE", 344, 349], ["critical reservoirs", "TREATMENT", 22, 41], ["viral concentrations", "PROBLEM", 65, 85], ["disease outbreaks", "PROBLEM", 148, 165], ["surveillance systems", "TEST", 176, 196], ["related viruses", "PROBLEM", 253, 268], ["community fecal pollution", "PROBLEM", 334, 359], ["viral concentrations", "OBSERVATION", 65, 85], ["disease", "OBSERVATION", 148, 155], ["viruses", "OBSERVATION", 261, 268], ["central", "OBSERVATION_MODIFIER", 272, 279]]], ["Traditional human and livestock disease detection and management systems are based on diagnostic analyses of clinical samples.", [["samples", "ANATOMY", 118, 125], ["human", "ORGANISM", 12, 17], ["samples", "CANCER", 118, 125], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Traditional human and livestock disease detection", "PROBLEM", 0, 49], ["management systems", "TREATMENT", 54, 72], ["diagnostic analyses", "TEST", 86, 105], ["clinical samples", "TEST", 109, 125], ["livestock disease", "OBSERVATION", 22, 39]]], ["Wastewater analysis, manure analysis, or polluted water analysis is equivalent to obtaining and analyzing a community-based urine and fecal sample of the representative sub-watershed.", [["urine", "ANATOMY", 124, 129], ["fecal sample", "ANATOMY", 134, 146], ["urine", "ORGANISM_SUBSTANCE", 124, 129], ["fecal", "ORGANISM_SUBSTANCE", 134, 139], ["Wastewater analysis", "TEST", 0, 19], ["manure analysis", "TEST", 21, 36], ["polluted water analysis", "TEST", 41, 64], ["fecal sample", "TEST", 134, 146], ["fecal", "ANATOMY", 134, 139]]], ["Monitoring temporal changes in pathogen concentration and diversity excreted in a sub-watershed allows early detection of outbreaks (critical moments for the onset of an outbreak).", [["Monitoring temporal changes in pathogen concentration", "PROBLEM", 0, 53], ["pathogen", "OBSERVATION_MODIFIER", 31, 39], ["concentration", "OBSERVATION_MODIFIER", 40, 53], ["diversity", "OBSERVATION_MODIFIER", 58, 67], ["excreted", "OBSERVATION_MODIFIER", 68, 76]]], ["In addition, carefully designed spatial sampling will allow detection of locations where an outbreak may begin to develop and spread (critical locations for the onset of an outbreak).", [["an outbreak", "PROBLEM", 89, 100]]], ["Modeling the fate of pathogens, including shedding rates, transport, growth and inactivation processes in the environmental, are critical for the effectiveness of the proposed method.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesFig.", [["pathogens", "PROBLEM", 21, 30], ["shedding rates", "PROBLEM", 42, 56], ["the proposed method", "TREATMENT", 163, 182], ["related virusesFig", "PROBLEM", 270, 288], ["pathogens", "OBSERVATION", 21, 30], ["virusesFig", "OBSERVATION", 278, 288]]], ["4 presents an example of potential surveillance systems that could be implemented.", [["potential surveillance systems", "TEST", 25, 55]]], ["Urban communities offer a convenient point of sampling at the influent of a wastewater treatment plant.", [["a wastewater treatment plant", "TREATMENT", 74, 102]]], ["Untreated wastewater can be considered as a population sample for the serviced community.", [["wastewater", "OBSERVATION", 10, 20]]], ["Wastewater can therefore be used as an epidemiological tool to help identify potential viral outbreaks.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesThe goal of wastewater-based epidemiology is to sample community wastewater, or polluted water, to identify spikes in concentrations of excreted viruses before clinical cases are reported.", [["Wastewater", "TREATMENT", 0, 10], ["an epidemiological tool", "TEST", 36, 59], ["potential viral outbreaks", "PROBLEM", 77, 102], ["surveillance systems", "TEST", 113, 133], ["related viruses", "PROBLEM", 190, 205], ["excreted viruses", "PROBLEM", 341, 357], ["viruses", "OBSERVATION", 198, 205], ["excreted viruses", "OBSERVATION", 341, 357]]], ["Already employed in Europe to quantify illicit drug use in a population [88,89], wastewater-based epidemiology can also be applied to quantify the approximate concentrations of viruses in the population serviced by a wastewater treatment plant.", [["wastewater", "TREATMENT", 81, 91], ["a wastewater treatment plant", "TREATMENT", 215, 243], ["viruses", "OBSERVATION", 177, 184]]], ["Urban wastewater treatment plants that serve metropolitan areas sometimes have several interceptors at which wastewater is collected.", [["Urban wastewater treatment plants", "TREATMENT", 0, 33]]], ["Sampling at each interceptor and mapping each interceptor to the specific neighborhoods it serves can facilitate virus occurrence data collection representative of each serviced area of the city.", [["Sampling", "TEST", 0, 8]]], ["Should viral concentrations be observed to be higher in one interceptor than the rest, the corresponding serviced area would therefore be of greater concern for a potential viral outbreak.", [["viral concentrations", "PROBLEM", 7, 27], ["a potential viral outbreak", "PROBLEM", 161, 187], ["viral", "OBSERVATION_MODIFIER", 173, 178], ["outbreak", "OBSERVATION", 179, 187]]], ["Sampling in rural areas is more complex and necessitates the determination of where in the environment to sample, which can be based upon watershed modeling and microbial source tracking.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesSeveral factors are of importance to attain reliable data when using wastewater-based epidemiology.", [["Sampling in rural areas", "PROBLEM", 0, 23], ["surveillance systems", "TEST", 197, 217], ["related viruses", "PROBLEM", 274, 289], ["rural", "ANATOMY_MODIFIER", 12, 17], ["more complex", "OBSERVATION_MODIFIER", 27, 39], ["viruses", "OBSERVATION", 282, 289]]], ["Normalization of population is vital to ensure that a significant increase in viral concentration in a wastewater sample does not correspond to an increase in population in the serviced area.", [["a significant increase in viral concentration", "PROBLEM", 52, 97], ["a wastewater sample", "TEST", 101, 120], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["viral concentration", "OBSERVATION", 78, 97], ["increase", "OBSERVATION_MODIFIER", 147, 155], ["population", "OBSERVATION", 159, 169]]], ["This can be performed with the quantification of biomarkers in the wastewater sample, substances that are natural excreted by humans in constant quantities.", [["wastewater sample", "ANATOMY", 67, 84], ["humans", "ORGANISM", 126, 132], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["constant quantities", "OBSERVATION_MODIFIER", 136, 155]]], ["Other factors that need to be considered include shedding rate (the number of viruses excreted by infected humans) and natural degradation (the rate at which viruses degrade in the wastewater environment).", [["humans", "ORGANISM", 107, 113], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 107, 113], ["shedding rate", "PROBLEM", 49, 62], ["natural degradation", "PROBLEM", 119, 138]]], ["Comparison and correlation with clinical data in the surrounding community is also a valuable tool to confirm the credibility of the methodology.Design of surveillance systems ::: One-health methodology: proposed approach for water-related virusesWhile wastewater-based epidemiology can primarily be utilized for the examination of waterborne viruses, it has the potential to be applied to non-waterborne viruses as well, provided those viruses can be detected in wastewater or human waste.", [["waterborne viruses", "DISEASE", 332, 350], ["human", "ORGANISM", 478, 483], ["human", "SPECIES", 478, 483], ["human", "SPECIES", 478, 483], ["clinical data", "TEST", 32, 45], ["surveillance systems", "TEST", 155, 175], ["related viruses", "PROBLEM", 232, 247], ["the examination", "TEST", 313, 328], ["waterborne viruses", "PROBLEM", 332, 350], ["non-waterborne viruses", "PROBLEM", 390, 412], ["viruses", "OBSERVATION", 240, 247], ["viruses", "OBSERVATION", 405, 412]]], ["As shown in Table 1, numerous viruses not typically classified as waterborne meet these criteria, such as influenza, coronavirus, herpesvirus, dengue virus, and Zika virus.", [["influenza, coronavirus, herpesvirus, dengue virus", "DISEASE", 106, 155], ["coronavirus", "ORGANISM", 117, 128], ["herpesvirus", "ORGANISM", 130, 141], ["dengue virus", "ORGANISM", 143, 155], ["Zika virus", "ORGANISM", 161, 171], ["coronavirus", "SPECIES", 117, 128], ["dengue virus", "SPECIES", 143, 155], ["Zika virus", "SPECIES", 161, 171], ["dengue virus", "SPECIES", 143, 155], ["Zika virus", "SPECIES", 161, 171], ["numerous viruses", "PROBLEM", 21, 37], ["influenza", "PROBLEM", 106, 115], ["coronavirus", "PROBLEM", 117, 128], ["herpesvirus", "PROBLEM", 130, 141], ["dengue virus", "PROBLEM", 143, 155], ["Zika virus", "PROBLEM", 161, 171], ["viruses", "OBSERVATION", 30, 37]]], ["Other critical pathways identified in step one (see Fig. 3) could fall under this methodology as well.Intervention approaches ::: One-health methodology: proposed approach for water-related virusesThe third and final step is to design intervention approaches.", [["related viruses", "PROBLEM", 182, 197], ["intervention approaches", "TREATMENT", 235, 258], ["viruses", "OBSERVATION", 190, 197]]], ["These interventions may include: (1) sustainable engineering technologies for human and animal water/wastewater/waste management, (2) medical and veterinary interventions to manage infections, and (3) education of local communities and governance to modify human behavior, current practices and policy based on relationships between environmental health, human health and animal health.Intervention approaches ::: One-health methodology: proposed approach for water-related virusesThe foremost intervention for waterborne viruses is that of drinking water and wastewater treatment facilities.", [["infections", "DISEASE", 181, 191], ["waterborne viruses", "DISEASE", 511, 529], ["human", "ORGANISM", 78, 83], ["human", "ORGANISM", 257, 262], ["human", "ORGANISM", 355, 360], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 355, 360], ["waste management", "TREATMENT", 112, 128], ["medical and veterinary interventions", "TREATMENT", 134, 170], ["infections", "PROBLEM", 181, 191], ["related viruses", "PROBLEM", 466, 481], ["The foremost intervention", "TREATMENT", 481, 506], ["waterborne viruses", "PROBLEM", 511, 529], ["viruses", "OBSERVATION", 474, 481]]], ["Both types of treatment plants provide the most immediate barrier between a drinking water source and consumption and utilize several unit processes, such as filtration and disinfection, to ensure the removal of pathogens, including viruses, from water.", [["treatment plants", "TREATMENT", 14, 30], ["several unit processes", "TREATMENT", 126, 148], ["filtration", "TREATMENT", 158, 168], ["disinfection", "TREATMENT", 173, 185], ["the removal", "TREATMENT", 197, 208], ["pathogens", "PROBLEM", 212, 221], ["viruses", "PROBLEM", 233, 240], ["pathogens", "OBSERVATION", 212, 221]]], ["Both types of treatment plants have been shown to be effective at reducing the concentrations of human viruses from influent to effluent, but it has also been shown that wastewater treatment plants may release viruses in effluent [14,75,[90], [91], [92], [93], [94], [95]].", [["human", "ORGANISM", 97, 102], ["[94]", "SIMPLE_CHEMICAL", 261, 265], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["treatment plants", "TREATMENT", 14, 30], ["human viruses", "PROBLEM", 97, 110], ["wastewater treatment plants", "TREATMENT", 170, 197]]], ["There also exist interventions to prevent non-point-source pollution of water sources.", [["interventions", "TREATMENT", 17, 30], ["water sources", "OBSERVATION", 72, 85]]], ["Similarly, stormwater management is implemented in several states based on multiple strategies [[96], [97], [98], [99]].Intervention approaches ::: One-health methodology: proposed approach for water-related virusesNumerous policy measures in the United States and abroad can be considered examples of the permanent implementation of interventions.", [["stormwater management", "TREATMENT", 11, 32], ["interventions", "TREATMENT", 334, 347], ["stormwater management", "OBSERVATION", 11, 32]]], ["Since the Safe Drinking Water Act in 1974, a number of additional policies have been put into effect to strengthen water quality and prevent disease.", [["disease", "PROBLEM", 141, 148], ["disease", "OBSERVATION", 141, 148]]], ["The EPA sets Maximum Contaminant Levels (MCLs) for several contaminants, including viruses; drinking water treatment facilities are required to attain a 4-log reduction in viral concentration to meet the MCL for viruses [100].", [["EPA", "CHEMICAL", 4, 7], ["EPA", "SIMPLE_CHEMICAL", 4, 7], ["The EPA sets", "TEST", 0, 12], ["Maximum Contaminant Levels", "TEST", 13, 39], ["several contaminants", "PROBLEM", 51, 71], ["viruses", "PROBLEM", 83, 90], ["a 4-log reduction in viral concentration", "TREATMENT", 151, 191], ["viruses", "PROBLEM", 212, 219]]], ["Another example, the Groundwater Rule, was put into effect in 2006 and requires the regular surveillance of groundwater sources that are used for drinking water to ensure that MCLs for pathogens are met [101].", [["MCLs", "GENE_OR_GENE_PRODUCT", 176, 180], ["the Groundwater Rule", "TEST", 17, 37], ["pathogens", "PROBLEM", 185, 194]]], ["There still exists a need, however, for the regulation of animal waste products, especially in rural areas in which animal waste is determined to be a critical pathway for viral transport.Intervention approaches ::: One-health methodology: proposed approach for water-related virusesThe modification of human behavior is also imperative to minimize the transmittance of viral disease along pathways in which interventions cannot be performed for reasons of cost, capability, or convenience.", [["viral disease", "DISEASE", 370, 383], ["human", "ORGANISM", 303, 308], ["human", "SPECIES", 303, 308], ["human", "SPECIES", 303, 308], ["animal waste products", "TREATMENT", 58, 79], ["related viruses", "PROBLEM", 268, 283], ["viral disease", "PROBLEM", 370, 383], ["waste products", "OBSERVATION", 65, 79], ["viruses", "OBSERVATION", 276, 283], ["viral disease", "OBSERVATION", 370, 383]]], ["It is also critical to educate the public to prevent situations in which people are leaving themselves vulnerable to transmission of disease.", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["disease", "PROBLEM", 133, 140], ["disease", "OBSERVATION", 133, 140]]], ["Especially in impoverished, high-risk areas, robust measures should be taken to educate the public on the concept of the critical pathways of transmission of viral disease.ConclusionsViral transmission involves complex systems that include interactions between humans, animals and the environment.", [["viral disease", "DISEASE", 158, 171], ["humans", "ORGANISM", 261, 267], ["humans", "SPECIES", 261, 267], ["humans", "SPECIES", 261, 267], ["viral disease", "PROBLEM", 158, 171], ["complex systems", "PROBLEM", 211, 226], ["viral disease", "OBSERVATION", 158, 171]]], ["Understanding the interactions between the involved human, animal and environmental systems, and the processes within each of the systems, is critical for efficient prevention and minimization of viral outbreaks.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["viral outbreaks", "PROBLEM", 196, 211]]], ["These systems vary in both spatial and temporal scales.", [["These systems", "TEST", 0, 13], ["both", "ANATOMY_MODIFIER", 22, 26], ["temporal", "OBSERVATION_MODIFIER", 39, 47]]], ["For example, urban systems are different than rural systems, and wet weather is different than dry weather with regards to the potential for viral transmission.", [["urban systems", "TEST", 13, 26], ["viral transmission", "PROBLEM", 141, 159], ["different", "OBSERVATION_MODIFIER", 31, 40]]], ["The most important step in the process of understanding water-related transmission is the identification of critical viral reservoirs and critical transport pathways in a certain environment at a certain time.", [["critical viral reservoirs", "TREATMENT", 108, 133]]], ["Much of the One-Health based approaches to manage viral disease that have been utilized thus far have been responsive in order to control existing zoonotic outbreaks.", [["viral disease", "DISEASE", 50, 63], ["viral disease", "PROBLEM", 50, 63], ["zoonotic", "OBSERVATION_MODIFIER", 147, 155], ["outbreaks", "OBSERVATION", 156, 165]]], ["This paper presents a three-step framework utilizing the One-Health approach to mitigate viral disease.", [["viral disease", "DISEASE", 89, 102], ["viral disease", "PROBLEM", 89, 102], ["viral disease", "OBSERVATION", 89, 102]]], ["Next, surveillance systems are designed to monitor these critical pathways to identify the times and locations where viral outbreaks are occurring or likely to occur.", [["surveillance systems", "TEST", 6, 26], ["viral outbreaks", "PROBLEM", 117, 132]]], ["Finally, water-related and other intervention approaches are implemented to mitigate the critical pathways and prevent the spread of viral disease.", [["viral disease", "DISEASE", 133, 146], ["other intervention approaches", "TREATMENT", 27, 56], ["viral disease", "PROBLEM", 133, 146], ["viral disease", "OBSERVATION", 133, 146]]], ["Identification and surveillance of critical pathways of potential exposure can allow early detection of outbreaks at a population level, which is a critical first step for prevention.", [["outbreaks", "PROBLEM", 104, 113]]], ["While it involves the interconnectivity of human, animal, and environmental health, One-Health has still only primarily been embraced by the veterinary community.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48]]], ["More deliberate efforts should be made to encourage environmental professionals to analyze the issues of viral disease through a One-Health lens.", [["viral disease", "DISEASE", 105, 118], ["viral disease", "PROBLEM", 105, 118], ["viral disease", "OBSERVATION", 105, 118]]], ["Only through the extensive participation of all related field stakeholders can One-Health truly reach its potential to mitigate viral disease.", [["viral disease", "DISEASE", 128, 141], ["viral disease", "PROBLEM", 128, 141]]]], "PMC7097140": [["Hosts that lack adaptive immune cells often die of acute infection and it has been presumed that this is due to the lack of an effective adaptive immune response to clear the pathogen.", [["immune cells", "ANATOMY", 25, 37], ["infection", "DISEASE", 57, 66], ["immune cells", "CELL", 25, 37], ["adaptive immune cells", "CELL_TYPE", 16, 37], ["lack adaptive immune cells", "PROBLEM", 11, 37], ["acute infection", "PROBLEM", 51, 66], ["the pathogen", "PROBLEM", 171, 183], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66]]], ["However, in this study the authors show that, following infection, the uncontrolled innate immune response that stems from a lack of T cells may also be the cause of death in immunocompromised hosts.", [["T cells", "ANATOMY", 133, 140], ["infection", "DISEASE", 56, 65], ["death", "DISEASE", 166, 171], ["T cells", "CELL", 133, 140], ["T cells", "CELL_TYPE", 133, 140], ["this study", "TEST", 12, 22], ["infection", "PROBLEM", 56, 65], ["a lack of T cells", "PROBLEM", 123, 140], ["death", "PROBLEM", 166, 171], ["immunocompromised hosts", "PROBLEM", 175, 198], ["infection", "OBSERVATION", 56, 65], ["immunocompromised hosts", "OBSERVATION", 175, 198]]]], "53111f99860d5673173061fb7ba8f694d73ad4b2": [["IntroductionOn December 2019 in Wuhan City (China), several cases of pneumonia of unknown etiology were detected.", [["pneumonia", "DISEASE", 69, 78], ["pneumonia", "PROBLEM", 69, 78], ["pneumonia", "OBSERVATION", 69, 78]]], ["The Chinese Country Office of the World Health Organization was informed and a novel coronavirus (officially named was identified on January 7 th , as the cause of such infection.", [["coronavirus", "DISEASE", 85, 96], ["infection", "DISEASE", 169, 178], ["coronavirus", "ORGANISM", 85, 96], ["a novel coronavirus", "PROBLEM", 77, 96], ["such infection", "PROBLEM", 164, 178], ["infection", "OBSERVATION", 169, 178]]], ["An international alert was issued because an eminent potential for worldwide spread had been recognized.IntroductionAccording to the website Worldometers [10] which features the first figures on China (Wuhan), on January 22 nd there were already 571 confirmed cases and 2 days later there were already 1, 287 with 41 deaths.", [["deaths", "DISEASE", 317, 323], ["worldwide spread", "PROBLEM", 67, 83]]], ["COVID-19 has been shown to be easily spreading and very lethal.", [["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5]]], ["Due to the highly interconnected world we presently live in, the disease quickly spread outside China reaching practically all countries around the world with several different degrees of seriousness.", [["the disease", "PROBLEM", 61, 72], ["seriousness", "PROBLEM", 188, 199], ["disease", "OBSERVATION", 65, 72]]], ["On March 11 th due to the worrying situation the World Health Organization (WHO) declared it a Pandemic.IntroductionThe scientific world community understood it was time for an international effort to provide scientific reliable information to help the world's leaders in the choice of public policies to face the pandemic.", [["Pandemic", "DISEASE", 95, 103], ["pandemic", "OBSERVATION", 314, 322]]], ["On March 16 th a group of about 30 researchers from the London Imperial College published a blunt paper [2] considering the various options of several different public policies measures that should be taken.", [["several different public policies measures", "TREATMENT", 143, 185]]], ["They have analyzed several possibilities varying from total no intervention to complete lockdown of the whole population and they have estimated the number of lives loss in each case.", [["intervention", "TREATMENT", 63, 75]]], ["Among the conclusions drawn from these papers it was clear that no easy choice was available for the governments, and that the main question to be answered was \" What is the optimum equilibrium between saving lives and minimizing the loss to the economy ?\"IntroductionAlthough the motivation for this study is the present situation of the epidemic in Brazil and a try to shed some light on this very crucial dilemma, we understand that the results presented here are general enough to work as a guideline to any other country and city facing the same uncertainties.", [["the loss", "PROBLEM", 230, 238], ["this study", "TEST", 296, 306]]], ["Given the continental size of Brazil and the ongoing local policy of quarantine it seems reasonable to face the problem locally.", [["size", "OBSERVATION_MODIFIER", 22, 26]]], ["At the present moment most of the Brazilian cities, specially the large ones, are fairly well isolated from the others so that a local approach is justified.", [["a local approach", "TREATMENT", 127, 143], ["large", "OBSERVATION_MODIFIER", 66, 71]]], ["We particularly study the case of S\u00e3o Paulo city because it was the Brazilian city where the first case of COVID-19 was diagnosed, it has been under quarantine practically since the beginning of the onset, it presents relatively reliable data on the epidemic and it is the largest and most important city in Brazil.IntroductionThis paper consists of using the logistic mathematical model to the epidemic situation in S\u00e3o Paulo city.", [["COVID-19", "CHEMICAL", 107, 115], ["COVID", "TEST", 107, 112], ["largest", "OBSERVATION_MODIFIER", 273, 280]]], ["We study the situation of the total number of ICU beds in S\u00e3o Paulo and then use the results the quarantine in Wuhan has produced in the decreasing number of cases of infected individuals, to infer similar results to S\u00e3o Paulo considering several levels of strictness of its quarantine model.", [["infected individuals", "PROBLEM", 167, 187], ["infected", "OBSERVATION", 167, 175]]], ["We conclude estimating the time period necessary to decrease the number of infected individuals in order to avoid overwhelming the ICU system of the hospitals network in the city of S\u00e3o Paulo.", [["infected", "OBSERVATION", 75, 83]]], ["In Section 4 we use the data of Wuhan to estimate quantitatively how the strictness of the quarantine regime influences on the decreasing of the parameter r.", [["the quarantine regime", "TREATMENT", 87, 108]]], ["In Section 5 we fit the logistic model to the data of S\u00e3o Paulo and finally in Section 6 we estimate when the total demand for ICU beds reaches 80% of the total number of such beds available and how long it can take to reduce these numbers based on the level of accession of the quarantine regime in the city.", [["ICU beds", "TREATMENT", 127, 135], ["such beds", "TREATMENT", 171, 180], ["these numbers", "TEST", 226, 239], ["the quarantine regime", "TREATMENT", 275, 296]]], ["In Section 7 we summarize the results and present suggestions of public policies to increase the rate of reduction of the number of new infected cases.", [["public policies", "TREATMENT", 65, 80], ["new infected cases", "PROBLEM", 132, 150], ["reduction", "OBSERVATION_MODIFIER", 105, 114], ["new", "OBSERVATION_MODIFIER", 132, 135], ["infected", "OBSERVATION", 136, 144]]], ["The data and theorem used in this study are presented in Section 8.The Logistic Model logThe logistic model (see [4] for more details) has been classically used modeling population growth in a scenario in which the rate of growth is exponentially quick in the beginning, being proportional to the number of the whole population, but it losses strength as it starts getting close to an upper threshold, for instance the natural storage capacity of the environment.", [["The data", "TEST", 0, 8], ["this study", "TEST", 29, 39], ["growth", "OBSERVATION_MODIFIER", 223, 229], ["exponentially", "OBSERVATION_MODIFIER", 233, 246], ["upper threshold", "OBSERVATION_MODIFIER", 385, 400]]], ["Here this idea seems to be very reasonable, for the spread of the total number of infected individuals of COVID-19 is exponentially quick as we see it in the early days, but it is reasonable to believe it will slow down as the number of exposed susceptible individual, not yet infected, decrease.", [["COVID", "TEST", 106, 111], ["infected", "OBSERVATION", 82, 90], ["infected", "OBSERVATION", 277, 285]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["1101 in which t 0 is the time chosen to represent the beginning of the outbreak, I 0 in the number of infected individuals at such an initial time, I = I(t) is the total number of infected individuals up to time t, r is a positive constant of proportion and T is the total number of susceptible exposed individuals.", [["infected", "OBSERVATION", 102, 110], ["infected", "OBSERVATION", 180, 188]]], ["We say that the rate of change in the number of infected individuals is proportion to the number of infected individuals as well as to the number of remaining non-infected individuals.", [["infected individuals", "PROBLEM", 100, 120], ["change", "OBSERVATION_MODIFIER", 24, 30], ["number", "OBSERVATION_MODIFIER", 38, 44], ["infected", "OBSERVATION", 48, 56], ["infected", "OBSERVATION", 100, 108], ["non-infected individuals", "OBSERVATION", 159, 183]]], ["The solution of such equation is broadly known to be:(which was not certified by peer review)(2) ?sol?(which was not certified by peer review)Clearly such a solution is a function of I 0 as well as of T and r.", [["I 0", "PROTEIN", 183, 186], ["The solution of such equation", "TREATMENT", 0, 29]]], ["We do not have any control on the number of cases at time t = 0 but we believe we do have relatively great amount of control on r and T as we shall point out in section 7.", [["great", "OBSERVATION_MODIFIER", 101, 106], ["amount", "OBSERVATION_MODIFIER", 107, 113]]], ["Furthermore we shall be studying the development of the epidemic in a relatively short period of time and very locally so that such approach is easily seen to be efficient.Fitting the Wuhan case to the ModelThe most valuable argument in favor of the use of the logistic model is the extremely nice way it shows to fit the iconic \"closed case\" of the COVID-19 epidemic in Wuhan as we see now.Fitting the Wuhan case to the ModelThroughout this study we shall consider the data for the Chinese city of Wuhan, updated until April 21 st .", [["the COVID", "TEST", 346, 355], ["this study", "TEST", 437, 447], ["epidemic", "OBSERVATION_MODIFIER", 56, 64]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We consider the Chinese quarantine policy used in there and we suppose the strict Chinese laws were so literally followed that the total amount of infected individual was the part of the population susceptible due to working conditions or that deliberately refused to quarantine.", [["the Chinese quarantine policy", "TREATMENT", 12, 41], ["infected", "OBSERVATION", 147, 155]]], ["By April 13 th , Continental China had 83, 607 confirmed cases meanwhile the Hubei province had 67, 803 confirmed cases (see [8] ), mostly in its capital, meaning that Wuhan represents approximately 80% of all the Chinese cases.(which was not certified by peer review)Wuhan has a population T 0 = 11, 08 million people living in a region of 8.494 Km 2 which features a demographic density of 1, 304.45 inhabitants per Km 2 (see [11] ).", [["people", "ORGANISM", 312, 318], ["people", "SPECIES", 312, 318], ["a demographic density", "TEST", 367, 388]]], ["Thus we can consider that the quarantine regime in Wuhan has isolated 99.50% of its whole population.", [["the quarantine regime", "TREATMENT", 26, 47]]], ["Furthermore, the demographic density of the susceptible exposed individuals during the epidemic was approximately 8 individuals per Km 2 .", [["the susceptible exposed individuals", "PROBLEM", 40, 75]]], ["That may have been the reason for the rapid success of the Chinese's public policies.(which was not certified by peer review)We consider the date of January 22 nd as the date of the beginning of the outbreak in Wuhan, with initial value of 571 infected individuals.", [["infected individuals", "PROBLEM", 244, 264]]], ["Furthermore, on April 8 th Wuhan lifted the quarantine restrictions which had been imposed to its population since January 23 rd , so Wuhan can be considered as the first city in the world \"free of COVID-19\".(which was not certified by peer review)We use software Mathematica to estimate the best values for the parameters I 0 , T and r of the logistic model to fit Wunha's data.", [["Wunha's data", "TEST", 366, 378]]], ["I 0 \u2192 1315.32, T \u2192 80875.7, r \u2192 0.224114, so that we get the following function for the total number of infected individuals for China:(which was not certified by peer review)(5) ?I_c?", [["T", "TEST", 15, 16]]], ["I c = 1.09042 \u00d7 10 8 1344.19 + 79777e \u22120.222593t , based on our previous comment we consider that the function of the total number of infected individuals for Wuhan is 80% of the one for the whole China, so we get:(which was not certified by peer review)Also r = 0.2226 indicates the rate of infection in Wuhan.", [["infection", "DISEASE", 292, 301], ["infection", "PROBLEM", 292, 301], ["infection", "OBSERVATION", 292, 301]]], ["Several peculiarities for Wuhan and S\u00e3o Paulo (climate conditions, demographic density, advance preparation for the outbreak) would justify this rate of infection to be different in both cities.", [["infection", "DISEASE", 153, 162], ["advance preparation", "TREATMENT", 88, 107], ["infection", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 153, 162]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020.Remark:We notice that the total number of infected individuals increased drastically on February 12 th , in China, after a change in the official methodology for diagnosing and counting cases, thousands of new cases were added to the total figures (see figure 3 ).", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["infected individuals", "PROBLEM", 315, 335], ["diagnosing", "TEST", 435, 445], ["med", "ANATOMY", 105, 108], ["infected", "OBSERVATION", 315, 323], ["increased", "OBSERVATION_MODIFIER", 336, 345], ["drastically", "OBSERVATION_MODIFIER", 346, 357]]], ["We believe this will cause no problem in our reasoning.The effects of non-pharmaceutical measures in Wuhan from an ongoing perspective quantifWuhanThe quarantine in Wuhan was declared on January 23 rd .", [["problem", "PROBLEM", 30, 37], ["non-pharmaceutical measures", "TREATMENT", 70, 97]]], ["Within about 15 days, around February 5 th , the results started to be felt in the number of new cases of infected individuals (see figure (3)). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020.", [["infected individuals", "PROBLEM", 106, 126], ["The copyright holder", "TREATMENT", 279, 299], ["infected", "OBSERVATION", 106, 114], ["med", "ANATOMY", 183, 186]]], ["As it can be seen the value of r has been decreasing since the beginning of the quarantine period, on January 23 rd , but not enough to be able to cause a decrease in the total amount of infected individuals predicted by the model, T .", [["a decrease", "PROBLEM", 153, 163], ["decreasing", "OBSERVATION_MODIFIER", 42, 52], ["decrease", "OBSERVATION_MODIFIER", 155, 163], ["total", "OBSERVATION_MODIFIER", 171, 176], ["amount", "OBSERVATION_MODIFIER", 177, 183], ["infected", "OBSERVATION", 187, 195]]], ["It is only after February 5 th (exactly, as expected, when the number of new cases start to decrease) that the decreasing in r suffices to cause an effective decrease in T .", [["an effective decrease in T", "PROBLEM", 145, 171], ["decreasing", "OBSERVATION_MODIFIER", 111, 121], ["effective", "OBSERVATION_MODIFIER", 148, 157], ["decrease", "OBSERVATION", 158, 166]]], ["We see that only when the fall of the value of the parameter r is about 58.41% the decrease in the value of T can be noticed.", [["T", "GENE_OR_GENE_PRODUCT", 108, 109], ["decrease", "OBSERVATION_MODIFIER", 83, 91]]], ["Such a consistent decrease in the values of r was only possible due to strict quarantine rules.(which was not certified by peer review)5.", [["consistent", "OBSERVATION_MODIFIER", 7, 17], ["decrease", "OBSERVATION_MODIFIER", 18, 26]]], ["Fitting the model to the data of S\u00e3o Paulo city fittingSampa S\u00e3o Paulo city is Brazilian financial capital and it was the city where the first case of COVID-19 was confirmed in Brazil.", [["COVID", "TEST", 151, 156]]], ["The population of S\u00e3o Paulo city is around 12 million people which puts it into a very nice position to be compared to Wuhan (11.08 million inhabitants).", [["people", "ORGANISM", 54, 60], ["people", "SPECIES", 54, 60], ["population", "OBSERVATION_MODIFIER", 4, 14]]], ["The demographic density of S\u00e3o Paulo though is 7, 398.26 inhabitants/km 2 (according to IBGE's census [9]) about 5.6 times that of Wuhan.(which was not certified by peer review)We have found some very trustable data of the epidemic for the city of S\u00e3o Paulo at the website of the state government (see [6] ).", [["very", "OBSERVATION_MODIFIER", 196, 200], ["trustable", "OBSERVATION", 201, 210]]], ["Yet we question the values of the number of infected individuals in some specific dates in which they are very discrepant from the ones of the previous and following days.", [["infected", "OBSERVATION", 44, 52]]], ["We attribute such distortions to several factors such as under notification, delay on the publication of the screening results as well as weekend and holiday periods.", [["the screening", "TEST", 105, 118]]], ["We believe such punctual discrepancies will not cause any problem in our analysis.(which was not certified by peer review)We now fit the data for the city of S\u00e3o Paulo, updated to April 21 st , (see Section 8) using again software Mathematica.", [["such punctual discrepancies", "PROBLEM", 11, 38], ["our analysis", "TEST", 69, 81]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.1101/2020.05.06.20093666 doi: medRxiv preprint (7) curve I sp (t) = 163133 12.9213 + 12612.2e \u22120.147662t , which means r = 0.147662 and T \u2248 12625.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We plot the graphic of the above function together with the official data obtained for S\u00e3o Paulo (see figure 4) to see that the matching is reasonably good: (7) and software Mathematica we have computed when the total number of infected individuals of a period of 15 consecutive days reaches 3, 840, for then, 30% of it: 1, 152 would represent 80% of all the available ICU beds putting under alert the health ICU system.", [["ICU beds", "TREATMENT", 369, 377], ["infected", "OBSERVATION", 228, 236]]], ["In figure (5) it is shown the period of time such a number of infected (minus the total number of casualties: 1114 ) is above 3, 840 individuals.", [["infected", "OBSERVATION", 62, 70]]], ["If non public more strict intervention is taken the total amount of simultaneously infected individual shall grow up to 6, 000 leading the number of total demand for ICU treatment to reach 1, 800 before it starts to decrease, causing total chaos in the system.(which was not certified by peer review)We now present a study of how the public policies can help speed up the reduction of such figures.", [["strict intervention", "TREATMENT", 19, 38], ["ICU treatment", "TREATMENT", 166, 179], ["total chaos in the system", "PROBLEM", 234, 259], ["a study", "TEST", 315, 322], ["infected", "OBSERVATION", 83, 91]]], ["We do our analysis considering the actions as if they were taken yesterday, April 21 st , the 56 th day from the beginning of the outbreak of the epidemic in S\u00e3o Paulo, because it is necessary to have updated data in order to .", [["our analysis", "TEST", 6, 18]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Therefore in order to decrease T from 6, 000 to, say, 5, 800 we need a reduction in r of approximately 0.0011302, (were this action taken around April 21 st ).", [["a reduction", "TREATMENT", 69, 80]]], ["But the current value of r is r = r 0 = 0.14766.", [["the current value", "TEST", 4, 21]]], ["Thus such a decrease represents a reduction of 0.76% in the value of the parameter r.(which was not certified by peer review)6.2.", [["a reduction", "TREATMENT", 32, 43], ["decrease", "OBSERVATION_MODIFIER", 12, 20], ["reduction", "OBSERVATION_MODIFIER", 34, 43]]], ["Estimating the necessary period of time for an specific reduction in the size of r.", [["r.", "SPECIES", 81, 83], ["an specific reduction", "TREATMENT", 44, 65], ["reduction", "OBSERVATION_MODIFIER", 56, 65], ["size", "OBSERVATION_MODIFIER", 73, 77], ["r.", "ANATOMY", 81, 83]]], ["So, what we must do first is to fit together the Wuhan and the S\u00e3o Paulo curves so that both curves can represent similar events at similar dates and after that quantify how long it took for the Chineses to get the reduction we want (0.76% in the value of r) at that .", [["the reduction", "TREATMENT", 211, 224]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["So the epidemic in S\u00e3o Paulo is in approximately 35 days of delay in relation to Wuhan (which first information of infected individuals is of 571 cases and it was done on January 22 nd (see [10] ).", [["epidemic", "OBSERVATION_MODIFIER", 7, 15]]], ["On the other hand the number of infected in S\u00e3o Paulo at time t 0 was just 1 individual.", [["infected", "OBSERVATION", 32, 40]]], ["These differences of initial date and data does cause a big difference in the real dates and in the order of magnitude of the figures concerning Wuhan and S\u00e3o Paulo so that we shall include 2 \"adjusting parameters\", \u00b5 0 and K in order to better compare both data.", [["a big difference", "PROBLEM", 54, 70]]], ["This demands us to use the norm of the C 1 -space, i.e. the space of functions with continuous first derivatives.", [["continuous first derivatives", "TREATMENT", 84, 112]]], ["Such a norm is given by:(which was not certified by peer review)In figure (Figure (6) ) we have plotted the values of the norms of the difference, I sp \u2212 I c for values of \u00b5 \u2208 (0.08, 0.085) and K \u2208 (5, 100, 6, 500).", [["sp \u2212 I c", "GENE_OR_GENE_PRODUCT", 149, 157], ["I c", "PROTEIN", 154, 157], ["values", "TEST", 162, 168], ["K \u2208", "TEST", 194, 197]]], ["After refining such analysis we have found the optimum values to be \u00b5 0 = 0.08 and K = 5, 925.", [["refining such analysis", "TEST", 6, 28], ["the optimum values", "TEST", 43, 61], ["K", "TEST", 83, 84]]], ["In figure (7) we have plotted both graphics to see how well they match for such values of \u00b5 0 and K. Figure 6 .", [["such values", "TEST", 75, 86]]], ["The values of the norms of the difference I sp \u2212 I w for several values of \u00b5 \u2208 (0.08, 0.085) and of K \u2208 (5, 100, 6, 500).fig7So we consider that the graphic of\u012a(t) = 0.08I c + 5, 925 = 0.1(0.8I c ) + 5, 925 = 0.1I w +5, 925 represents very well the curve of I sp translated 35 days backwards.", [["K", "CHEMICAL", 100, 101], ["I sp", "PROTEIN", 258, 262], ["The values", "TEST", 0, 10], ["several values", "TEST", 57, 71], ["K \u2208", "TEST", 100, 103], ["the graphic", "TEST", 145, 156]]], ["We now use it to estimate how long the quarantine period in Wuhan took to produce a reduction of 0.76% in the value of the parameter r.fig7.", [["a reduction", "TREATMENT", 82, 93]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020 . . https://doi.org/10.1101 We have computed the values of the parameter r relative to the data of Wuhan on days 21 st and 22 nd and they were found to be r 21 = 0.2825 and r 22 = 0.22563 respectively which means a decrease of 20.13% in the value of the parameter r at this position on the curve.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 277, 300], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108], ["decrease", "OBSERVATION_MODIFIER", 488, 496]]], ["We suppose linearity of these relations in here and therefore, under this hypothesis, a decrease of 0.76% could be achieved after 54 minutes.", [["linearity", "OBSERVATION_MODIFIER", 11, 20]]], ["As we have already pointed out the demographic density of the exposed (non quarantined) susceptible individuals of Wuhan was 8 individuals per km 2 on the other hand the mean level of quarantined portion of the population in S\u00e3o Paulo is accounted to be around 50% of its total population (according to website [7] ) which means about 6 million individual wandering over a total area of 1, 622 km 2 meaning a demographical density of approximately 3, 700 individuals per km 2 which means approximately 462.5 times the demographical density of exposed individuals in Wuhan.", [["a demographical density", "TEST", 407, 430], ["population", "OBSERVATION", 211, 221]]], ["We use a simple rule of direct proportion to estimate the time spent in the city of S\u00e3o Paulo (under a quarantine of 50% of the total population) to decrease the number of total infected individuals from 6000 to 5800,( i.e. around 3.3%): 54 \u00d7 462.5 = 1387.5 minutes, i.e. 17.45 days.(which was not certified by peer review)The final conclusion is that a decrease of 0.76% in the value of r in the city of S\u00e3o Paulo, would take 17.45 days and that would cause a reduction of about 3.3% in the number of total simultaneously infected individual, supposing a quarantine accession of 50% of the whole population.(which was not certified by peer review)We repeat the above analysis for several other cases of quarantine accession and corresponding reductions in r of 2%, 3%, 5% and 7%.", [["the total population", "TREATMENT", 124, 144], ["total infected individuals", "PROBLEM", 172, 198], ["the above analysis", "TEST", 658, 676], ["quarantine accession", "TREATMENT", 704, 724], ["decrease", "OBSERVATION_MODIFIER", 354, 362], ["reduction", "OBSERVATION_MODIFIER", 461, 470], ["total", "OBSERVATION_MODIFIER", 502, 507], ["simultaneously", "OBSERVATION_MODIFIER", 508, 522], ["infected", "OBSERVATION", 523, 531], ["quarantine accession", "OBSERVATION", 704, 724], ["reductions", "OBSERVATION_MODIFIER", 743, 753]]], ["We point out that the level of imprecision of our forecasting increases when the percentages of reduction of r increases.", [["reduction", "OBSERVATION_MODIFIER", 96, 105]]], ["Total amount of days to a decrease of \u03b7% in the value of the parameter r under quarantine regime of \u2206% of accession.(which was not certified by peer review)table2 .", [["quarantine regime", "TREATMENT", 79, 96], ["decrease", "OBSERVATION_MODIFIER", 26, 34]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 10, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We have used the logistic model to represent the COVID-19 epidemic in the city of Wuhan in China with astonishing good fitting.", [["the logistic model", "TREATMENT", 13, 31], ["the COVID", "TEST", 45, 54]]], ["We analyze the effect some non-pharmaceutical measures has had in the epidemic spreading in Wuhan.", [["some non-pharmaceutical measures", "TREATMENT", 22, 54]]], ["Specifically we estimate how many days of a 99.40% effective quarantine are necessary to decrease the spreading parameter r by 0.76%.(which was not certified by peer review)We use the same model to the ongoing epidemic in S\u00e3o Paulo to forecast its final endings.", [["a 99.40% effective quarantine", "TREATMENT", 42, 71]]], ["We conclude that if nothing else be done the number of infected people in S\u00e3o Paulo will reach 20, 000 around May 1 st .(which was not certified by peer review)Based on the official number of ICU beds in the public and private health system we mathematically estimate the amount of reduction in the parameter r which is necessary to cause a decrease in the value of the total number of simultaneously infected individual in need of special intensive care in order to guarantee this number remains below 80% of the total capacity of ICU beds.", [["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70], ["a decrease", "PROBLEM", 339, 349], ["special intensive care", "TREATMENT", 432, 454], ["ICU beds", "TREATMENT", 532, 540], ["amount", "OBSERVATION_MODIFIER", 272, 278], ["reduction", "OBSERVATION_MODIFIER", 282, 291], ["decrease", "OBSERVATION_MODIFIER", 341, 349]]], ["Then, based on the experience in Wuhan, we have estimated how restrict a quarantine must be in order to produce this desired reduction in the parameter r.(which was not certified by peer review)Based on this study we strongly advice the local government of the city of S\u00e3o Paulo to urgently adopt the implementation of the public measures listed below:(which was not certified by peer review)(1) The most important measure to be taken undoubtedly is to increase the level of social adherence to the quarantine by any means as possible such as advertising campaigns, heavy fines to the infractors, etc. This makes the results of quarantine for S\u00e3o Paulo closer to those of Wuhan making more effective the decrease in r.(which was not certified by peer review)(2) Decrease the number of infected (or possibly infected) individuals in public areas by adopting the use of infrared cameras to detect fevers, massive screening of the population and consequent massive hospitalization of infected individuals.", [["fevers", "DISEASE", 895, 901], ["this study", "TEST", 203, 213], ["infrared cameras", "TREATMENT", 868, 884], ["fevers", "PROBLEM", 895, 901], ["the population", "PROBLEM", 924, 938], ["infected individuals", "PROBLEM", 981, 1001], ["decrease", "OBSERVATION_MODIFIER", 704, 712], ["infected", "OBSERVATION", 785, 793], ["possibly", "UNCERTAINTY", 798, 806], ["infected", "OBSERVATION_MODIFIER", 807, 815], ["fevers", "OBSERVATION", 895, 901], ["massive", "OBSERVATION_MODIFIER", 954, 961], ["infected", "OBSERVATION", 981, 989]]], ["This promotes a decrease in the number of I(t) in contact with T \u2212 I(t).(which was not certified by peer review)(3) Reinforce the importance of sanitation measures such as frequent hand washing and to make mandatory the use of face masks, gloves and goggles in public areas.", [["hand", "ANATOMY", 181, 185], ["T \u2212 I", "GENE_OR_GENE_PRODUCT", 63, 68], ["hand", "ORGANISM_SUBDIVISION", 181, 185], ["I(t)", "PROTEIN", 42, 46], ["sanitation measures", "TREATMENT", 144, 163], ["frequent hand washing", "TREATMENT", 172, 193], ["face masks", "TREATMENT", 227, 237], ["gloves", "TREATMENT", 239, 245], ["decrease", "OBSERVATION_MODIFIER", 16, 24]]], ["This causes a direct decrease in the rate of contagious determined by r.", [["r.", "SPECIES", 70, 72], ["a direct decrease", "PROBLEM", 12, 29], ["decrease", "OBSERVATION_MODIFIER", 21, 29]]], ["Such measures shall decrease the value of the parameter r pushing the curve of total number of infected individuals forward as well as decreasing the final number of total infected individuals.", [["total infected individuals", "PROBLEM", 166, 192], ["infected", "OBSERVATION", 95, 103], ["infected", "OBSERVATION", 172, 180]]], ["Both consequences shall relieve the demand pressure on the need of hospitalization as well as on the demand for ICU beds as a whole.Appendix appendixWe present the Implicit Function Theorem used in Section 6: Theorem 1.", [["the demand pressure", "TREATMENT", 32, 51], ["ICU beds", "TREATMENT", 112, 120]]], ["Suppose F : R 2 \u2192 R is a continuously differentiable function defining a curve F (x, y) = 0.", [["R 2 \u2192 R", "GENE_OR_GENE_PRODUCT", 12, 19]]], ["Let (x 0 , y 0 ) be a point on the curve such that F (x 0 , y 0 ) = 0 and \u2202F \u2202y (x 0 , y 0 ) = 0 then for the curve around (x 0 , y 0 ) we can write y = f (x), where f is a real differentiable function.", [["the curve such", "TEST", 31, 45], ["the curve", "TEST", 106, 115]]], ["Furthermore:Appendix appendixf (x) = \u2212 \u2202F \u2202x (x 0 , y 0 ) \u2202F \u2202y (x 0 , y 0 ) . .", [["Appendix", "TEST", 12, 20], ["\u2202y", "TEST", 61, 63], ["Appendix", "ANATOMY", 12, 20]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Appendix appendixThe copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.1101/2020.05.06.20093666 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Appendix appendix", "PROBLEM", 202, 219], ["The copyright holder", "TREATMENT", 219, 239], ["medRxiv preprint", "TREATMENT", 343, 359], ["med", "ANATOMY", 105, 108], ["appendix", "ANATOMY", 211, 219]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Appendix appendixThe copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.1101/2020.05.06.20093666 doi: medRxiv preprint Table 3 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Appendix appendix", "PROBLEM", 202, 219], ["The copyright holder", "TREATMENT", 219, 239], ["med", "ANATOMY", 105, 108], ["appendix", "ANATOMY", 211, 219]]], ["Total number of infected individuals in Wuhan and in S\u00e3o Paulo up to the mentioned dates.Appendix appendixtable3 .", [["infected", "OBSERVATION_MODIFIER", 16, 24], ["individuals", "OBSERVATION", 25, 36]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Appendix appendixThe copyright holder for this preprint this version posted May 10, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Appendix appendix", "PROBLEM", 202, 219], ["The copyright holder", "TREATMENT", 219, 239], ["med", "ANATOMY", 105, 108], ["appendix", "ANATOMY", 211, 219]]]], "fb4cdfdd952f7140a732d294b97f611c456aa6f0": [["BackgroundFrom the early practice of scarification to prevent smallpox through the creation of targeted, recombinant vaccines, the development of effective vaccines has been one of the great achievements in public health and medicine, resulting in millions of lives saved.", [["smallpox", "DISEASE", 62, 70], ["scarification", "PROBLEM", 37, 50], ["smallpox", "TREATMENT", 62, 70], ["targeted, recombinant vaccines", "TREATMENT", 95, 125], ["effective vaccines", "TREATMENT", 146, 164], ["effective", "OBSERVATION_MODIFIER", 146, 155], ["vaccines", "OBSERVATION", 156, 164]]], ["Modern vaccines typically protect by eliciting immunity following exposure to an inactivated or attenuated whole pathogen or recombinant components of a pathogen [1] .", [["Modern vaccines", "TREATMENT", 0, 15], ["attenuated whole pathogen", "PROBLEM", 96, 121]]], ["This approach works well for diseases in which natural infection leads to immunity and protection against re-infection and has resulted in the eradication of smallpox and dramatic declines in such diseases as diphtheria, measles, and polio [2] .", [["infection", "DISEASE", 55, 64], ["smallpox", "DISEASE", 158, 166], ["diphtheria", "DISEASE", 209, 219], ["measles", "DISEASE", 221, 228], ["diseases", "PROBLEM", 29, 37], ["natural infection", "PROBLEM", 47, 64], ["protection", "TREATMENT", 87, 97], ["re-infection", "PROBLEM", 106, 118], ["smallpox", "PROBLEM", 158, 166], ["such diseases", "PROBLEM", 192, 205], ["diphtheria", "PROBLEM", 209, 219], ["measles", "PROBLEM", 221, 228], ["infection", "OBSERVATION", 55, 64], ["dramatic", "OBSERVATION_MODIFIER", 171, 179], ["declines", "OBSERVATION_MODIFIER", 180, 188]]], ["However, it has been more challenging to develop effective vaccines against diseases for which prior infection does not offer full future protection, such as HIV, malaria, hepatitis C virus, and influenza A [1] .BackgroundAlthough cellular immunity is certainly important, humoral immunity appears to play the most significant role in the protection associated with most vaccines [3] .", [["cellular", "ANATOMY", 231, 239], ["infection", "DISEASE", 101, 110], ["HIV, malaria, hepatitis C virus", "DISEASE", 158, 189], ["influenza", "DISEASE", 195, 204], ["HIV", "ORGANISM", 158, 161], ["hepatitis C virus", "ORGANISM", 172, 189], ["cellular", "CELL", 231, 239], ["HIV", "SPECIES", 158, 161], ["hepatitis C virus", "SPECIES", 172, 189], ["HIV", "SPECIES", 158, 161], ["hepatitis C virus", "SPECIES", 172, 189], ["effective vaccines", "TREATMENT", 49, 67], ["diseases", "PROBLEM", 76, 84], ["prior infection", "PROBLEM", 95, 110], ["full future protection", "TREATMENT", 126, 148], ["HIV", "PROBLEM", 158, 161], ["malaria", "PROBLEM", 163, 170], ["hepatitis C virus", "PROBLEM", 172, 189], ["influenza", "PROBLEM", 195, 204]]], ["Passive immunization achieved through the infusion of serum has played a significant historical role in the treatment and prevention of infection [4, 5] .", [["serum", "ANATOMY", 54, 59], ["infection", "DISEASE", 136, 145], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["Passive immunization", "TREATMENT", 0, 20], ["the infusion of serum", "TREATMENT", 38, 59], ["the treatment", "TREATMENT", 104, 117], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["The recent development of hybridoma technology and humanized monoclonal antibodies have resulted in a new class of antibody-based drugs with demonstrated and potential efficacy in cancer, inflammatory diseases, addiction, and infectious diseases [6] .", [["cancer", "ANATOMY", 180, 186], ["cancer", "DISEASE", 180, 186], ["inflammatory diseases, addiction", "DISEASE", 188, 220], ["infectious diseases", "DISEASE", 226, 245], ["cancer", "CANCER", 180, 186], ["humanized monoclonal antibodies", "PROTEIN", 51, 82], ["hybridoma technology", "TREATMENT", 26, 46], ["humanized monoclonal antibodies", "TREATMENT", 51, 82], ["antibody-based drugs", "TREATMENT", 115, 135], ["cancer", "PROBLEM", 180, 186], ["inflammatory diseases", "PROBLEM", 188, 209], ["hybridoma", "OBSERVATION", 26, 35], ["efficacy", "OBSERVATION_MODIFIER", 168, 176], ["cancer", "OBSERVATION", 180, 186], ["inflammatory", "OBSERVATION_MODIFIER", 188, 200]]], ["Within this context, there has been an increased interest in passive immunization utilizing monoclonal antibodies produced in plants or transgenic animals for infections such as Ebola virus and MERS-CoV [7, 8] .", [["infections", "DISEASE", 159, 169], ["Ebola virus", "DISEASE", 178, 189], ["transgenic animals", "ORGANISM", 136, 154], ["Ebola virus", "ORGANISM", 178, 189], ["MERS-CoV", "ORGANISM", 194, 202], ["monoclonal antibodies", "PROTEIN", 92, 113], ["Ebola virus", "SPECIES", 178, 189], ["Ebola virus", "SPECIES", 178, 189], ["MERS-CoV", "SPECIES", 194, 202], ["an increased interest", "PROBLEM", 36, 57], ["passive immunization", "TREATMENT", 61, 81], ["monoclonal antibodies", "TREATMENT", 92, 113], ["transgenic animals", "TREATMENT", 136, 154], ["infections", "PROBLEM", 159, 169], ["Ebola virus", "PROBLEM", 178, 189], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["interest", "OBSERVATION_MODIFIER", 49, 57]]], ["However, logistical requirements including the need for high antibody concentrations requiring repeated injections due to the short half-life of antibodies, a cold-chain for delivery, and trained medical personnel for delivery create potential limitations to the use of this therapy, especially in low resource areas [1, 9] .", [["antibodies", "PROTEIN", 145, 155], ["logistical requirements", "PROBLEM", 9, 32], ["high antibody concentrations", "TREATMENT", 56, 84], ["repeated injections", "TREATMENT", 95, 114], ["delivery", "TREATMENT", 174, 182], ["delivery", "TREATMENT", 218, 226], ["this therapy", "TREATMENT", 270, 282]]], ["The development of passive immunization by gene therapy could be a solution to some of those logistical issues and holds potential promise as either an adjunct to standard vaccination in populations who do not generate a sufficient immune response or for pathogens able to evade current vaccination strategies due to antigenic variability.BackgroundOriginally proposed as a concept in 2002 [10] , passive immunization by vector-mediated delivery of genes encoding broadly neutralizing antibodies for in vivo expression has been referred to as Immunoprophylaxis by Gene Transfer (IGT) [11] , Vector-Mediated Antibody Gene transfer [11] , or Vectored Immunoprophylaxis (VIP) [6, 12] ; and for sake of consistency, 'VIP' is used here.", [["VIP", "GENE_OR_GENE_PRODUCT", 713, 716], ["neutralizing antibodies", "PROTEIN", 472, 495], ["passive immunization", "TREATMENT", 19, 39], ["gene therapy", "TREATMENT", 43, 55], ["a solution", "TREATMENT", 65, 75], ["standard vaccination in populations", "TREATMENT", 163, 198], ["pathogens", "PROBLEM", 255, 264], ["current vaccination strategies", "TREATMENT", 279, 309], ["antigenic variability", "PROBLEM", 317, 338], ["passive immunization", "TREATMENT", 397, 417], ["vector-mediated delivery of genes encoding broadly neutralizing antibodies", "TREATMENT", 421, 495], ["Vector-Mediated Antibody Gene transfer", "TREATMENT", 591, 629], ["Vectored Immunoprophylaxis (VIP)", "TREATMENT", 640, 672], ["passive", "OBSERVATION_MODIFIER", 19, 26]]], ["Rather than passively transfering pre-formed antibodies, VIP is a process in which genes encoding previously characterized neutralizing antibodies are vectored into non-hematopoietic cells which then secrete the monoclonal antibodes encoded by those genes [1] (See Fig. 1 .)", [["non-hematopoietic cells", "ANATOMY", 165, 188], ["VIP", "GENE_OR_GENE_PRODUCT", 57, 60], ["non-hematopoietic cells", "CELL", 165, 188], ["pre-formed antibodies", "PROTEIN", 34, 55], ["VIP", "PROTEIN", 57, 60], ["neutralizing antibodies", "PROTEIN", 123, 146], ["non-hematopoietic cells", "CELL_TYPE", 165, 188], ["monoclonal antibodes", "PROTEIN", 212, 232], ["passively transfering pre-formed antibodies", "PROBLEM", 12, 55], ["neutralizing antibodies", "TREATMENT", 123, 146], ["non-hematopoietic cells", "PROBLEM", 165, 188], ["non-hematopoietic cells", "OBSERVATION", 165, 188]]], ["This vectored delivery and production of specified antibodies allows for protection without generating a standard immune response and results in endogenous antibody production that has the potential to be sustained [9] .", [["antibodies", "PROTEIN", 51, 61], ["endogenous antibody", "PROTEIN", 145, 164], ["This vectored delivery", "TREATMENT", 0, 22], ["specified antibodies", "TREATMENT", 41, 61], ["protection", "TREATMENT", 73, 83], ["endogenous antibody production", "PROBLEM", 145, 175]]], ["The approach has several benefits, including: 1) it does not require the host have the ability to respond immunologically, 2) the antibody can naturally be selected for a specific pathogen targets, as well as specific epitopes, 3) the antibody can be genetically modified to further enhance its activity, and, 4) vectors can be selected or engineered to have tropic characteristics targeting specific tissues and cells, potentially allowing either systemic or enhanced localized antibody production [9] .Infections for which VIP has been testedVIP has been demonstrated to be effective in a host of animal models for the prevention of infection with several pathogens, especially those commonly afflicting travelers (see Table 1 ), including influenza A virus [13, 14] , malaria (Plasmodium falciparum) [15] , hepatitis C virus [16] , respiratory syncitial virus [17] , Bacillus anthracis [18] , dengue virus [19] , and chickungunya virus [20] .", [["tissues", "ANATOMY", 401, 408], ["cells", "ANATOMY", 413, 418], ["Infections", "DISEASE", 504, 514], ["testedVIP", "CHEMICAL", 538, 547], ["infection", "DISEASE", 635, 644], ["influenza A virus", "DISEASE", 742, 759], ["malaria", "DISEASE", 771, 778], ["Plasmodium falciparum", "DISEASE", 780, 801], ["hepatitis C", "DISEASE", 810, 821], ["respiratory syncitial virus", "DISEASE", 835, 862], ["dengue virus", "DISEASE", 896, 908], ["tissues", "TISSUE", 401, 408], ["cells", "CELL", 413, 418], ["VIP", "GENE_OR_GENE_PRODUCT", 525, 528], ["influenza A virus", "ORGANISM", 742, 759], ["malaria", "ORGANISM", 771, 778], ["Plasmodium falciparum", "ORGANISM", 780, 801], ["hepatitis C virus [16]", "ORGANISM", 810, 832], ["respiratory syncitial virus", "ORGANISM", 835, 862], ["Bacillus anthracis [18", "ORGANISM", 870, 892], ["dengue virus", "ORGANISM", 896, 908], ["chickungunya virus", "ORGANISM", 920, 938], ["epitopes", "PROTEIN", 218, 226], ["antibody", "PROTEIN", 235, 243], ["influenza A virus", "SPECIES", 742, 759], ["Plasmodium falciparum", "SPECIES", 780, 801], ["hepatitis C virus", "SPECIES", 810, 827], ["respiratory syncitial virus", "SPECIES", 835, 862], ["Bacillus anthracis", "SPECIES", 870, 888], ["dengue virus", "SPECIES", 896, 908], ["chickungunya virus", "SPECIES", 920, 938], ["influenza A virus", "SPECIES", 742, 759], ["Plasmodium falciparum", "SPECIES", 780, 801], ["hepatitis C virus", "SPECIES", 810, 827], ["respiratory syncitial virus", "SPECIES", 835, 862], ["Bacillus anthracis", "SPECIES", 870, 888], ["dengue virus", "SPECIES", 896, 908], ["chickungunya virus", "SPECIES", 920, 938], ["the antibody", "TEST", 126, 138], ["a specific pathogen targets", "PROBLEM", 169, 196], ["tropic characteristics targeting specific tissues and cells", "PROBLEM", 359, 418], ["systemic or enhanced localized antibody production", "PROBLEM", 448, 498], ["Infections", "PROBLEM", 504, 514], ["animal models", "TREATMENT", 599, 612], ["infection", "PROBLEM", 635, 644], ["several pathogens", "PROBLEM", 650, 667], ["influenza A virus", "PROBLEM", 742, 759], ["malaria (Plasmodium falciparum)", "PROBLEM", 771, 802], ["hepatitis C virus", "PROBLEM", 810, 827], ["respiratory syncitial virus", "PROBLEM", 835, 862], ["Bacillus anthracis", "PROBLEM", 870, 888], ["dengue virus", "PROBLEM", 896, 908], ["chickungunya virus", "PROBLEM", 920, 938], ["infection", "OBSERVATION", 635, 644]]], ["In addition to the protection conferred by systemic neutralizing antibodies, protection against infection with influenza A virus has also been demonstrated following intranasal administration of vectored local antibody production [21] .Infections for which VIP has been testedBy far, the most extensive and promising exploration of VIP for an infectious disease has been against HIV.", [["infection", "DISEASE", 96, 105], ["influenza A virus", "DISEASE", 111, 128], ["Infections", "DISEASE", 236, 246], ["infectious disease", "DISEASE", 343, 361], ["influenza A virus", "ORGANISM", 111, 128], ["VIP", "GENE_OR_GENE_PRODUCT", 257, 260], ["VIP", "GENE_OR_GENE_PRODUCT", 332, 335], ["HIV", "ORGANISM", 379, 382], ["systemic neutralizing antibodies", "PROTEIN", 43, 75], ["influenza A virus", "SPECIES", 111, 128], ["HIV", "SPECIES", 379, 382], ["influenza A virus", "SPECIES", 111, 128], ["HIV", "SPECIES", 379, 382], ["the protection", "TREATMENT", 15, 29], ["systemic neutralizing antibodies", "TREATMENT", 43, 75], ["protection", "TREATMENT", 77, 87], ["infection", "PROBLEM", 96, 105], ["influenza A virus", "PROBLEM", 111, 128], ["intranasal administration", "TREATMENT", 166, 191], ["vectored local antibody production", "TREATMENT", 195, 229], ["Infections", "PROBLEM", 236, 246], ["VIP", "TREATMENT", 332, 335], ["an infectious disease", "PROBLEM", 340, 361], ["HIV", "PROBLEM", 379, 382], ["infectious", "OBSERVATION", 343, 353]]], ["In the initial study demonstrating the potential of VIP, a recombinant adeno-associated virus (rAAV) vector using a dual-promoter system generated both light and heavy chains of IgG1b12, one of the early broadly neutralizing antibodies described for HIV.", [["VIP", "GENE_OR_GENE_PRODUCT", 52, 55], ["recombinant adeno-associated virus", "ORGANISM", 59, 93], ["rAAV", "ORGANISM", 95, 99], ["IgG1b12", "GENE_OR_GENE_PRODUCT", 178, 185], ["HIV", "ORGANISM", 250, 253], ["recombinant adeno-associated virus (rAAV) vector", "DNA", 59, 107], ["IgG1b12", "PROTEIN", 178, 185], ["early broadly neutralizing antibodies", "PROTEIN", 198, 235], ["HIV", "SPECIES", 250, 253], ["adeno-associated virus", "SPECIES", 71, 93], ["rAAV", "SPECIES", 95, 99], ["HIV", "SPECIES", 250, 253], ["the initial study", "TEST", 3, 20], ["VIP", "TREATMENT", 52, 55], ["a recombinant adeno-associated virus (rAAV) vector", "TREATMENT", 57, 107], ["a dual-promoter system", "TREATMENT", 114, 136], ["IgG1b12", "TREATMENT", 178, 185], ["the early broadly neutralizing antibodies", "TREATMENT", 194, 235], ["HIV", "PROBLEM", 250, 253], ["neutralizing antibodies", "OBSERVATION", 212, 235]]], ["The rAAV was injected into the quadricep muscles of immunodeficient mice and biologically active antibody was found in sera for over 6 months [10] .", [["quadricep muscles", "ANATOMY", 31, 48], ["sera", "ANATOMY", 119, 123], ["rAAV", "ORGANISM", 4, 8], ["quadricep muscles", "TISSUE", 31, 48], ["immunodeficient", "ORGANISM", 52, 67], ["mice", "ORGANISM", 68, 72], ["sera", "ORGANISM_SUBSTANCE", 119, 123], ["mice", "SPECIES", 68, 72], ["rAAV", "SPECIES", 4, 8], ["mice", "SPECIES", 68, 72], ["The rAAV", "TREATMENT", 0, 8], ["immunodeficient mice", "TREATMENT", 52, 72], ["biologically active antibody", "PROBLEM", 77, 105], ["quadricep muscles", "ANATOMY", 31, 48], ["immunodeficient", "OBSERVATION", 52, 67]]], ["This study provided the first evidence that rAAV vectors could transfer antibody genes to muscle, and muscle tissue was a suitable platform to produce and distribute the antibodies throughout the circulation [11] .", [["muscle", "ANATOMY", 90, 96], ["muscle tissue", "ANATOMY", 102, 115], ["rAAV", "ORGANISM", 44, 48], ["muscle", "ORGAN", 90, 96], ["muscle tissue", "TISSUE", 102, 115], ["antibody genes", "DNA", 72, 86], ["antibodies", "PROTEIN", 170, 180], ["rAAV", "SPECIES", 44, 48], ["This study", "TEST", 0, 10], ["rAAV vectors", "TREATMENT", 44, 56], ["muscle", "ANATOMY", 90, 96], ["muscle tissue", "ANATOMY", 102, 115]]], ["Follow-on studies used a native macaque SIV gp120-specific Fab molecule as an immunoadhesin, a chimeric, antibody-like molecules that combine the functional domain of a binding protein with immunoglobulin constant domains, which were considered to be superior to single chain (scFv) or whole antibody (IgG) molecules with respect to achievable steady-state serum concentrations [22] .", [["serum", "ANATOMY", 357, 362], ["macaque", "ORGANISM", 32, 39], ["SIV", "ORGANISM", 40, 43], ["Fab", "GENE_OR_GENE_PRODUCT", 59, 62], ["immunoadhesin", "GENE_OR_GENE_PRODUCT", 78, 91], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 190, 204], ["scFv", "GENE_OR_GENE_PRODUCT", 277, 281], ["serum", "ORGANISM_SUBSTANCE", 357, 362], ["native macaque SIV gp120", "PROTEIN", 25, 49], ["Fab molecule", "PROTEIN", 59, 71], ["immunoadhesin", "PROTEIN", 78, 91], ["chimeric, antibody-like molecules", "PROTEIN", 95, 128], ["binding protein", "PROTEIN", 169, 184], ["immunoglobulin constant domains", "PROTEIN", 190, 221], ["single chain", "PROTEIN", 263, 275], ["scFv", "PROTEIN", 277, 281], ["whole antibody (IgG) molecules", "PROTEIN", 286, 316], ["macaque SIV", "SPECIES", 32, 43], ["studies", "TEST", 10, 17], ["a native macaque SIV gp120", "TREATMENT", 23, 49], ["an immunoadhesin", "TEST", 75, 91], ["a chimeric, antibody-like molecules", "PROBLEM", 93, 128], ["immunoglobulin constant domains", "PROBLEM", 190, 221], ["whole antibody (IgG) molecules", "TREATMENT", 286, 316], ["serum concentrations", "TEST", 357, 377]]], ["Six of nine rhesus macaques were completely protected against intravenous challenge with virulent SIV and still had stable immunoadhesin levels 6 years after injection [11] .", [["intravenous", "ANATOMY", 62, 73], ["rhesus", "ORGANISM", 12, 18], ["macaques", "ORGANISM", 19, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 73], ["SIV", "ORGANISM", 98, 101], ["immunoadhesin", "GENE_OR_GENE_PRODUCT", 123, 136], ["immunoadhesin", "PROTEIN", 123, 136], ["rhesus macaques", "SPECIES", 12, 27], ["rhesus macaques", "SPECIES", 12, 27], ["SIV", "SPECIES", 98, 101], ["intravenous challenge", "TREATMENT", 62, 83], ["virulent SIV", "PROBLEM", 89, 101], ["stable", "OBSERVATION_MODIFIER", 116, 122]]], ["The three subjects not protected were found to have developed an immune response to the immunoadhesin by 3 weeks after injection [11] .Infections for which VIP has been testedAnother group used an rAAV vector injected into the quadriceps muscle of a humanized mouse to express an array of broadly neutralizing antibodies: 2G12, IgG1b12, 2F5, 4E10 and VRC01.", [["quadriceps muscle", "ANATOMY", 227, 244], ["Infections", "DISEASE", 135, 145], ["VIP", "GENE_OR_GENE_PRODUCT", 156, 159], ["rAAV", "ORGANISM", 197, 201], ["quadriceps muscle", "TISSUE", 227, 244], ["mouse", "ORGANISM", 260, 265], ["2G12", "GENE_OR_GENE_PRODUCT", 322, 326], ["Ig", "GENE_OR_GENE_PRODUCT", 328, 330], ["2F5", "GENE_OR_GENE_PRODUCT", 337, 340], ["4E10", "GENE_OR_GENE_PRODUCT", 342, 346], ["VRC01", "GENE_OR_GENE_PRODUCT", 351, 356], ["immunoadhesin", "PROTEIN", 88, 101], ["broadly neutralizing antibodies", "PROTEIN", 289, 320], ["2G12", "PROTEIN", 322, 326], ["IgG1b12", "PROTEIN", 328, 335], ["2F5", "PROTEIN", 337, 340], ["4E10", "PROTEIN", 342, 346], ["VRC01", "PROTEIN", 351, 356], ["mouse", "SPECIES", 260, 265], ["rAAV", "SPECIES", 197, 201], ["mouse", "SPECIES", 260, 265], ["Infections", "PROBLEM", 135, 145], ["an rAAV vector", "TREATMENT", 194, 208], ["broadly neutralizing antibodies", "TEST", 289, 320], ["VRC01", "TEST", 351, 356], ["quadriceps muscle", "ANATOMY", 227, 244]]], ["Though VRC01 serum levels as low as 8.3 \u03bcg/mL provided The genetic sequences of the antibody variable regions are determined. c The genetic sequence for the BNA can then be placed downstream from an appropriate promoter (Prom) within a suitable vector. d The vector can then be administered to the subject in an appropriate tissue platform, such as muscle.", [["serum", "ANATOMY", 13, 18], ["tissue", "ANATOMY", 324, 330], ["muscle", "ANATOMY", 349, 355], ["VRC01", "GENE_OR_GENE_PRODUCT", 7, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["c", "GENE_OR_GENE_PRODUCT", 126, 127], ["BNA", "GENE_OR_GENE_PRODUCT", 157, 160], ["tissue", "TISSUE", 324, 330], ["muscle", "ORGAN", 349, 355], ["VRC01", "PROTEIN", 7, 12], ["antibody variable regions", "DNA", 84, 109], ["BNA", "DNA", 157, 160], ["promoter", "DNA", 211, 219], ["Prom", "DNA", 221, 225], ["VRC01 serum levels", "TEST", 7, 25], ["the BNA", "TREATMENT", 153, 160], ["an appropriate promoter (Prom)", "TREATMENT", 196, 226], ["The vector", "TREATMENT", 255, 265], ["muscle", "ANATOMY", 349, 355]]], ["The BNA produced by the vector and secreted by the tissue confers the host subject with broad and lasting protection from the targeted pathogen protection from an intravenous challenge with HIV, they achieved concentrations as high as 100 \u03bcg/mL for at least 12 months [12] .", [["tissue", "ANATOMY", 51, 57], ["intravenous", "ANATOMY", 163, 174], ["BNA", "CHEMICAL", 4, 7], ["BNA", "GENE_OR_GENE_PRODUCT", 4, 7], ["tissue", "TISSUE", 51, 57], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 163, 174], ["HIV", "ORGANISM", 190, 193], ["BNA", "PROTEIN", 4, 7], ["HIV", "SPECIES", 190, 193], ["HIV", "SPECIES", 190, 193], ["The BNA", "TEST", 0, 7], ["the targeted pathogen protection", "TREATMENT", 122, 154], ["an intravenous challenge", "TREATMENT", 160, 184], ["HIV", "PROBLEM", 190, 193]]], ["They followed-up that study by optimizing the broadly neutralizing antibody, and although muscle was chosen as a platform for expression and secretion of the IgG1 isotype, antibodies were found to effectively reach the vaginal mucosa.", [["muscle", "ANATOMY", 90, 96], ["vaginal mucosa", "ANATOMY", 219, 233], ["muscle", "ORGAN", 90, 96], ["IgG1", "GENE_OR_GENE_PRODUCT", 158, 162], ["vaginal mucosa", "MULTI-TISSUE_STRUCTURE", 219, 233], ["neutralizing antibody", "PROTEIN", 54, 75], ["IgG1 isotype", "PROTEIN", 158, 170], ["antibodies", "PROTEIN", 172, 182], ["the broadly neutralizing antibody", "TEST", 42, 75], ["the IgG1 isotype", "TEST", 154, 170], ["antibodies", "PROBLEM", 172, 182], ["muscle", "ANATOMY", 90, 96], ["IgG1 isotype", "OBSERVATION", 158, 170], ["vaginal mucosa", "ANATOMY", 219, 233]]], ["Animals receiving VIP that expressed a modified VRC07 antibody (concentration of nearly 100 \u03bcg/ml in the serum and 1 \u03bcg/ml in vaginal wash fluid) were completely resistant to repetitive intravaginal challenge by a heterosexually transmitted founder HIV strain [23] .Infections for which VIP has been testedSaunders, et al., used an rAAV serotype 8 vector to produce a full length IgG of a simianized form of the broadly neutralizing antibody VRC07 in macaques which was protective against simian-human immunodeficiency virus (SHIV) infection 5.5 weeks after treatment [24] .", [["serum", "ANATOMY", 105, 110], ["vaginal wash fluid", "ANATOMY", 126, 144], ["Infections", "DISEASE", 266, 276], ["simian-human immunodeficiency virus (SHIV) infection", "DISEASE", 489, 541], ["Animals", "ORGANISM", 0, 7], ["VIP", "GENE_OR_GENE_PRODUCT", 18, 21], ["VRC07", "GENE_OR_GENE_PRODUCT", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["VIP", "GENE_OR_GENE_PRODUCT", 287, 290], ["rAAV serotype 8", "ORGANISM", 332, 347], ["IgG", "GENE_OR_GENE_PRODUCT", 380, 383], ["VRC07", "GENE_OR_GENE_PRODUCT", 442, 447], ["macaques", "ORGANISM", 451, 459], ["simian-", "ORGANISM", 489, 496], ["human immunodeficiency virus", "ORGANISM", 496, 524], ["SHIV", "ORGANISM", 526, 530], ["VRC07 antibody", "PROTEIN", 48, 62], ["full length IgG", "PROTEIN", 368, 383], ["VRC07", "PROTEIN", 442, 447], ["HIV", "SPECIES", 249, 252], ["macaques", "SPECIES", 451, 459], ["simian-", "SPECIES", 489, 496], ["human immunodeficiency virus (SHIV", "SPECIES", 496, 530], ["HIV", "SPECIES", 249, 252], ["rAAV", "SPECIES", 332, 336], ["simian-human immunodeficiency virus", "SPECIES", 489, 524], ["SHIV", "SPECIES", 526, 530], ["VIP", "TREATMENT", 18, 21], ["a modified VRC07 antibody", "TREATMENT", 37, 62], ["the serum", "TEST", 101, 110], ["vaginal wash fluid", "TREATMENT", 126, 144], ["repetitive intravaginal challenge", "TREATMENT", 175, 208], ["Infections", "PROBLEM", 266, 276], ["an rAAV serotype 8 vector", "TREATMENT", 329, 354], ["the broadly neutralizing antibody VRC07", "TREATMENT", 408, 447], ["simian-human immunodeficiency virus", "PROBLEM", 489, 524], ["SHIV) infection", "PROBLEM", 526, 541], ["vaginal", "ANATOMY", 126, 133]]], ["SHIVs are chimeric viruses constructed to express the HIV envelope glycoprotein to be used in vaccine experiments to evaluate neutralizing antibodies.", [["SHIVs", "GENE_OR_GENE_PRODUCT", 0, 5], ["HIV", "ORGANISM", 54, 57], ["SHIVs", "PROTEIN", 0, 5], ["HIV envelope glycoprotein", "PROTEIN", 54, 79], ["neutralizing antibodies", "PROTEIN", 126, 149], ["HIV", "SPECIES", 54, 57], ["HIV", "SPECIES", 54, 57], ["chimeric viruses", "PROBLEM", 10, 26], ["the HIV envelope glycoprotein", "TREATMENT", 50, 79], ["neutralizing antibodies", "PROBLEM", 126, 149], ["chimeric viruses", "OBSERVATION", 10, 26]]], ["The antibody reached levels up to 66 \u03bcg/ml for 16 weeks, but immune suppression with cyclosporine was needed to sustain expression due to the development of anti-idiotypic antibodies [24] .Infections for which VIP has been testedThe approach to preventing HIV was enhanced further by fusing the immunoadhesin form of CD4-Ig with a small CCR5-mimetic sulfopeptide at the carboxy-terminus (eCD4-Ig). eCD4-Ig is more potent than the best broadly neutralizing antiody and binds avidly to the HIV-1 envelope glycoprotein.", [["cyclosporine", "CHEMICAL", 85, 97], ["Infections", "DISEASE", 189, 199], ["cyclosporine", "CHEMICAL", 85, 97], ["carboxy", "CHEMICAL", 370, 377], ["cyclosporine", "SIMPLE_CHEMICAL", 85, 97], ["VIP", "GENE_OR_GENE_PRODUCT", 210, 213], ["HIV", "ORGANISM", 256, 259], ["immunoadhesin", "GENE_OR_GENE_PRODUCT", 295, 308], ["CD4-Ig", "GENE_OR_GENE_PRODUCT", 317, 323], ["CCR5", "GENE_OR_GENE_PRODUCT", 337, 341], ["sulfopeptide", "GENE_OR_GENE_PRODUCT", 350, 362], ["eCD4-Ig", "GENE_OR_GENE_PRODUCT", 388, 395], ["eCD4-Ig", "GENE_OR_GENE_PRODUCT", 398, 405], ["HIV-1", "ORGANISM", 488, 493], ["anti-idiotypic antibodies", "PROTEIN", 157, 182], ["immunoadhesin form", "PROTEIN", 295, 313], ["CD4", "PROTEIN", 317, 320], ["Ig", "PROTEIN", 321, 323], ["CCR5", "PROTEIN", 337, 341], ["mimetic sulfopeptide", "PROTEIN", 342, 362], ["carboxy-terminus", "PROTEIN", 370, 386], ["eCD4", "PROTEIN", 388, 392], ["Ig", "PROTEIN", 393, 395], ["eCD4", "PROTEIN", 398, 402], ["Ig", "PROTEIN", 403, 405], ["antiody", "PROTEIN", 456, 463], ["HIV-1 envelope glycoprotein", "PROTEIN", 488, 515], ["HIV-1", "SPECIES", 488, 493], ["HIV", "SPECIES", 256, 259], ["HIV-1", "SPECIES", 488, 493], ["The antibody", "TEST", 0, 12], ["levels", "TEST", 21, 27], ["immune suppression", "PROBLEM", 61, 79], ["cyclosporine", "TREATMENT", 85, 97], ["anti-idiotypic antibodies", "PROBLEM", 157, 182], ["Infections", "PROBLEM", 189, 199], ["HIV", "PROBLEM", 256, 259], ["CD4", "TEST", 317, 320], ["a small CCR5-mimetic sulfopeptide", "TREATMENT", 329, 362], ["eCD4", "TEST", 398, 402], ["the HIV", "TEST", 484, 491], ["small", "OBSERVATION_MODIFIER", 331, 336], ["more potent", "OBSERVATION_MODIFIER", 409, 420], ["neutralizing", "OBSERVATION", 443, 455]]], ["Rhesus macaques expressed 17-77 \u03bcg/mL of fully functional rhesus eCD4-Ig for more than 40 weeks after injection with a self complimentary serotype 1 AAV (scAAV1) vector and were completely protected from multiple challenges with a simian/human immunodeficiency virus, SHIV-AD8 [25] .", [["simian/human immunodeficiency virus", "DISEASE", 231, 266], ["Rhesus macaques", "ORGANISM", 0, 15], ["rhesus", "ORGANISM", 58, 64], ["eCD4-Ig", "GENE_OR_GENE_PRODUCT", 65, 72], ["AAV", "ORGANISM", 149, 152], ["scAAV1", "GENE_OR_GENE_PRODUCT", 154, 160], ["simian", "ORGANISM", 231, 237], ["human immunodeficiency virus", "ORGANISM", 238, 266], ["SHIV", "ORGANISM", 268, 272], ["rhesus eCD4", "PROTEIN", 58, 69], ["Ig", "PROTEIN", 70, 72], ["serotype 1 AAV (scAAV1) vector", "DNA", 138, 168], ["Rhesus macaques", "SPECIES", 0, 15], ["simian", "SPECIES", 231, 237], ["human", "SPECIES", 238, 243], ["immunodeficiency virus", "SPECIES", 244, 266], ["Rhesus macaques", "SPECIES", 0, 15], ["human immunodeficiency virus", "SPECIES", 238, 266], ["SHIV-AD8", "SPECIES", 268, 276], ["injection", "TREATMENT", 102, 111], ["a self complimentary serotype 1 AAV (scAAV1) vector", "TREATMENT", 117, 168], ["a simian/human immunodeficiency virus", "PROBLEM", 229, 266]]], ["Of note, the rhesus eCD4-Ig was also markedly less immunogenic than rhesus forms of four well-characterized broadly neutralizing antibodies [25] .Infections for which VIP has been testedIn addition to disease prevention as noted above, studies have also demonstrated an application for VIP in the effective treatment of previously-infected animals.", [["Infections", "DISEASE", 146, 156], ["rhesus", "ORGANISM", 13, 19], ["eCD4-Ig", "GENE_OR_GENE_PRODUCT", 20, 27], ["rhesus", "ORGANISM", 68, 74], ["VIP", "GENE_OR_GENE_PRODUCT", 167, 170], ["VIP", "GENE_OR_GENE_PRODUCT", 286, 289], ["animals", "ORGANISM", 340, 347], ["rhesus eCD4-Ig", "PROTEIN", 13, 27], ["neutralizing antibodies", "PROTEIN", 116, 139], ["rhesus", "SPECIES", 68, 74], ["the rhesus eCD4", "TEST", 9, 24], ["Infections", "PROBLEM", 146, 156], ["disease prevention", "TREATMENT", 201, 219], ["studies", "TEST", 236, 243], ["VIP", "TREATMENT", 286, 289], ["the effective treatment", "TREATMENT", 293, 316], ["disease", "OBSERVATION", 201, 208], ["infected", "OBSERVATION", 331, 339]]], ["Using HIV-1-infected humanized mice, Horwitz, et al., demonstrated that following initial treatment with anti-retroviral therapy (ART), a single injection of adeno-associated virus directing expression of broadly neutralizing antibody 10-1074, produced durable viremic control after the ART was stopped [26] .Infections for which VIP has been testedThe first human trial using the VIP approach started in January 2014 and is a phase 1, randomized, blinded, doseescalation study of an rAAV1 vector coding for PG9, a potent broadly neutralizing antibody, in high risk, healthy adult males (ClinicalTrials.gov number, NCT01937455).", [["HIV-1-infected", "DISEASE", 6, 20], ["10-1074", "CHEMICAL", 235, 242], ["Infections", "DISEASE", 309, 319], ["PG9", "CHEMICAL", 508, 511], ["HIV-1", "ORGANISM", 6, 11], ["mice", "ORGANISM", 31, 35], ["adeno-associated virus", "ORGANISM", 158, 180], ["VIP", "GENE_OR_GENE_PRODUCT", 330, 333], ["human", "ORGANISM", 359, 364], ["rAAV1", "ORGANISM", 484, 489], ["PG9", "GENE_OR_GENE_PRODUCT", 508, 511], ["rAAV1 vector", "DNA", 484, 496], ["PG9", "PROTEIN", 508, 511], ["HIV-1", "SPECIES", 6, 11], ["mice", "SPECIES", 31, 35], ["human", "SPECIES", 359, 364], ["HIV-1", "SPECIES", 6, 11], ["mice", "SPECIES", 31, 35], ["adeno-associated virus", "SPECIES", 158, 180], ["human", "SPECIES", 359, 364], ["initial treatment", "TREATMENT", 82, 99], ["anti-retroviral therapy", "TREATMENT", 105, 128], ["a single injection of adeno-associated virus", "TREATMENT", 136, 180], ["broadly neutralizing antibody", "TEST", 205, 234], ["durable viremic control", "TREATMENT", 253, 276], ["the ART", "TREATMENT", 283, 290], ["Infections", "PROBLEM", 309, 319], ["the VIP approach", "TREATMENT", 377, 393], ["doseescalation study", "TEST", 457, 477], ["an rAAV1 vector", "TREATMENT", 481, 496], ["a potent broadly neutralizing antibody", "PROBLEM", 513, 551], ["high risk", "OBSERVATION_MODIFIER", 556, 565]]], ["Another study evaluating using VIP in HIV-positive subjects is scheduled to get underway soon [6] .VectorsMany options exist for vectoring the transgene into the host tissue, each with distinct advantages and limitations.", [["tissue", "ANATOMY", 167, 173], ["HIV-positive", "DISEASE", 38, 50], ["VIP", "GENE_OR_GENE_PRODUCT", 31, 34], ["HIV", "ORGANISM", 38, 41], ["tissue", "TISSUE", 167, 173], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["Another study", "TEST", 0, 13], ["VIP", "TREATMENT", 31, 34], ["Vectors", "TREATMENT", 99, 106], ["vectoring", "TREATMENT", 129, 138], ["host tissue", "ANATOMY", 162, 173]]], ["Naked plasmid DNA is relatively easy to use, does not elicit significant immunogenicity, and has the potential for inexpensive large-scale production [20, 27] .", [["plasmid", "ANATOMY", 6, 13], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["Naked plasmid DNA", "DNA", 0, 17], ["significant", "OBSERVATION_MODIFIER", 61, 72], ["immunogenicity", "OBSERVATION", 73, 87]]], ["Recent advances in both the mechanism of delivery [28] and optimization of plasmid and electroporation conditions [29] have improved the concentration and duration of antibody production, but it has yet to prove as potent as viral vectoring.VectorsViral vectors offer the advantage of efficient, rapid delivery of the transgene into host cells and the potential for integration into the host genome, allowing for sustained expression [1] .", [["plasmid", "ANATOMY", 75, 82], ["cells", "ANATOMY", 338, 343], ["host cells", "CELL", 333, 343], ["plasmid", "DNA", 75, 82], ["host cells", "CELL_TYPE", 333, 343], ["host genome", "DNA", 387, 398], ["delivery", "TREATMENT", 41, 49], ["plasmid and electroporation conditions", "TREATMENT", 75, 113], ["antibody production", "PROBLEM", 167, 186], ["VectorsViral vectors", "TREATMENT", 241, 261], ["the transgene into host cells", "TREATMENT", 314, 343]]], ["The life cycle of a virus consists of attachment, penetration, uncoating, replication, gene expression, assembly and budding.", [["a virus", "PROBLEM", 18, 25], ["penetration", "PROBLEM", 50, 61]]], ["Replication and gene expression typically take place in the nucleus where viral genomes persist episomally or integrate into the host genome (i.e., a provirus).", [["nucleus", "ANATOMY", 60, 67], ["nucleus", "CELLULAR_COMPONENT", 60, 67], ["viral genomes", "DNA", 74, 87], ["host genome", "DNA", 129, 140], ["Replication", "TREATMENT", 0, 11], ["viral genomes", "PROBLEM", 74, 87], ["nucleus", "ANATOMY", 60, 67], ["host genome", "OBSERVATION", 129, 140]]], ["Vectors that persist episomally can provide sustained transgene expression in post-mitotic tissue, but since they do not alter the host genome, they may be lost if and when the cells divide.", [["post-mitotic tissue", "ANATOMY", 78, 97], ["cells", "ANATOMY", 177, 182], ["post-mitotic tissue", "TISSUE", 78, 97], ["cells", "CELL", 177, 182], ["Vectors", "TREATMENT", 0, 7], ["post-mitotic tissue", "OBSERVATION", 78, 97]]], ["Vectors that integrate into to the host genome may provide life-long transgene expression in dividing cells but could also lead to insertional mutagenesis resulting in apoptosis or malignant transformation [30] .", [["cells", "ANATOMY", 102, 107], ["malignant transformation", "DISEASE", 181, 205], ["cells", "CELL", 102, 107], ["host genome", "DNA", 35, 46], ["dividing cells", "CELL_TYPE", 93, 107], ["Vectors", "TREATMENT", 0, 7], ["life-long transgene expression in dividing cells", "TREATMENT", 59, 107], ["insertional mutagenesis", "PROBLEM", 131, 154], ["apoptosis", "PROBLEM", 168, 177], ["malignant transformation", "PROBLEM", 181, 205], ["malignant", "OBSERVATION_MODIFIER", 181, 190]]], ["Adenoviral vectors produce rapid, but transient, gene expression that could be ideal for responding to a disease outbreak, but would have limitations for long term protection [1] .", [["Adenoviral", "ORGANISM", 0, 10], ["Adenoviral", "SPECIES", 0, 10], ["Adenoviral vectors", "TREATMENT", 0, 18], ["a disease outbreak", "PROBLEM", 103, 121], ["long term protection", "TREATMENT", 154, 174]]], ["Adenovirus serotype 5 (Ad5) has successfully transduced protective antibodies for respiratory syncytial virus (RSV), influenza A virus (IAV), and Bacillus anthracis [14, 17, 18] .", [["respiratory syncytial virus (RSV)", "DISEASE", 82, 115], ["influenza A virus", "DISEASE", 117, 134], ["Adenovirus serotype 5", "ORGANISM", 0, 21], ["Ad5", "ORGANISM", 23, 26], ["respiratory syncytial virus", "ORGANISM", 82, 109], ["RSV", "ORGANISM", 111, 114], ["influenza A virus", "ORGANISM", 117, 134], ["IAV", "ORGANISM", 136, 139], ["Bacillus anthracis", "ORGANISM", 146, 164], ["protective antibodies", "PROTEIN", 56, 77], ["Adenovirus serotype", "SPECIES", 0, 19], ["respiratory syncytial virus", "SPECIES", 82, 109], ["influenza A virus", "SPECIES", 117, 134], ["Bacillus anthracis", "SPECIES", 146, 164], ["Ad5", "SPECIES", 23, 26], ["respiratory syncytial virus", "SPECIES", 82, 109], ["RSV", "SPECIES", 111, 114], ["influenza A virus", "SPECIES", 117, 134], ["IAV", "SPECIES", 136, 139], ["Bacillus anthracis", "SPECIES", 146, 164], ["Adenovirus serotype", "TREATMENT", 0, 19], ["successfully transduced protective antibodies", "TREATMENT", 32, 77], ["respiratory syncytial virus", "PROBLEM", 82, 109], ["RSV", "PROBLEM", 111, 114], ["influenza A virus (IAV), and Bacillus anthracis", "PROBLEM", 117, 164], ["syncytial virus", "OBSERVATION", 94, 109]]], ["The Ad5 genome is easy to engineer and remains episomal, but there is significant pre-existing immunity to Ad5, estimated at 50% of the adult population worldwide and even higher in sub-Saharan Arica, which decreases the ability to transfer the transgene.", [["Ad5", "ORGANISM", 4, 7], ["Ad5", "ORGANISM", 107, 110], ["Ad5 genome", "DNA", 4, 14], ["Ad5", "SPECIES", 4, 7], ["Ad5", "SPECIES", 107, 110], ["Ad5 genome", "OBSERVATION", 4, 14], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["higher", "OBSERVATION_MODIFIER", 172, 178]]], ["Additionally, it can result in systemic cytokine release creating a sepsis presentation and there is significant tissue tropism for the liver when delivered intravenously.", [["tissue", "ANATOMY", 113, 119], ["liver", "ANATOMY", 136, 141], ["intravenously", "ANATOMY", 157, 170], ["sepsis", "DISEASE", 68, 74], ["tissue", "TISSUE", 113, 119], ["liver", "ORGAN", 136, 141], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 170], ["cytokine", "PROTEIN", 40, 48], ["systemic cytokine release", "TREATMENT", 31, 56], ["a sepsis presentation", "PROBLEM", 66, 87], ["significant tissue tropism", "PROBLEM", 101, 127], ["sepsis", "OBSERVATION", 68, 74], ["significant tissue tropism", "OBSERVATION", 101, 127], ["liver", "ANATOMY", 136, 141]]], ["Alternative adenoviral vectors are being researched [31] .VectorsLentivral vectors are better suited for long term expression since they typically integrate into the genome and can transduce dividing and non-dividing cells.", [["cells", "ANATOMY", 217, 222], ["adenoviral", "ORGANISM", 12, 22], ["cells", "CELL", 217, 222], ["VectorsLentivral vectors", "DNA", 58, 82], ["dividing and non-dividing cells", "CELL_TYPE", 191, 222], ["Alternative adenoviral vectors", "TREATMENT", 0, 30], ["VectorsLentivral vectors", "TREATMENT", 58, 82], ["non-dividing cells", "OBSERVATION", 204, 222]]], ["They have successfully been utilized to transduce hematopoietic stem cells to produce broadly neutralizing antibodies against HIV in mouse models [32, 33] .", [["hematopoietic stem cells", "ANATOMY", 50, 74], ["hematopoietic stem cells", "CELL", 50, 74], ["HIV", "ORGANISM", 126, 129], ["mouse", "ORGANISM", 133, 138], ["hematopoietic stem cells", "CELL_TYPE", 50, 74], ["neutralizing antibodies", "PROTEIN", 94, 117], ["HIV", "SPECIES", 126, 129], ["mouse", "SPECIES", 133, 138], ["HIV", "SPECIES", 126, 129], ["mouse", "SPECIES", 133, 138], ["hematopoietic stem cells", "TREATMENT", 50, 74], ["broadly neutralizing antibodies", "TEST", 86, 117], ["HIV in mouse models", "PROBLEM", 126, 145], ["hematopoietic stem cells", "OBSERVATION", 50, 74]]], ["However, because they can integrate into the host genome, there is concern for mutagenesis.", [["mutagenesis", "PROBLEM", 79, 90], ["host genome", "OBSERVATION", 45, 56], ["concern for", "UNCERTAINTY", 67, 78]]], ["Newer generation lentiviral vectors contain deletions in their long-terminal repeat (LTR) and a self-inactivating (SIN) LTR, leaving them replication incompetent, which should make them much safer, but this question is not fully answered [30] .VectorsAlthough other viral vectors are being explored, rAAV vectors are currently the favored vehicle for delivering the antiody genes into the host tissue due to their efficiency in gene transfer [34] .", [["LTR", "ANATOMY", 85, 88], ["tissue", "ANATOMY", 394, 400], ["lentiviral", "ORGANISM", 17, 27], ["long-terminal repeat", "CELLULAR_COMPONENT", 63, 83], ["LTR", "CELLULAR_COMPONENT", 85, 88], ["LTR", "CELLULAR_COMPONENT", 120, 123], ["rAAV", "ORGANISM", 300, 304], ["tissue", "TISSUE", 394, 400], ["long-terminal repeat", "DNA", 63, 83], ["LTR", "DNA", 85, 88], ["self-inactivating (SIN) LTR", "DNA", 96, 123], ["antiody genes", "DNA", 366, 379], ["rAAV", "SPECIES", 300, 304], ["Newer generation lentiviral vectors", "TREATMENT", 0, 35], ["a self-inactivating (SIN) LTR", "TREATMENT", 94, 123], ["other viral vectors", "TREATMENT", 260, 279], ["rAAV vectors", "TREATMENT", 300, 312], ["the antiody genes", "TREATMENT", 362, 379], ["lentiviral vectors", "OBSERVATION", 17, 35], ["viral vectors", "OBSERVATION", 266, 279], ["host tissue", "OBSERVATION", 389, 400]]], ["In contrast to other viral vectors, such as adenovirus, rAAV's have not been associated with any human diseases and do not stimulate signficant immunologic reaction, and are therefore able to induce long-term expression of non-self-proteins [34] .", [["adenovirus", "ORGANISM", 44, 54], ["rAAV", "ORGANISM", 56, 60], ["human", "ORGANISM", 97, 102], ["non-self-proteins", "PROTEIN", 223, 240], ["human", "SPECIES", 97, 102], ["adenovirus", "SPECIES", 44, 54], ["rAAV", "SPECIES", 56, 60], ["human", "SPECIES", 97, 102], ["other viral vectors", "TREATMENT", 15, 34], ["adenovirus", "PROBLEM", 44, 54], ["rAAV's", "TREATMENT", 56, 62], ["any human diseases", "PROBLEM", 93, 111], ["signficant immunologic reaction", "PROBLEM", 133, 164]]], ["They are engineered to consist of the antibody gene expression cassette flanked by the AAV ITRs (inverted terminal repeats), which are the only part of the AAV genome present in the rAAV vector and are required for rAAV vector genome replication and packaging.", [["AAV", "ORGANISM", 87, 90], ["ITRs", "GENE_OR_GENE_PRODUCT", 91, 95], ["AAV", "ORGANISM", 156, 159], ["rAAV", "ORGANISM", 182, 186], ["rAAV", "ORGANISM", 215, 219], ["antibody gene expression cassette", "DNA", 38, 71], ["AAV ITRs", "DNA", 87, 95], ["inverted terminal repeats", "DNA", 97, 122], ["AAV genome", "DNA", 156, 166], ["rAAV vector", "DNA", 182, 193], ["rAAV", "SPECIES", 182, 186], ["rAAV", "SPECIES", 215, 219], ["the antibody gene expression cassette", "TREATMENT", 34, 71], ["the AAV genome", "PROBLEM", 152, 166], ["the rAAV vector", "TREATMENT", 178, 193], ["rAAV vector genome replication", "TREATMENT", 215, 245], ["packaging", "TREATMENT", 250, 259], ["AAV genome", "OBSERVATION", 156, 166]]], ["Despite a relativley small packaging capacity of 5 kb, both heavy-and light-chain antibody genes can be incorporated into a single vector, either using a promoter for each gene cassette or a single promoter for expression with the heavy and light chain separated by a foot-and-mouth disease virus 2A peptide [9] .'Immunization' site selectionAll studies to date have targeted skeletal muscle as the platform for transfection and antibody production.", [["skeletal muscle", "ANATOMY", 376, 391], ["foot-and-mouth disease virus 2A", "ORGANISM", 268, 299], ["skeletal muscle", "TISSUE", 376, 391], ["heavy-and light-chain antibody genes", "DNA", 60, 96], ["promoter", "DNA", 154, 162], ["gene cassette", "DNA", 172, 185], ["heavy and light chain", "PROTEIN", 231, 252], ["foot-and-mouth disease virus", "SPECIES", 268, 296], ["foot-and-mouth disease virus", "SPECIES", 268, 296], ["light-chain antibody genes", "TREATMENT", 70, 96], ["a promoter for each gene cassette", "TREATMENT", 152, 185], ["a single promoter", "TREATMENT", 189, 206], ["the heavy and light chain", "TREATMENT", 227, 252], ["Immunization'", "TREATMENT", 314, 327], ["All studies", "TEST", 342, 353], ["antibody production", "PROBLEM", 429, 448], ["foot", "ANATOMY", 268, 272], ["skeletal muscle", "ANATOMY", 376, 391]]], ["Muscle offers some significant advantages.", [["Muscle", "ANATOMY", 0, 6], ["Muscle", "ORGAN", 0, 6]]], ["It is easily accessible for localized vector administration, and some muscle groups can be removed in the event of mutagenesis or auto-immunity without functional consequence.", [["muscle", "ANATOMY", 70, 76], ["muscle", "ORGAN", 70, 76], ["localized vector administration", "TREATMENT", 28, 59], ["some muscle groups", "TREATMENT", 65, 83], ["mutagenesis", "PROBLEM", 115, 126], ["functional consequence", "PROBLEM", 152, 174], ["muscle", "ANATOMY", 70, 76]]], ["However, muscle has certain disadvantages as well.", [["muscle", "ANATOMY", 9, 15], ["muscle", "ORGAN", 9, 15], ["muscle", "ANATOMY", 9, 15]]], ["It is a tissue that does not normally produce circulating proteins and therefore may not do it efficiently.", [["tissue", "ANATOMY", 8, 14], ["tissue", "TISSUE", 8, 14], ["circulating proteins", "PROTEIN", 46, 66], ["tissue", "OBSERVATION", 8, 14], ["proteins", "OBSERVATION", 58, 66], ["may not do", "UNCERTAINTY", 81, 91]]], ["It also contains antigenpresenting dendritic cells that could induce immune responses which might eliminate transduced cells or induce auto-immunity.", [["dendritic cells", "ANATOMY", 35, 50], ["cells", "ANATOMY", 119, 124], ["antigenpresenting dendritic cells", "CELL", 17, 50], ["cells", "CELL", 119, 124], ["antigenpresenting dendritic cells", "CELL_TYPE", 17, 50], ["transduced cells", "CELL_LINE", 108, 124], ["antigenpresenting dendritic cells", "PROBLEM", 17, 50], ["transduced cells", "PROBLEM", 108, 124], ["dendritic cells", "OBSERVATION", 35, 50]]], ["Additionally, the removal of muscle tissue would likely have a significant effect on a subject's lifestyle in the event of a potential unexpected VIP-induced pathology.'Immunization' site selectionOther platforms have been considered.", [["muscle tissue", "ANATOMY", 29, 42], ["muscle tissue", "TISSUE", 29, 42], ["VIP", "GENE_OR_GENE_PRODUCT", 146, 149], ["Immunization' site", "DNA", 169, 187], ["the removal of muscle tissue", "TREATMENT", 14, 42], ["unexpected VIP-induced pathology", "PROBLEM", 135, 167], ["Immunization' site selectionOther platforms", "TREATMENT", 169, 212], ["muscle tissue", "ANATOMY", 29, 42], ["significant", "OBSERVATION_MODIFIER", 63, 74], ["effect", "OBSERVATION", 75, 81]]], ["For example, some authors have suggested the liver as an alternative site [35] .", [["liver", "ANATOMY", 45, 50], ["liver", "ORGAN", 45, 50], ["liver", "ANATOMY", 45, 50]]], ["Unlike muscle, it is designed to secrete circulating proteins.", [["muscle", "ANATOMY", 7, 13], ["muscle", "ORGAN", 7, 13], ["circulating proteins", "PROTEIN", 41, 61], ["muscle", "ANATOMY", 7, 13]]], ["It is also thought to be less immunogenic.", [["thought to be", "UNCERTAINTY", 11, 24], ["less", "OBSERVATION_MODIFIER", 25, 29], ["immunogenic", "OBSERVATION", 30, 41]]], ["However, transduction would require systemic administration of the vector, and there would be no simple means of eliminating expression in the event of a complication.", [["systemic administration of the vector", "TREATMENT", 36, 73], ["a complication", "PROBLEM", 152, 166], ["complication", "OBSERVATION", 154, 166]]], ["Another potential site could be the salivary glands.", [["salivary glands", "ANATOMY", 36, 51], ["salivary glands", "ORGAN", 36, 51], ["salivary glands", "ANATOMY", 36, 51]]], ["While it is well-know that the salivary glands secrete proteins into the oral cavity, it may be less well appreciated that they have also been used as a platform to deliver therapeutic proteins, including the IgG Fc fragment and a host of other proteins, into the systemic circulation [36, 37] .", [["salivary glands", "ANATOMY", 31, 46], ["oral cavity", "ANATOMY", 73, 84], ["salivary glands", "ORGAN", 31, 46], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 73, 84], ["IgG Fc fragment", "GENE_OR_GENE_PRODUCT", 209, 224], ["IgG Fc fragment", "PROTEIN", 209, 224], ["the salivary glands secrete proteins into the oral cavity", "PROBLEM", 27, 84], ["therapeutic proteins", "TREATMENT", 173, 193], ["the IgG Fc fragment", "TREATMENT", 205, 224], ["oral cavity", "ANATOMY", 73, 84], ["systemic circulation", "ANATOMY", 264, 284]]], ["Transgenes delivered to the salivary gland tend to favor being sorted either into the saliva or the blood, though it is currently a challenge to predict which direction a particular protein will sort [7] .", [["salivary gland", "ANATOMY", 28, 42], ["saliva", "ANATOMY", 86, 92], ["blood", "ANATOMY", 100, 105], ["salivary gland", "ORGAN", 28, 42], ["saliva", "ORGANISM_SUBSTANCE", 86, 92], ["blood", "ORGANISM_SUBSTANCE", 100, 105]]], ["The major paired salivary glands are also easily accessible, and the parotid glands are encapsulated, which minimizes vector spillage into the general circulation.", [["salivary glands", "ANATOMY", 17, 32], ["parotid glands", "ANATOMY", 69, 83], ["salivary glands", "ORGAN", 17, 32], ["parotid glands", "ORGAN", 69, 83], ["salivary glands", "ANATOMY", 17, 32], ["parotid glands", "ANATOMY", 69, 83], ["encapsulated", "OBSERVATION", 88, 100], ["vector spillage", "OBSERVATION", 118, 133], ["circulation", "OBSERVATION_MODIFIER", 151, 162]]], ["Futhermore, in the event of complications, the transfected glands could be removed without creating major disability.Potential safety issuesSafety concerns associated with VIP include genotoxic events typically associated with any viral vector mediated gene therapy, such as inflammation, a random insertion disrupting normal genes, activation of proto-oncogenes, and insertional mutagenesis [38] .", [["glands", "ANATOMY", 59, 65], ["inflammation", "DISEASE", 275, 287], ["glands", "ORGAN", 59, 65], ["VIP", "GENE_OR_GENE_PRODUCT", 172, 175], ["normal genes", "DNA", 319, 331], ["proto-oncogenes", "DNA", 347, 362], ["complications", "PROBLEM", 28, 41], ["the transfected glands", "PROBLEM", 43, 65], ["VIP", "TREATMENT", 172, 175], ["genotoxic events", "PROBLEM", 184, 200], ["any viral vector mediated gene therapy", "TREATMENT", 227, 265], ["inflammation", "PROBLEM", 275, 287], ["a random insertion", "TREATMENT", 289, 307], ["complications", "OBSERVATION", 28, 41], ["inflammation", "OBSERVATION", 275, 287]]], ["There are many factors which affect the likelihood of developing a genotoxic event including the vector, the targeted insertion site, the transgene, the targeted cell type, and host factors including age and underlying disease [39] .", [["cell", "ANATOMY", 162, 166], ["cell", "CELL", 162, 166], ["targeted insertion site", "DNA", 109, 132], ["a genotoxic event", "PROBLEM", 65, 82], ["the vector", "TREATMENT", 93, 103], ["the targeted insertion site", "TREATMENT", 105, 132], ["underlying disease", "PROBLEM", 208, 226], ["genotoxic event", "OBSERVATION", 67, 82], ["targeted cell type", "OBSERVATION", 153, 171]]], ["The risk of genotoxicity or carcinogenicity can potentially be decreased by selection of the promoter and the integration site, using novel techniques such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9 (an RNA-guided gene-editing platform that allows for cutting of DNA in a specified gene), but much more work needs to be done to better characterize safety and efficacy of these methods [39] .Potential safety issuesAs the purpose of VIP is to produce a monoclonal antibody, the possibility of producing a paraproteinemia similar to that caused by multiple myeloma, other hematologic malignancies, primary amyloidosis, or a monoclonal gammopathy of undertermined significance (MGUS) is a concern.", [["myeloma", "ANATOMY", 586, 593], ["hematologic malignancies", "ANATOMY", 601, 625], ["paraproteinemia", "DISEASE", 535, 550], ["multiple myeloma", "DISEASE", 577, 593], ["hematologic malignancies", "DISEASE", 601, 625], ["primary amyloidosis", "DISEASE", 627, 646], ["monoclonal gammopathy", "DISEASE", 653, 674], ["MGUS", "DISEASE", 706, 710], ["Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9", "GENE_OR_GENE_PRODUCT", 159, 229], ["DNA", "CELLULAR_COMPONENT", 294, 297], ["VIP", "GENE_OR_GENE_PRODUCT", 463, 466], ["myeloma", "CANCER", 586, 593], ["hematologic malignancies", "CANCER", 601, 625], ["MGUS", "CANCER", 706, 710], ["promoter", "DNA", 93, 101], ["Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Cas9", "DNA", 159, 229], ["monoclonal antibody", "PROTEIN", 483, 502], ["genotoxicity", "PROBLEM", 12, 24], ["carcinogenicity", "PROBLEM", 28, 43], ["novel techniques", "TREATMENT", 134, 150], ["Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)", "TREATMENT", 159, 224], ["gene-editing platform", "TREATMENT", 245, 266], ["cutting of DNA", "TREATMENT", 283, 297], ["Potential safety issues", "PROBLEM", 422, 445], ["a monoclonal antibody", "PROBLEM", 481, 502], ["a paraproteinemia", "PROBLEM", 533, 550], ["multiple myeloma", "PROBLEM", 577, 593], ["other hematologic malignancies", "PROBLEM", 595, 625], ["primary amyloidosis", "PROBLEM", 627, 646], ["a monoclonal gammopathy of undertermined significance (MGUS", "PROBLEM", 651, 710], ["genotoxicity", "OBSERVATION", 12, 24], ["carcinogenicity", "OBSERVATION", 28, 43], ["paraproteinemia", "OBSERVATION", 535, 550], ["multiple", "OBSERVATION_MODIFIER", 577, 585], ["myeloma", "OBSERVATION", 586, 593], ["hematologic malignancies", "OBSERVATION", 601, 625], ["amyloidosis", "OBSERVATION", 635, 646], ["monoclonal", "OBSERVATION_MODIFIER", 653, 663], ["gammopathy", "OBSERVATION", 664, 674]]], ["The most benign of these is MGUS, but it has been increasingly recognized to have pathologic associations including is nephropathy secondary to monoclonal gammopathy of renal significance (MGRS), neuropathy, oculopathy, and dermopathy as well as possible associations with autoimmunity and coagulopathy and an epidemiologic association with early mortality from a variety of apparently unrelated causes [40] [41] [42] .", [["renal", "ANATOMY", 169, 174], ["MGUS", "DISEASE", 28, 32], ["nephropathy", "DISEASE", 119, 130], ["monoclonal gammopathy of renal significance", "DISEASE", 144, 187], ["neuropathy", "DISEASE", 196, 206], ["oculopathy", "DISEASE", 208, 218], ["dermopathy", "DISEASE", 224, 234], ["autoimmunity", "DISEASE", 273, 285], ["coagulopathy", "DISEASE", 290, 302], ["MGUS", "CANCER", 28, 32], ["renal", "ORGAN", 169, 174], ["MGUS", "PROBLEM", 28, 32], ["pathologic associations", "PROBLEM", 82, 105], ["nephropathy", "PROBLEM", 119, 130], ["monoclonal gammopathy of renal significance", "PROBLEM", 144, 187], ["neuropathy", "PROBLEM", 196, 206], ["oculopathy", "PROBLEM", 208, 218], ["dermopathy", "PROBLEM", 224, 234], ["autoimmunity", "PROBLEM", 273, 285], ["coagulopathy", "PROBLEM", 290, 302], ["early mortality", "PROBLEM", 341, 356], ["most benign", "OBSERVATION_MODIFIER", 4, 15], ["MGUS", "OBSERVATION", 28, 32], ["nephropathy", "OBSERVATION", 119, 130], ["monoclonal", "OBSERVATION_MODIFIER", 144, 154], ["gammopathy", "OBSERVATION", 155, 165], ["renal", "ANATOMY", 169, 174], ["neuropathy", "OBSERVATION", 196, 206], ["dermopathy", "OBSERVATION", 224, 234], ["coagulopathy", "OBSERVATION", 290, 302]]], ["Any of these conditions could result from a monoclonal gammopathy produced by VIP.", [["gammopathy", "DISEASE", 55, 65], ["VIP", "GENE_OR_GENE_PRODUCT", 78, 81], ["these conditions", "PROBLEM", 7, 23], ["a monoclonal gammopathy", "PROBLEM", 42, 65], ["monoclonal gammopathy", "OBSERVATION", 44, 65]]], ["However, it should be noted that MGUS is very common, occurring in 3% of the population older than 50 years old, and most of these associations remain either unclear or uncommon [40] .", [["MGUS", "DISEASE", 33, 37], ["MGUS", "PROBLEM", 33, 37], ["MGUS", "OBSERVATION", 33, 37]]], ["However, the potential for autoimmunity should be of particular concern.", [["autoimmunity", "DISEASE", 27, 39], ["autoimmunity", "PROBLEM", 27, 39]]], ["It is possible that the monoclonal antibody could interact with self-antigen and either stimulate an autoimmune antibody that interacts with self-antigen [40] or neutralizes the intended effect of the monoclonal antibody.ConclusionVectored Immunoprophylaxis has demonstrated great promise in a variety of pre-clinical studies as a potential adjunct to vaccination in patients not able to respond effectively to immunization or as an alternative to vaccination for infectious diseases not effectively covered by current vaccines.", [["infectious diseases", "DISEASE", 464, 483], ["patients", "ORGANISM", 367, 375], ["monoclonal antibody", "PROTEIN", 24, 43], ["self-antigen", "PROTEIN", 64, 76], ["autoimmune antibody", "PROTEIN", 101, 120], ["monoclonal antibody", "PROTEIN", 201, 220], ["patients", "SPECIES", 367, 375], ["the monoclonal antibody", "PROBLEM", 20, 43], ["an autoimmune antibody", "PROBLEM", 98, 120], ["neutralizes", "TREATMENT", 162, 173], ["the monoclonal antibody", "TEST", 197, 220], ["ConclusionVectored Immunoprophylaxis", "TREATMENT", 221, 257], ["pre-clinical studies", "TEST", 305, 325], ["vaccination", "TREATMENT", 352, 363], ["immunization", "TREATMENT", 411, 423], ["vaccination", "TREATMENT", 448, 459], ["infectious diseases", "PROBLEM", 464, 483], ["current vaccines", "TREATMENT", 511, 527], ["monoclonal antibody", "OBSERVATION", 201, 220], ["great", "OBSERVATION_MODIFIER", 275, 280]]], ["The rapid identification of specific neutralizing antibodies is likely to increase the potential for this method.", [["neutralizing antibodies", "PROTEIN", 37, 60], ["specific neutralizing antibodies", "PROBLEM", 28, 60], ["this method", "TREATMENT", 101, 112], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["neutralizing antibodies", "OBSERVATION", 37, 60]]], ["One could imagine uses for VIP such as an adjunct to vaccination for influenza in the elderly and immunocompromised, for HIV protection in high risk populations, or as part of a ring vaccination strategy in an outbreak of a disease such as Ebola.", [["influenza", "DISEASE", 69, 78], ["Ebola", "DISEASE", 240, 245], ["VIP", "GENE_OR_GENE_PRODUCT", 27, 30], ["HIV", "ORGANISM", 121, 124], ["Ebola", "ORGANISM", 240, 245], ["HIV", "SPECIES", 121, 124], ["VIP", "TREATMENT", 27, 30], ["vaccination", "TREATMENT", 53, 64], ["influenza", "PROBLEM", 69, 78], ["immunocompromised", "PROBLEM", 98, 115], ["HIV protection", "TREATMENT", 121, 135], ["high risk populations", "PROBLEM", 139, 160], ["a ring vaccination strategy", "TREATMENT", 176, 203], ["a disease", "PROBLEM", 222, 231], ["Ebola", "PROBLEM", 240, 245]]], ["Many important questions remain, including the ability to produce equally effective clinical results in human trials, the duration of response, and the potential for side-effects.", [["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["side-effects", "PROBLEM", 166, 178]]], ["Mutagenesis at the site of transfection is a common concern, but the development of an immune response to the transgene product or the off-target binding of the antibodies are more likely scenarios, either of which could result in decreased efficacy of the procedure or a significant auto-immune reaction.", [["antibodies", "PROTEIN", 161, 171], ["Mutagenesis", "TREATMENT", 0, 11], ["the transgene product", "TREATMENT", 106, 127], ["the antibodies", "PROBLEM", 157, 171], ["the procedure", "TREATMENT", 253, 266], ["a significant auto-immune reaction", "PROBLEM", 270, 304], ["transfection", "OBSERVATION", 27, 39], ["more likely", "UNCERTAINTY", 176, 187], ["decreased", "OBSERVATION_MODIFIER", 231, 240], ["significant", "OBSERVATION_MODIFIER", 272, 283], ["auto-immune", "OBSERVATION", 284, 295]]], ["Questions also remain concerning the best vector and the optimal tissue site for transfection.", [["tissue site", "ANATOMY", 65, 76], ["tissue", "TISSUE", 65, 71]]], ["Despite these questions and concerns, the advantages offered in settings ranging from chronic protection of the aged or immunocompromised to rapid protection for early responders in the event of a bioterror or emerging infection event are significant and intriguing.", [["infection", "DISEASE", 219, 228], ["immunocompromised", "PROBLEM", 120, 137], ["rapid protection", "TREATMENT", 141, 157], ["a bioterror or emerging infection event", "PROBLEM", 195, 234], ["chronic", "OBSERVATION_MODIFIER", 86, 93], ["infection", "OBSERVATION", 219, 228]]], ["Further preclinical and clinical studies are certainly warranted.", [["clinical studies", "TEST", 24, 40]]]], "d77d46a447e665ddfcc2fe9a89a28b83f3050c5b": [["2014 \ub144 \uc11c\uc544\ud504\ub9ac\uce74 EVD \uc720\ud589\uc758 \uc218\ub9ac\ubaa8\ub378= \u2212 \ufffd + + ( + ) + \ufffd , = ( + + ( + ) + ) \u2212 , = \u2212 \ufffd(1 \u2212 )(1 \u2212 ) + (1 \u2212 ) + \u210e \ufffd , = \u210e \u2212 \ufffd(1 \u2212 \u210e ) \u210e + \u210e \u210e \ufffd , = \u2212 \ufffd + + ( + ) + \ufffd , = \ufffd + + ( + ) + \ufffd \u2212 , = \u2212 \ufffd(1 \u2212 )(1 \u2212 ) + (1 \u2212 ) + \u210e \ufffd , = \u210e \u2212 \ufffd(1 \u2212 \u210e ) \u210e + \u210e \u210e \ufffd , = (1 \u2212 )(1 \u2212 ) + (1 \u2212 \u210e ) \u210e + (1 \u2212 )(1 \u2212 ) + (1 \u2212 \u210e ) \u210e , = (1 \u2212 ) + \u210e \u210e + (1 \u2212 ) + \u210e \u210e \u2212 .2014 \ub144 \uc2dc\uc5d0\ub77c\ub9ac\uc628 \ub370\uc774\ud130\ub97c \uc774\uc6a9\ud55c EVD \uc804\ud30c\uc728 \ucd94\uc815Probability of community to be hospitalized 0.62 [8] Probability of HCW to be hospitalized 0.69 [8] Fatality rate of not hospitalized community 0.84 [8] Fatality rate of not hospitalized HCW 0.69 [8] \u210e Fatality rate of hospitalized community 0.57 [8] \u210e Fatality rate of hospitalized HCW 0.66 [8] (0) Number of susceptible community 7079000 [9] (0)", [["+ + ( + ) + ) \u2212", "SIMPLE_CHEMICAL", 51, 66], ["1 \u2212 )(1 \u2212 ) + (1 \u2212 ) + \u210e \ufffd", "SIMPLE_CHEMICAL", 75, 101], ["\u210e \u2212 \ufffd(1 \u2212 \u210e ) \u210e + \u210e \u210e \ufffd", "SIMPLE_CHEMICAL", 106, 129], ["\u2212 \ufffd + + ( + ) + \ufffd", "SIMPLE_CHEMICAL", 134, 151], ["\ufffd + + ( + ) + \ufffd \u2212", "SIMPLE_CHEMICAL", 156, 173], ["\u2212 \ufffd(1 \u2212 )(1 \u2212 ) + (1 \u2212 ) + \u210e \ufffd", "SIMPLE_CHEMICAL", 178, 208], ["\u210e \u2212 \ufffd(1 \u2212 \u210e ) \u210e + \u210e \u210e \ufffd", "SIMPLE_CHEMICAL", 213, 236], ["(1 \u2212 )(1 \u2212 ) + (1 \u2212 \u210e ) \u210e + (1 \u2212 )(1 \u2212 ) + (1 \u2212 \u210e ) \u210e , = (1 \u2212 ) + \u210e \u210e + (1 \u2212 ) + \u210e \u210e \u2212", "SIMPLE_CHEMICAL", 241, 328], ["EVD", "TEST", 13, 16], ["\uc218\ub9ac\ubaa8\ub378", "TEST", 21, 25], ["\ufffd", "TEST", 110, 111], ["\u210e", "TEST", 116, 117], ["\u210e", "TEST", 126, 127], ["\ufffd", "TEST", 128, 129], ["\ufffd", "TEST", 136, 137], ["\ufffd", "TEST", 217, 218], ["\u210e", "TEST", 227, 228], ["\u210e", "TEST", 231, 232], ["\u210e", "TEST", 233, 234], ["\ufffd", "TEST", 235, 236], ["\u210e", "TEST", 310, 311], ["\u2212", "TEST", 317, 318], ["\u2212", "TEST", 327, 328], ["Fatality rate", "TEST", 462, 475], ["Fatality rate", "TEST", 515, 528], ["HCW", "TEST", 549, 552], ["Fatality rate", "TEST", 564, 577], ["Fatality rate", "TEST", 615, 628], ["hospitalized HCW", "TEST", 632, 648]]]]}